meta_review	first_author_meta	year_meta	Link_MA	amstar	amstar_rank	intervention_type	intervention_general	intervention_precise	intervention_comment	intervention_label	duration_month	dose	dose_unit	setting	sett_home	sett_clin	sett_class	intervention_imp	parent_imp	prof_imp	tech_imp	outcome_general	outcome_precise	outcome_type	outcome_measure	outcome_test	outcome_observation	outcome_report	link_cct	author	year	design	measure	n_cases	n_controls	multiple_es	reverse_es	value	se	ci_lo	ci_up	mean_cases	sd_cases	mean_controls	sd_controls	mean_change_cases	sd_change_cases	mean_change_controls	sd_change_controls	n_cases_exp	n_exp	n_cases_nexp	n_nexp	n_controls_exp	n_controls_nexp	rob	design_num	low_RoB_num	random_num	attrition_num	reporting_num	blinding_num	RoB_SeqGen	RoB_Conceal	RoB_BlindPers	RoB_BlindOut	RoB_Attrition	RoB_Reporting	type_comp	active_controls	perc_female	mean_age	mean_IQ	available_age	available_IQ	available_control	available_rob	country	continent	diagnostic_criteria	AMS_1_PICO	AMS_2_protocol	AMS_3_selection	AMS_4_search	AMS_5_screening_duplicate	AMS_6_extraction_duplicate	AMS_7_excluded	AMS_8_description	AMS_9_RoB	AMS_10_funding_primary	AMS_11_stat	AMS_12_MA_RoB	AMS_13_interpreting_RoB	AMS_14_heterogeneity	AMS_15_publication_bias	AMS_16_CoI	n_tot	id_row	paper	trial_id	Duration_cct	IQ_cct	Age_cct	min_age_meta	max_age_meta	min_IQ_meta	max_IQ_meta	n_cct_intervention	n_outcome_intervention	outcome_intervention	n_meta_intervention	meta_intervention	URL_meta	min_age_intervention	max_age_intervention	min_IQ_intervention	max_IQ_intervention
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	1.38089758	7	day/week	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation		0	100	0	10.1007/s10803-006-0079-0	Elder	2006	RCT	SMD	7	7		reverse	0.26		-0.79	1.31	33,6	8,6	31,2	8,7											low	100	100	0	100	100	100	unclear	low	low	low	low	low	No intervention ()	0	20	7.3		1	0	1	1	USA	North America	DSM	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	14	1	Keller (2021)	Elder_2006	< 2 months		6-12 yo	6.760303	8.9	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	ECO scale	0	100	0	10.1007/s10803-019-04333-1	Gonzalez-Domenech	2020	RCT	SMD	15	16		reverse	-0.31		-1.02	0.4	54,9	20,9	62,9	28,9											high	100	0	100	0	100	0	low	unclear	high	high	high	low	No intervention ()	0	46	8.9		1	0	1	1	Spain	Europe	ICD	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	31	2	Keller (2021)	Gonzalez-Domenech_2020	2-6 months		6-12 yo	6.760303	8.9	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation		0	100	0	10.1080/10284150290028945	Knivsberg	2002	RCT	SMD	10	10		reverse	-1.37		-2.36	-0.37	5,6	2,4	11,2	5											high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	No intervention ()	0		7.375		1	0	1	1	Norway	Europe		1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	20	3	Keller (2021)	Knivsberg_2002	7-12 months		6-12 yo	6.760303	8.9	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1179/147683010X12611460763922	Whiteley	2010	RCT	SMD	26	29		reverse	-0.01		-0.54	0.52	0,0168	0,5221	0,0252	0,6572											high	100	0	0	100	0	100	unclear	unclear	high	low	low	high	No intervention ()	0	11	6.760303		1	0	1	1	Denmark	Europe	ICD	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	4	Keller (2021)	Whiteley_2010	7-12 months		6-12 yo	6.760303	8.9	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	3			Home	100	0	0			100		Adverse events				0	0	0		Johnson	2011	RCT	RR	8	14	outcomes		1.88888888888889	0.27055982	1.11148979205757	3.21001709603025															high	100	0	0	0	0	100	unclear	unclear	high	low	high	high	No intervention ()	0	22	3.306818		1	0	1	1			DSM	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	22	5	Keller (2021)	Johnson_2011	2-6 months		< 6 yo	3.306818	6.760303	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Adverse events				0	0	0	10.1179/147683010X12611460763922	Whiteley	2010	RCT	RR	38	34	outcomes		0.897435897435897	1.98640065	0.0182884179351727	44.0383193812315															high	100	0	0	100	0	100	unclear	unclear	high	low	low	high	No intervention ()	0	11	6.760303		1	0	1	1	Denmark	Europe	ICD	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	72	6	Keller (2021)	Whiteley_2010	7-12 months		6-12 yo	3.306818	6.760303	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	3			Home	100	0	0			100		Adverse events				0	0	0		Johnson	2011	RCT	RR	8	14	outcomes		1.88888888888889	0.27055982	1.11148979205757	3.21001709603025															high	100	0	0	0	0	100	unclear	unclear	high	low	high	high	No intervention ()	0	22	3.306818		1	0	1	1			DSM	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	22	7	Keller (2021)	Johnson_2011	2-6 months		< 6 yo	3.306818	6.760303	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Adverse events				0	0	0	10.1179/147683010X12611460763922	Whiteley	2010	RCT	RR	38	34	outcomes		0.897435897435897	1.98640065	0.0182884179351727	44.0383193812315															high	100	0	0	100	0	100	unclear	unclear	high	low	low	high	No intervention ()	0	11	6.760303		1	0	1	1	Denmark	Europe	ICD	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	72	8	Keller (2021)	Whiteley_2010	7-12 months		6-12 yo	3.306818	6.760303	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Keller (2021)	Keller	2021	https://doi.org/10.3390/nu13020470	3.0	Low	Complementary	DIET	GFCF	Gluten & Casein Free Diet	Gluten & Casein Free Diet	3			Home	100	0	0			100		Adverse events				0	0	0		Johnson	2011	RCT	RR	8	14	outcomes		2.33333333333333	0.62201669	0.689469754442226	7.89656748445615															high	100	0	0	0	0	100	unclear	unclear	high	low	high	high	No intervention ()	0	22	3.306818		1	0	1	1			DSM	1	1	1	0.0	0.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	22	9	Keller (2021)	Johnson_2011	2-6 months		< 6 yo	3.306818	6.760303	Inf	-Inf	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	1.38089758	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s10803-006-0079-0	Elder	2006	RCT	SMD	7	7		reverse	0.26		-0.79	1.31	33.6	8.6	31.2	8.7											low	100	100	0	100	100	100	unclear	low	low	low	low	low	No intervention ()	0	20	7.32		1	0	1	1	USA	North America	DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	14	10	Yu (2022)	Elder_2006	< 2 months		6-12 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Ketogenic diet	Ketogenic diet	6	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	15	15	outcomes	reverse	-1.04		-1.81	-0.27	34.270000000000003	3.28	38.93	5.23											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	30	11	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	10	15	outcomes	reverse	-1.03		-1.89	-0.17	33.700000000000003	4.33	38.93	5.23											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	12	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	1.38089758	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s12519-016-0040-z	Ghalichi	2016	RCT	SMD	38	38		reverse	-0.32		-0.77	0.13	75.82	15.37	80.92	16.24											high	100	0	0	100	100	0	unclear	unclear	high	unclear	low	low	No intervention ()	0	26	7.92		1	0	1	1	Iran	Asia	ADI-R	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	76	13	Yu (2022)	Ghalichi_2016	< 2 months		6-12 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s10803-019-04333-1	Gonzalez-Domenech	2020	RCT	SMD	15	16		reverse	-0.31		-1.02	0.4	54.9	20.9	62.9	28.9											low	100	100	100	100	100	0	low	unclear	high	unclear	low	low	No intervention ()	0	46	8.954839		1	0	1	1	Spain	Europe	ICD	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	31	14	Yu (2022)	Gonzalez-Domenech_2020	2-6 months		6-12 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Report	Diagnosis of psychotic behaviour in children / standardized Danish scheme to evaluate behavior	0	0	100	10.1080/10284150290028945	Knivsberg	2002	RCT	SMD	10	10		reverse	-1.37		-2.36	-0.37	5.6	2.4	11.2	5											high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	No intervention ()	0		7.4		1	0	1	1	Norway	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	20	15	Yu (2022)	Knivsberg_2002	7-12 months		6-12 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Ketogenic diet	Ketogenic diet	2.30149597	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Report	ABC: Autism children behavior checklist	0	0	100	https://caod.oriprobe.com/articles/55388755/Effect_of_ketogenic_diet_on_children_s_autistic_pe.htm	Luo	2018	RCT	SMD	50	50		reverse	-0.59		-1.00	-0.19	76.36	8.35	81.57	9.02											high	100	0	0	100	100	0	unclear	unclear	high	unclear	low	low	No intervention ()	0	23	3.6		1	0	1	1	China	Asia	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	100	16	Yu (2022)	Luo_2018	2-6 months		< 6 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	6	7	day/week	Home	100	0	0			100		Overall ASD symptoms	clinician-reported core symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1007/s10803-019-04266-9	Piwowarczyk	2019	RCT	SMD	26	31		reverse	-0.27		-0.80	0.25	11.38	5.96	13	5.69											low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	15	3.793509	101	1	1	1	1	Poland	Europe	DSM-5 + ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	17	Yu (2022)	Piwowarczyk_2019	2-6 months	Average (80-119)	< 6 yo	3.6	8.954839	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	1.38089758	7	day/week	Home	100	0	0			100		Social-communication	Social behaviors	Observation	Behavioral Response Frequencies: child responding	0	100	0	10.1007/s10803-006-0079-0	Elder	2006	RCT	SMD	6	8	outcomes	reverse	0.84		-0.28	1.96	27.7	21.8	14.3	6.5											low	100	100	0	100	100	100	unclear	low	low	low	low	low	No intervention ()	0	20	7.32		1	0	1	1	USA	North America	DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	14	18	Yu (2022)	Elder_2006	< 2 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Ketogenic diet	Ketogenic diet	6	7	day/week	Home	100	0	0			100		Social-communication	Social behaviors	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	15	15	outcomes	reverse	-0.34		-1.06	0.38	16.73	4.17	17.93	2.43											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	30	19	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Social-communication	Social behaviors	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	10	15	outcomes	reverse	-0.79		-1.62	0.05	15	4.9000000000000004	17.93	2.43											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	20	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	1.38089758	7	day/week	Home	100	0	0			100		Social-communication	Social behaviors	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s12519-016-0040-z	Ghalichi	2016	RCT	SMD	38	38	outcomes	reverse	-0.47		-0.92	-0.01	2	5.3	18	47.7											high	100	0	0	100	100	0	unclear	unclear	high	unclear	low	low	No intervention ()	0	26	7.92		1	0	1	1	Iran	Asia	ADI-R	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	76	21	Yu (2022)	Ghalichi_2016	< 2 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	6	7	day/week	Home	100	0	0			100		Social-communication	Social behaviors	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1007/s10803-019-04266-9	Piwowarczyk	2019	RCT	SMD	26	31	outcomes	reverse	-0.33		-0.86	0.19	8.23	4.48	9.74	4.54											low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	15	3.793509	101	1	1	1	1	Poland	Europe	DSM-5 + ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	22	Yu (2022)	Piwowarczyk_2019	2-6 months	Average (80-119)	< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Ketogenic diet	Ketogenic diet	6	7	day/week	Home	100	0	0			100		Global cognition (IQ)	Cognition	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	15	15	outcomes	reverse	-0.68		-1.42	0.06	15.07	5.41	19.4	6.95											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	30	23	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.4	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Global cognition (IQ)	Cognition	Report	Diagnosis of psychotic behaviour in children / standardized Danish scheme to evaluate behavior	0	0	100	10.1080/10284150290028945	Knivsberg	2002	RCT	SMD	9	9		reverse	0.34		-0.60	1.27	86.7	38.5	74.3	31.4											high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	No intervention ()	0		7.4		1	0	1	1	Norway	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	18	24	Yu (2022)	Knivsberg_2002	7-12 months		6-12 yo	3.793509	7.4	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Global cognition (IQ)	Cognition	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	10	15	outcomes	reverse	-0.84		-1.68	0	14.1	4.3600000000000003	19.4	6.95											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	25	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.4	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	6	7	day/week	Home	100	0	0			100		Global cognition (IQ)	Cognition	Report	VABS - Vineland (maladaptive behaviour)	0	0	100	10.1007/s10803-019-04266-9	Piwowarczyk	2019	RCT	SMD	26	30		reverse	-0.14000000000000001		-0.67	0.38	17.57	6.57	18.5	6.11											low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	15	3.793509	101	1	1	1	1	Poland	Europe	DSM-5 + ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	56	26	Yu (2022)	Piwowarczyk_2019	2-6 months	Average (80-119)	< 6 yo	3.793509	7.4	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	1.38089758	7	day/week	Home	100	0	0			100		Social-communication	Communication		Ecological Communication Orientation	0	0	0	10.1007/s10803-006-0079-0	Elder	2006	RCT	SMD	6	7	outcomes	reverse	0.02		-1.08	1.11	175.8	86.4	174.4	86											low	100	100	0	100	100	100	unclear	low	low	low	low	low	No intervention ()	0	20	7.32		1	0	1	1	USA	North America	DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	27	Yu (2022)	Elder_2006	< 2 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Ketogenic diet	Ketogenic diet	6	7	day/week	Home	100	0	0			100		Social-communication	Communication	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	15	15	outcomes	reverse	-0.87		-1.62	-0.11	15.47	3.78	23	11.33											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	30	28	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Social-communication	Communication	Report	Diagnosis of psychotic behaviour in children / standardized Danish scheme to evaluate behavior	0	0	100	10.1080/10284150290028945	Knivsberg	2002	RCT	SMD	9	9		reverse	0.33		-0.61	1.26	66.6	35.1	55.7	28.3											high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	No intervention ()	0		7.4		1	0	1	1	Norway	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	18	29	Yu (2022)	Knivsberg_2002	7-12 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Social-communication	Communication	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	10	15	outcomes	reverse	-0.53		-1.34	0.28000000000000003	17.899999999999999	4.84	23	11.33											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	30	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	1.38089758	7	day/week	Home	100	0	0			100		Social-communication	Communication	Observation	Childhood Autism Rating Scale	0	100	0	10.1007/s12519-016-0040-z	Ghalichi	2016	RCT	SMD	38	38	outcomes	reverse	0.04		-0.41	0.49	32.97	9.28	32.58	9.4											high	100	0	0	100	100	0	unclear	unclear	high	unclear	low	low	No intervention ()	0	26	7.92		1	0	1	1	Iran	Asia	ADI-R	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	76	31	Yu (2022)	Ghalichi_2016	< 2 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	6	7	day/week	Home	100	0	0			100		Social-communication	Communication	Report	Social Communication Questionnaire	0	0	100	10.1007/s10803-019-04266-9	Piwowarczyk	2019	RCT	SMD	21	27	outcomes	reverse	-0.09		-0.66	0.49	13.85	4.94	14.33	5.95											low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	15	3.793509	101	1	1	1	1	Poland	Europe	DSM-5 + ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	48	32	Yu (2022)	Piwowarczyk_2019	2-6 months	Average (80-119)	< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	1.38089758	7	day/week	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behaviors	Observation	Behavioral Response Frequencies: intelligible words	0	100	0	10.1007/s10803-006-0079-0	Elder	2006	RCT	SMD	6	7		reverse	0.07		-1.03	1.16	26.8	35.1	24	43.5											low	100	100	0	100	100	100	unclear	low	low	low	low	low	No intervention ()	0	20	7.32		1	0	1	1	USA	North America	DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	33	Yu (2022)	Elder_2006	< 2 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Ketogenic diet	Ketogenic diet	6	7	day/week	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behaviors	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	15	15	outcomes	reverse	-0.42		-1.14	0.31	11.8	4.78	13.72	4.18											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	30	34	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	12	7	day/week	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behaviors	Report	Diagnosis of psychotic behaviour in children / standardized Danish scheme to evaluate behavior	0	0	100	10.1080/10284150290028945	Knivsberg	2002	RCT	SMD	10	10		reverse	-0.12		-1.00	0.76	26.3	11.5	27.8	12.2											high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	No intervention ()	0		7.4		1	0	1	1	Norway	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	20	35	Yu (2022)	Knivsberg_2002	7-12 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten & Casein Free Diet	Gluten & Casein Free Diet	6	7	day/week	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behaviors	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1007/s11011-017-0088-z	El-Rashidy	2017	RCT	SMD	10	15	outcomes	reverse	-0.65		-1.47	0.17	11.3	2.4500000000000002	13.72	4.18											low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	No intervention ()	0	27	5.29		1	0	1	1	Egypt	Africa	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	36	Yu (2022)	El-Rashidy_2017	2-6 months		< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	1.38089758	7	day/week	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behaviors	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1007/s12519-016-0040-z	Ghalichi	2016	RCT	SMD	38	38		reverse	-0.67		-1.13	-0.21	14.5	7.92	19.32	6.27											high	100	0	0	100	100	0	unclear	unclear	high	unclear	low	low	No intervention ()	0	26	7.92		1	0	1	1	Iran	Asia	ADI-R	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	76	37	Yu (2022)	Ghalichi_2016	< 2 months		6-12 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Yu (2022)	Yu	2022	https://doi.org/10.3389/fneur.2022.844117	4.5	Low	Complementary	DIET	DIET	Gluten Free diet	Gluten Free diet	6	7	day/week	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behaviors	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1007/s10803-019-04266-9	Piwowarczyk	2019	RCT	SMD	26	31		reverse	-0.04		-0.57	0.48	3.15	2.49	3.25	1.99											low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	15	3.793509	101	1	1	1	1	Poland	Europe	DSM-5 + ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	38	Yu (2022)	Piwowarczyk_2019	2-6 months	Average (80-119)	< 6 yo	3.793509	7.92	101	101	9	5	Overall ASD symptoms | Adverse events | Social-communication | Global cognition (IQ) | Restricted/repetitive behaviors	2	Keller (2021) | Yu (2022)	https://doi.org/10.3390/nu13020470 | https://doi.org/10.3389/fneur.2022.844117	3.306818	8.954839	101	101
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	4.60299194	2000	IU/day	Home	100	0	0			100		Overall ASD symptoms	core symptoms in children with ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	SMD	18	20		reverse					-24.6	19.489999999999998	-12.7	18	-24.60	19.490000	-12.70	18.050000							low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.16	7.373684		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	38	39	Zhang (2023)	Kerley_2017	2-6 months		6-12 yo	5.2	7.373684	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Overall ASD symptoms	core symptoms in children with ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	19	16		reverse					-11	25	-5.8	12	-11.00	25.000000	-5.80	12.000000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.14	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	35	40	Zhang (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.373684	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	unclear vitamin D3 OR D2	unclear vitamin D3 OR D2	3.45224396	2500	IU/day	Home	100	0	0			100		Social-communication	lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.nut.2020.110986	Javadfar	2020	RCT	MD	22	21	outcomes	reverse	-0.41		-2.81	1.99					-0.50	0.790000	-0.09	5.560000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.28	8.914186		1	0	1	1	Iran	Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	43	41	Zhang (2023)	Javadfar_2020	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	4.60299194	2000	IU/day	Home	100	0	0			100		Social-communication	lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20	outcomes	reverse	1.4		-1.41	4.21					-3.20	4.030000	-4.60	4.790000							low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.16	7.373684		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	38	42	Zhang (2023)	Kerley_2017	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Social-communication	lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	-1.8		-5.48	1.88					-1.80	4.300000	0.00	6.400000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.14	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	35	43	Zhang (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	unclear vitamin D3 OR D2	unclear vitamin D3 OR D2	3.45224396	2500	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behavior	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.nut.2020.110986	Javadfar	2020	RCT	MD	22	21		reverse	-0.55000000000000004		-1.1399999999999999	0.04					-0.69	1.380000	-0.14	0.260000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.28	8.914186		1	0	1	1	Iran	Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	43	44	Zhang (2023)	Javadfar_2020	2-6 months		6-12 yo	5.2	10	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	4.60299194	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behavior	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20		reverse	2.2000000000000002		-1.73	6.13					-0.80	6.170000	-3.00	6.170000							low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.16	7.373684		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	38	45	Zhang (2023)	Kerley_2017	2-6 months		6-12 yo	5.2	10	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypical behavior	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16		reverse	0.6		-1.29	2.4900000000000002					-0.70	3.300000	-1.30	2.400000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.14	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	35	46	Zhang (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	10	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	unclear vitamin D3 OR D2	unclear vitamin D3 OR D2	3.45224396	2500	IU/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.nut.2020.110986	Javadfar	2020	RCT	MD	22	21	outcomes	reverse	-0.22		-0.44	0					-0.27	0.500000	-0.05	0.160000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.28	8.914186		1	0	1	1	Iran	Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	43	47	Zhang (2023)	Javadfar_2020	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	4.60299194	2000	IU/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20	outcomes	reverse	2.4		-0.21	5.01					-0.10	4.100000	-2.50	4.100000							low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.16	7.373684		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	38	48	Zhang (2023)	Kerley_2017	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	-0.9		-2.39	0.59					-0.80	1.700000	0.10	2.600000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.14	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	35	49	Zhang (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	unclear vitamin D3 OR D2	unclear vitamin D3 OR D2	3.45224396	2500	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.nut.2020.110986	Javadfar	2020	RCT	MD	22	21		reverse	-1.8		-2.71	-0.89					-1.23	1.490000	0.57	1.550000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.28	8.914186		1	0	1	1	Iran	Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	43	50	Zhang (2023)	Javadfar_2020	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	4.60299194	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20		reverse	1.6		-2.5099999999999998	5.71					-3.50	6.450000	-5.10	6.450000							low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.16	7.373684		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	38	51	Zhang (2023)	Kerley_2017	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16		reverse	-4.8		-8.51	-1.0900000000000001					-4.00	4.900000	0.80	6.100000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.14	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	35	52	Zhang (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	unclear vitamin D3 OR D2	unclear vitamin D3 OR D2	3.45224396	2500	IU/day	Home	100	0	0			100		ADHD symptoms	hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.nut.2020.110986	Javadfar	2020	RCT	MD	22	21		reverse	-0.4		-2.15	1.35					-0.82	4.120000	-0.42	0.790000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.28	8.914186		1	0	1	1	Iran	Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	43	53	Zhang (2023)	Javadfar_2020	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	4.60299194	2000	IU/day	Home	100	0	0			100		ADHD symptoms	hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20		reverse	1.8		-5.46	9.06					-3.50	11.400000	-5.30	11.400000							low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.16	7.373684		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	38	54	Zhang (2023)	Kerley_2017	2-6 months		6-12 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		ADHD symptoms	hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16		reverse	-4.4000000000000004		-8.34	-0.46					-5.20	6.300000	-0.80	5.600000							low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.14	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	35	55	Zhang (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.914186	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	3	2500	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	GARS-2: Gilliam Autism Rating Scale-Second Edition - stereotypy subscale	0	0	100	10.1080/20473869.2018.1502068	Moradi	2018	RCT	MD	25	25		reverse	-1.96		-3.29	-0.63					-2.32	2.070000	-0.36	2.690000							high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	7.62	100	1	1	1	1	Iran	Asia	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	50	56	Zhang (2023)	Moradi_2018	2-6 months	Average (80-119)	6-12 yo	5.2	10	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhang (2023)	Zhang	2023	https://doi.org/10.9758/cpn.2023.21.2.240	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	2.30149597	5357.14285714286	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	GARS-2: Gilliam Autism Rating Scale-Second Edition - stereotypy subscale	0	0	100	vitamin D3(50,000 IU/week or 50,000 IU/2 weeks)	Ansari	2020	RCT	MD	10	10		reverse	-0.6		-2.2999999999999998	1.1000000000000001					-0.70	1.830000	-0.10	2.050000							high	100	0	0	0	100	0	unclear	unclear	unclear	unclear	unclear	low	Placebo ()	0	0	10		1	0	1	1	Iran	Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	20	57	Zhang (2023)	Ansari_2020	2-6 months		6-12 yo	5.2	10	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	5	2000	IU/day	Home	100	0	0			100		Social-communication	social interaction	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20	outcomes	reverse	1.4		-16.65	19.45															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.158	7.1		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	38	58	Li (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Social-communication	social interaction	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	-1.8		-5.48	1.88															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	35	59	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Social-communication	social interaction	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	15	16	outcomes	reverse	-1.4		-5	2.2															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	31	60	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	5	2000	IU/day	Home	100	0	0			100		Social-communication	communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20	outcomes	reverse	2.4		-0.21	5.01															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.158	7.1		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	38	61	Li (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Social-communication	communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	-0.9		-2.39	0.59															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	35	62	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Social-communication	communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	15	16	outcomes	reverse	-0.8		-2.56	0.96															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	31	63	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	5	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20		reverse	2.2		-1.73	6.13															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.158	7.1		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	38	64	Li (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	0.6		-1.29	2.49															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	35	65	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	15	16	outcomes	reverse	0.8		-0.82	2.42															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	31	66	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	5	2000	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20		reverse	1.8		-5.46	9.06															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.158	7.1		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	38	67	Li (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	-4.4		-8.34	-0.46															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	35	68	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	15	16	outcomes	reverse	-3.7		-7.91	0.51															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	31	69	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	5	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	MD	18	20		reverse	1.6		-2.51	5.71															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	13.158	7.1		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	38	70	Li (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	19	16	outcomes	reverse	-4.8		-8.51	-1.09															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	35	71	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Li (2022)	Li	2022	https://doi.org/10.1080/1028415X.2020.1815332	4.0	Critically low	Complementary	VIT-D	VIT-D	vitamin D3	vitamin D3	12	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	MD	15	16	outcomes	reverse	-3.5		-7.45	0.45															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.5299145299145	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	1	1	0	1	31	72	Li (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.1	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Song (2020)	Song	2020	https://doi.org/10.9758/cpn.2020.18.2.203	4.0	Critically low	Complementary	VIT-D	VIT-D	Vitamin D	Vitamin D	12	800	IU/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.5428/pcar20180508	Fang	2018	RCT	SMD	12	12		reverse	-0.93		-1.78	-0.08	185	44	232	53											high	100	0	100	0	100	0	low	low	unclear	unclear	unclear	low	Active ()	100	37.5	10		1	0	1	1	China	Asia	DSM-5	1	1	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	0	1	24	73	Song (2020)	Fang_2018	7-12 months		6-12 yo	5.5	10	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Song (2020)	Song	2020	https://doi.org/10.9758/cpn.2020.18.2.203	4.0	Critically low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	SRS: Social Responsiveness Scale	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	SMD	18	20		reverse	-0.23		-0.87	0.41	125	56	138	56											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	13.16	7.47		1	0	1	1	Ireland	Europe	DSM/ADOS	1	1	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	0	1	38	74	Song (2020)	Kerley_2017	2-6 months		6-12 yo	5.5	10	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Song (2020)	Song	2020	https://doi.org/10.9758/cpn.2020.18.2.203	4.0	Critically low	Complementary	VIT-D	VIT-D	Vitamin D	Vitamin D	12	2000	IU/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report + Observation	CARS + SRS	0	100	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	19	16		reverse	-0.43		-1.1	0.25	90	30	102	24											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	17.45	5.5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	0	1	35	75	Song (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	5.5	10	Inf	-Inf	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		Acceptability	acceptability			0	0	0		IRCT20131013014994N5		RCT	RR	26	26		reverse	0.8	0.61080023	0.241643928244153	2.64852506185612															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	52	76	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1136/archdischild-2017-312783	Kerley	2017	RCT	RR	22	20		reverse	8.21739130434783	1.45983729	0.470022030079834	143.664584907439															high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	42	77	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	RR	31	29		reverse	0.863523573200992	0.30580318	0.47421365568746	1.57244092937986															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	78	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist-H	0	0	100		IRCT20131013014994N5		RCT	G	22	21			0.04		-0.56	0.64	0.82	8.2652	0.42	10.7650											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	79	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist-H	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	G	18	20			-0.15		-0.79	0.48	3.50	11.4000	5.30	11.4000											high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	80	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist-H	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	19	16			0.66		-0.03	1.34	5.20	6.5466	0.80	6.5466											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	81	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	CARS: Childhood Autism Rating Scale	0	100	0		IRCT20131013014994N5		RCT	G	22	21			0.31		-0.29	0.91	2.11	5.3717	0.33	5.7955											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	82	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	G	18	20			0.23		-0.41	0.87	24.60	51.3100	12.70	51.3100											high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	83	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	19	16			0.26		-0.41	0.93	11.00	19.3240	5.80	19.3240											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	84	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist-I	0	0	100		IRCT20131013014994N5		RCT	G	22	21			0.18		-0.42	0.78	1.23	7.5203	-0.57	11.5641											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	85	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist-I	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	G	18	20			-0.24		-0.88	0.40	3.50	6.4500	5.10	6.4500											high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	86	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist-I	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	19	16			0.88		0.18	1.58	4.00	5.3301	-0.80	5.3301											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	87	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist-S	0	0	100		IRCT20131013014994N5		RCT	G	22	21			0.11		-0.49	0.70	0.69	5.3956	0.14	4.7750											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	88	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist-S	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	G	18	20			-0.35		-0.99	0.29	0.80	6.1700	3.00	6.1700											high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	89	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist-S	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	19	16			-0.19		-0.86	0.48	0.70	3.0807	1.30	3.0807											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	90	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	2.99194476	2500	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	GARS-2: Gilliam Autism Rating Scale-Second Edition - stereotypy subscale	0	0	100	10.1080/20473869.2018.1502068	Moradi	2018	RCT	G	25	25			0.80		0.23	1.38	2.32	2.0700	0.36	2.6900											high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	high	Placebo ()	0	0	7.62	100	1	1	1	1	Iran	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	91	Siafis (child) (2022)	Moradi_2018	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist-L/SW	0	0	100		IRCT20131013014994N5		RCT	G	22	21			0.05		-0.55	0.65	0.50	6.5701	0.09	8.6950											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	92	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist-L/SW	0	0	100	10.1136/archdischild-2017-312783	Kerley	2017	RCT	G	18	20			-0.05		-0.69	0.59	3.20	28.3400	4.60	28.3400											high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	93	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist-L/SW	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	19	16			0.34		-0.33	1.01	1.80	5.1418	0	5.1418											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	94	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	VIT	VIT	4.60299194	2000	IU/day	Home	100	0	0			100		Tolerability				0	0	0	10.1136/archdischild-2017-312783	Kerley	2017	RCT	RR	22	20		reverse	0.91304347826087	1.97709451	0.0189489680215864	43.9943954860774															high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	42	95	Siafis (child) (2022)	Kerley_2017	2-6 months		6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	oral	oral	11.96777906	2000	IU/day	Home	100	0	0			100		Tolerability				0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	RR	31	29		reverse	0.9375	1.98378846	0.0192029289534011	45.7693850835362															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	96	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	VIT-D	VIT-D	HUEY 2020	HUEY 2020	3.45224396			Home	100	0	0			100		Tolerability				0	0	0		IRCT20131013014994N5		RCT	RR	26	26		reverse	5	1.52509866	0.251653903039328	99.3427866528778															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	7.69230769230769	8.88	100	1	1	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	52	97	Siafis (child) (2022)	IRCT20131013014994N5_NA	2-6 months	Average (80-119)	6-12 yo	5.2	8.88	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social-communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-1.06		-1.65	-0.47															low	100	100	100	100	100	100	low	low	high	low	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	50	98	Chen (2022a)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.62		-0.99	-0.24															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	99	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-communication	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	-0.44		-1.44	0.55															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	100	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Socia awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes	reverse	-1.70		-2.49	-0.91															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	14.7	7.294118	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	34	101	Chen (2022a)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Socia awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.73		-1.30	-0.16															low	100	100	100	100	100	100	low	low	high	low	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	50	102	Chen (2022a)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Socia awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	25	25	outcomes	reverse	-0.22		-0.59	0.14															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	50	103	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Socia awareness	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	58	58	outcomes	reverse	-1.43		-2.52	-0.33															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	104	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social cognition	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	8	8	outcomes	reverse	-1.67		-2.46	-0.89															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	14.7	7.294118	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	105	Chen (2022a)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social cognition	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.84		-1.42	-0.26															low	100	100	100	100	100	100	low	low	high	low	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	50	106	Chen (2022a)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognition	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.45		-0.82	-0.08															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	107	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognition	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	-0.03		-1.01	0.95															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	108	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes	reverse	-0.46		-1.15	0.22															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	14.7	7.294118	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	34	109	Chen (2022a)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.81		-1.39	-0.23															low	100	100	100	100	100	100	low	low	high	low	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	50	110	Chen (2022a)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.33		-0.70	0.03															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	111	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	-0.02		-1.00	0.96															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	112	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	SMD	8	8		reverse	-0.60		-1.36	0.15															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	113	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	10.2	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58		reverse	-0.05		-0.41	0.31															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	114	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	10.2	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58		reverse	-0.02		-0.38	0.34															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	115	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.38	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	1.61104718	1.5	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	SMD	14	10		reverse	-0.08		-0.90	0.73															high	100	0	100	100	100	0	low	high	high	high	low	low	WLC ()	0	15.3846153846154	7.38		1	0	1	1	UK	UK	Clinician	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	24	116	Chen (2022a)	Harris_2017	< 2 months		6-12 yo	7.38	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	SMD	8	8		reverse	-0.22		-1.20	0.76															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	117	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.38	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.30		-0.67	0.06															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	118	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	1.61104718	1.5	hour/week	Clinic	0	100	0			100		Social-communication	Lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	SMD	14	10	outcomes	reverse	-0.12		-0.93	0.70															high	100	0	100	100	100	0	low	high	high	high	low	low	WLC ()	0	15.3846153846154	7.38		1	0	1	1	UK	UK	Clinician	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	24	119	Chen (2022a)	Harris_2017	< 2 months		6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	-0.75		-1.77	0.26															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	120	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58		reverse	-0.50		-0.87	-0.13															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	121	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.38	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	1.61104718	1.5	hour/week	Clinic	0	100	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	SMD	14	10		reverse	-0.4		-1.22	0.42															high	100	0	100	100	100	0	low	high	high	high	low	low	WLC ()	0	15.3846153846154	7.38		1	0	1	1	UK	UK	Clinician	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	24	122	Chen (2022a)	Harris_2017	< 2 months		6-12 yo	7.38	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	SMD	8	8		reverse	-1.69		-2.83	-0.55															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	123	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.38	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Innapropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.33		-0.69	0.04															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	12.9310344827586	10.2	86.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	116	124	Chen (2022a)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	1.61104718	1.5	hour/week	Clinic	0	100	0			100		Social-communication	Innapropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	SMD	14	10	outcomes	reverse	-0.02		-0.83	0.79															high	100	0	100	100	100	0	low	high	high	high	low	low	WLC ()	0	15.3846153846154	7.38		1	0	1	1	UK	UK	Clinician	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	24	125	Chen (2022a)	Harris_2017	< 2 months		6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Chen (2022a)	Chen	2022a	https://doi.org/10.3390/ijerph192114449	1.0	Critically low	Complementary	AAI	HORSE	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Innapropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	-0.30		-1.28	0.69															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	0.0	0	0.0	0.5	1.0	0	1	0	0	0	0	1	16	126	Chen (2022a)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Equine-Assisted Therapy	Equine-Assisted Therapy	5.75373993	1.08	hour/week	Clinic	0	100	0			100		Social-communication	Socialization/Social Interaction	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1007/s10803-015-2530-6	Borgi	2016	RCT	SMD	13	13	outcomes		0.21		-0.4	0.82															high	100	0	0	100	0	100	high	unclear	unclear	low	low	high	WLC ()	0	0	9		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	26	127	Dimolareva (2020)	Borgi_2016	2-6 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	1	hour/week	Clinic	0	100	0			100		Social-communication	Socialization/Social Interaction	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1016/j.rasd.2011.09.007	Gabriels	2012	NRCT	SMD	41	15	outcomes		0.09		-0.37	0.54															high	0	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	high	WLC ()	0	14.3	11		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	56	128	Dimolareva (2020)	Gabriels_2012	2-6 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.76179517	1.5	hour/week	Clinic	0	100	0			100		Social-communication	Socialization/Social Interaction	Report	BASC: Behavior Assessment System for Children	0	0	100	10.14204/ejrep.32.13115	Garcia-Gomez	2013	NRCT	SMD	6	6			1.1		0.22	1.98															high	0	0	0	0	0	0	high	unclear	unclear	unclear	high	unclear	TAU ()	0	18.8	10.5		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	12	129	Dimolareva (2020)	Garcia-Gomez_2013	2-6 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Equine-Assisted Activities	Equine-Assisted Activities	2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Socialization/Social Interaction	Report	PedQol: Pediatric Quality of Life Inventory	0	0	100	10.1007/s10803-014-2062-5	Lanning	2014	NRCT	SMD	7	7			0.2		-0.74	1.13															high	0	0	0	100	100	0	high	low	unclear	unclear	low	low	Active: Social Circles ()	0	16	9.5		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	14	130	Dimolareva (2020)	Lanning_2014	2-6 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Animal-Assisted Intervention	Animal-Assisted Intervention	1.84119678	0.67	hour/week	Clinic	0	100	0			100		Social-communication	Socialization/Social Interaction	Report	SSRS: Social Skill Rating System	0	0	100	10.1089/acm.2013.0165	O'Haire	2014	NRCT	SMD	27	37			0.21		-0.07	0.49															high	0	0	0	0	100	0	high	unclear	unclear	unclear	unclear	low	WLC ()	0	21.88	8.5		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	64	131	Dimolareva (2020)	O'Haire_2014	< 2 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Socialization/Social Interaction	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	56	55	outcomes		0.12		-0.2	0.44															high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	Placebo ()	0	12.93	11	86.5	1	1	1	1	USA	North America	SCQ	1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	111	132	Dimolareva (2020)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Equine-Assisted Therapy	Equine-Assisted Therapy	5.75373993	1.08	hour/week	Clinic	0	100	0			100		Social-communication	Communication	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1007/s10803-015-2530-6	Borgi	2016	RCT	SMD	13	13	outcomes		0.4		-0.23	1.04															high	100	0	0	100	0	100	high	unclear	unclear	low	low	high	WLC ()	0	0	9		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	26	133	Dimolareva (2020)	Borgi_2016	2-6 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	1	hour/week	Clinic	0	100	0			100		Social-communication	Communication	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1016/j.rasd.2011.09.007	Gabriels	2012	NRCT	SMD	41	15	outcomes		0.34		-0.11	0.79															high	0	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	high	WLC ()	0	14.3	11		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	56	134	Dimolareva (2020)	Gabriels_2012	2-6 months		6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Communication	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8			0.23		-0.59	1.05															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	18.75	11	101	1	1	1	1	USA	North America	ADOS2	1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	16	135	Dimolareva (2020)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	56	55	outcomes		0.62		0.29	0.95															high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	Placebo ()	0	12.93	11	86.5	1	1	1	1	USA	North America	SCQ	1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	111	136	Dimolareva (2020)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Communication	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	56	55	outcomes		-0.02		-0.33	0.3															high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	Placebo ()	0	12.93	11	86.5	1	1	1	1	USA	North America	SCQ	1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	111	137	Dimolareva (2020)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	1.84119678	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Communication	Report	PRES	0	0	100	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	18	11			0.04		-0.54	0.62															high	0	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	44.8	9.5	67	1	1	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	29	138	Dimolareva (2020)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	8.5	11	67	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Therapeutic Horseback Riding	Therapeutic Horseback Riding	1.61104718	1.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Global ASD Scores	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.3390/ijerph14070776.	Harris	2017	NRCT	SMD	10	14		reverse	-0.14		-0.77	0.5															high	0	0	0	100	100	0	high	unclear	unclear	high	low	low	WLC ()	0	15.4	7.5		1	0	1	1	UK	UK	Clinician	1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	24	139	Dimolareva (2020)	Harris_2017	< 2 months		6-12 yo	7.5	10	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Equine-Assisted Therapy	Equine-Assisted Therapy	2.07134638	1	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Global ASD Scores	Report	CBCL: Child Behavior Check List	0	0	100	10.1016/j.rasd.2013.02.008	Jenkins	2013	NRCT	SMD	4	3		reverse	1.41		-0.33	3.15															high	0	0	0	100	0	0	unclear	unclear	unclear	unclear	low	high	WLC ()	0	14.2857142857143	10		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	7	140	Dimolareva (2020)	Jenkins_2013	2-6 months		6-12 yo	7.5	10	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Equine-Assisted Activities	Equine-Assisted Activities	5.52359033	1	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Global ASD Scores	Observation	CARS: Childhood Autism Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/22164808/	Kern	2011	NRCT	SMD	18	11		reverse	-0.31		-0.8	0.18															low	0	100	0	100	100	100	unclear	high	low	low	low	low	WLC ()	0	25	7.5		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	29	141	Dimolareva (2020)	Kern_2011	2-6 months		6-12 yo	7.5	10	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Dimolareva (2020)	Dimolareva	2020	https://doi.org/10.1007/s1080 3-020-04715 -w	2.0	Critically low	Complementary	AAI	AAI	Equine-Assisted Therapy	Equine-Assisted Therapy	2.76179517	2	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Global ASD Scores	Observation	CARS: Childhood Autism Rating Scale	0	100	0	https://www.clinicalneuropsychiatry.org/download/dance-and-equine-assisted-therapy-in-autism-spectrum-disorder-crossover-randomized-clinical-trial/	Souza-Santos	2018	RCT	SMD	15	30		reverse	2.63		0.7	4.56															high	100	0	100	100	0	0	low	unclear	unclear	unclear	low	unclear	Active: dance ()	0	20	8.5		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.0	1.0	0	0	1	1	1	1	0	45	142	Dimolareva (2020)	Souza-Santos_2018	2-6 months		6-12 yo	7.5	10	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	SRS total score	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15		reverse	-0.73		-1.43	-0.03	73.599999999999994	24.1	94.4	32.1											high	100	0	0	0	0	0	unclear	unclear	high	high	high	unclear	WLC ()	0	14.71	6.89	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	34	143	Madigand (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	6.89	9.065	70	90	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	SRS total score	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25		reverse	-0.81		-1.38	-0.23	66.2	23.3	91	36											high	100	0	100	100	100	0	low	unclear	high	high	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	50	144	Madigand (2023)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	6.89	9.065	70	90	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	"Occupational therapy in 
an equine environment (OTee)"	"Occupational therapy in 
an equine environment (OTee)"	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	SRS total score	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	SMD	12	12		reverse	-0.59		-1.41	0.23	68.900000000000006	8.0299999999999994	74.67	10.72											high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	WLC ()	0	20.83	9.065	90	1	1	1	1			ADOS	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	24	145	Madigand (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	6.89	9.065	70	90	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.69		-1.27	-0.12	22.4	9	30.7	14											high	100	0	100	100	100	0	low	unclear	high	high	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	50	146	Madigand (2023)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.33		-0.7	0.03	30.2	8.75	33.6	11.38											high	100	0	100	100	0	0	low	unclear	low	high	low	high	Placebo ()	0	12.93	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	116	147	Madigand (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	0.38		-0.62	1.37	34.57	3.95	31.29	10.98											high	100	0	0	100	100	0	unclear	unclear	unclear	high	low	low	Placebo ()	0	18.75	10.84	101.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	16	148	Madigand (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	"Occupational therapy in 
an equine environment (OTee)"	"Occupational therapy in 
an equine environment (OTee)"	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	SMD	12	12	outcomes	reverse	-0.4		-1.2	0.41	66.75	12.39	71	7.86											high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	WLC ()	0	20.83	9.065	90	1	1	1	1			ADOS	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	24	149	Madigand (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes	reverse	-0.44		-1.1299999999999999	0.24	16.100000000000001	5.8	18.899999999999999	6.6											high	100	0	0	0	0	0	unclear	unclear	high	high	high	unclear	WLC ()	0	14.71	6.89	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	34	150	Madigand (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.83		-1.41	-0.25	13.2	5.5	18.3	6.5											high	100	0	100	100	100	0	low	unclear	high	high	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	50	151	Madigand (2023)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.27		-0.63	0.1	17.600000000000001	5.55	19.100000000000001	5.64											high	100	0	100	100	0	0	low	unclear	low	high	low	high	Placebo ()	0	12.93	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	116	152	Madigand (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	0.42		-0.56999999999999995	1.42	21.29	3.3	18.71	7.43											high	100	0	0	100	100	0	unclear	unclear	unclear	high	low	low	Placebo ()	0	18.75	10.84	101.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	16	153	Madigand (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	"Occupational therapy in 
an equine environment (OTee)"	"Occupational therapy in 
an equine environment (OTee)"	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	SMD	12	12	outcomes	reverse	-0.94		-1.79	-0.09	71.099999999999994	7.15	78.22	7.5											high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	WLC ()	0	20.83	9.065	90	1	1	1	1			ADOS	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	24	154	Madigand (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes	reverse	-0.4		-1.08	0.28000000000000003	9.9	2.7	11.1	3.2											high	100	0	0	0	0	0	unclear	unclear	high	high	high	unclear	WLC ()	0	14.71	6.89	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	34	155	Madigand (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.34		-0.9	0.22	9.1999999999999993	3	10.5	4.4000000000000004											high	100	0	100	100	100	0	low	unclear	high	high	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	50	156	Madigand (2023)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.06		-0.43	0.3	12.2	3.14	12.4	3.36											high	100	0	100	100	0	0	low	unclear	low	high	low	high	Placebo ()	0	12.93	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	116	157	Madigand (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	-0.7		-1.72	0.32	11.29	1.38	13.57	4.12											high	100	0	0	100	100	0	unclear	unclear	unclear	high	low	low	Placebo ()	0	18.75	10.84	101.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	16	158	Madigand (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	"Occupational therapy in 
an equine environment (OTee)"	"Occupational therapy in 
an equine environment (OTee)"	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	SMD	12	12	outcomes	reverse	-0.51		-1.32	0.31	72.3	9.24	76.56	6.86											high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	WLC ()	0	20.83	9.065	90	1	1	1	1			ADOS	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	24	159	Madigand (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes	reverse	-0.57999999999999996		-1.27	0.12	12.5	5.9	16.2	6.7											high	100	0	0	0	0	0	unclear	unclear	high	high	high	unclear	WLC ()	0	14.71	6.89	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	34	160	Madigand (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25	outcomes	reverse	-0.68		-1.25	-0.11	9.6	4.8	13.8	7.1											high	100	0	100	100	100	0	low	unclear	high	high	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	50	161	Madigand (2023)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.23		-0.59	0.14000000000000001	11.9	4.97	13.2	6.36											high	100	0	100	100	0	0	low	unclear	low	high	low	high	Placebo ()	0	12.93	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	116	162	Madigand (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8	outcomes	reverse	0.67		-0.34	1.69	16.43	4.28	12.71	6.05											high	100	0	0	100	100	0	unclear	unclear	unclear	high	low	low	Placebo ()	0	18.75	10.84	101.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	16	163	Madigand (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	"Occupational therapy in 
an equine environment (OTee)"	"Occupational therapy in 
an equine environment (OTee)"	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	SMD	12	12	outcomes	reverse	-0.4		-1.2	0.41	66.75	12.39	71	7.86											high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	WLC ()	0	20.83	9.065	90	1	1	1	1			ADOS	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	24	164	Madigand (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	6.89	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Equineassisted activities	Equineassisted activities	2.76179517	1.16666666666667	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Autistic mannerism	Report	SRS: Social Responsiveness Scale	0	0	100	10.1163/15685306-12341479	Coman	2018	RCT	SMD	25	25		reverse	-0.93		-1.51	-0.34	11.7	5	17.7	7.5											high	100	0	100	100	100	0	low	unclear	high	high	low	low	WLC ()	0	16	8.7	70	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	50	165	Madigand (2023)	Coman_2018	2-6 months	Limit (70-79)	6-12 yo	8.7	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Autistic mannerism	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58		reverse	-0.16		-0.52	0.2	18.399999999999999	6.04	19.399999999999999	6.37											high	100	0	100	100	0	0	low	unclear	low	high	low	high	Placebo ()	0	12.93	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	116	166	Madigand (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	8.7	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Madigand (2023)	Madigand	2023	https://doi.org/10.1016/j.pnpbp.2023.110765	2.0	Critically low	Complementary	AAI	HORSE	Therapeutic horse riding	Therapeutic horse riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Autistic mannerism	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	SMD	8	8		reverse	0.23		-0.75	1.22	20.29	4.96	18.86	6.47											high	100	0	0	100	100	0	unclear	unclear	unclear	high	low	low	Placebo ()	0	18.75	10.84	101.5	1	1	1	1	USA	North America	ADOS2	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	0	1	1	16	167	Madigand (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	8.7	10.84	70	101.5	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	G	19	15	outcomes	reverse	-0.46		-1.1499999999999999	0.23															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	WLC ()	0	14.7058823529412	7.294118	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	34	168	Xiao (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.1		-0.47	0.26															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	169	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-1.51		-2.75	-0.27															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	170	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	G	20	9	outcomes	reverse	0.2		-0.59	0.98															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	WLC ()	0	23.8095238095238	8.918966	90	1	1	1	1			ADOS	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	29	171	Xiao (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	G	19	15	outcomes	reverse	-1.88		-2.71	-1.05															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	WLC ()	0	14.7058823529412	7.294118	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	34	172	Xiao (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.36		-0.73	0															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	173	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-0.19		-1.24	0.86															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	174	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social cognitive	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	G	20	9	outcomes	reverse	0.15		-0.64	0.93															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	WLC ()	0	23.8095238095238	8.918966	90	1	1	1	1			ADOS	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	29	175	Xiao (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.57999999999999996		-0.95	-0.21															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	176	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-1.27		-2.4500000000000002	-0.08															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	177	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	G	20	9	outcomes	reverse	-0.28999999999999998		-1.08	0.5															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	WLC ()	0	23.8095238095238	8.918966	90	1	1	1	1			ADOS	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	29	178	Xiao (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Social mannerism	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.09		-0.46	0.27															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	179	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Social mannerism	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-0.49		-1.56	0.57999999999999996															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	180	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	G	19	15	outcomes	reverse	-0.41		-1.0900000000000001	0.28000000000000003															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	WLC ()	0	14.7058823529412	7.294118	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	34	181	Xiao (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.24		-0.61	0.12															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	182	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-0.72		-1.82	0.37															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	183	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	G	20	9	outcomes	reverse	0.11		-0.68	0.89															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	WLC ()	0	23.8095238095238	8.918966	90	1	1	1	1			ADOS	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	29	184	Xiao (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Language (Expressive skills)		Test	SALT: Systematic Analysis of Language Transcripts	100	0	0	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes		0.48		0.11	0.85															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	185	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	10.25	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Language (Expressive skills)		Test	SALT: Systematic Analysis of Language Transcripts	100	0	0		Pan	2018/2019	RCT	G	7	7	outcomes		0.82		-0.28999999999999998	1.93															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	186	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	10.25	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Language (Expressive skills)		Test	SALT: Systematic Analysis of Language Transcripts	100	0	0	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes		0.48		0.11	0.85															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	187	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	10.25	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Language (Expressive skills)		Test	SALT: Systematic Analysis of Language Transcripts	100	0	0		Pan	2018/2019	RCT	G	7	7	outcomes		0.91		-0.21	2.0299999999999998															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	188	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	10.25	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.44		-0.81	-7.0000000000000007E-2															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	189	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	36	28	outcomes	reverse	-0.49		-0.99	0.02															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	12.9310344827586	10.28125	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	64	190	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			1.61104718	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	G	10	14		reverse	-0.5		-1.32	0.33															high	100	0	0	100	100	0	unclear	high	unclear	high	low	low	WLC ()	0	15.3846153846154	7.5		1	0	1	1	UK	UK	Clinician	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	24	191	Xiao (2023)	Harris_2017	< 2 months		6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	G	7	7		reverse	-0.85		-1.96	0.26															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	192	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	G	20	9		reverse	-0.09		-0.88	0.69															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	WLC ()	0	23.8095238095238	8.918966	90	1	1	1	1			ADOS	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	29	193	Xiao (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.23		-0.6	0.13															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	194	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			1.61104718	0.75	hour/week	Clinic	0	100	0			100		Social-communication	lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	G	10	14	outcomes	reverse	0.27		-0.54	1.0900000000000001															high	100	0	0	100	100	0	unclear	high	unclear	high	low	low	WLC ()	0	15.3846153846154	7.5		1	0	1	1	UK	UK	Clinician	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	24	195	Xiao (2023)	Harris_2017	< 2 months		6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	lethargy	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-0.95		-2.0699999999999998	0.18															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	196	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.03		-0.39	0.34															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	197	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			1.61104718	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	G	10	14		reverse	0.17		-0.64	0.98															high	100	0	0	100	100	0	unclear	high	unclear	high	low	low	WLC ()	0	15.3846153846154	7.5		1	0	1	1	UK	UK	Clinician	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	24	198	Xiao (2023)	Harris_2017	< 2 months		6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-0.55000000000000004		-1.63	0.52															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	199	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms		Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.47		-0.84	-0.1															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	200	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms		Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	36	28	outcomes	reverse	-0.2		-0.7	0.28999999999999998															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	12.9310344827586	10.28125	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	64	201	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			1.61104718	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms		Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	G	10	14		reverse	-1.1299999999999999		-2.0099999999999998	-0.24															high	100	0	0	100	100	0	unclear	high	unclear	high	low	low	WLC ()	0	15.3846153846154	7.5		1	0	1	1	UK	UK	Clinician	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	24	202	Xiao (2023)	Harris_2017	< 2 months		6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms		Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	G	7	7		reverse	-1.19		-2.35	-0.02															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	203	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		ADHD symptoms		Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1007/s10803-021-05278-0	Peters	2021/2022	RCT	G	20	9		reverse	0.09		-0.69	0.88															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	WLC ()	0	23.8095238095238	8.918966	90	1	1	1	1			ADOS	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	29	204	Xiao (2023)	Peters_2021/2022	2-6 months	Average (80-119)	6-12 yo	7.5	10.84	86.5	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	inappropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	G	58	58	outcomes	reverse	-0.23		-0.59	0.14000000000000001															high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	12.9310344827586	10.25	86.5	1	1	1	1	USA	North America	SCQ	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	116	205	Xiao (2023)	Gabriels_2015	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			1.61104718	0.75	hour/week	Clinic	0	100	0			100		Social-communication	inappropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3390/ijerph14070776.	Harris	2017	RCT	G	10	14	outcomes	reverse	0.06		-0.75	0.87															high	100	0	0	100	100	0	unclear	high	unclear	high	low	low	WLC ()	0	15.3846153846154	7.5		1	0	1	1	UK	UK	Clinician	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	24	206	Xiao (2023)	Harris_2017	< 2 months		6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Xiao (2023)	Xiao	2023	https://doi.org/10.3390/ijerph20032630	3.0	Critically low	Complementary	AAI	AAI			2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	inappropriate speech	Report	ABC: Aberrant Behavior Checklist	0	0	100		Pan	2018/2019	RCT	G	7	7	outcomes	reverse	-0.42		-1.49	0.64															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	18.75	10.84	101	1	1	1	1	USA	North America	ADOS2	1	1	0	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	0	1	14	207	Xiao (2023)	Pan_2018/2019	2-6 months	Average (80-119)	6-12 yo	7.294118	10.84	70	101	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.76179517	1800	mg/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15		reverse	-0.70299999999999996		-1.4339999999999999	2.7E-2															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	6.9	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADOS, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	29	208	Liu (2022)	Hardan_2012	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.76179517	1680	mg/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	15	16		reverse	0.248		-0.51400000000000001	1.01															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	22.42	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	31	209	Liu (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.30149597	750	mg/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	G	20	20		reverse	-0.41899999999999998		-1.0329999999999999	0.19500000000000001															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17.5	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	40	210	Liu (2022)	Nikoo_2015	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	1.84119678	1200	mg/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	G	20	20		reverse	-0.87		-1.5920000000000001	-0.14799999999999999															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37.5	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	40	211	Liu (2022)	Ghanizadeh_2013	< 2 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15		reverse	-0.36399999999999999		-1.0780000000000001	0.35															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	6.9	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADOS, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	29	212	Liu (2022)	Hardan_2012	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.76179517	1680	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	15	16		reverse	0.40300000000000002		-0.36399999999999999	1.17															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	22.42	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	31	213	Liu (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.30149597	750	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	G	20	20		reverse	-0.18		-0.78900000000000003	0.42899999999999999															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17.5	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	40	214	Liu (2022)	Nikoo_2015	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	1.84119678	1200	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	G	20	20		reverse	-0.78300000000000003		-1.4990000000000001	-6.7000000000000004E-2															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37.5	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	40	215	Liu (2022)	Ghanizadeh_2013	< 2 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.76179517	1800	mg/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15		reverse	-0.730		-1.462	3.0000000000000001E-3															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	6.9	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADOS, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	29	216	Liu (2022)	Hardan_2012	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.76179517	1680	mg/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	15	16		reverse	0.159		-0.601	0.91900000000000004															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	22.42	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	31	217	Liu (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	2.30149597	750	mg/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	G	20	20		reverse	-0.17899999999999999		-0.788	0.430															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17.5	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	40	218	Liu (2022)	Nikoo_2015	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Liu (2022)	Liu	2022	https://doi.org/10.1016/j.pnpbp.2021.110476	0.0	Critically low	Complementary	NAC	NAC	N-Acetyl Cysteine	N-Acetyl Cysteine	1.84119678	1200	mg/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	G	20	20		reverse	-0.610		-1.315	0.096															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37.5	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	0	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	40	219	Liu (2022)	Ghanizadeh_2013	< 2 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	MD	17	14			3.40		-3.14	9.94															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	220	Lee (2020)	Ghanizadeh_2013	< 2 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	14	15			8.20		0.55	15.85															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	29	221	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	MD	20	20			4.10		-1.13	9.33															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	40	222	Lee (2020)	Nikoo_2015	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	MD	13	12			-4.30		-14.37	5.77															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	23	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	25	223	Lee (2020)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Social-communication	Language	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	MD	17	14	outcomes		0.20		-2.46	2.86															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	224	Lee (2020)	Ghanizadeh_2013	< 2 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	Language	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	14	15	outcomes		1.90		-0.54	4.34															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	29	225	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Social-communication	Language	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	MD	20	20	outcomes		0.90		-1.13	2.93															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	40	226	Lee (2020)	Nikoo_2015	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Social-communication	Language	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	MD	13	12	outcomes		-0.80		-3.43	1.83															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	23	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	25	227	Lee (2020)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	MD	17	14			1.9		-2.78	6.58															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	228	Lee (2020)	Ghanizadeh_2013	< 2 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	14	15			8		1.8	14.2															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	29	229	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	MD	20	20			3.9		0.13	7.67															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	40	230	Lee (2020)	Nikoo_2015	2-6 months		6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	MD	13	12			-4.2		-12.72	4.32															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	23	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	25	231	Lee (2020)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7.1	8.35	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	MD	17	14	outcomes		2.1		-3.06	7.26															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	232	Lee (2020)	Ghanizadeh_2013	< 2 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	14	15	outcomes		0.4		-5.95	6.75															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	29	233	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	MD	20	20	outcomes		1.3		-3.48	6.08															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	40	234	Lee (2020)	Nikoo_2015	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	MD	13	12	outcomes		-2.3		-8.94	4.34															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	23	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	25	235	Lee (2020)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	MD	17	14			2		-1.88	5.88															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	37	8.35		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	236	Lee (2020)	Ghanizadeh_2013	< 2 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	14	15	outcomes		2.6		-1.92	7.12															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	29	237	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	MD	20	20			1.4		-1.71	4.51															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	40	238	Lee (2020)	Nikoo_2015	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	MD	13	12			-0.3		-3.83	3.23															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	23	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	25	239	Lee (2020)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	37	41			8.10		-3.67	19.87															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	78	240	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15			11.90		-9.95	33.75															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	241	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	SRS: Social Responsiveness Scale	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	MD	14	15			2.7		-17.02	22.42															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	23	7.63	86.27	1	1	1	1	USA	North America	DSM-IV, ADI-R	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	29	242	Lee (2020)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.37	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		1,4		-0,01	2,81															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	243	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	Social awareness	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		1,10		-1,64	3,84															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	244	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Social-communication	Social cognition	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		1,10		-0,9	3,1															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	245	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	Social cognition	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		0,8		-3,57	5,17															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	246	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Social-communication	Social communication SRS	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		3,4		-0,54	7,34															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	247	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	Social communication SRS	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		1,5		-6,88	9,88															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	248	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		0		-2,26	2,26															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	249	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	Social motivation	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		1,2		-3,23	5,63															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	250	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Social mannerisms	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		0,80		-1,97	3,57															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	251	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Social mannerisms	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		4,6		-0,01	9,21															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	252	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotyped behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		-0.1		-1.62	1.42															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	253	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotyped behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		0.9		-2.38	4.18															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	254	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Self-injurious behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		0.6		-0.65	1.85															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	255	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Self-injurious behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		1.3		-1.43	4.03															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	256	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Compulsive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		-0.6		-1.84	0.64															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	257	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Compulsive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		1.60		-1.43	4.63															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	258	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Ritualistic behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		-0.5		-1.98	0.98															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	259	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Ritualistic behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		0		-3.04	3.04															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	260	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Sameness behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		-0.7		-2.97	1.57															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	261	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Sameness behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		1.2		-3.75	6.15															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	262	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	MD	48	50	outcomes		-0.5		-1.65	0.65															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10	6.37	73	1	1	1	1	Australia		DSM-IV-TR	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	98	263	Lee (2020)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Lee (2020)	Lee	2020	https://doi.org/10.1177/0004867420952540	4.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	MD	16	15	outcomes		0.8		-1.64	3.24															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7	7.1		1	0	1	1	USA	North America	DSM-IV-TR, ADI-R and/or ADOS	1	0	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	0	1	31	264	Lee (2020)	Hardan_2012	2-6 months		6-12 yo	6.37	8.35	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	5.52359033	500	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1177/0004867416652735	Dean	2017/2019	RCT	RR	51	51		reverse	1.21428571428571	0.30172241	0.672193489862596	2.19354965222851															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	102	265	Siafis (child) (2022)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	15	18		reverse	0.4	0.73786479	0.0941864321091796	1.69875847738377															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	33	266	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.9375	0.73314391	0.222801466261083	3.94479562791602															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	31	267	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	5.52359033	500	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	DBC: Developmental Behaviour Checklist-ADHD	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	G	48	15			0.19		-0.20	0.59	0.20	0.5568	0.10	0.4583											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	63	268	Siafis (child) (2022)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	12			0.76		0	1.52	11.00	10.4096	2.80	10.5731											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	26	269	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	13	12			-0.32		-1.11	0.47	3.20	14.8108	7.50	10.6532											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	270	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	5.52359033	500	mg/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	G	48	50			-0.01		-0.40	0.39	10.80	27.9630	11.00	26.3699											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	98	271	Siafis (child) (2022)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15			0.37		-0.36	1.11	18.10	27.5349	6.20	34.0040											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	272	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	13	12			0.10		-0.69	0.88	22.70	30.3985	20.00	23.0215											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	273	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	5.52359033	500	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	DBC: Developmental Behaviour Checklist-Disruptive	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	G	48	50			-0.04		-0.43	0.36	3.50	7.7505	3.80	7.8937											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	98	274	Siafis (child) (2022)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15			0.91		0.14	1.68	9.70	7.0619	1.70	9.7535											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	275	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	13	12			-0.37		-1.16	0.43	2.10	13.0399	6,3	8.4125											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	276	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	G	48	50			0.01		-0.39	0.41	4.20	22.2583	4.00	15.3189											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	98	277	Siafis (child) (2022)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15			0.41		-0.33	1.1399999999999999	3.50	5.6027	0.90	6.7639											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	278	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	13	12			-0.06		-0.85	0.72	0.90	4.4800	1.20	4.5177											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	279	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	5.52359033	500	mg/day	Home	100	0	0			100		Social-communication	social-communication	Report	CCC-2: Children Communication Checklist-SIDC	0	0	100	10.1177/0004867416652735	Dean	2017/2019	RCT	G	48	50			-0.30		-0.70	0.09	3.05	8.4504	5.50	7.5624											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	98	280	Siafis (child) (2022)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15			0.05		-0.68	0.77	4.20	9.4504	3.80	7.7505											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	281	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Social-communication	social-communication	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	13	12			-0.13		-0.92	0.65	4.90	18.7502	7.60	20.8516											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	282	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	15	18		reverse	3.5625	1.59735252	0.155627355963319	81.5499702571015															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	33	283	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	7	7.63	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.46875	1.17082592	0.0472424542732784	4.65104038052238															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	31	284	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7	7.63	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1800	mg/day	Home	100	0	0			100		Adverse events				0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	15	18		reverse	1.11428571428571	0.16164599	0.811714392322618	1.52964227911304															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	33	285	Siafis (child) (2022)	Hardan_2012	2-6 months		6-12 yo	7	7.63	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	NAC	NAC	oral	oral	2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events				0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	1.00189753320683	0.06163327	0.887893692908442	1.13053924705538															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	31	286	Siafis (child) (2022)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7	7.63	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	G	17	14		reverse	-0.87		-1.61	-0.13	9.7	4.1	15.1	7.8											low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	44.6428571428571	8.3		1	0	1	1	Iran		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	287	Iffland (2023)	Ghanizadeh_2013	< 2 months		6-12 yo	7.1	8.3	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	G	14	15		reverse	-0.7		-1.46	0.05	7.2	5.7	13.1	9.9											high	100	0	0	0	0	100	unclear	low	low	low	unclear	unclear	Placebo ()	0	6.06060606060606	7.1		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	288	Iffland (2023)	Hardan_2012	2-6 months		6-12 yo	7.1	8.3	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	G	20	20		reverse	-1.04		-1.7	-0.37	-9.25	4.08	-5.35	3.23											low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	289	Iffland (2023)	Nikoo_2015	2-6 months		6-12 yo	7.1	8.3	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	G	13	12		reverse	0.25		-0.54	1.04	14.9	14	12	7.3											high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	290	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	7.1	8.3	86.27	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Adverse events	Abdominal pain			0	0	0	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	RR	17	14		reverse	2.5	1.59513148	0.109688634408253	56.9794676879462															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	44.6428571428571	8.3		1	0	1	1	Iran		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	291	Iffland (2023)	Ghanizadeh_2013	< 2 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Adverse events	Abdominal pain			0	0	0	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	RR	20	20		reverse	1.33333333333333	0.69522179	0.341322469007393	5.20849911506784															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	292	Iffland (2023)	Nikoo_2015	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Adverse events	Constipation			0	0	0	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	RR	17	14		reverse	4.11764705882353	1.03428618	0.542329373630976	31.2633210101118															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	44.6428571428571	8.3		1	0	1	1	Iran		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	293	Iffland (2023)	Ghanizadeh_2013	< 2 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Constipation			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.313725490196078	1.59541316	0.0137572511702055	7.15431316772999															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	294	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	RR	17	14		reverse	0.277777777777778	1.59513148	0.0121876260453614	6.33105196532735															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	44.6428571428571	8.3		1	0	1	1	Iran		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	295	Iffland (2023)	Ghanizadeh_2013	< 2 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	RR	20	20		reverse	2	0.80622577	0.411878736633813	9.71159626420886															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	296	Iffland (2023)	Nikoo_2015	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.313725490196078	1.59541316	0.0137572511702055	7.15431316772999															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	297	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Adverse events	Dry mouth			0	0	0	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	RR	20	20		reverse	1	0.94868330	0.155768383385261	6.41978801003991															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	298	Iffland (2023)	Nikoo_2015	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Dry mouth			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.313725490196078	1.59541316	0.0137572511702055	7.15431316772999															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	299	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Adverse events	Nausea			0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	14	15		reverse	2.14285714285714	0.60158521	0.659056977071574	6.96728339801068															high	100	0	0	0	0	100	unclear	low	low	low	unclear	unclear	Placebo ()	0	6.06060606060606	7.1		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	300	Iffland (2023)	Hardan_2012	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Adverse events	Nausea			0	0	0	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	RR	20	20		reverse	3	1.11055542	0.340263034122125	26.4501256306607															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	301	Iffland (2023)	Nikoo_2015	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Nausea			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.625	0.83914639	0.120669444581974	3.23714923320658															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	302	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Adverse events	Fever			0	0	0	10.1177/0004867416652735	Dean	2017/2019	RCT	RR	34	37		reverse	2.17647058823529	1.20148292	0.206561170835074	22.932791300043															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	19.3877551020408	6.4	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	71	303	Iffland (2023)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Fever			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	4.70588235294118	1.50952856	0.244190085327216	90.6888938183068															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	304	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Adverse events	Decreased appetite			0	0	0	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	RR	17	14		reverse	1.64705882352941	1.17036229	0.166147924009394	16.3276356556385															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	44.6428571428571	8.3		1	0	1	1	Iran		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	305	Iffland (2023)	Ghanizadeh_2013	< 2 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Adverse events	Decreased appetite			0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	14	15		reverse	0.714285714285714	0.83380939	0.139358071150133	3.66110177488752															high	100	0	0	0	0	100	unclear	low	low	low	unclear	unclear	Placebo ()	0	6.06060606060606	7.1		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	306	Iffland (2023)	Hardan_2012	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Adverse events	Increased appetite			0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	14	15		reverse	5.33333333333333	1.50692844	0.278162711694297	102.258294331359															high	100	0	0	0	0	100	unclear	low	low	low	unclear	unclear	Placebo ()	0	6.06060606060606	7.1		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	307	Iffland (2023)	Hardan_2012	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Increased appetite			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	2.82352941176471	1.59541316	0.123815260531849	64.38881850957															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	308	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.30149597	750	mg/day	Home	100	0	0			100		Adverse events	Headache			0	0	0	10.1097/WNF.0000000000000063	Nikoo	2015	RCT	RR	20	20		reverse	2	0.80622577	0.411878736633813	9.71159626420886															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	17	7.55		1	0	1	1	Iran		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	309	Iffland (2023)	Nikoo_2015	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Adverse events	Headache			0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.9375	0.73314391	0.222801466261083	3.94479562791602															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	310	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Acceptability				0	0	0	10.1177/0004867416652735	Dean	2017/2019	RCT	RR	51	51		reverse	1	0.33857121	0.515000510301101	1.94174564878652															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	19.3877551020408	6.4	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	102	311	Iffland (2023)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			1.84119678	1200	mg/day	Home	100	0	0			100		Acceptability				0	0	0	10.1186/1471-244X-13-196	Ghanizadeh	2013	RCT	RR	20	20		reverse	0.571428571428572	0.54116277	0.197844220024941	1.65044302130097															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Active ()	100	44.6428571428571	8.3		1	0	1	1	Iran		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	312	Iffland (2023)	Ghanizadeh_2013	< 2 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Acceptability				0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	RR	15	18		reverse	0.4	0.73786479	0.0941864321091796	1.69875847738377															high	100	0	0	0	0	100	unclear	low	low	low	unclear	unclear	Placebo ()	0	6.06060606060606	7.1		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	33	313	Iffland (2023)	Hardan_2012	2-6 months		6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Acceptability				0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	RR	16	15		reverse	0.9375	0.73314391	0.222801466261083	3.94479562791602															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	17.0731707317073	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	31	314	Iffland (2023)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.4	8.3	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	800	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	GARS: Gilliam Autism Rating Scale	0	0	100		Chez	2002	RCT	MD	14	17	outcomes	reverse	-10.15		-26.38	6.08															high	100	0	0	100	100	0	high	low	low	unclear	low	low	Placebo ()	0	32.258064516129	7.45		1	0	1	1	USA	North America	DSM-4	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	31	315	Abraham (2021)	Chez_2002	< 2 months		6-12 yo	4.2	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	2	500	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	GARS: Gilliam Autism Rating Scale	0	0	100	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	MD	21	22		reverse	-0.34		-9.14	8.46															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	27.906976744186	8.59		1	0	1	1	Iran	Asia	DSM-5	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	43	316	Abraham (2021)	Mehrazad-Saber_2018	2-6 months		6-12 yo	4.2	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	800	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	GARS: Gilliam Autism Rating Scale	0	0	100		Chez	2002	RCT	MD	14	17	outcomes	reverse	-3.49		-10.25	3.27															high	100	0	0	100	100	0	high	low	low	unclear	low	low	Placebo ()	0	32.258064516129	7.45		1	0	1	1	USA	North America	DSM-4	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	31	317	Abraham (2021)	Chez_2002	< 2 months		6-12 yo	7.45	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	2	500	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	GARS: Gilliam Autism Rating Scale	0	0	100	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	MD	21	22	outcomes	reverse	0.28		-6.13	6.69															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	27.906976744186	8.59		1	0	1	1	Iran	Asia	DSM-5	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	43	318	Abraham (2021)	Mehrazad-Saber_2018	2-6 months		6-12 yo	7.45	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	GARS: Gilliam Autism Rating Scale	0	0	100		Chez	2002	RCT	MD	14	17		reverse	-1.52		-8.77	5.73															high	100	0	0	100	100	0	high	low	low	unclear	low	low	Placebo ()	0	32.258064516129	7.45		1	0	1	1	USA	North America	DSM-4	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	31	319	Abraham (2021)	Chez_2002	< 2 months		6-12 yo	7.45	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	2	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	GARS: Gilliam Autism Rating Scale	0	0	100	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	MD	21	22		reverse	0.11		-5.32	5.54															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	27.906976744186	8.59		1	0	1	1	Iran	Asia	DSM-5	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	43	320	Abraham (2021)	Mehrazad-Saber_2018	2-6 months		6-12 yo	7.45	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	800	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	GARS: Gilliam Autism Rating Scale	0	0	100		Chez	2002	RCT	MD	14	17	outcomes	reverse	-5.15		-12.07	1.77															high	100	0	0	100	100	0	high	low	low	unclear	low	low	Placebo ()	0	32.258064516129	7.45		1	0	1	1	USA	North America	DSM-4	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	31	321	Abraham (2021)	Chez_2002	< 2 months		6-12 yo	7.45	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	2	500	mg/day	Home	100	0	0			100		Social-communication	Social communication	Report	GARS: Gilliam Autism Rating Scale	0	0	100	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	MD	21	22	outcomes	reverse	0		-12.52	12.52															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0	27.906976744186	8.59		1	0	1	1	Iran	Asia	DSM-5	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	43	322	Abraham (2021)	Mehrazad-Saber_2018	2-6 months		6-12 yo	7.45	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	800	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0		Chez	2002	RCT	MD	14	17	outcomes	reverse	-0.87		-7.96	6.22															high	100	0	0	100	100	0	high	low	low	unclear	low	low	Placebo ()	0	32.258064516129	7.45		1	0	1	1	USA	North America	DSM-4	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	31	323	Abraham (2021)	Chez_2002	< 2 months		6-12 yo	4.2	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Abraham (2021)	Abraham	2021	https://doi.org/10.1007/s00726-021-02960-6	3.0	Critically low	Complementary	L-CARNO	L-CARNO	oral	oral	2	225	mg/day	Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	CARS: Childhood Autism Rating Scale	0	100	0		Ann Abraham	2020	RCT	MD	32	31		reverse	-0.9		-12.73	10.93															high	100	0	100	100	100	0	low	low	high	high	low	low	Active ()	100	31.7460317460317	4.2		1	0	1	1	India	Asia	CARS 2-ST	1	0	1	1.0	1.0	0	0.0	0.5	1.0	0	1	1	1	1	1	1	63	324	Abraham (2021)	Ann Abraham_2020	2-6 months		< 6 yo	4.2	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	5.98388953	2200	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.rasd.2012.07.006	Fahmy	2013	RCT	RR	16	14		reverse	0.21875	1.05644282	0.0275868621248963	1.73457794088206															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Placebo ()	0	12.5	5.75		1	0	1	1	Egypt		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	30	325	Siafis (child) (2022)	Fahmy_2013	2-6 months		< 6 yo	5.75	8.92	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	2.99194476			Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.12659/msm.881792	Geier	2011	RCT	RR	19	11		reverse	0.771929824561404	0.66316865	0.21042030183149	2.83183537358763															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	10.5263157894737	6.3		1	0	1	1	USA		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	30	326	Siafis (child) (2022)	Geier_2011	2-6 months		6-12 yo	5.75	8.92	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral				Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1177/0004563218796860	Ghodsi	2018	RCT	RR	22	22		reverse	1	0.63960215	0.285476039927089	3.5029209465544															high	100	0	100	0	0	0	low	unclear	unclear	unclear	high	high	Placebo ()	0	22.7272727272727	8.92		1	0	1	1	Iran		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	44	327	Siafis (child) (2022)	Ghodsi_2018			6-12 yo	5.75	8.92	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	500	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	RR	25	25		reverse	1.33333333333333	0.70945989	0.331929143045669	5.3558954223347															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	24	8.59		1	0	1	1	Iran	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	328	Siafis (child) (2022)	Mehrazad-Saber_2018	< 2 months		6-12 yo	5.75	8.92	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	5.98388953	2200	mg/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1016/j.rasd.2012.07.006	Fahmy	2013	RCT	G	16	14			1.06		0.28999999999999998	1.84	8.19	6.0424	2.00	5.1801											low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Placebo ()	0	12.5	5.75		1	0	1	1	Egypt		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	30	329	Siafis (child) (2022)	Fahmy_2013	2-6 months		< 6 yo	5.75	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	2.99194476			Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.12659/msm.881792	Geier	2011	RCT	G	16	11			0.35		-0.42	1.1200000000000001	1.90	5.5669	-0.20	6.1555											high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	10.5263157894737	6.3		1	0	1	1	USA		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	27	330	Siafis (child) (2022)	Geier_2011	2-6 months		6-12 yo	5.75	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	500	mg/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	GARS: Gilliam Autism Rating Scale	0	0	100	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	G	21	22			0.03		-0.56999999999999995	0.63	-1.54	10.4064	-1.88	11.3953											high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	24	8.59		1	0	1	1	Iran	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	331	Siafis (child) (2022)	Mehrazad-Saber_2018	< 2 months		6-12 yo	5.75	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	2.99194476			Home	100	0	0			100		Social-communication	social-communication	Observation	ATEC: Autism Treatment Evaluation Checklist	0	100	0	10.12659/msm.881792	Geier	2011	RCT	G	15	8			0.35		-0.51	1.22	3.70	6.5826	1.10	8.0728											high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	10.5263157894737	6.3		1	0	1	1	USA		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	23	332	Siafis (child) (2022)	Geier_2011	2-6 months		6-12 yo	6.3	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	500	mg/day	Home	100	0	0			100		Social-communication	social-communication	Report	GARS: Gilliam Autism Rating Scale	0	0	100	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	G	21	22			-0.03		-0.63	0.56000000000000005	-1.19	9.5282	-0.91	6.4023											high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	24	8.59		1	0	1	1	Iran	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	43	333	Siafis (child) (2022)	Mehrazad-Saber_2018	< 2 months		6-12 yo	6.3	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	2.99194476			Home	100	0	0			100		Tolerability				0	0	0	10.12659/msm.881792	Geier	2011	RCT	RR	19	11		reverse	0.192982456140351	1.09077617	0.0227534610109291	1.63677202163108															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	10.5263157894737	6.3		1	0	1	1	USA		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	30	334	Siafis (child) (2022)	Geier_2011	2-6 months		6-12 yo	5.75	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	1.84119678	500	mg/day	Home	100	0	0			100		Tolerability				0	0	0	10.1111/bcpt.12979	Mehrazad-Saber	2018	RCT	RR	25	25		reverse	1	1.98067588	0.0206084646823471	48.5237505759749															high	100	0	100	0	100	100	low	unclear	low	low	high	low	Placebo ()	0	24	8.59		1	0	1	1	Iran	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	335	Siafis (child) (2022)	Mehrazad-Saber_2018	< 2 months		6-12 yo	5.75	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	L-CARNO	L-CARNO	oral	oral	5.98388953	2200	mg/day	Home	100	0	0			100		Tolerability				0	0	0	10.1016/j.rasd.2012.07.006	Fahmy	2013	RCT	RR	16	14		reverse	0.882352941176471	1.96837745	0.0186275788599503	41.7953787046721															low	100	100	100	0	100	100	low	unclear	low	low	unclear	low	Placebo ()	0	12.5	5.75		1	0	1	1	Egypt		(CARS)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	30	336	Siafis (child) (2022)	Fahmy_2013	2-6 months		< 6 yo	5.75	8.59	Inf	-Inf	6	5	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Acceptability | Tolerability	2	Abraham (2021) | Siafis (child) (2022)	https://doi.org/10.1007/s00726-021-02960-6 | https://doi.org/10.1186/s13229-022-00488-4	4.2	8.92	Inf	-Inf
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			1.84119678	42	IU/day	Home	100	0	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	38	39							12.07	14.87	12.4	15.04											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.922	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	77	337	Hu (2023)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	32	IU/day	Home	100	0	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1038/s41380-022-01845-8	Guastella	2022	RCT	SMD	45	42							6.46	14.07	3.08	16.4											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	13.3333333333333	7.279		1	0	1	1				1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	87	338	Hu (2023)	Guastella_2022	2-6 months		6-12 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1159/000524543	Le	2022	RCT	SMD	41	41							11.32	15.14	-1.16	10.54											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.3170731707317	5		1	0	1	1	China		DSM-5	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	82	339	Hu (2023)	Le_2022	< 2 months		< 6 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1056/NEJMoa2103583	Sikich	2021	RCT	SMD	139	138							4.9000000000000004	0.43	5.7	0.51											low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	12.31	10.4		1	0	1	1	USA		DSM-5-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	277	340	Hu (2023)	Sikich_2021	2-6 months		6-12 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			1.15074799	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1038/mp.2015.162	Yatawara	2016	RCT	SMD	31	31							13.5	17.2	5.2	17.3											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	12.9032258064516	6.2		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	62	341	Hu (2023)	Yatawara_2016	< 2 months		6-12 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			1.84119678	42	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	26	24							6.73	6.49	3.44	6.37											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.922	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	50	342	Hu (2023)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	32	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1038/s41380-022-01845-8	Guastella	2022	RCT	SMD	45	42							-0.23400000000000001	5.53	-0.89100000000000001	5.17											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	13.3333333333333	7.279		1	0	1	1				1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	87	343	Hu (2023)	Guastella_2022	2-6 months		6-12 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1159/000524543	Le	2022	RCT	SMD	41	41							2.44	6.03	-0.55000000000000004	5.31											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.3170731707317	5		1	0	1	1	China		DSM-5	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	82	344	Hu (2023)	Le_2022	< 2 months		< 6 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Hu (2023)	Hu	2023	https://doi.org/10.1007/s00228-023-03545-w	3.5	Critically low	Complementary	OXYT	OXYT			1.15074799	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1038/mp.2015.162	Yatawara	2016	RCT	SMD	31	31							5.7	12.3	5.9	13.3											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	12.9032258064516	6.2		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	62	345	Hu (2023)	Yatawara_2016	< 2 months		6-12 yo	5	13.922	84.61538	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Bakermans-Kranenburg (2013)	Bakermans-Kranenburg	2013	https://doi.org/10.1038/tp.2013.34	0.0	Critically low	Complementary	OXYT	OXYT			0.2301496	24	IU/day	Home	100	0	0			100		Social-communication		Test	Cyberball	100	0	0		Andari	2010	RCT	SMD	7	6			0.57																		high	100	0	0	100	100	0	unclear	unclear	low	unclear	low	low	Placebo ()	0	15	26	99	1	1	1	1	France	Europe		1	0	1	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	13	346	Bakermans-Kranenburg (2013)	Andari_2010	< 2 months	Average (80-119)	>= 20 yo	15	33	99	100.5	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Bakermans-Kranenburg (2013)	Bakermans-Kranenburg	2013	https://doi.org/10.1038/tp.2013.34	0.0	Critically low	Complementary	OXYT	OXYT			0.2301496	24	IU/day	Home	100	0	0			100		Social-communication		Test	RMET: Reading the Mind in the Eyes Test	100	0	0	10.1016/j.biopsych.2009.09.020	Guastella	2010	RCT	SMD	8	8			0.61																		high	100	0	0	100	100	0	unclear	low	unclear	unclear	low	low	Placebo ()	0	0	15	100.5	1	1	1	1	Australia	Oceania		1	0	1	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	16	347	Bakermans-Kranenburg (2013)	Guastella_2010	< 2 months	Average (80-119)	13-19 yo	15	33	99	100.5	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Bakermans-Kranenburg (2013)	Bakermans-Kranenburg	2013	https://doi.org/10.1038/tp.2013.34	0.0	Critically low	Complementary	OXYT	OXYT			0.03278689			Home	100	0	0			100		Social-communication		Test	Vocal intonation	100	0	0	10.1016/j.biopsych.2006.05.030	Hollander	2007	RCT	SMD	8	7			0.66																		high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0	7	33		1	0	1	0			DSM IV	1	0	1	0.0	0.0	0	0.0	0.5	0.0	0	1	0	0	1	1	1	15	348	Bakermans-Kranenburg (2013)	Hollander_2007	< 2 months		>= 20 yo	15	33	99	100.5	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.92059839	24	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	SMD	20	20		reverse	0.056		-0.639	0.750															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	0	24.5	100	1	1	1	1	Belgium		DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	40	349	Kiani (2023)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30	outcomes	reverse	-0.295		-0.952	0.362															high	100	0	0	100	0	100	unclear	unclear	unclear	low	low	unclear	Placebo ()	0	26.5625	24.45	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	60	350	Kiani (2023)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30	outcomes	reverse	-0.19500000000000001		-0.859	0.470															high	100	0	0	100	0	100	unclear	unclear	unclear	low	low	unclear	Placebo ()	0	26.5625	24.45	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	60	351	Kiani (2023)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	SMD	16	16		reverse	-0.346		-1.049	0.358															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	15.625	8.74	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	32	352	Kiani (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.42622951	16	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1038/tp.2017.103	Quintana	2017	RCT	SMD	9	8	outcomes	reverse	-0.124		-0.797	0.549															high	100	0	100	0	0	100	low	low	low	low	high	unclear	Placebo ()	0	0	24.76	100	1	1	1	1	Norway	Europe		1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	17	353	Kiani (2023)	Quintana_2017	< 2 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.42622951	16	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1038/tp.2017.103	Quintana	2017	RCT	SMD	9	8	outcomes	reverse	-0.385		-1.063	0.293															high	100	0	100	0	0	100	low	low	low	low	high	unclear	Placebo ()	0	0	24.76	100	1	1	1	1	Norway	Europe		1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	17	354	Kiani (2023)	Quintana_2017	< 2 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	SMD	10	10		reverse	-0.050		-0.974	0.874															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	20	355	Kiani (2023)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Anxiety	Anxiety			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	SMD	53	53		reverse	-0.096		-0.482	0.291															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	106	356	Kiani (2023)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	8.74	32.2	66.2	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors			0	0	0		Anagnostou	2012	RCT	SMD	10	9	outcomes	reverse	-0.007		-0.907	0.894															low	100	100	100	100	0	100	low	low	unclear	low	low	unclear	Placebo ()	0	15.7894736842105	33.373684	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	19	357	Kiani (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	66.2	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors			0	0	0		Anagnostou	2012	RCT	SMD	10	9	outcomes	reverse	-0.532		-1.448	0.385															low	100	100	100	100	0	100	low	low	unclear	low	low	unclear	Placebo ()	0	15.7894736842105	33.373684	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	19	358	Kiani (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	66.2	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.84119678	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	25	25		reverse	-0.117		-0.672	0.439															high	100	0	0	100	0	100	unclear	unclear	low	low	low	unclear	Placebo ()	0	0	13.925	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	50	359	Kiani (2023)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	6.2	33.373684	66.2	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	SMD	16	16		reverse	-0.011		-0.709	0.687															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	15.625	8.74	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	32	360	Kiani (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	6.2	33.373684	66.2	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	SMD	10	10		reverse	0.525		-0.415	1.465															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	20	361	Kiani (2023)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	66.2	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.15074799	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted/repetitive behaviors			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	SMD	20	19		reverse	-0.200		-0.906	0.506															high	100	0	0	100	0	100	unclear	unclear	low	low	low	unclear	Placebo ()	0	30.7692307692308	6.2		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	39	362	Kiani (2023)	Yatawara_2016	< 2 months		6-12 yo	6.2	33.373684	66.2	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.13114754	18	IU/day	Home	100	0	0			100		Overall ASD symptoms	ASD symptom severity reduction			0	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	SMD	19	19		reverse	0.237		-0.401	0.876															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	11.265	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	38	363	Kiani (2023)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	11.265	32.2	89.555	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Overall ASD symptoms	ASD symptom severity reduction			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30	outcomes	reverse	-0.17199999999999999		-0.827	0.482															high	100	0	0	100	0	100	unclear	unclear	unclear	low	low	unclear	Placebo ()	0	26.5625	24.45	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	60	364	Kiani (2023)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	11.265	32.2	89.555	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Overall ASD symptoms	ASD symptom severity reduction			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30	outcomes	reverse	0.074		-0.589	0.737															high	100	0	0	100	0	100	unclear	unclear	unclear	low	low	unclear	Placebo ()	0	26.5625	24.45	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	60	365	Kiani (2023)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	11.265	32.2	89.555	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	ASD symptom severity reduction			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	SMD	10	10		reverse	-0.033		-0.957	0.891															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	20	366	Kiani (2023)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	11.265	32.2	89.555	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	ASD symptom severity reduction			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	SMD	53	53		reverse	-0.235		-0.623	0.153															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	106	367	Kiani (2023)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	11.265	32.2	89.555	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0		Anagnostou	2012	RCT	SMD	10	9	outcomes	reverse	1.123		0.154	2.092															low	100	100	100	100	0	100	low	low	unclear	low	low	unclear	Placebo ()	0	15.7894736842105	33.373684	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	19	368	Kiani (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0		Anagnostou	2012	RCT	SMD	10	9	outcomes	reverse	-0.258		-1.162	0.646															low	100	100	100	100	0	100	low	low	unclear	low	low	unclear	Placebo ()	0	15.7894736842105	33.373684	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	19	369	Kiani (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.92059839	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	SMD	20	20	outcomes	reverse	-0.150		-0.845	0.546															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	0	24.5	100	1	1	1	1	Belgium		DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	40	370	Kiani (2023)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.92059839	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	SMD	20	20	outcomes	reverse	-8.8999999999999996E-2		-0.784	0.606															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	0	24.5	100	1	1	1	1	Belgium		DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	40	371	Kiani (2023)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			0.13114754	18	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	SMD	19	19		reverse	-0.078		-0.714	0.558															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	11.265	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	38	372	Kiani (2023)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.84119678	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	25	25		reverse	0.059		-0.496	0.614															high	100	0	0	100	0	100	unclear	unclear	low	low	low	unclear	Placebo ()	0	0	13.925	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	50	373	Kiani (2023)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30	outcomes	reverse	0.132		-0.522	0.786															high	100	0	0	100	0	100	unclear	unclear	unclear	low	low	unclear	Placebo ()	0	26.5625	24.45	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	60	374	Kiani (2023)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30	outcomes	reverse	0.132		-0.532	0.795															high	100	0	0	100	0	100	unclear	unclear	unclear	low	low	unclear	Placebo ()	0	26.5625	24.45	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	60	375	Kiani (2023)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Kiani (2023)	Kiani	2023	https://doi.org/10.2174/1871527321666220517112612	3.5	Critically low	Complementary	OXYT	OXYT			1.15074799	24	IU/day	Home	100	0	0			100		Social-communication	Social-Communication			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	SMD	20	19		reverse	-0.730		-1.457	-0.003															high	100	0	0	100	0	100	unclear	unclear	low	low	low	unclear	Placebo ()	0	30.7692307692308	6.2		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	1	1	1	1	39	376	Kiani (2023)	Yatawara_2016	< 2 months		6-12 yo	6.2	33.373684	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Nasal discomfort			0	0	0		Anagnostou	2012	RCT	RR	10	9	outcomes	reverse	4.54545454545455	1.48630108	0.246851371058031	83.6987736233244															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.4	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	19	377	Cai (2018)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Adverse events	Nasal discomfort			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24	outcomes	reverse	0.615384615384615	0.86787391	0.112308084723124	3.37195871326347															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	13.9	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	50	378	Cai (2018)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	2.76179517	24	IU/day	Home	100	0	0			100		Adverse events	Nasal discomfort			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20	outcomes	reverse	1	1.19373364	0.0963589556929912	10.3778625744564															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.2	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	60	379	Cai (2018)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Nasal discomfort			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT cross over	RR	29	29	outcomes	reverse	0.8	0.39501200	0.368854562846533	1.73510121458435															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	58	380	Cai (2018)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Nasal discomfort			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT cross over	RR	18	18	outcomes	reverse	1	0.94280904	0.157572160174808	6.34629872999529															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	36	381	Cai (2018)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report + Observation	ABC: Aberrant Behavior Checklist	0	100	100		Anagnostou	2012	RCT	RR	10	9		reverse	4.54545454545455	1.48630108	0.246851371058031	83.6987736233244															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.4	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	19	382	Cai (2018)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24		reverse	0.185185185185185	1.52412695	0.00933828291681962	3.67236173047441															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	13.9	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	50	383	Cai (2018)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	2.76179517	24	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report + Observation	ABC: Aberrant Behavior Checklist	0	100	100	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20		reverse	0.170731707317073	1.61079402	0.00726446821005541	4.01258771331045															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.2	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	60	384	Cai (2018)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.84119678	16	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report + Observation	ABC: Aberrant Behavior Checklist	0	100	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT cross over	RR	29	29		reverse	0.75	0.47191223	0.297419095149441	1.89127063182465															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	58	385	Cai (2018)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Disruptive behaviors	Disruptive behaviors	Report + Observation	ABC: Aberrant Behavior Checklist	0	100	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT cross over	RR	18	18		reverse	1	1.97350876	0.0209000004000004	47.8468890364223															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	36	386	Cai (2018)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	tiredness	Report + Observation		0	100	100		Anagnostou	2012	RCT	RR	10	9	outcomes	reverse	0.9	1.33749351	0.0654283502414324	12.3799545152992															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.4	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	19	387	Cai (2018)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Adverse events	tiredness	Report		0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24	outcomes	reverse	0.184615384615385	1.05823995	0.0232002363705509	1.46907297375424															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	13.9	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	50	388	Cai (2018)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	2.76179517	24	IU/day	Home	100	0	0			100		Adverse events	tiredness	Report + Observation		0	100	100	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20	outcomes	reverse	1	1.19373364	0.0963589556929912	10.3778625744564															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.2	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	60	389	Cai (2018)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	tiredness	Report + Observation		0	100	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT cross over	RR	29	29	outcomes	reverse	7	1.48964681	0.377666424227676	129.744125653226															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	58	390	Cai (2018)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	tiredness	Report + Observation		0	100	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT cross over	RR	18	18	outcomes	reverse	1	1.37436854	0.0676293753614011	14.7864739938252															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	36	391	Cai (2018)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Diarrheoa	Report + Observation		0	100	100		Anagnostou	2012	RCT	RR	10	9	outcomes	reverse	0.909090909090909	1.95168925	0.0198301690992758	41.6762094591477															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.4	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	19	392	Cai (2018)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Adverse events	Diarrheoa	Report		0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24	outcomes	reverse	0.925925925925926	1.98064711	0.0190829876997247	44.9268654254885															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	13.9	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	50	393	Cai (2018)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	2.76179517	24	IU/day	Home	100	0	0			100		Adverse events	Diarrheoa	Report + Observation		0	100	100	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20	outcomes	reverse	0.51219512195122	1.98191592	0.0105299315865382	24.9141070665658															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.2	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	60	394	Cai (2018)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Diarrheoa	Report + Observation		0	100	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT cross over	RR	29	29	outcomes	reverse	1.25	0.61727991	0.372803863233867	4.19121193231792															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	58	395	Cai (2018)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Diarrheoa	Report + Observation		0	100	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT cross over	RR	18	18	outcomes	reverse	0.333333333333333	1.60043854	0.0144738141994636	7.67669873192296															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	36	396	Cai (2018)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Skin irritation	Report + Observation		0	100	100		Anagnostou	2012	RCT	RR	10	9	outcomes	reverse	0.909090909090909	1.95168925	0.0198301690992758	41.6762094591477															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.4	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	19	397	Cai (2018)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	Sorbitol, benzyl alcohol, glycerol, distilled water, oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Adverse events	Skin irritation	Report		0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24	outcomes	reverse	0.923076923076923	1.38559438	0.0610685792680604	13.952690829387															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	13.9	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	50	398	Cai (2018)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	2.76179517	24	IU/day	Home	100	0	0			100		Adverse events	Skin irritation	Report + Observation		0	100	100	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20	outcomes	reverse	0.51219512195122	1.98191592	0.0105299315865382	24.9141070665658															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.2	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	60	399	Cai (2018)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Skin irritation	Report + Observation		0	100	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT cross over	RR	29	29	outcomes	reverse	1.66666666666667	0.68144539	0.438330190472576	6.33718105244583															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	58	400	Cai (2018)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Cai (2018)	Cai	2018	https://doi.org/10.1111/pcn.12627	3.0	Critically low	Complementary	OXYT	OXYT	Syntocinon	Syntocinon	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Skin irritation	Report + Observation		0	100	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT cross over	RR	18	18	outcomes	reverse	1	1.97350876	0.0209000004000004	47.8468890364223															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	1.0	1.0	0	1.0	0.5	1.0	0	1	0	0	1	0	1	36	401	Cai (2018)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	13.9	33.4	32	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Keech (2018)	Keech	2018	https://doi.org/10.1016/j.psyneuen.2017.09.022	2.0	Critically low	Complementary	OXYT	OXYT	Intranasal oxytocin	Intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Emotion recognition	Test	DANVA+RMET: Diagnostic Analysis of Nonverbal Accuracy ; Reading the Mind in the Eyes Test	100	0	0		Anagnostou	2012	RCT	G	10	9			0.79		-0.12	1.71															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.37	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	19	402	Keech (2018)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	13.95	33.37	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Keech (2018)	Keech	2018	https://doi.org/10.1016/j.psyneuen.2017.09.022	2.0	Critically low	Complementary	OXYT	OXYT	Intranasal oxytocin	Intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Social-communication	Emotion recognition	Test	DANVA+RMET: Diagnostic Analysis of Nonverbal Accuracy ; Reading the Mind in the Eyes Test	100	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24			0.05		-0.54	0.64															high	100	0	0	100	0	0	unclear	low	low	unclear	low	unclear	Placebo ()	0	0	13.95	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	50	403	Keech (2018)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	13.95	33.37	84.61538	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0		Anagnostou	2012	RCT	G	10	9			1.187		0.248	2.127															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	15.79	33.2	107	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	19	404	Ooi (2016)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0		Andari	2010	RCT	G	7	6			0.155		-0.590	0.901															high	100	0	0	100	100	0	unclear	unclear	low	unclear	low	low	Placebo ()	0	18.18	28	99	1	1	1	1	France	Europe		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	13	405	Ooi (2016)	Andari_2010	< 2 months	Average (80-119)	>= 20 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.13114754	18	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	G	19	19			-0.230		-0.855	0.395															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	11.5	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	38	406	Ooi (2016)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.03278689	21	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0	10.1073/pnas.1312857110	Gordon	2013	RCT	G	11	10			-0.182		-0.839	0.476															high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0	14.29	13.2	100.5	1	1	1	0				1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	21	407	Ooi (2016)	Gordon_2013	< 2 months	Average (80-119)	13-19 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0	10.1016/j.biopsych.2009.09.020	Guastella	2010	RCT	G	8	8			0.235		-0.443	0.913															high	100	0	0	100	100	0	unclear	low	unclear	unclear	low	low	Placebo ()	0	0	15.5	100.5	1	1	1	1	Australia	Oceania		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	16	408	Ooi (2016)	Guastella_2010	< 2 months	Average (80-119)	13-19 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	G	25	25			0.069		-0.478	0.615															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	15	86.59	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	50	409	Ooi (2016)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social cognition			0	0	0	10.1001/jamapsychiatry.2013.3181	Watanabe	2014	RCT	G	11	10			0.245		-0.191	0.680															high	100	0	0	100	100	0	unclear	low	low	unclear	low	low	Placebo ()	0	0	28.5	106.4	1	1	1	1	Japan	Asia		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	21	410	Ooi (2016)	Watanabe_2014	< 2 months	Average (80-119)	>= 20 yo	11.5	33.2	86.59	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	restricted, repetitive behaviors.			0	0	0		Anagnostou	2012	RCT	G	10	9			0.141		-0.721	1.002															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	15.79	33.2	107	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	19	411	Ooi (2016)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	11.5	37.5	86.59	111.91	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.13114754	18	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	restricted, repetitive behaviors.			0	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	G	19	19			-0.494		-1.127	0.138															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	11.5	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	38	412	Ooi (2016)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	11.5	37.5	86.59	111.91	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	restricted, repetitive behaviors.			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	G	25	25			0.157		-0.389	0.704															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	15	86.59	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	50	413	Ooi (2016)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	11.5	37.5	86.59	111.91	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Ooi (2016)	Ooi	2016	https://doi.org/10.1055/s-0042-109400	3.0	Critically low	Complementary	OXYT	OXYT	Intravenous oxytocin	Intravenous oxytocin	0.03278689			Clinic	0	100	0			100		Restricted/repetitive behaviors	restricted, repetitive behaviors.			0	0	0	10.1038/sj.npp.1300021	Hollander	2003	RCT	G	17	16			0.423		-0.281	1.128															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	6.67	37.5	111.91	1	1	1	1	USA	North America		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	0	1	1	1	1	33	414	Ooi (2016)	Hollander_2003	< 2 months	Average (80-119)	>= 20 yo	11.5	37.5	86.59	111.91	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social Function	Report	PNAS: Positive and Negative Affect Schedule	0	0	100		Andari	2010	RCT	SMD	7	6			-0.21		-0.98	0.56															high	100	0	0	100	100	0	unclear	unclear	low	unclear	low	low	Placebo ()	0	15.38	26	100	1	1	1	1	France	Europe		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	13	415	Wang (2019)	Andari_2010	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	21	IU/day	Home	100	0	0			100		Social-communication	Social Function	Test	RMET: Reading the Mind in the Eyes Test	100	0	0	10.1016/j.biopsych.2009.09.020	Guastella	2010	RCT	SMD	8	8			0.24		-0.48	0.96															high	100	0	0	100	100	0	unclear	low	unclear	unclear	low	low	Placebo ()	0	0	14.88	100	1	1	1	1	Australia	Oceania		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	16	416	Wang (2019)	Guastella_2010	< 2 months	Average (80-119)	13-19 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social Function	Report	SRS: Social Responsiveness Scale	0	0	100		Anagnostou	2012	RCT	SMD	10	9			-1.12		-2.10	-0.15															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.2	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	19	417	Wang (2019)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.03278689	24	IU/day	Home	100	0	0			100		Social-communication	Social Function			0	0	0	10.1016/j.biopsych.2013.02.007	Domes	2013	RCT	SMD	7	7			-0.19		-0.93	0.55															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	24	100	1	1	1	1	Germany	Europe		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	14	418	Wang (2019)	Domes_2013	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social Function	Test	The Sally–Anne Task	100	0	0		Aoki	2014	RCT	SMD	10	10			0.31		-0.31	0.94															low	100	100	100	100	100	0	low	low	low	unclear	low	low	Placebo ()	0	0	30.8	100	1	1	1	1	Japan	Asia		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	20	419	Wang (2019)	Aoki_2014	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.13114754	18	IU/day	Home	100	0	0			100		Social-communication	Social Function	Test	Facial Emotion Task, Social Reciprocity	100	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	SMD	19	19			0.00		-0.64	0.64															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	11.23	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	38	420	Wang (2019)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social Function	Test	Friend or Foe Task	100	0	0	10.1001/jamapsychiatry.2013.3181	Watanabe	2014	RCT	SMD	20	20			0.22		-0.26	0.70															high	100	0	0	100	100	0	unclear	low	low	unclear	low	low	Placebo ()	0	0	28.5	106.4	1	1	1	1	Japan	Asia		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	40	421	Wang (2019)	Watanabe_2014	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.2301496	24	IU/day	Home	100	0	0			100		Social-communication	Social Function			0	0	0		Auyeung	2015	RCT	SMD	16	16			0.19		-0.30	0.69															low	100	100	100	100	100	0	low	low	low	unclear	low	low	Placebo ()	0		34.23	100	1	1	1	1	UK	Europe		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	32	422	Wang (2019)	Auyeung_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Social-communication	Social Function	Report	SRS: Social Responsiveness Scale	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	25	25			-0.06		-0.61	0.5															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	0	13.92	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	50	423	Wang (2019)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	24	IU/day	Home	100	0	0			100		Social-communication	Social Function	Report	SRS: Social Responsiveness Scale	0	0	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	SMD	10	10			-0.36		-1.40	0.69															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	20	424	Wang (2019)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	28	IU/day	Home	100	0	0			100		Social-communication	Social Function		Interaction Rating Scale Advanced	0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30			0.22		-0.44	0.87															low	100	100	100	100	100	0	low	unclear	low	unclear	low	low	Placebo ()	0	21.67	24	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	60	425	Wang (2019)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	16	IU/day	Home	100	0	0			100		Social-communication	Social Function		Interaction Rating Scale Advanced	0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	SMD	15	14			-0.83		-1.61	-0.06															high	100	0	100	0	100	0	low	low	low	unclear	high	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	29	426	Wang (2019)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.15074799	18	IU/day	Home	100	0	0			100		Social-communication	Social Function	Report	SRS: Social Responsiveness Scale	0	0	100	10.1038/mp.2015.162	Yatawara	2016	RCT	SMD	16	15			0.26		-0.24	0.76															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	12.9032258064516	6.2		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	31	427	Wang (2019)	Yatawara_2016	< 2 months		6-12 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.42622951	16	IU/day	Home	100	0	0			100		Social-communication	Social Function	Test	RMET: Reading the Mind in the Eyes Test	100	0	0	10.1038/tp.2017.103	Quintana	2017	RCT	SMD	9	8			1.23		0.49	1.96															high	100	0	0	100	100	0	unclear	low	low	unclear	low	low	Placebo ()	0	0	24.76	100	1	1	1	1	Norway	Europe		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	17	428	Wang (2019)	Quintana_2017	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social Function	Observation		0	100	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	SMD	53	53			-0.20		-0.58	0.19															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.28	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	106	429	Wang (2019)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	34.23	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	Intravenous oxytocin	Intravenous oxytocin	0.03278689			Clinic	0	100	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1038/sj.npp.1300021	Hollander	2003	RCT	SMD	8	7			-0.39		-1.11	0.34															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	6.67	32.9	100	1	1	1	1	USA	North America		1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	15	430	Wang (2019)	Hollander_2003	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	YBOCS: Yale Brown Obsessive Compulsive Scale	0	0	100		Anagnostou	2012	RCT	SMD	10	9			0.48		-0.44	1.39															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.2	100	1	1	1	1	USA	North America	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	19	431	Wang (2019)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.13114754	18	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	SRS: Social Responsiveness Scale	0	0	100	10.1007/s10803-013-1899-3	Dadds	2014	RCT	SMD	19	19			0.08		-0.56	0.71															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	0	11.23	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	38	432	Wang (2019)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	25	25			-0.12		-0.67	0.44															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	0	13.92	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	50	433	Wang (2019)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	SMD	10	10			0.28		-0.76	1.31															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	20	434	Wang (2019)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	28	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	30	30			-0.47		-1.12	0.18															low	100	100	100	100	100	0	low	unclear	low	unclear	low	low	Placebo ()	0	21.67	24	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	60	435	Wang (2019)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	16	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	SMD	15	14			0.26		-0.48	0.99															high	100	0	100	0	100	0	low	low	low	unclear	high	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	29	436	Wang (2019)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.15074799	18	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1038/mp.2015.162	Yatawara	2016	RCT	SMD	16	15			0.60		0.09	1.11															low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	12.9032258064516	6.2		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	31	437	Wang (2019)	Yatawara_2016	< 2 months		6-12 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Wang (2019)	Wang	2019	https://doi.org/10.1016/j.rasd.2019.03.007	2.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	repetitive behaviors	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	SMD	53	53			-0.30		-0.69	0.09															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.28	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	0	1.0	0.5	1.0	0	1	1	1	1	1	1	106	438	Wang (2019)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	16	IU/day	Home	100	0	0			100		Overall ASD symptoms	Global symptom			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	G	20	40	outcomes	reverse	0.04		-0.95	1.04															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.27	100	1	1	1	1	Japan	Asia	DISCO	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	439	Martins (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	32.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	32	IU/day	Home	100	0	0			100		Overall ASD symptoms	Global symptom			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	G	20	40	outcomes	reverse	-0.15		-1.18	0.88															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.27	100	1	1	1	1	Japan	Asia	DISCO	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	440	Martins (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	32.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	16	IU/day	Home	100	0	0			100		Overall ASD symptoms	Global symptom			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14		reverse	-0.15		-0.50	0.21															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	29	441	Martins (2021)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	6.2	32.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	Global symptom			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52		reverse	0.13		-1.02	1.27															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	103	442	Martins (2021)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	32.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	Global symptom			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9		reverse	0.10		-0.29	0.48															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	18	443	Martins (2021)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	32.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.15074799	24	IU/day	Home	100	0	0			100		Overall ASD symptoms	Global symptom			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	G	15	16		reverse	0.02		-0.54	0.58															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.9	6.2		1	0	1	1	Australia	Oceania	DSM + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	31	444	Martins (2021)	Yatawara_2016	< 2 months		6-12 yo	6.2	32.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0		Anagnostou	2012	RCT	G	10	9		reverse	0.12		-0.14	0.37															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.2	100	1	1	1	1	USA	North America	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	19	445	Martins (2021)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24		reverse	-0.03		-0.24	0.18															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo ()	0	0	13.93	84.61538	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	50	446	Martins (2021)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	16	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	G	20	40	outcomes	reverse	-0.12		-0.26	0.02															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.27	100	1	1	1	1	Japan	Asia	DISCO	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	447	Martins (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	32	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	G	20	40	outcomes	reverse	0.09		-0.05	0.22															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.27	100	1	1	1	1	Japan	Asia	DISCO	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	448	Martins (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	16	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14		reverse	0.15		-0.02	0.32															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	29	449	Martins (2021)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52		reverse	0.06		-0.72	0.84															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	103	450	Martins (2021)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9		reverse	0.05		-0.72	0.81															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	18	451	Martins (2021)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.15074799	24	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	G	15	16		reverse	-0.29		-0.51	-0.07															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.9	6.2		1	0	1	1	Australia	Oceania	DSM + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	31	452	Martins (2021)	Yatawara_2016	< 2 months		6-12 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.13114754	18	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	G	19	19		reverse	-0.76		-2.59	1.08															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo ()	0	0	11.23	89.555	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	38	453	Martins (2021)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.92059839	24	IU/day	Home	100	0	0			100		Social-communication	Social functioning			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	22	17		reverse	-0.13		-0.39	0.13															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	24.5	100	1	1	1	1	Belgium		DSM + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	39	454	Martins (2021)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0		Anagnostou	2012	RCT	G	10	9		reverse	-0.40		-1.43	0.64															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	15.79	33.2	100	1	1	1	1	USA	North America	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	19	455	Martins (2021)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	42	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24		reverse	-0.01		-0.41	0.40															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo ()	0	0	13.93	84.61538	1	1	1	1	Australia	Oceania	DSM	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	50	456	Martins (2021)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	16	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	G	20	40	outcomes	reverse	0.04		-0.95	1.04															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.27	100	1	1	1	1	Japan	Asia	DISCO	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	457	Martins (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	2.76179517	32	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	G	20	40	outcomes	reverse	-0.15		-1.18	0.88															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.67	24.27	100	1	1	1	1	Japan	Asia	DISCO	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	458	Martins (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.84119678	16	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14		reverse	-0.15		-0.50	0.21															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.5	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	29	459	Martins (2021)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52		reverse	0.13		-1.02	1.27															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	103	460	Martins (2021)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9		reverse	0.1		-0.29	0.48															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	32.2	105	1	1	1	1	Japan	Asia	ADI-R + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	18	461	Martins (2021)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	1.15074799	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	G	15	16		reverse	0.02		-0.54	0.58															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.9	6.2		1	0	1	1	Australia	Oceania	DSM + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	31	462	Martins (2021)	Yatawara_2016	< 2 months		6-12 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Martins (2021)	Martins	2021	https://doi.org/10.1111/bph.15451	3.0	Critically low	Complementary	OXYT	OXYT	intranasal oxytocin	intranasal oxytocin	0.92059839	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive/stereotypical behaviours			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	22	17		reverse	-0.09		-0.72	0.54															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	24.5	100	1	1	1	1	Belgium		DSM + ADOS	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	39	463	Martins (2021)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	6.2	33.2	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	YBOCS-C	0	0	100		Anagnostou	2012	RCT	G	10	9			0.12		-0.78	1.03	2.60	3.5086	2.20	2.5000											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	19	464	Siafis (adult) (2022)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	22	17			0.51		-0.13	1.15	4.77	6.4700	1.76	4.7500											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	465	Siafis (adult) (2022)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1038/tp.2016.152	Kosaka	2016	RCT	G	40	9			0.57		0.03	1.12	1.60	3.4631	-0,5	3.8936											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	49	466	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14			0.11		-0.61	0.84	-0.07	2.5200	-0,43	3.5200											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	467	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9			0.20		-0.73	1.13	0.22	0.4400	0.11	0.6000											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	18	468	Siafis (adult) (2022)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52			0.47		0.07	0.86	0.50	0.8000	0.10	0.9000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	103	469	Siafis (adult) (2022)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	42	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24			0.16		-0.40	0.71	6.73	20.8183	3.44	19.8430											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	470	Siafis (child) (2022)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	96	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	CYBOCS	0	0	100		NCT01908205		RCT	G	25	29			-0.06		-0.60	0.47	2.77	3.4643	2.99	3.3388											high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	6.66666666666667	12.5	100	1	1	1	1	Canada, USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	471	Siafis (child) (2022)	NCT01908205_NA	2-6 months	Average (80-119)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist	0	0	100		NCT01944046		RCT	G	139	138			-0.09		-0.33	0.14	1.10	4.2546	1.50	4.2351											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	277	472	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1073/pnas.1705521114	Parker	2017	RCT	G	16	18			0.14		-0.54	0.81	0.83	5.7193	0.11	4.7072											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	34	473	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.15074799	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	RBS-R: Repetitive Behavior Scale-Revised	0	0	100	10.1038/mp.2015.162	Yatawara	2016	RCT	G	15	16			-0.01		-0.72	0.69	4.60	16.0150	4.80	13.2917											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	5.7		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	31	474	Siafis (child) (2022)	Yatawara_2016	< 2 months		< 6 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	42	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24		reverse	0.132275132275132	1.48616192	0.00718546512423096	2.4350143401853															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	475	Siafis (child) (2022)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678			Home	100	0	0			100		Acceptability	acceptability			0	0	0		NCT01308749		RCT	RR	12	13		reverse	3.23076923076923	1.58691998	0.144051307111616	72.459389864457															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.6	83.33333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	476	Siafis (child) (2022)	NCT01308749_NA	< 2 months	Average (80-119)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	96	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0		NCT01908205		RCT	RR	30	30		reverse	5	1.06458129	0.620578554228847	40.2849886281776															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	6.66666666666667	12.5	100	1	1	1	1	Canada, USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	477	Siafis (child) (2022)	NCT01908205_NA	2-6 months	Average (80-119)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Acceptability	acceptability			0	0	0		NCT01944046		RCT	RR	146	144		reverse	1.0901225666907	0.29403549	0.612620986922992	1.9398081942591															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	290	478	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	17	18		reverse	7.38888888888889	1.47564466	0.409739777544884	133.244761686251															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	479	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.15074799	24	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	RR	17	22		reverse	0.517647058823529	0.77183024	0.114038279432127	2.34972395973524															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	5.7		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	480	Siafis (child) (2022)	Yatawara_2016	< 2 months		< 6 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.45	1.13529242	0.0486239067808009	4.16461805327327															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	19	481	Siafis (adult) (2022)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	24	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	RR	22	18		reverse	2.47826086956522	1.60329561	0.107008756790698	57.3950872976785															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	482	Siafis (adult) (2022)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20		reverse	0.75	0.87082337	0.13608650829122	4.13340019567752															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	483	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.9375	1.96744335	0.0198280708083396	44.3263622818179															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	484	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	RR	10	10		reverse	1	1.34164079	0.0721096341381319	13.8677724821682															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	20	485	Siafis (adult) (2022)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	RR	53	53		reverse	3	1.13824316	0.322290068676784	27.9251546191014															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	106	486	Siafis (adult) (2022)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist	0	0	100		NCT01944046		RCT	G	139	138			-0.02		-0.26	0.21	4.50	9.6489	4.70	9.6129											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	277	487	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	8.722571	10.4	66.2	66.2	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1073/pnas.1705521114	Parker	2017	RCT	G	16	18			0.03		-0.64	0.7	4.50	12.3483	4.17	10.2512											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	34	488	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.722571	10.4	66.2	66.2	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1038/tp.2016.152	Kosaka	2016	RCT	G	40	20			0.09		-0.45	0.63	3.45	6.4018	2.80	8.2505											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	489	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	22.6	23.3	32	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		ADHD symptoms	ADHD	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14			-0.15		-0.88	0.58	3.13	6.8100	4.07	5.3700											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	490	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	23.3	32	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678			Home	100	0	0			100		Adverse events	any adverse events			0	0	0		NCT01308749		RCT	RR	12	13		reverse	1.28205128205128	0.16397087	0.929679250307157	1.76798125726296															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.6	83.33333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	491	Siafis (child) (2022)	NCT01308749_NA	< 2 months	Average (80-119)	6-12 yo	8.722571	12.5	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0		NCT01908205		RCT	RR	30	30		reverse	1.12	0.09511897	0.929506874201957	1.34953278433469															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	6.66666666666667	12.5	100	1	1	1	1	Canada, USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	492	Siafis (child) (2022)	NCT01908205_NA	2-6 months	Average (80-119)	6-12 yo	8.722571	12.5	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Adverse events	any adverse events			0	0	0		NCT01944046		RCT	RR	146	144		reverse	0.986301369863014	0.05359951	0.887944155873013	1.09555357255235															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	290	493	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	8.722571	12.5	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	17	18		reverse	0.970588235294118	0.24466986	0.600857743352796	1.56782788091361															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	494	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.722571	12.5	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	1.62	0.31622777	0.871648630405885	3.01084623832649															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	19	495	Siafis (adult) (2022)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	23.3	33.8	100	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20		reverse	0.875	0.56378821	0.289808194200717	2.64183351375406															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	496	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	23.3	33.8	100	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	42	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24			-0.01		-0.57	0.54	12.07	25.4698	12.40	25.9706											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	497	Siafis (child) (2022)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	5.7	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678			Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0		NCT01308749		RCT	G	11	13			0.04		-0.76	0.84	0.36	1.29	0.31	1.05											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.6	83.33333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	24	498	Siafis (child) (2022)	NCT01308749_NA	< 2 months	Average (80-119)	6-12 yo	5.7	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100		NCT01944046		RCT	G	139	138			-0.09		-0.33	0.15	4.90	8.7601	5.70	8.8996											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	277	499	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	5.7	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1073/pnas.1705521114	Parker	2017	RCT	G	14	18			0.67		-0.05	1.39	9.73	9.88	3.18	9.25											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	32	500	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5.7	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.15074799	24	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1038/mp.2015.162	Yatawara	2016	RCT	G	15	16			-0.05		-0.76	0.65	0.60	6.9195	1.00	7.3546											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	5.7		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	31	501	Siafis (child) (2022)	Yatawara_2016	< 2 months		< 6 yo	5.7	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100		Anagnostou	2012	RCT	G	10	9			0.29		-0.62	1.20	19.10	25.9347	12.00	20.2235											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	19	502	Siafis (adult) (2022)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	24	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	17	15			-0.06		-0.75	0.64	0	15.8600	0.87	12.8300											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	32	503	Siafis (adult) (2022)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14			-0.05		-0.77	0.68	1.53	2.3700	1.64	2.2900											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	504	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	CARS: Childhood Autism Rating Scale	0	100	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9			-0.18		-1.11	0.75	-0.50	3.0199	0.10	3.3181											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	18	505	Siafis (adult) (2022)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52			0.02		-0.36	0.41	0.57	1.0300	0.54	1.3900											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	103	506	Siafis (adult) (2022)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	42	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	DBC-Disruptive/antisocial	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24			-0.04		-0.60	0.51	3.50	10.2650	3.91	9.1501											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	507	Siafis (child) (2022)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	8.722571	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100		NCT01944046		RCT	G	139	138			-0.06		-0.30	0.17	2.20	7.3595	2.70	8.2243											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	277	508	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	8.722571	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1073/pnas.1705521114	Parker	2017	RCT	G	16	18			0.22		-0.45	0.90	4.34	10.7184	2.16	8.4260											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	34	509	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.722571	13.85	66.2	84.61538	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	24	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	POMS-Anger	0	0	100	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	22	18			-0.17		-0.79	0.45	0	4.0500	0.61	2.7300											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	510	Siafis (adult) (2022)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	25	32	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1038/tp.2016.152	Kosaka	2016	RCT	G	40	20			-0.01		-0.55	0.52	3.20	6.3955	3.30	11.2343											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	511	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	22.6	25	32	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14			-0.29		-1.02	0.45	3.07	6.3700	5.00	6.8000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	512	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	25	32	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Quality of life	quality of life	Report	WHOQOL	0	0	100		Anagnostou	2012	RCT	G	10	9			0.90		-0.06	1.86	11.70	16.1521	-2.00	12.3000											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	19	513	Siafis (adult) (2022)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	25	35.1	100	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	24	IU/day	Home	100	0	0			100		Quality of life	quality of life	Report	WHO-QOL	0	0	100	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	22	17			0.41		-0.23	1.05	1.77	8.0400	-1.35	6.7400											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	514	Siafis (adult) (2022)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	25	35.1	100	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Quality of life	quality of life	Report	WHOQOL	0	0	100	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9			0.06		-0.86	0.99	0.03	0.6139	-0.02	0.8982											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	18	515	Siafis (adult) (2022)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	25	35.1	100	105	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	42	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	SRS: Social Responsiveness Scale	0	0	100	10.1111/jcpp.12305	Guastella	2015	RCT	G	26	24			0		-0.56	0.55	9.29	19.3026	9.35	20.3423											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	516	Siafis (child) (2022)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	8.722571	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678			Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100		NCT01308749		RCT	G	11	11			0.29		-0.55	1.13	3.70	3.3200	2.20	6.3000											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.6	83.33333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	22	517	Siafis (child) (2022)	NCT01308749_NA	< 2 months	Average (80-119)	6-12 yo	8.722571	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	96	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100		NCT01908205		RCT	G	25	29			-0.08		-0.62	0.45	2.43	6.3836	3.06	8.0446											high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	6.66666666666667	12.5	100	1	1	1	1	Canada, USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	518	Siafis (child) (2022)	NCT01908205_NA	2-6 months	Average (80-119)	6-12 yo	8.722571	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Social-communication	social-communication	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100		NCT01944046		RCT	G	102	102			-0.02		-0.30	0.25	4.50	16.9908	4.90	14.9368											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	204	519	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	8.722571	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	VABS: Vineland Adaptative Behavior Scale	0	0	100	10.1073/pnas.1705521114	Parker	2017	RCT	G	9	12			0.11		-0.76	0.97	4.71	14.6904	3.17	13.4288											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	21	520	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.722571	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1038/tp.2016.152	Kosaka	2016	RCT	G	40	20			0.37		-0.17	0.91	7.85	10.7371	3.90	9.8747											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	521	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14			-0.83		-1.59	-0.06	1.20	4.3100	5.43	5.6000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	522	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	social-communication	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9			0.73		-0.23	1.69	0.44	1.2000	-0,78	1.9000											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	18	523	Siafis (adult) (2022)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Social-communication	social-communication	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52			-0.11		-0.5	0.27	0.80	1.7000	1.00	1.8000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	103	524	Siafis (adult) (2022)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	42	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24		reverse	0.308641975308642	1.60923262	0.0131726665735847	7.23163137776871															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	50	525	Siafis (child) (2022)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678			Home	100	0	0			100		Tolerability	tolerability			0	0	0		NCT01308749		RCT	RR	12	13		reverse	3.23076923076923	1.58691998	0.144051307111616	72.459389864457															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.6	83.33333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	526	Siafis (child) (2022)	NCT01308749_NA	< 2 months	Average (80-119)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	96	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0		NCT01908205		RCT	RR	30	30		reverse	1	1.98380540	0.0204824442200506	48.8222982206921															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	6.66666666666667	12.5	100	1	1	1	1	Canada, USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	527	Siafis (child) (2022)	NCT01908205_NA	2-6 months	Average (80-119)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	5.52359033			Home	100	0	0			100		Tolerability	tolerability			0	0	0		NCT01944046		RCT	RR	146	144		reverse	1.64383561643836	0.72079094	0.400239574924622	6.75144514227556															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.6438356164384	10.4		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	290	528	Siafis (child) (2022)	NCT01944046_NA	2-6 months		6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	48	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	17	18		reverse	1.05555555555556	1.97276782	0.0220931725463249	50.4317579798896															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	8.722571	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	529	Siafis (child) (2022)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.15074799	24	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1038/mp.2015.162	Yatawara	2016	RCT	RR	17	22		reverse	1.29411764705882	1.37685218	0.0870953681365746	19.2288122808425															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	5.88235294117647	5.7		1	0	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	530	Siafis (child) (2022)	Yatawara_2016	< 2 months		< 6 yo	5.7	13.85	66.2	100	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.45	1.13529242	0.0486239067808009	4.16461805327327															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	19	531	Siafis (adult) (2022)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	0.92059839	24	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	RR	22	18		reverse	0.826086956521739	1.97582645	0.017186966942387	39.7056480077557															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	532	Siafis (adult) (2022)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	2.76179517	24	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	RR	40	20		reverse	0.5	1.38744369	0.0329591340006724	7.58515075046873															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	60	533	Siafis (adult) (2022)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.84119678	16	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.9375	1.96744335	0.0198280708083396	44.3263622818179															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	22.6	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	29	534	Siafis (adult) (2022)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	RR	10	10		reverse	1	1.95401684	0.0217139007669791	46.0534480069435															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	20	535	Siafis (adult) (2022)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	OXYT	OXYT	intranasal	intranasal	1.38089758	48	IU/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	RR	53	53		reverse	3	1.62161328	0.124968779504872	72.0179874978221															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	106	536	Siafis (adult) (2022)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	22.6	35.1	32	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Linden (2023)	Linden	2023	https://doi.org/10.1177/13623613221117931	5.0	High	Complementary	OXYT	OXYT			0.92059839	24	IU/day	Home	100	0	0			100		Anxiety				0	0	0	10.1186/s13229-020-0313-1	Bernaerts	2020	RCT	G	22	18		reverse	0.05	0.32000000			0.17	0.94	0.11	1.21											high	100	0	100	100	0	0	low	low	low	unclear	low	unclear	Placebo ()	0	0	25	100	1	1	1	1	Belgium		DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	40	537	Linden (2023)	Bernaerts_2020	< 2 months	Average (80-119)	>= 20 yo	25	27.6	100	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Linden (2023)	Linden	2023	https://doi.org/10.1177/13623613221117931	5.0	High	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Anxiety				0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	G	51	52		reverse	0.23	0.20000000			3.9	0.8	3.7	0.9											high	100	0	100	100	0	0	low	low	high	high	low	unclear	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	103	538	Linden (2023)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	25	27.6	100	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	G	15	14		reverse	-0.51		-1.25	0.24	11.9	9.4	17.4	11.7											low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	539	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	8.704118	30	32	66.2	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	G	16	18		reverse	-0.34		-1.02	0.34	8.86	8.87	11.78	8.11											high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	15.625	8.704118	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	34	540	Iffland (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.704118	30	32	66.2	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Disruptive behaviors	irritability			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	G	146	144		reverse	-0.20		-0.43	0.03	8.7	6.04	9.9	6											high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	541	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	8.704118	30	32	66.2	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Cardiac			0	0	0		NCT01908205		RCT	RR	30	30		reverse	3	1.61311827	0.127066918497065	70.8288208012842															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	542	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Cardiac			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.328798185941043	1.62879323	0.0135051091880905	8.0049887470333															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	543	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Cardiac			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	RR	53	53		reverse	3	1.62161328	0.124968779504872	72.0179874978221															high	100	0	100	0	100	0	low	low	unclear	unclear	unclear	low	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	106	544	Iffland (2023)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Constipation			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.952380952380952	0.48550416	0.367746725120122	2.4664515453177															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	545	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Constipation			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.767123287671233	0.49007601	0.293570026375119	2.00455797805316															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	546	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.380952380952381	0.77613205	0.0832196523525897	1.74387554442568															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	547	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	1.86666666666667	1.16700675	0.189543468257042	18.3833527817437															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	548	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.142857142857143	1.49036846	0.007696584184089	2.65158709073767															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	549	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Diarrhoea			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.854794520547945	0.36027210	0.421888380519296	1.7319122926766															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	550	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Dry mouth			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.333333333333333	1.61311827	0.0141185464996739	7.86986897792047															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	551	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Dry mouth			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.493150684931507	1.21910059	0.0452146673380992	5.37873244161832															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	552	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Gastrointestinal disorders			0	0	0		NCT01908205		RCT	RR	30	30		reverse	1	1.39044357	0.065531828165233	15.2597604553101															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	553	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Gastrointestinal disorders			0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	RR	53	53		reverse	1.33333333333333	0.73864571	0.313474608548674	5.67120184313663															high	100	0	100	0	100	0	low	low	unclear	unclear	unclear	low	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	106	554	Iffland (2023)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Salivary hypersecretion			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.3125	1.59295323	0.0137697410197554	7.09209053822384															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	555	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Salivary hypersecretion			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.328798185941043	1.62879323	0.0135051091880905	8.0049887470333															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	556	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Stomatitis			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.3125	1.59295323	0.0137697410197554	7.09209053822384															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	557	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Stomatitis			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	146		reverse	0.0666666666666667	1.45592853	0.00384255530966182	1.15663772835467															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	292	558	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Vomiting			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.311111111111111	1.09326945	0.0365025224713892	2.65160095532177															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	559	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Vomiting			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.111111111111111	1.46891324	0.00624332981223179	1.97741900294268															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	560	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Vomiting			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.493150684931507	0.48601054	0.190233379367956	1.27841706253882															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	561	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Decreased appetite			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.933333333333333	1.36451631	0.0643514574379198	13.5367736146687															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	562	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Decreased appetite			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.666666666666667	0.87559504	0.11983975024795	3.70865629747129															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	563	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Decreased appetite			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	17	144		reverse	5.86425339366516	0.34966586	2.95513011397354	11.6372093744706															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	161	564	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Increased appetite			0	0	0		NCT01908205		RCT	RR	30	30		reverse	4	1.08781126	0.474365799122664	33.7292444556329															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	565	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Increased appetite			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.62035225048924	0.31798282	0.868844329266651	3.0218778292328															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	566	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Thirst			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.3125	1.59295323	0.0137697410197554	7.09209053822384															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	567	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Thirst			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.97260273972603	0.60100436	0.607384623898471	6.40642093275161															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	568	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Aggression			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.761904761904762	0.35690468	0.378532237094854	1.53355199194749															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	569	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	64	IU/day	Home	100	0	0			100		Adverse events	Aggression			0	0	0	https://scholars.duke.edu/publication/953784	Sikich	2013	RCT	RR	12	13		reverse	0.270833333333333	1.04390785	0.0350046827473183	2.09545377039773															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	47.9166666666667	10.3	100	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	570	Iffland (2023)	Sikich_2013	< 2 months	Average (80-119)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Aggression			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.13424657534247	0.28228443	0.652268688723862	1.97237015346103															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	571	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Agitation			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.933333333333333	0.72702918	0.224485563274034	3.88047720488702															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	572	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	64	IU/day	Home	100	0	0			100		Adverse events	Agitation			0	0	0	https://scholars.duke.edu/publication/953784	Sikich	2013	RCT	RR	12	13		reverse	1.08333333333333	0.91637525	0.179780292841183	6.52802981107543															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	47.9166666666667	10.3	100	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	573	Iffland (2023)	Sikich_2013	< 2 months	Average (80-119)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Agitation			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.17123287671233	0.31833602	0.627588744404333	2.18580473872878															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	574	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Decreased attention			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.3125	1.59295323	0.0137697410197554	7.09209053822384															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	575	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Decreased attention			0	0	0		NCT01908205		RCT	RR	30	30		reverse	3	1.61311827	0.127066918497065	70.8288208012842															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	576	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Dizziness			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.111111111111111	1.46891324	0.00624332981223179	1.97741900294268															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	577	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Dizziness			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.493150684931507	1.21910059	0.0452146673380992	5.37873244161832															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	578	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Fatigue			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.9	1.33749351	0.0654283502414324	12.3799545152992															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	579	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Fatigue			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	1.05820105820106	0.33688583	0.546777269395801	2.04798103771802															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	580	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Fatigue			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.4	0.79582243	0.0840726456735151	1.90311603397541															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	581	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Headache			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	2.72727272727273	1.57345403	0.124853888694865	59.5737674387033															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	582	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Headache			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	15		reverse	0.242424242424242	1.59959749	0.0105437766453053	5.57385795355739															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	36	583	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Headache			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	2.8125	1.59295323	0.123927669177799	63.8288148440145															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	584	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Headache			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.4	0.79582243	0.0840726456735151	1.90311603397541															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	585	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Adverse events	Headache			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	14	18		reverse	3.8	1.59604775	0.166427576303432	86.7644672879985															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	15.625	8.704118	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	32	586	Iffland (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Headache			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.493150684931507	0.35009981	0.248298526466301	0.979456469232896															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	587	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Insomnia			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.106060606060606	1.45916025	0.00607455753232759	1.851797780839															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	588	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Insomnia			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	4.6875	1.50692844	0.244478945825065	89.8754540021713															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	589	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Insomnia			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.333333333333333	1.61311827	0.0141185464996739	7.86986897792047															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	590	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Adverse events	Insomnia			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	14	18		reverse	1.28571428571429	1.36858170	0.0879438781643964	18.7967742495921															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	15.625	8.704118	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	32	591	Iffland (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	64	IU/day	Home	100	0	0			100		Adverse events	Insomnia			0	0	0	https://scholars.duke.edu/publication/953784	Sikich	2013	RCT	RR	12	13		reverse	0.866666666666667	0.53827836	0.301764901311477	2.4890605496092															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	47.9166666666667	10.3	100	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	592	Iffland (2023)	Sikich_2013	< 2 months	Average (80-119)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Insomnia			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.704500978473581	0.20820446	0.468443958260021	1.05951121776394															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	593	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Irritability			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	4.54545454545455	1.48630108	0.246851371058031	83.6987736233244															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	594	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Irritability			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.846560846560847	0.14295631	0.639695863944616	1.12032187063174															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	595	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Irritability			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.111111111111111	1.46891324	0.00624332981223179	1.97741900294268															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	596	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	64	IU/day	Home	100	0	0			100		Adverse events	Irritability			0	0	0	https://scholars.duke.edu/publication/953784	Sikich	2013	RCT	RR	12	13		reverse	0.361111111111111	1.08308676	0.0432230821781333	3.01693511884425															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	47.9166666666667	10.3	100	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	597	Iffland (2023)	Sikich_2013	< 2 months	Average (80-119)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Irritability			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.939334637964775	0.28952597	0.532568387292466	1.65678170754034															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	598	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Restlessness			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.3125	1.59295323	0.0137697410197554	7.09209053822384															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	599	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Restlessness			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	3.61643835616438	0.64066268	1.03026277423949	12.6944569006594															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	600	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Sedation			0	0	0		NCT01908205		RCT	RR	30	30		reverse	3	1.61311827	0.127066918497065	70.8288208012842															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	601	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Sedation			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.64383561643836	0.34574495	0.83475637952093	3.23710677769491															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	602	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Somnolence			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	4.6875	1.50692844	0.244478945825065	89.8754540021713															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	603	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Somnolence			0	0	0		NCT01908205		RCT	RR	30	30		reverse	3	1.61311827	0.127066918497065	70.8288208012842															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	604	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Tics			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.303030303030303	1.57345403	0.0138726542994294	6.61930749318925															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	605	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Tics			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.73972602739726	0.75467846	0.168533962661082	3.24679125185782															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	606	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Mood related symptoms				0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.303030303030303	1.57345403	0.0138726542994294	6.61930749318925															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	607	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	10.5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Mood related symptoms				0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	29	29		reverse	5	1.52752523	0.250459880973004	99.8163853742893															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	58	608	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	10.5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Mood related symptoms				0	0	0		NCT01908205		RCT	RR	30	30		reverse	3	1.61311827	0.127066918497065	70.8288208012842															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	609	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	10.5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Mood related symptoms				0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	0.591780821917808	0.72079094	0.144086246972864	2.4305202512192															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	610	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	10.5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Cold symptoms			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.680272108843537	0.49521520	0.25772391621136	1.79560418324124															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	611	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Adverse events	Cold symptoms			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	14	18		reverse	0.422222222222222	1.59604775	0.0184919529226036	9.64049636533317															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	15.625	8.704118	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	32	612	Iffland (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Cough			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.303030303030303	1.57345403	0.0138726542994294	6.61930749318925															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	613	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Cough			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	1.86666666666667	0.78224342	0.402921061470052	8.64795806834098															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	614	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Cough			0	0	0		NCT01908205		RCT	RR	30	14		reverse	0.933333333333333	1.18120197	0.0921713262195369	9.45099899112082															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	44	615	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Adverse events	Cough			0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	14	18		reverse	3.8	1.59604775	0.166427576303432	86.7644672879985															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	15.625	8.704118	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	32	616	Iffland (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Cough			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.42465753424658	0.28323724	0.817746140030144	2.48200387691309															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	617	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Epistaxis			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	15	14		reverse	0.3125	1.59295323	0.0137697410197554	7.09209053822384															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	29	618	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Epistaxis			0	0	0		NCT01908205		RCT	RR	30	30		reverse	1.75	0.57113087	0.571334653852632	5.36025598893556															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	619	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Epistaxis			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.08493150684932	0.42085072	0.475525199273861	2.47531860846019															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	620	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Adverse events	Nasal congestion			0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	4.54545454545455	1.48630108	0.246851371058031	83.6987736233244															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	621	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Nasal congestion			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.793650793650794	0.15685399	0.583599747586101	1.07930406904367															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	622	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	16	IU/day	Home	100	0	0			100		Adverse events	Nasal congestion			0	0	0	10.3389/fpsyt.2016.00002	Munesue	2016	RCT	RR	29	29		reverse	0.5	0.65653216	0.138079375102377	1.8105528056934															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	30	32	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	58	623	Iffland (2023)	Munesue_2016	< 2 months	Low (< 70)	>= 20 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Nasal congestion			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.714285714285714	0.52553827	0.254995769583336	2.00083351369448															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	624	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Nasal congestion			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	2.95918367346939	1.62879323	0.121545982692815	72.0448987232997															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	625	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	24	IU/day	Home	100	0	0			100		Adverse events	Skin rash			0	0	0	10.1159/000524543	Le	2022	RCT	RR	21	20		reverse	0.952380952380952	0.63433505	0.2747032070433	3.30185252738996															low	100	100	100	100	0	100	low	unclear	low	low	low	unclear	Placebo ()	0	7.31707317073171	5		1	0	1	1	China		DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	41	626	Iffland (2023)	Le_2022	< 2 months		< 6 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Adverse events	Skin rash			0	0	0		NCT01908205		RCT	RR	30	30		reverse	0.5	1.19721900	0.047851476646507	5.22449916952039															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	627	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	64	IU/day	Home	100	0	0			100		Adverse events	Skin rash			0	0	0	https://scholars.duke.edu/publication/953784	Sikich	2013	RCT	RR	12	13		reverse	7.53846153846154	1.46197217	0.429387851343397	132.347485354019															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	47.9166666666667	10.3	100	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	628	Iffland (2023)	Sikich_2013	< 2 months	Average (80-119)	6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Adverse events	Skin rash			0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.12720156555773	0.34660469	0.571440655518425	2.22347387629096															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	629	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	5	33.2	32	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Quality of life				0	0	0		Anagnostou	2012	RCT	G	10	9		reverse	-0.25		-1.15	0.66	59.5	16	63.2	12.3											low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	630	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	32	33.2	105	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	Takamitsu = wanatabe	Takamitsu = wanatabe	1.38089758	48	IU/day	Home	100	0	0			100		Quality of life				0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	G	9	9		reverse	0.75		-0.22	1.71	3.28	0.57	2.66	0.96											low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	32	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	18	631	Iffland (2023)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	32	33.2	105	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	NCT00490802 = Anagnostou	NCT00490802 = Anagnostou	1.38089758	48	IU/day	Home	100	0	0			100		Acceptability				0	0	0		Anagnostou	2012	RCT	RR	10	9		reverse	0.181818181818182	1.48630108	0.00987405484232123	3.34795094493298															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	15.7894736842105	33.2	109	1	1	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	19	632	Iffland (2023)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	42	IU/day	Home	100	0	0			100		Acceptability				0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	RR	26	24		reverse	0.185185185185185	1.52412695	0.00933828291681962	3.67236173047441															low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Placebo ()	0	0	13.9	86.5	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	50	633	Iffland (2023)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			2.76179517	96	IU/day	Home	100	0	0			100		Acceptability				0	0	0		NCT01908205		RCT	RR	30	30		reverse	5	1.06458129	0.620578554228847	40.2849886281776															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	12.962962962963	13.5	100	1	1	1	1	Canada		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	634	Iffland (2023)	NCT01908205_NA	2-6 months	Average (80-119)	13-19 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.84119678	12	IU/day	Home	100	0	0			100		Acceptability				0	0	0		NCT02940574		RCT	RR	21	18		reverse	0.857142857142857	1.37725284	0.0576412597825792	12.7459719014168															high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Placebo ()	0	0	29		1	0	1	1	Belgium			1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	39	635	Iffland (2023)	NCT02940574_NA	< 2 months		>= 20 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			0.92059839	48	IU/day	Home	100	0	0			100		Acceptability				0	0	0	10.1073/pnas.1705521114	Parker	2017	RCT	RR	14	18		reverse	8.86666666666667	1.47187501	0.495333959163345	158.7167128831															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	15.625	8.704118	66.2	1	1	1	1	USA		DSM-IV-TR, DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	32	636	Iffland (2023)	Parker_2017	< 2 months	Low (< 70)	6-12 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	64	IU/day	Home	100	0	0			100		Acceptability				0	0	0	https://scholars.duke.edu/publication/953784	Sikich	2013	RCT	RR	12	13		reverse	3.23076923076923	1.58691998	0.144051307111616	72.459389864457															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	47.9166666666667	10.3	100	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	25	637	Iffland (2023)	Sikich_2013	< 2 months	Average (80-119)	6-12 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			5.52359033	48	IU/day	Home	100	0	0			100		Acceptability				0	0	0	10.1056/NEJMoa2103583	Sikich	2021	RCT	RR	146	144		reverse	1.0901225666907	0.29403549	0.612620986922992	1.9398081942591															high	100	0	100	0	0	100	low	unclear	low	low	high	high	Placebo ()	0	12.6353790613718	10.5		1	0	1	1	USA		DSM-5-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	638	Iffland (2023)	Sikich_2021	2-6 months		6-12 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT	Takamitsu = wanatabe	Takamitsu = wanatabe	1.38089758	48	IU/day	Home	100	0	0			100		Acceptability				0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	RR	10	10		reverse	1	1.34164079	0.0721096341381319	13.8677724821682															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Placebo ()	0	0	32	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	20	639	Iffland (2023)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Acceptability				0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	RR	53	53		reverse	3	1.13824316	0.322290068676784	27.9251546191014															high	100	0	100	0	100	0	low	low	unclear	unclear	unclear	low	Placebo ()	0	0	26.95	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	106	640	Iffland (2023)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	8.704118	33.2	66.2	109	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	SECRET	SECRET			0.03278689			Clinic	0	100	0			100		Disruptive behaviors	irritability			0	0	0		Carey	2002	RCT	G	4	4		reverse	0.92		-0.60	2.44	23	12.7	12.5	6											high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	high	unclear	Placebo ()	0	0	5	45.83333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	8	641	Iffland (2023)	Carey_2002	< 2 months	Low (< 70)	< 6 yo	5	7.5	45.83333	92.5	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	SECRET	SECRET			0.03278689			Clinic	0	100	0			100		Disruptive behaviors	irritability			0	0	0	10.1521/scpq.20.2.155.66514	Handen	2005	RCT	G	4	4		reverse	-0.05		-1.44	1.33	9.6	7.6	10	5.7											high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	12.5	7.5	92.5	1	1	1	1	USA			1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	8	642	Iffland (2023)	Handen_2005	< 2 months	Average (80-119)	6-12 yo	5	7.5	45.83333	92.5	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Iffland (2023)	Iffland	2023	https://doi.org/10.1002/14651858.CD011769.pub2	5.0	High	Complementary	SECRET	SECRET			0.03278689			Clinic	0	100	0			100		Disruptive behaviors	irritability			0	0	0	10.1097/00004583-200111000-00009	Owley	2001	RCT	G	26	27		reverse	-0.09		-0.62	0.45	10.1	10.2	10.9	8.1											high	100	0	0	100	100	0	unclear	unclear	low	unclear	low	low	Placebo ()	0	14.2857142857143	6.708333	56.4	1	1	1	1	USA		ADI-R+ADOS	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	53	643	Iffland (2023)	Owley_2001	< 2 months	Low (< 70)	6-12 yo	5	7.5	45.83333	92.5	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Lee (2022)	Lee	2022	https://doi.org/10.1016/j.explore.2022.02.001	4.5	Low	Complementary	HERB	HERB	"SupplementedLiz-
hong decoction(150
cc tid,p.o.)"	"SupplementedLiz-
hong decoction(150
cc tid,p.o.)"	5.52359033			Home	100	0	0			100		Overall ASD symptoms	Clinical efficacy rate			0	0	0		Zhou	2015	NRCT	RR	30	30			1.07407407407407	0.06966440	0.936991792482862	1.23121154940018															high	0	0	0	100	0	0	unclear	unclear	low	unclear	low	unclear	Active ()	100	8.33	4.87		1	0	1	1			DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	644	Lee (2022)	Zhou_2015	2-6 months		< 6 yo	4.81	6.44	Inf	-Inf	6	1	Overall ASD symptoms	1	Lee (2022)	https://doi.org/10.1016/j.explore.2022.02.001	4.81	6.44	Inf	-Inf
Lee (2022)	Lee	2022	https://doi.org/10.1016/j.explore.2022.02.001	4.5	Low	Complementary	HERB	HERB	"Modified Yinhuo
decoction (150ccbid,
p.o.)"	"Modified Yinhuo
decoction (150ccbid,
p.o.)"	2.76179517			Home	100	0	0			100		Overall ASD symptoms	Clinical efficacy rate			0	0	0		Jiang	2016	NRCT	RR	30	30			1.36842105263158	0.15628964	1.0073624691735	1.8588901558162															high	0	0	0	100	0	0	unclear	unclear	low	unclear	low	unclear	Active ()	100	26.67	6.02		1	0	1	1			DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	645	Lee (2022)	Jiang_2016	2-6 months		6-12 yo	4.81	6.44	Inf	-Inf	6	1	Overall ASD symptoms	1	Lee (2022)	https://doi.org/10.1016/j.explore.2022.02.001	4.81	6.44	Inf	-Inf
Lee (2022)	Lee	2022	https://doi.org/10.1016/j.explore.2022.02.001	4.5	Low	Complementary	HERB	HERB	"YinhuoDecoction
(qd, p.o.)"	"YinhuoDecoction
(qd, p.o.)"	1.38089758			Home	100	0	0			100		Overall ASD symptoms	Clinical efficacy rate			0	0	0		Qu	2019	NRCT	RR	30	30			1.5	0.16101530	1.09404400230421	2.05659004140709															high	0	0	0	100	0	0	unclear	unclear	low	unclear	low	unclear	Active ()	100	40	6.15		1	0	1	1			DSM	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	60	646	Lee (2022)	Qu_2019	< 2 months		6-12 yo	4.81	6.44	Inf	-Inf	6	1	Overall ASD symptoms	1	Lee (2022)	https://doi.org/10.1016/j.explore.2022.02.001	4.81	6.44	Inf	-Inf
Lee (2022)	Lee	2022	https://doi.org/10.1016/j.explore.2022.02.001	4.5	Low	Complementary	HERB	HERB	"YangxinKangbiao
Decoction (bidp.o.)"	"YangxinKangbiao
Decoction (bidp.o.)"	4.60299194			Home	100	0	0			100		Overall ASD symptoms	Clinical efficacy rate			0	0	0		Cao	2019	NRCT	RR	48	48			1.4	0.12440334	1.09707349435628	1.78657128267423															high	0	0	0	100	0	0	unclear	unclear	low	unclear	low	unclear	Active ()	100	11.46	4.81		1	0	1	1			DSM-IV	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	96	647	Lee (2022)	Cao_2019	2-6 months		< 6 yo	4.81	6.44	Inf	-Inf	6	1	Overall ASD symptoms	1	Lee (2022)	https://doi.org/10.1016/j.explore.2022.02.001	4.81	6.44	Inf	-Inf
Lee (2022)	Lee	2022	https://doi.org/10.1016/j.explore.2022.02.001	4.5	Low	Complementary	HERB	HERB	"decoctionbasedon
symptoms (200mlbid
p.o.)"	"decoctionbasedon
symptoms (200mlbid
p.o.)"	5.52359033			Home	100	0	0			100		Overall ASD symptoms	Clinical efficacy rate			0	0	0		Li	2020	RCT	RR	41	41			1.28571428571429	0.12129128	1.01368061386681	1.63075154232652															high	100	0	0	100	0	0	unclear	unclear	low	unclear	low	unclear	Active ()	100	41.46	5		1	0	1	1			DSM	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	82	648	Lee (2022)	Li_2020	2-6 months		< 6 yo	4.81	6.44	Inf	-Inf	6	1	Overall ASD symptoms	1	Lee (2022)	https://doi.org/10.1016/j.explore.2022.02.001	4.81	6.44	Inf	-Inf
Lee (2022)	Lee	2022	https://doi.org/10.1016/j.explore.2022.02.001	4.5	Low	Complementary	HERB	HERB	"PeiyuanGubenPow-
der (qdp.o.)"	"PeiyuanGubenPow-
der (qdp.o.)"	1.84119678			Home	100	0	0			100		Overall ASD symptoms	Clinical efficacy rate			0	0	0		Lai	2021	RCT	RR	29	28			1.62931034482759	0.17128921	1.16466809072807	2.27932079610998															high	100	0	0	0	0	0	unclear	unclear	low	unclear	high	unclear	Active ()	100	80.7	6.44		1	0	1	1			DSM-V, TCM diagnostic criteria	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	649	Lee (2022)	Lai_2021	< 2 months		6-12 yo	4.81	6.44	Inf	-Inf	6	1	Overall ASD symptoms	1	Lee (2022)	https://doi.org/10.1016/j.explore.2022.02.001	4.81	6.44	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Liu	2015	RCT	SMD	20	25	outcomes	reverse	-1.05		-1.68	-0.42															high	100	0	0	0	0	0	high	high	high	high	high	high	no intervention ()	0		5.15		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	45	650	Li (2018)	Liu_2015			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Sun	2014	RCT	SMD	22	21		reverse	-0.8		-1.42	-0.17															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		6		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	43	651	Li (2018)	Sun_2014			6-12 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Yu	2016	RCT	SMD	40	40		reverse	-0.21		-0.65	0.23															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		5		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	80	652	Li (2018)	Yu_2016			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Xie	2014	RCT	SMD	47	39		reverse	-0.64		-1.08	-0.21															high	100	0	0	0	0	0	high	high	high	high	high	high	no intervention ()	0		4		1	0	1	0	China	Asia	ICD-10	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	86	653	Li (2018)	Xie_2014			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Wang	2016	RCT	SMD	35	35	outcomes	reverse	0.03		-0.44	0.5															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4.07		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	70	654	Li (2018)	Wang_2016			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Li	2013	RCT	SMD	24	26		reverse	-0.59		-1.16	-0.02															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4.5		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	50	655	Li (2018)	Li_2013			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Zhang	2013	RCT	SMD	43	43		reverse	-0.65		-1.09	-0.22															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		5.6		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	86	656	Li (2018)	Zhang_2013			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Wu	2016	RCT	SMD	45	45		reverse	-0.9		-1.34	-0.47															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		6		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	90	657	Li (2018)	Wu_2016			6-12 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Zhang	2014	RCT	SMD	40	40		reverse	-0.39		-0.84	0.05															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4.5		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	80	658	Li (2018)	Zhang_2014			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Behavior Checklist	0	0	100		Wang	2017	RCT	SMD	32	32		reverse	-0.85		-1.36	-0.33															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		5		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	64	659	Li (2018)	Wang_2017			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	Childhood Autism Rating Scale	0	100	0		Liu	2015	RCT	SMD	20	25	outcomes	reverse	-1.15		-1.79	-0.52															high	100	0	0	0	0	0	high	high	high	high	high	high	no intervention ()	0		5.15		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	45	660	Li (2018)	Liu_2015			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	Childhood Autism Rating Scale	0	100	0		Wang	2016	RCT	SMD	35	35	outcomes	reverse	-0.12		-0.58	0.35															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4.07		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	70	661	Li (2018)	Wang_2016			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Treatment Evaluation Checklist	0	0	100		Wei	2012	RCT	SMD	43	43		reverse	-0.75		-1.19	-0.31															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		5		1	0	1	0	China	Asia	CCMD-3 (Chinese Classification of Mental Disorder-3)	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	86	662	Li (2018)	Wei_2012			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	Autism Treatment Evaluation Checklist	0	0	100		Ye	2014	RCT	SMD	50	50		reverse	-0.75		-1.16	-0.34															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		6		1	0	1	0	China	Asia	CCMD-3 (Chinese Classification of Mental Disorder-3)	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	100	663	Li (2018)	Ye_2014			6-12 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Liu	2015	RCT	SMD	20	25			0.88		0.26	1.5															high	100	0	0	0	0	0	high	high	high	high	high	high	no intervention ()	0		5.15		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	45	664	Li (2018)	Liu_2015			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Wang	2016	RCT	SMD	35	35			0.26		-0.21	0.73															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4.07		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	70	665	Li (2018)	Wang_2016			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Li	2013	RCT	SMD	24	26			0.41		-0.15	0.97															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4.5		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	50	666	Li (2018)	Li_2013			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Zhang	2013	RCT	SMD	43	43			0.67		0.23	1.1															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		5.6		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	86	667	Li (2018)	Zhang_2013			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Wu	2016	RCT	SMD	45	45			0.66		0.24	1.09															high	100	0	0	0	0	0	high	high	high	high	high	high	Active ()	100		6		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	90	668	Li (2018)	Wu_2016			6-12 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Wang	2017	RCT	SMD	32	32			0.71		0.2	1.21															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		5		1	0	1	0	China	Asia	DSM-IV	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	64	669	Li (2018)	Wang_2017			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Li (2018)	Li	2018	https://doi.org/10.1042/BSR20181412	2.5	Critically low	Complementary	SENS	AIT							0	0	0			100		Global cognition (IQ)	Cognition(IQ)	Test	Intelligence Quotient	100	0	0		Chen	2017	RCT	SMD	48	48			0.61		0.2	1.02															high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		4		1	0	1	0	China	Asia	CCMD-3 (Chinese Classification of Mental Disorder-3)	1	0	1	0.5	1.0	1	0.0	0.5	0.0	0	1	0	0	1	1	1	96	670	Li (2018)	Chen_2017			< 6 yo	4	6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		Acceptability	acceptability			0	0	0		Arnold	2019	RCT	RR	6	4		reverse	1.33333333333333	1.04083300	0.173372447834989	10.2540963110229															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	671	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.3390/nu11040820	Liu	2019	RCT	RR	39	41		reverse	0.525641025641026	0.67079709	0.141158078950347	1.95736928337016															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	80	672	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		Acceptability	acceptability			0	0	0		NCT03337035		RCT	RR	18	17		reverse	0.944444444444444	0.62098383	0.279636606592826	3.18976588762846															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	673	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	6			Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	RR	42	43		reverse	1.02380952380952	0.36708697	0.498602175667649	2.10224903178475															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	19.0476190476191	4.15	62.5	1	1	1	1	Italy	Europe		1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	85	674	Siafis (child) (2022)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.54098361			Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.phrs.2020.104784	Wang	2020	RCT	RR	16	10		reverse	0.9375	0.33952581	0.481910490427965	1.82379563727588															high	100	0	100	0	100	0	low	unclear	unclear	unclear	high	low	Placebo ()	0	6.25	4.3		1	0	1	1	China	Asia	CCMD-3, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	26	675	Siafis (child) (2022)	Wang_2020	2-6 months		< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		ADHD symptoms	ADHD		ABC: Aberrant Behavior Checklist-H	0	0	0		Arnold	2019	RCT	G	6	4			-0.31		-1.59	0.97	4.67	10.7479	8.25	10.0074											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	676	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	8.83	10.11	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		ADHD symptoms	ADHD		SNAP-IV-ADHD	0	0	0	10.3390/nu11040820	Liu	2019	RCT	G	36	35			0.03		-0.44	0.49	1.44	9.7361	1.16	10.0108											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	71	677	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	8.83	10.11	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		ADHD symptoms	ADHD		ABC: Aberrant Behavior Checklist-H	0	0	0		NCT03337035		RCT	G	12	11			-0.37		-1.20	0.46	2.33	8.9100	5.64	8.3100											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	23	678	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	8.83	10.11	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS: Social Responsiveness Scale	0	0	0		Arnold	2019	RCT	G	6	4			0.19		-1.08	1.46	6.50	9.8292	4.50	8.9960											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	679	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS: Social Responsiveness Scale	0	0	0	10.3390/nu11040820	Liu	2019	RCT	G	36	35			0.24		-0.23	0.71	6.10	23.6129	0.09	25.9159											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	71	680	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS: Social Responsiveness Scale	0	0	0		NCT03337035		RCT	G	12	11			-0.41		-1.24	0.42	12.31	22.2100	22.09	23.7100											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	23	681	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	6			Home	100	0	0			100		Overall ASD symptoms	OV ASD		ADOS: Autism Diagnostic Observation Scale	0	0	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	G	31	32			0.44		-0.06	0.94	0.65	1.5200	-0.03	1.5200											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	19.0476190476191	4.15	62.5	1	1	1	1	Italy	Europe		1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	63	682	Siafis (child) (2022)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		Disruptive behaviors	irritability		ABC: Aberrant Behavior Checklist	0	0	0		Arnold	2019	RCT	G	6	4			0.05		-1.22	1.31	4.33	11.3006	3.75	11.6949											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	683	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	8.83	10.11	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		Disruptive behaviors	irritability		CBCL: Child Behavior Check List	0	0	0	10.3390/nu11040820	Liu	2019	RCT	G	36	35			-0.08		-0.55	0.38	0.21	7.0100	0.77	6.1172											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	71	684	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	8.83	10.11	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		Disruptive behaviors	irritability		ABC: Aberrant Behavior Checklist	0	0	0		NCT03337035		RCT	G	12	11			-0.66		-1.50	0.19	-0.92	6.2000	3.45	6.6700											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	23	685	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	8.83	10.11	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC: Aberrant Behavior Checklist	0	0	0		Arnold	2019	RCT	G	6	4			0.07		-1.2	1.33	2.33	6.4004	1.75	9.2290											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	686	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		Restricted/repetitive behaviors	RRB		SRS: Social Responsiveness Scale	0	0	0	10.3390/nu11040820	Liu	2019	RCT	G	36	35			0.03		-0.44	0.49	0.85	6.8092	0.68	6.5551											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	71	687	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC: Aberrant Behavior Checklist	0	0	0		NCT03337035		RCT	G	12	11			-0.34		-1.17	0.48	1.17	6.6400	3.18	4.3800											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	23	688	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	6			Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ADOS: Autism Diagnostic Observation Scale	0	0	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	G	31	32			0.01		-0.48	0.51	-0.29	1.5136	-0.31	1.3253											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	19.0476190476191	4.15	62.5	1	1	1	1	Italy	Europe		1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	63	689	Siafis (child) (2022)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		Social-communication	social-communication		ABC: Aberrant Behavior Checklist	0	0	0		Arnold	2019	RCT	G	6	4			0.45		-0.84	1.74	5.50	12.4680	-1,25	15.4771											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	690	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		Social-communication	social-communication		SRS: Social Responsiveness Scale	0	0	0	10.3390/nu11040820	Liu	2019	RCT	G	36	35			0.09		-0.37	0.56	2.47	19.5500	0.50	22.2125											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	71	691	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		Social-communication	social-communication		ABC: Aberrant Behavior Checklist	0	0	0		NCT03337035		RCT	G	12	11			0.22		-0.60	1.04	3.50	6.3600	1.82	8.3000											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	23	692	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	6			Home	100	0	0			100		Social-communication	social-communication		ADOS: Autism Diagnostic Observation Scale	0	0	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	G	31	32			0.31		-0.19	0.81	0.91	1.6868	0.32	2.0431											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	19.0476190476191	4.15	62.5	1	1	1	1	Italy	Europe		1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	63	693	Siafis (child) (2022)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.54098361			Home	100	0	0			100		Social-communication	social-communication		ATEC: Autism Treatment Evaluation Checklist	0	0	0	10.1016/j.phrs.2020.104784	Wang	2020	RCT	G	7	4			0.22		-1.01	1.46	7.42	6.8417	5.75	6.8756											high	100	0	100	0	100	0	low	unclear	unclear	unclear	high	low	Placebo ()	0	6.25	4.3		1	0	1	1	China	Asia	CCMD-3, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	11	694	Siafis (child) (2022)	Wang_2020	2-6 months		< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	1.84119678			Home	100	0	0			100		Tolerability				0	0	0		Arnold	2019	RCT	RR	6	4		reverse	0.714285714285714	1.91236577	0.0168291920114076	30.3166118306103															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	16.6666666666667	8.83		1	0	1	1	USA	North America	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	10	695	Siafis (child) (2022)	Arnold_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	0.92059839			Home	100	0	0			100		Tolerability				0	0	0	10.3390/nu11040820	Liu	2019	RCT	RR	39	41		reverse	1.05	1.98776017	0.0213405092356271	51.6623098271442															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	10.11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	80	696	Siafis (child) (2022)	Liu_2019	< 2 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	6			Home	100	0	0			100		Tolerability				0	0	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	RR	42	41		reverse	0.13953488372093	1.49621153	0.00743199193914055	2.61975308025766															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	19.0476190476191	4.15	62.5	1	1	1	1	Italy	Europe		1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	83	697	Siafis (child) (2022)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.68239356			Home	100	0	0			100		Tolerability				0	0	0		NCT03337035		RCT	RR	18	17		reverse	0.947368421052632	1.97276782	0.0198287753601364	45.2628520373525															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	16.6666666666667	9.85		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	35	698	Siafis (child) (2022)	NCT03337035_NA	2-6 months		6-12 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PROB	PROB	oral	oral	3.54098361			Home	100	0	0			100		Tolerability				0	0	0	10.1016/j.phrs.2020.104784	Wang	2020	RCT	RR	16	10		reverse	0.647058823529412	1.96220982	0.0138263560504115	30.2816678220003															high	100	0	100	0	100	0	low	unclear	unclear	unclear	high	low	Placebo ()	0	6.25	4.3		1	0	1	1	China	Asia	CCMD-3, DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	26	699	Siafis (child) (2022)	Wang_2020	2-6 months		< 6 yo	4.15	10.11	62.5	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	The eight probiotic species found in VISBIOME are primarily Lactobacillus and Bifidobacterium	The eight probiotic species found in VISBIOME are primarily Lactobacillus and Bifidobacterium	1.84119678			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0		Arnold	2019	RCT	SMD	10	10		reverse	-0.5		-1.39	0.39	-4.7	6.26	-1.7	5.19											low	100	100	100	100	100	0	low	low	low	unclear	low	low	Placebo ()	0	30.77	7.5		1	0	1	1	USA	North America	DSM-5	1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	20	700	Rahim (2023)	Arnold_2019	< 2 months		6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	De Simone’s probiotics included in the mix are: Lactobacillus casei, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, and Streptococcus thermophilus.	De Simone’s probiotics included in the mix are: Lactobacillus casei, Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, and Streptococcus thermophilus.	6			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1177/13623613221082710	Billeci	2023	RCT	SMD	20	26		reverse	-0.15		-0.73	0.44	-1.5	1.1000000000000001	-1.2	2.5											low	100	100	100	100	100	0	low	low	low	unclear	low	low	Placebo ()	0	23.91	3.88		1	0	1	1	Italy	Europe		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	46	701	Rahim (2023)	Billeci_2023	2-6 months		< 6 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Prebiotic: Bimuno® galactooligosaccharide (B-GOS®) prebiotic intervention	Prebiotic: Bimuno® galactooligosaccharide (B-GOS®) prebiotic intervention	1.38089758			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1186/s40168-018-0523-3	Grimaldi	2018	RCT	SMD	63	22		reverse	0.79		0.28999999999999998	1.29	-1.7	1.8	-3.2	2.1											low	100	100	100	100	100	0	low	low	low	unclear	low	low	Placebo ()	0	24.39	7		1	0	1	1	UK	Europe		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	85	702	Rahim (2023)	Grimaldi_2018	< 2 months		6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Probiotics: Lactobacillus plantarum	Probiotics: Lactobacillus plantarum	4.14269275			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.1038/s41598-019-42183-0	Kang	2019	RCT	SMD	10	10		reverse	-0.61		-1.52	0.28999999999999998	-1.38	1.3240000000000001	-0.57999999999999996	1.167											high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0		12		1	0	1	1	USA	North America		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	20	703	Rahim (2023)	Kang_2019	2-6 months		6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Probiotics: Lactobacillus and Enterococcus Powder	Probiotics: Lactobacillus and Enterococcus Powder	3			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Observation		0	100	0	10.7499/j.issn.1008-8830.2108085	Li	2021	RCT	SMD	21	20		reverse	-0.56999999999999995		-1.2	0.05	-27	25.24	-12	26.06											low	100	100	100	100	100	100	low	low	low	low	low	low	Active ()	100		4.5		1	0	1	1	China	Asia		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	41	704	Rahim (2023)	Li_2021	2-6 months		< 6 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Probiotics: Lactobacillus plantarum PS128	Probiotics: Lactobacillus plantarum PS128	0.92059839			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Report	CBCL: Child Behavior Check List	0	0	100	10.3390/nu11040820	Liu	2019	RCT	SMD	36	35		reverse	-0.04		-0.5	0.43	-1.1399999999999999	8.69	-0.79	9.73											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	10.01		1	0	1	1	Taiwan	Asia	DSM-5	1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	71	705	Rahim (2023)	Liu_2019	< 2 months		6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Probiotics: Bifidobacterium infantis +BCP	Probiotics: Bifidobacterium infantis +BCP	4.60299194			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1371/journal.pone.0210064	Sanctuary	2019	RCT	SMD	8	8		reverse	0.87		-0.17	1.91	-6.75	16.239999999999998	-21.5	15.65											low	100	100	100	100	100	100	low	low	low	low	low	low	Active ()	100	31.25	6.8	57	1	1	1	1	USA	North America		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	16	706	Rahim (2023)	Sanctuary_2019	2-6 months	Low (< 70)	6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Probiotic supplement, DSF	Probiotic supplement, DSF	6			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	SMD	32	31		reverse	-0.4		-0.9	0.1	-0.65	1.48	0.03	1.86											high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	16.47	4.15	62.5	1	1	1	1	Italy	Europe		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	63	707	Rahim (2023)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Probiotics: Lactobacillus plantarum	Probiotics: Lactobacillus plantarum	1.38089758			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Observation	CGI: Clinical Global Impression	0	100	0	10.3390/nu13051552 	Kong	2021	RCT	SMD	64	64		reverse	-0.06		-0.41	0.28000000000000003	-12.12	10.91	-11.43	10.31											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	25.71	10.3		1	0	1	1	USA	North America		1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	128	708	Rahim (2023)	Kong_2021	< 2 months		6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Rahim (2023)	Rahim	2023	https://doi.org/10.3389/fnut.2023.1294089	3.5	Critically low	Complementary	PROB	PROB	Prebiotics: Lactobacillus plantarum +FOS	Prebiotics: Lactobacillus plantarum +FOS	0.69044879			Home	100	0	0			100		Overall ASD symptoms	Autism-Related Behavioral Symptoms	Test		100	0	0	10.1016/j.phrs.2020.104784	Wang	2020	RCT	SMD	26	24		reverse	-2.41		-3.15	-1.67	-25.73	6.16	-12.2	4.74											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Placebo ()	0	6.25	6		1	0	1	1	China	Asia	CCMD-3, DSM-5	1	0	1	1.0	0.5	1	0.0	0.5	1.0	0	1	0	1	1	1	1	50	709	Rahim (2023)	Wang_2020	< 2 months		6-12 yo	3.88	12	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Song (2022)	Song	2022	https://doi.org/10.1099/jmm.0.001510	4.5	Critically low	Complementary	PROB	PROB	"Streptococcus thermophilus, Bififidobacterium breve,Bififidobacterium infantis, Lactobacillus acidophilus, 
Lacobacillus plantarum, Lactobacillus para-casei, Lactobacillus delbrueckii subsp. bulgaricus."	"Streptococcus thermophilus, Bififidobacterium breve,Bififidobacterium infantis, Lactobacillus acidophilus, 
Lacobacillus plantarum, Lactobacillus para-casei, Lactobacillus delbrueckii subsp. bulgaricus."	6			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.3389/fpsyt.2020.550593	Elisa	2020	RCT	SMD	31	32		reverse	-0.48		-0.98	0.02	6.19	1.56	7	1.8											low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo ()	0		4.718413		1	0	1	1	Italy	Europe	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	63	710	Song (2022)	Elisa_2020	2-6 months		< 6 yo	4.36	10.011408	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Song (2022)	Song	2022	https://doi.org/10.1099/jmm.0.001510	4.5	Critically low	Complementary	PROB	PROB	"FOS＋Bifidobacterium infantis Bi-26, Lactobacillus rhamnosus HN001, Bifidobacterium lactis BL-04,and 
Lactobacillus paracasei LPC-37"	"FOS＋Bifidobacterium infantis Bi-26, Lactobacillus rhamnosus HN001, Bifidobacterium lactis BL-04,and 
Lactobacillus paracasei LPC-37"	3.54098361			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ATEC: Autism Treatment Evaluation Checklist	0	0	100	10.1016/j.phrs.2020.104784	Wang	2020	RCT	SMD	7	3		reverse	-0.12		-1.47	1.24	59.3	6.52	60	2.61											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	6.25	4.36		1	0	1	1	China	Asia	DSM-5 and CCMD-3	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	10	711	Song (2022)	Wang_2020	2-6 months		< 6 yo	4.36	10.011408	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Song (2022)	Song	2022	https://doi.org/10.1099/jmm.0.001510	4.5	Critically low	Complementary	PROB	PROB	Lactobacillus plantarum PS128	Lactobacillus plantarum PS128	0.92059839			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	CGI: Clinical Global Impression	0	100	0	10.3390/nu11040820	Liu	2019	RCT	SMD	36	35		reverse	-0.02		-0.48	0.45	3.64	1.1000000000000001	3.66	1											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Placebo ()	0	0	10.011408		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	71	712	Song (2022)	Liu_2019	< 2 months		6-12 yo	4.36	10.011408	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Song (2022)	Song	2022	https://doi.org/10.1099/jmm.0.001510	4.5	Critically low	Complementary	PROB	PROB	"Streptococcus thermophilus, Bififidobacterium breve,Bififidobacterium infantis, Lactobacillus acidophilus, 
Lacobacillus plantarum, Lactobacillus para-casei, Lactobacillus delbrueckii subsp. bulgaricus."	"Streptococcus thermophilus, Bififidobacterium breve,Bififidobacterium infantis, Lactobacillus acidophilus, 
Lacobacillus plantarum, Lactobacillus para-casei, Lactobacillus delbrueckii subsp. bulgaricus."	6			Home	100	0	0			100		Adverse events	Severity of gastrointestinal problems in ASD	Report	6-Gastrointestinal Severity Index	0	0	100	10.3389/fpsyt.2020.550593	Elisa	2020	RCT	SMD	31	32		reverse	-0.04		-0.54	0.45	1.23	1.48	1.29	1.19											low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo ()	0		4.718413		1	0	1	1	Italy	Europe	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	63	713	Song (2022)	Elisa_2020	2-6 months		< 6 yo	4.36	4.718413	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Song (2022)	Song	2022	https://doi.org/10.1099/jmm.0.001510	4.5	Critically low	Complementary	PROB	PROB	"FOS＋Bifidobacterium infantis Bi-26, Lactobacillus rhamnosus HN001, Bifidobacterium lactis BL-04,and 
Lactobacillus paracasei LPC-37"	"FOS＋Bifidobacterium infantis Bi-26, Lactobacillus rhamnosus HN001, Bifidobacterium lactis BL-04,and 
Lactobacillus paracasei LPC-37"	3.54098361			Home	100	0	0			100		Adverse events	Severity of gastrointestinal problems in ASD	Report	6-Gastrointestinal Severity Index	0	0	100	10.1016/j.phrs.2020.104784	Wang	2020	RCT	SMD	7	3		reverse	-2.56		-4.41	-0.72	1.44	0.38	2.5	0.5											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	6.25	4.36		1	0	1	1	China	Asia	DSM-5 and CCMD-3	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	10	714	Song (2022)	Wang_2020	2-6 months		< 6 yo	4.36	4.718413	Inf	-Inf	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	DSF	DSF	1.84119678			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	SRS: social responsiveness scale	0	0	100		Arnold	2019	RCT Crossover controlled trial	SMC	10	10		reverse	-0.5		-1.39	0.39	-4.7	6.26	-1.7	5.19											low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Placebo ()	0	16.6666666666667	7.5		1	0	1	1	USA	North America	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	20	715	He (2023)	Arnold_2019	< 2 months		6-12 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	Bifidobacterium triple live dispersion	Bifidobacterium triple live dispersion	3			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ATEC: autism treatment evaluation checklist;	0	0	100	10.7499/j.issn.1008-8830.2108085	Li	2021	RCT	SMC	21	20		reverse	-0.57		-1.2	0.05	-27	25.24	-12	26.06											low	100	100	100	100	100	0	low	unclear	low	unclear	low	low	Active ()	100		4.5		1	0	1	1	China	Asia		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	41	716	He (2023)	Li_2021	2-6 months		< 6 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	Lactobacillus plantarum PS128	Lactobacillus plantarum PS128	0.92059839			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ABC-T: autism behavior checklist-Taiwan version	0	0	100	10.3390/nu11040820	Liu	2019	RCT	SMC	36	35		reverse	-0.04		-0.5	0.43	-1.14	8.69	-0.79	9.73											low	100	100	100	100	100	0	low	low	low	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Taiwan	Asia	DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	71	717	He (2023)	Liu_2019	< 2 months		6-12 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	Bifidobacterium infantis	Bifidobacterium infantis	5			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ABC: aberrant behavior checklist	0	0	100	10.1371/journal.pone.0210064	Sanctuary	2019	RCT Crossover controlled trial	SMC	8	8		reverse	0.88		-0.16	1.92	-6.75	16.24	-21.5	15.56											low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	31.25	6.8	57	1	1	1	1	USA	North America		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	16	718	He (2023)	Sanctuary_2019	2-6 months	Low (< 70)	6-12 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	DSF	DSF	6			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Observation	ADOS: Autism Diagnostic Observation Scale	0	100	0	10.3389/fpsyt.2020.550593	Santocchi	2020	RCT	SMC	32	31		reverse	-0.4		-0.9	0.1	-0.65	1.48	0.03	1.86											high	100	0	100	100	100	0	low	low	low	high	low	low	Placebo ()	0	19.0476190476191	4.15	62.5	1	1	1	1	Italy	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	63	719	He (2023)	Santocchi_2020	2-6 months	Low (< 70)	< 6 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	DSF	DSF	2.76179517			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ATEC: autism treatment evaluation checklist	0	0	100	https://clinicaltrials.gov/study/NCT03369431	Simmons	2022	RCT Crossover controlled trial	SMC	64	64		reverse	-0.03		-0.38	0.31	-12.12	20.91	-11.43	20.31											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0		8		1	0	1	1	USA	North America		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	128	720	He (2023)	Simmons_2022	2-6 months		6-12 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
He (2023)	He	2023	https://doi.org/10.3390/nu15061415	4.5	Critically low	Complementary	PROB	PROB	Probiotics+FOS	Probiotics+FOS	3.55120829			Home	100	0	0			100		Overall ASD symptoms	Overall ASD symptoms	Report	ATEC: autism treatment evaluation checklist	0	0	100	10.1016/j.phrs.2020.104784	Wang	2020	RCT	SMC	7	4		reverse	-2.16		-3.82	-0.49	-25.73	6.16	-12.2	4.76											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	6.25	5		1	0	1	1	China	Asia	CCMD-3, DSM-5	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	0	1	1	11	721	He (2023)	Wang_2020	2-6 months		< 6 yo	4.15	11	57	62.5	13	8	Acceptability | ADHD symptoms | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Tolerability | Adverse events	4	Siafis (child) (2022) | Rahim (2023) | Song (2022) | He (2023)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.3389/fnut.2023.1294089 | https://doi.org/10.1099/jmm.0.001510 | https://doi.org/10.3390/nu15061415	3.88	12	57	62.5
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.76179517	1.5	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.sleep.2010.01.010	Cortesi	2012	RCT	RR	40	40		reverse	0.666666666666667	0.60553007	0.203460735538968	2.18442365927317															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	17.5	6.8		1	0	1	1	Italy	Europe	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	80	722	Siafis (child) (2022)	Cortesi_2012	2-6 months		6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	RR	60	65		reverse	0.464285714285714	0.35591976	0.2311137959071	0.932706001577006															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	25	9		1	0	1	1	Finland, France, Netherlands, UK, USA	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	125	723	Siafis (child) (2022)	Gringras_2017	2-6 months		6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	0.46029919			Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1007/s10803-021-05139-w	Hayashi	2021	RCT	RR	130	66		reverse	3.58015267175572	1.50437872	0.187660150977345	68.3016244329198															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	40	10.8	91.53846	1	1	1	1	Japan			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	196	724	Siafis (child) (2022)	Hayashi_2021	< 2 months	Average (80-119)	6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1007/s10803-010-1036-5	Wright	2011	RCT	RR	9	11		reverse	1.22222222222222	1.34088769	0.0882641827683251	16.924499991291															high	100	0	0	0	0	100	unclear	low	low	low	high	high	Placebo ()	0	22.2222222222222	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	20	725	Siafis (child) (2022)	Wright_2011	2-6 months		6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		ADHD symptoms	ADHD		SDQ: Strength and Difficulties Questionnaire	0	0	0	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	G	54	49			0.36		-0.03	0.75	0.47	1.4700	-0.07	1.4700											high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	25	9		1	0	1	1	Finland, France, Netherlands, UK, USA	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	103	726	Siafis (child) (2022)	Gringras_2017	2-6 months		6-12 yo	9	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	0.46029919			Home	100	0	0			100		ADHD symptoms	ADHD		ABC: Aberrant Behavior Checklist	0	0	0	10.1007/s10803-021-05139-w	Hayashi	2021	RCT	G	130	66			0		-0.3	0.3	1.00	9.8914	1.00	9.9300											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	40	10.8	91.53846	1	1	1	1	Japan			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	196	727	Siafis (child) (2022)	Hayashi_2021	< 2 months	Average (80-119)	6-12 yo	9	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	RR	60	65		reverse	1.105	0.08692848	0.931898514596073	1.31025533454064															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	25	9		1	0	1	1	Finland, France, Netherlands, UK, USA	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	125	728	Siafis (child) (2022)	Gringras_2017	2-6 months		6-12 yo	9	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	0.46029919			Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1007/s10803-021-05139-w	Hayashi	2021	RCT	RR	130	66		reverse	1.18461538461538	0.31016737	0.645004027124587	2.17566643067857															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	40	10.8	91.53846	1	1	1	1	Japan			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	196	729	Siafis (child) (2022)	Hayashi_2021	< 2 months	Average (80-119)	6-12 yo	9	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		Disruptive behaviors	irritability		SDQ: Strength and Difficulties Questionnaire	0	0	0	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	G	54	49			0.28		-0.10	0.67	0.24	1.0100	-0,05	1.0100											high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	25	9		1	0	1	1	Finland, France, Netherlands, UK, USA	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	103	730	Siafis (child) (2022)	Gringras_2017	2-6 months		6-12 yo	9	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	0.46029919			Home	100	0	0			100		Disruptive behaviors	irritability		ABC: Aberrant Behavior Checklist-I	0	0	0	10.1007/s10803-021-05139-w	Hayashi	2021	RCT	G	130	66			0.06		-0.24	0.36	0.50	8.2929	0	8.3100											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	40	10.8	91.53846	1	1	1	1	Japan			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	196	731	Siafis (child) (2022)	Hayashi_2021	< 2 months	Average (80-119)	6-12 yo	9	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.76179517	1.5	mg/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1016/j.sleep.2010.01.010	Cortesi	2012	RCT	RR	40	40		reverse	1	1.98776747	0.0203240035707186	49.2029041679923															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	17.5	6.8		1	0	1	1	Italy	Europe	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	80	732	Siafis (child) (2022)	Cortesi_2012	2-6 months		6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	RR	60	65		reverse	1.08333333333333	1.40283596	0.0692892684459198	16.9378482041142															high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	25	9		1	0	1	1	Finland, France, Netherlands, UK, USA	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	125	733	Siafis (child) (2022)	Gringras_2017	2-6 months		6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	0.46029919			Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1007/s10803-021-05139-w	Hayashi	2021	RCT	RR	130	66		reverse	1.53435114503817	1.62607125	0.0633593051123695	37.1568695727429															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	40	10.8	91.53846	1	1	1	1	Japan			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	196	734	Siafis (child) (2022)	Hayashi_2021	< 2 months	Average (80-119)	6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	MELAT	MELAT	oral	oral	2.99194476	5	mg/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1007/s10803-010-1036-5	Wright	2011	RCT	RR	9	11		reverse	1.2	1.95362910	0.0260764904004088	55.2221552014311															high	100	0	0	0	0	100	unclear	low	low	low	high	high	Placebo ()	0	22.2222222222222	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	20	735	Siafis (child) (2022)	Wright_2011	2-6 months		6-12 yo	6.8	10.8	91.53846	91.53846	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		ADHD symptoms	ADHD		ABC-H	0	0	0		NCT02909959		RCT	G	24	24			0.05		-0.52	0.61	0.60	27.9242	-0.50	17.6363											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	736	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		ADHD symptoms	ADHD		ABC: Aberrant Behavior Checklist-H	0	0	0	10.1073/pnas.1416940111	Singh	2014	RCT	G	26	14			0.56		-0.10	1.23	4.75	5.8100	1.47	5.51											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	737	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Adverse events	any adverse events			0	0	0		NCT02909959		RCT	RR	24	24		reverse	1	0.24397502	0.619909208932088	1.61313944944082															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	738	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1073/pnas.1416940111	Singh	2014	RCT	RR	29	15		reverse	0.646551724137931	0.59063574	0.203167025698661	2.05756387163809															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	44	739	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100		NCT02909959		RCT	G	24	24			0.02		-0.55000000000000004	0.59	0.30	36.2524	-0.30	22.5353											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	740	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Overall ASD symptoms	OV ASD	Report	SRS: Social Responsiveness Scale	0	0	100	10.1073/pnas.1416940111	Singh	2014	RCT	G	29	15			0.86		0.2	1.51	15.30	13.8900	3.20	13.8900											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	44	741	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist-I	0	0	100		NCT02909959		RCT	G	24	24			0		-0.57	0.56000000000000005	-0,1	24.9848	0	15.6767											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	742	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Disruptive behaviors	irritability	Report	ABC: Aberrant Behavior Checklist-I	0	0	100	10.1073/pnas.1416940111	Singh	2014	RCT	G	26	14			0.83		0.15	1.51	4.56	4.4900	0.81	4.2700											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	743	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist-S	0	0	100		NCT02909959		RCT	G	24	24			0		-0.56999999999999995	0.56999999999999995	0	15.6767	0	9.7980											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	744	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Restricted/repetitive behaviors	RRB	Report	ABC: Aberrant Behavior Checklist-S	0	0	100	10.1073/pnas.1416940111	Singh	2014	RCT	G	26	14			0.47		-0.19	1.1299999999999999	2.66	3.0100	1.23	2.97											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	745	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100		NCT02909959		RCT	G	24	24			-0.02		-0.59	0.54	-0.30	24.9848	0.20	15.6767											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	746	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Social-communication	social-communication	Report	ABC: Aberrant Behavior Checklist	0	0	100	10.1073/pnas.1416940111	Singh	2014	RCT	G	26	14			0.62		-0.05	1.28	4.52	4.69	1.63	4.34											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	40	747	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Acceptability				0	0	0	10.1073/pnas.1416940111	Singh	2014	RCT	RR	29	15		reverse	1.55172413793103	1.11003780	0.176176764993125	13.667226778354															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	44	748	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Acceptability				0	0	0		NCT02909959		RCT	RR	24	24		reverse	1	1.97989899	0.0206398685275337	48.4499210189249															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	749	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	4.14269275			Home	100	0	0			100		Tolerability				0	0	0	10.1073/pnas.1416940111	Singh	2014	RCT	RR	29	15		reverse	1.6	1.60338184	0.0690746803467016	37.0613369059513															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	17.9		1	0	1	1	USA		DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	44	750	Siafis (adult) (2022)	Singh_2014	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Siafis (adult) (2022)	Siafis (adult)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	SULFO	SULFO	oral	oral	2.76179517			Home	100	0	0			100		Tolerability				0	0	0		NCT02909959		RCT	RR	24	24		reverse	1	1.97989899	0.0206398685275337	48.4499210189249															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	16.8		1	0	1	1	USA		DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	751	Siafis (adult) (2022)	NCT02909959_NA	2-6 months		13-19 yo	16.8	17.9	Inf	-Inf	2	8	ADHD symptoms | Adverse events | Overall ASD symptoms | Disruptive behaviors | Restricted/repetitive behaviors | Social-communication | Acceptability | Tolerability	1	Siafis (adult) (2022)	https://doi.org/10.1186/s13229-022-00488-4	16.8	17.9	Inf	-Inf
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5		reverse	-0.989		-2.12	0.142															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	placebo ()	0	0	11.3		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	12	752	Cheng (2017)	Amminger_2007	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	14	12		reverse	-0.383		-1.122	0.356															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	753	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28		reverse	-0.255		-0.769	0.259															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	754	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	3.68239356	1.44	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	-0.126		-1.141	0.89															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	13	755	Cheng (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Lethargy	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5	outcomes	reverse	-0.128		-1.189	0.932															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	placebo ()	0	0	11.3		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	12	756	Cheng (2017)	Amminger_2007	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Lethargy	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	14	12	outcomes	reverse	-0.148		-0.881	0.585															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	757	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Lethargy	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	-0.619		-1.143	-0.094															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	758	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	3.68239356	1.44	g/day	Home	100	0	0			100		Social-communication	Lethargy	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.685		-1.733	0.363															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	13	759	Cheng (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5		reverse	-0.807		-1.915	0.3															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	placebo ()	0	0	11.3		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	12	760	Cheng (2017)	Amminger_2007	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	14	12		reverse	-0.194		-0.928	0.54															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	761	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28		reverse	-0.461		-0.98	0.058															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	762	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	3.68239356	1.44	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	-0.247		-1.265	0.772															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	13	763	Cheng (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5	outcomes	reverse	-0.343		-1.411	0.725															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	placebo ()	0	0	11.3		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	12	764	Cheng (2017)	Amminger_2007	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	14	12	outcomes	reverse	-0.226		-0.96	0.509															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	765	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.12		-0.393	0.633															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	766	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	3.68239356	1.44	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-1.025		-2.113	0.063															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	13	767	Cheng (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5		reverse	-0.017		-1.076	1.042															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	placebo ()	0	0	11.3		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	12	768	Cheng (2017)	Amminger_2007	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	14	12		reverse	0.059		-0.673	0.792															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	769	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28		reverse	0.017		-0.495	0.529															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	770	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	3.68239356	1.44	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	-0.04		-1.054	0.975															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	13	771	Cheng (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	changes of SRS total score	Report	Social Responsiveness Scale	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	14	12	outcomes	reverse	0.368		-0.37	1.107															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	772	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	changes of SRS total score	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.428		-0.09	0.947															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	773	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	3.68239356	1.44	g/day	Home	100	0	0			100		Overall ASD symptoms	changes of SRS total score	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	0.127		-0.889	1.142															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	13	774	Cheng (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Acceptability	Drop out rate	Report		0	0	100		Bent	2014	RCT	RR	29	28		reverse	1.93103448275862	0.55208963	0.654410843698416	5.69809349815925															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent reported	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	775	Cheng (2017)	Bent_2014	< 2 months		6-12 yo	3.694595	11.3	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Acceptability	Drop out rate	Report		0	0	100		Amminger	2007	RCT	RR	7	5		reverse	0.357142857142857	1.07570575	0.0433710139645096	2.94092779367662															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	placebo ()	0	0	11.3		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	12	776	Cheng (2017)	Amminger_2007	< 2 months		6-12 yo	3.694595	11.3	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Acceptability	Drop out rate	Report		0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	14	12		reverse	1.01298701298701	0.11432525	0.809636441189779	1.26741168785883															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	26	777	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	3.694595	11.3	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	5.52359033	1.5	g/day	Home	100	0	0			100		Acceptability	Drop out rate	Report		0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT	RR	18	19		reverse	2.11111111111111	0.80113224	0.439122906936671	10.1493000093013															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	27	3.694595		1	0	1	1	Canada	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	37	778	Cheng (2017)	Mankad_2015	2-6 months		< 6 yo	3.694595	11.3	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	5.52359033	0.2	g/day	Home	100	0	0			100		Acceptability	Drop out rate	Report		0	0	100	10.1097/MPG.0000000000000260	Voigt	2014	RCT	RR	24	24		reverse	0.727272727272727	0.15691148	0.534729333945154	0.989146445234968															high	100	0	100	0	0	100	low	low	low	low	high	high	placebo ()	0	17	6.15		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	48	779	Cheng (2017)	Voigt_2014	2-6 months		6-12 yo	3.694595	11.3	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	PUFAs / omega 3	PUFAs / omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Tolerability	Discontinue due to side effect	Report		0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	29	28		reverse	1.03978779840849	0.06307757	0.918867713478661	1.17662058407309															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	57	780	Cheng (2017)	Bent_2011	2-6 months		< 6 yo	3.694595	6.15	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	5.52359033	1.5	g/day	Home	100	0	0			100		Tolerability	Discontinue due to side effect	Report		0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT	RR	18	19		reverse	0.996913580246914	0.07868895	0.854431711690371	1.16315519763956															low	100	100	100	100	100	100	low	low	low	low	low	low	placebo ()	0	27	3.694595		1	0	1	1	Canada	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	37	781	Cheng (2017)	Mankad_2015	2-6 months		< 6 yo	3.694595	6.15	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Cheng (2017)	Cheng	2017	https://doi.org/10.2147/NDT.S147305	3.5	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	5.52359033	0.2	g/day	Home	100	0	0			100		Tolerability	Discontinue due to side effect	Report		0	0	100	10.1097/MPG.0000000000000260	Voigt	2014	RCT	RR	24	24		reverse	0.869565217391304	0.10072203	0.713784990563093	1.05934374817867															high	100	0	100	0	0	100	low	low	low	low	high	high	placebo ()	0	17	6.15		1	0	1	1	USA	North America	DSM-IV	1	0	1	0.5	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	48	782	Cheng (2017)	Voigt_2014	2-6 months		6-12 yo	3.694595	6.15	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.5	1.5	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5		reverse	0.27		-0.88	1.43															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo (coconut oil) ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	783	De Andrade (2021)	Amminger_2007	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	3	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12		reverse	0.38		-0.41	1.18															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + CGI	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	25	784	De Andrade (2021)	Bent_2011	2-6 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	23	16		reverse	-0.18		-0.82	0.46															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	785	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	7	5		reverse	-0.45		-1.62	0.72															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	786	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	-0.32		-1.42	0.78															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	787	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.5	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5		reverse	0.37		-0.79	1.53															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo (coconut oil) ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	788	De Andrade (2021)	Amminger_2007	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	3	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12		reverse	-0.06		-0.84	0.73															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + CGI	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	25	789	De Andrade (2021)	Bent_2011	2-6 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28		reverse	-0.14		-0.66	0.38															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	790	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16		reverse	-0.56		-1.21	0.09															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	791	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	-0.03		-1.12	1.06															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	792	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.5	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5		reverse	0.27		-0.88	1.43															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo (coconut oil) ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	793	De Andrade (2021)	Amminger_2007	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	3	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12		reverse	0.38		-0.41	1.18															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + CGI	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	25	794	De Andrade (2021)	Bent_2011	2-6 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	23	16	outcomes	reverse	-0.18		-0.82	0.46															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	795	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	7	5	outcomes	reverse	-0.45		-1.62	0.72															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	796	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	stereotypy	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.32		-1.42	0.78															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	797	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.5	1.5	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5	outcomes	reverse	-0.46		-1.63	0.71															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo (coconut oil) ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	798	De Andrade (2021)	Amminger_2007	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	3	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12	outcomes	reverse	0.23		-0.56	1.01															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + CGI	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	25	799	De Andrade (2021)	Bent_2011	2-6 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	-0.33		-0.85	0.19															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	800	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	-0.45		-1.1	0.19															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	801	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Social-communication	inappropriate speech	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.37		-1.48	0.73															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	802	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	3	1.3	g/day	Home	100	0	0			100		Social-communication	lethargy	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12	outcomes	reverse	-0.13		-0.65	0.39															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + CGI	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	25	803	De Andrade (2021)	Bent_2011	2-6 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	lethargy	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.15		-0.64	0.93															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	804	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Social-communication	lethargy	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	-0.61		-1.26	0.05															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	805	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.5	1.5	g/day	Home	100	0	0			100		Social-communication	social withdrawal	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	G	7	5	outcomes	reverse	-0.19		-1.34	0.96															low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	Placebo (coconut oil) ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	12	806	De Andrade (2021)	Amminger_2007	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Social-communication	social withdrawal	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-1.33		-2.58	-0.08															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	807	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.35		-0.17	0.87															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	808	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	-0.52		-1.17	0.13															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	809	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	omega-3	omega-3	2	1	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35	outcomes	reverse	-0.1		-0.58	0.37															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.1764705882353	11		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	68	810	De Andrade (2021)	Parellada_2017	2-6 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-1.07		-2.27	0.13															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	811	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	social awareness	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.19		-0.33	0.71															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	812	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Social-communication	social awareness	Report	Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	-0.57999999999999996		-1.23	7.0000000000000007E-2															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	813	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	omega-3	omega-3	2	1	g/day	Home	100	0	0			100		Social-communication	social awareness	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35	outcomes	reverse	0.35		-0.13	0.83															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.1764705882353	11		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	68	814	De Andrade (2021)	Parellada_2017	2-6 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Social-communication	social awareness	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.37		-1.47	0.74															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	815	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	social motivation	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	-0.27		-0.79	0.25															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	816	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Social-communication	social motivation	Report	Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	-0.64		-1.29	0.02															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	817	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	omega-3	omega-3	2	1	g/day	Home	100	0	0			100		Social-communication	social motivation	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35	outcomes	reverse	0.11		-0.37	0.59															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.1764705882353	11		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	68	818	De Andrade (2021)	Parellada_2017	2-6 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Social-communication	social motivation	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.78		-1.93	0.37															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	819	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	social cognition	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.25		-0.27	0.77															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	820	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Social-communication	social cognition	Report	Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	0.15		-0.49	0.79															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	821	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	omega-3	omega-3	2	1	g/day	Home	100	0	0			100		Social-communication	social cognition	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35	outcomes	reverse	0.49		0.01	0.98															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.1764705882353	11		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	68	822	De Andrade (2021)	Parellada_2017	2-6 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Social-communication	social cognition	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.30		-1.4	0.8															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	823	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	autistic mannerisms	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28	outcomes	reverse	0.19		-0.33	0.71															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	824	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	autistic mannerisms	Report	Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16	outcomes	reverse	-0.58		-1.23	0.07															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	825	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	omega-3	omega-3	2	1	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	autistic mannerisms	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35		reverse	0.3		-0.18	0.78															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.1764705882353	11		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	68	826	De Andrade (2021)	Parellada_2017	2-6 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	autistic mannerisms	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6	outcomes	reverse	-0.37		-1.47	0.74															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	827	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	3	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS-total score	Report	Social Responsiveness Scale	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12		reverse	0.25		-0.54	1.04															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + CGI	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	25	828	De Andrade (2021)	Bent_2011	2-6 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	1.38089758	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS-total score	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	G	29	28		reverse	-0.43		-0.95	0.1															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo (Orange-flavored pudding with an identical appearance and taste, but included safflower oil) ()	0	12.280701754386	6.5		1	0	1	1	USA	North America	Other	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	57	829	De Andrade (2021)	Bent_2014	< 2 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	12	0.7	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS-total score	Report	Social Responsiveness Scale	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16		reverse	-0.69		-1.35	-0.03															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.4383561643836	5.25		1	0	1	1	New Zealand	Oceania	DSM	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	39	830	De Andrade (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	omega-3	omega-3	2	1	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS-total score	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35		reverse	0.3		-0.18	0.78															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.1764705882353	11		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	68	831	De Andrade (2021)	Parellada_2017	2-6 months		6-12 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Andrade (2021)	De Andrade	2021	https://doi.org/10.1080/1028415X.2021.1913950	3.5	Low	Complementary	PUFA	n-3	w-3 and omega-6	w-3 and omega-6	4	1.44	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS-total score	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6		reverse	-0.16		-1.25	0.93															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.69230769230769	14.6	100	1	1	1	1	Japan	Asia	DSM + ABC	1	1	1	0.5	1.0	0	0.0	0.5	1.0	0	1	0	1	1	1	1	13	832	De Andrade (2021)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.25	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	irritability - T+C	Report	Aberrant Behavior Checklist - Clinicians/teachers	0	0	100		Amminger	2007	RCT	MD	7	5			0.1		-6.97	7.17	4.7	3.5	4.6	7.5											high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	12	833	Horvath (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	irritability - T+C	Report	Aberrant Behavior Checklist - Clinicians/teachers	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		1.1		-2.92	5.12	1.3	8.6	0.2	6.8											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	834	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Lethargy - T+C	Report	Aberrant Behavior Checklist - Clinicians/teachers	0	0	100		Amminger	2007	RCT	MD	7	5	outcomes		1		-6.75	8.75	5.6	8.1	4.6	5.6											high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	12	835	Horvath (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Lethargy - T+C	Report	Aberrant Behavior Checklist - Clinicians/teachers	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		0.9		-2.62	4.42	2.5	7.9	1.6	5.5											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	836	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy - T+C	Report	Aberrant Behavior Checklist - Clinicians/teachers	0	0	100		Amminger	2007	RCT	MD	7	5			2.4		-1	5.8	1.4	2.2	-1	3.4											high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	12	837	Horvath (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy - T+C	Report	Aberrant Behavior Checklist - Clinicians/teachers	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		0.3		-1.63	2.23	1	4.2	0.7	3.2											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	838	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity - T+C	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5			7		-1.86	15.86	4	2.4	-3	9.9											high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	12	839	Horvath (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity - T+C	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		1.6		-3.11	6.31	2.6	8	1	10											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	840	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	inappropriate speech - T+C	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5	outcomes		1.1		-2.28	4.48	0.7	3	-0.4	2.9											high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	12	841	Horvath (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech - T+C	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		0.9		-0.5	2.3	1	2.6	0.1	2.8											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	842	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	irritability - P	Report	Aberrant Behavior Checklist - Parents	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12			-0.3		-4.15	3.55	0.8	4.7	1.1	1											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	25	843	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	irritability - P	Report	Aberrant Behavior Checklist - Parents	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		-0.1		-3.09	2.89	2	6.9	2.1	4											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	844	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Lethargy - P	Report	Aberrant Behavior Checklist - Parents	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12	outcomes		0.8		-3.35	4.95	2.7	4.8	1.9	5.7											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	25	845	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Lethargy - P	Report	Aberrant Behavior Checklist - Parents	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		2.2		0.39	4.01	2.1	4.2	-0.1	2.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	846	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy - P	Report	Aberrant Behavior Checklist - Parents	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12			0.4		-1.21	2.01	0.7	1.2	0.3	2.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	25	847	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy - P	Report	Aberrant Behavior Checklist - Parents	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		1.5		-0.16	3.16	2	3.7	0.5	2.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	848	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity - P	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	14	13			2.4		-2.44	7.24	2.7	4.8	0.3	7.2											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	27	849	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity - P	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		1.9		-1.92	5.72	5.3	7.2	3.4	7.5											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	850	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech - P	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	14	13	outcomes		0.5		-1.2	2.2	1.2	2	0.7	2.3											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	27	851	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	inappropriate speech - P	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		-0.3		-1.58	0.98	0.6	2.7	0.9	2.2000000000000002											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	852	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Mood related symptoms	internalizing	Report	Behavior Assessment System for Children	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	14	13	outcomes		3.2		-2.4	8.8	0.3	6.6	-2.9	7.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	27	853	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	3.7	5.5	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	6	1.5	g/day	Home	100	0	0			100		Mood related symptoms	internalizing	Report	Behavior Assessment System for Children	0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT	MD	19	19	outcomes		-4.8		-10.49	0.89	-2.2	8.75	2.6	8.92											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM + ADI-R + ADOS	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	38	854	Horvath (2017)	Mankad_2015	2-6 months		< 6 yo	3.7	5.5	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS Total	Report	Social Responsiveness Scale	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12	outcomes		-2.6		-7.99	2.79	-0.9	6.5	1.7	7.2											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	25	855	Horvath (2017)	Bent_2011	2-6 months		< 6 yo	5.5	6.5	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Horvath (2017)	Horvath	2017	https://doi.org/10.3945/jn.116.242354.	3.0	Critically low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	SRS Total	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	MD	29	28	outcomes		-3.5		-7.68	0.68	2.6	8.3	6.1	7.8											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	1.0	1.0	0	0.0	0.5	1.0	1	1	1	1	1	1	1	57	856	Horvath (2017)	Bent_2014	< 2 months		6-12 yo	5.5	6.5	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Social Withdrawal/Lethargy	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5	outcomes						5.5	8.1	4.6	5.6											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	12	857	James (2011)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Social Withdrawal/Lethargy	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12	outcomes						2.7	4.8	1.9	5.7											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	ADOS SCQ DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	25	858	James (2011)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Inappropriate Speech	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5	outcomes						0.7	3	-0.4	2.9											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	12	859	James (2011)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Inappropriate Speech	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12	outcomes						1.2	2	0.7	2.3											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	ADOS SCQ DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	25	860	James (2011)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5							1.4	2.2	-1	3.4											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	12	861	James (2011)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Stereotypy	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12							0.7	1.2	0.3	2.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	ADOS SCQ DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	25	862	James (2011)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5							4	2.4	-3	9.9											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	12	863	James (2011)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12							2.7	4.8	0.3	7.2											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	ADOS SCQ DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	25	864	James (2011)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5							4.7	3.5	4.6	7.5											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	12	865	James (2011)	Amminger_2007	< 2 months		6-12 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
James (2011)	James	2011	https://doi.org/10.1002/14651858.CD007992.pub2.	5.0	Low	Complementary	PUFA	n-3	Omega 3	Omega 3	2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12							0.8	4.7	1.1	5.1											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	ADOS SCQ DSM-IV-TR	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	0	1	25	866	James (2011)	Bent_2011	2-6 months		< 6 yo	5.5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Social interaction	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5	outcomes	reverse	-1		-8.75	6.75															low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	12	867	Mazahery (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Social interaction	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12	outcomes	reverse	-0.8		-4.95	3.35															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	868	Mazahery (2017)	Bent_2011	2-6 months		< 6 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Social interaction	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	28	29	outcomes	reverse	-2.2		-4.02	-0.38															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.28	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	869	Mazahery (2017)	Bent_2014	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	3.68239356	1.4	g/day	Home	100	0	0			100		Social-communication	Social interaction	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	MD	7	6	outcomes	reverse	-3.5		-16.1	9.1															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	7.69	17	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	870	Mazahery (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Communication	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5	outcomes	reverse	-1.1		-4.48	2.28															low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	12	871	Mazahery (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Communication	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12	outcomes	reverse	-0.5		-2.2	1.2															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	872	Mazahery (2017)	Bent_2011	2-6 months		< 6 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Communication	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	28	29	outcomes	reverse	0.3		-0.98	1.58															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.28	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	873	Mazahery (2017)	Bent_2014	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	3.68239356	1.4	g/day	Home	100	0	0			100		Social-communication	Communication	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	MD	7	6	outcomes	reverse	-4.4		-7.98	-0.82															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	7.69	17	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	874	Mazahery (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive and restrictive interests and behaviors	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5		reverse	-2.4		-5.8	1	-1.4	2.2000000000000002	1	3.4											low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	12	875	Mazahery (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive and restrictive interests and behaviors	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12		reverse	-0.4		-2.01	1.21	-0.7	1.2	-0.3	2.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	876	Mazahery (2017)	Bent_2011	2-6 months		< 6 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive and restrictive interests and behaviors	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	28	29		reverse	-1.5		-3.4	0.4	-2	3.7	-0.5	3.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.28	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	877	Mazahery (2017)	Bent_2014	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	3.68239356	1.4	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Repetitive and restrictive interests and behaviors	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	MD	7	6		reverse	-1.4		-4.69	1.89	-4.2	2.5	-2.8	3.4											low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	7.69	17	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	878	Mazahery (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5		reverse	-3.4		-12.26	5.46															low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	12	879	Mazahery (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12		reverse	-2.4		-7.24	2.44															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	880	Mazahery (2017)	Bent_2011	2-6 months		< 6 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	28	29		reverse	-1.9		-5.72	1.92															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.28	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	881	Mazahery (2017)	Bent_2014	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	3.68239356	1.4	g/day	Home	100	0	0			100		ADHD symptoms	Hyperactivity	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	MD	7	6		reverse	-0.4		-12.53	11.73															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	7.69	17	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	882	Mazahery (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	MD	7	5		reverse	-0.1		-7.17	6.97															low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	12	883	Mazahery (2017)	Amminger_2007	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	MD	13	12		reverse	0.3		-3.55	4.15															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	DSM + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	25	884	Mazahery (2017)	Bent_2011	2-6 months		< 6 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	MD	28	29		reverse	0.1		-2.92	3.12															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.28	6.5		1	0	1	1	USA	North America	ADI-R + ADOS + SCQ	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	57	885	Mazahery (2017)	Bent_2014	< 2 months		6-12 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Mazahery (2017)	Mazahery	2017	https://doi.org/10.3390/nu9020155	2.0	Critically low	Complementary	PUFA	n-3	n-3 LCPUFA	n-3 LCPUFA	3.68239356	1.4	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	MD	7	6		reverse	-0.4		-12.53	11.73															low	100	100	0	100	100	100	unclear	low	unclear	low	low	low	Placebo ()	0	7.69	17	100	1	1	1	1	Japan	Asia	DSM-IV	1	0	1	0.0	0.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	13	886	Mazahery (2017)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.5	17	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Adaptive behaviors	Adaptive behaviors		Echelle utilisee non precisee	0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12			-0,11		-0,89	0,68	31.7	9	32.7	9											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	25	887	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.8	6.1	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	5.98388953	0.2	g/day	Home	100	0	0			100		Adaptive behaviors	Adaptive behaviors		Echelle utilisee non precisee	0	0	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT	SMD	19	15			-0,83		-1,54	-0,12	26.3	6.8	33.3	9.7											high	100	0	100	0	0	0	low	low	unclear	unclear	high	unclear	Placebo ()	0	16.7	6.1		1	0	1	1	USA	North America	DSM-IV CARS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	34	888	De Crescenzo (2020)	Voigt_2014	2-6 months		6-12 yo	5.8	6.1	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5	outcomes		-0,46		-1,63	0,71	7.6	4	9.4	2.9											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	12	889	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Social communication	Test	Expressive Vocabulary Test	100	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12	outcomes		0,72		-0,09	1,54	-73	33	-92.2	14											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	25	890	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Social communication		Echelle utilisee non precisee	0	0	0		Bent	2014	RCT	SMD	29	28	outcomes		0,47		-0,05	1	6.4	3.4	4.9	2.8											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	891	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	11.96777906	0.7	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	23	16	outcomes		-0,45		-1,1	0,19	2.9	2.2	3.9	2.1											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	17.8	5.3		1	0	1	1	New Zealand	Oceania	DSM-V	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	39	892	De Crescenzo (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	omega-3	omega-3	1.84119678	1	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	SMD	40	37	outcomes		-0,10		-0,55	0,34	82.46	10.69	83.61	11.35											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.2	9.7		1	0	1	1	Spain	Europe	DSM-IV-TR (Pervasive developmental disorder)	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	77	893	De Crescenzo (2020)	Parellada_2017	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	3.68239356	1.4	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	SMD	7	6	outcomes		-1,07		-2,27	0,13	23.3	6.3	30.7	6.6											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	894	De Crescenzo (2020)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause	Report		0	0	100		Amminger	2007	RCT	RR	7	6		reverse	0.291666666666667	1.54880907	0.0140132261527536	6.07065378929378															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	895	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause	Report		0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	14	13		reverse	1.54761904761905	0.62046892	0.458690727693424	5.22165496694784															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	27	896	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause			0	0	0		Bent	2014	RCT	RR	29	28		reverse	1.93103448275862	0.55208963	0.654410843698416	5.69809349815925															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	897	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	5.52359033	1.5	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause	Report		0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT	RR	18	19		reverse	2.11111111111111	0.80113224	0.439122906936671	10.1493000093013															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.3	3.694595		1	0	1	1	Canada	North America	DSM-IV ADOS ADI-R	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	37	898	De Crescenzo (2020)	Mankad_2015	2-6 months		< 6 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	11.96777906	0.7	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause	Report		0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	RR	28	28		reverse	0.416666666666667	0.46033114	0.169026258555098	1.02712509047533															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	17.8	5.3		1	0	1	1	New Zealand	Oceania	DSM-V	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	56	899	De Crescenzo (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	omega-3	omega-3	1.84119678	1	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause	Report		0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	RR	40	37		reverse	3.2375	0.76865474	0.717678064790339	14.6046072246363															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.2	9.7		1	0	1	1	Spain	Europe	DSM-IV-TR (Pervasive developmental disorder)	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	77	900	De Crescenzo (2020)	Parellada_2017	< 2 months		6-12 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	5.98388953	0.2	g/day	Home	100	0	0			100		Acceptability	Discontinuation due to any cause	Report		0	0	100	10.1097/MPG.0000000000000260	Voigt	2014	RCT	RR	24	24		reverse	0.555555555555556	0.47726070	0.218013028924011	1.4157042669969															high	100	0	100	0	0	0	low	low	unclear	unclear	high	unclear	Placebo ()	0	16.7	6.1		1	0	1	1	USA	North America	DSM-IV CARS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	48	901	De Crescenzo (2020)	Voigt_2014	2-6 months		6-12 yo	3.694595	10.4	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5		reverse	0.27		-0.88	1.43	29.3	5.7	27.6	5.9											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	12	902	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report + Observation	Echelle utilisee non precisee	0	100	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12		reverse	-0.28		-1.07	0.51	16	13	19.2	8											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	25	903	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report + Observation	Echelle utilisee non precisee	0	100	100		Bent	2014	RCT	SMD	29	28		reverse	-0.22		-0.74	0.3	22.9	8.4	24.7	7.6											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	904	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	11.96777906	0.7	g/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	23	16		reverse	-0.48		-1.13	0.17	14	8.8	19	12											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	17.8	5.3		1	0	1	1	New Zealand	Oceania	DSM-V	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	39	905	De Crescenzo (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	3.68239356	1.4	g/day	Home	100	0	0			100		ADHD symptoms	ADHD symptoms	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	SMD	7	6		reverse	-0.32		-1.42	0.78	12	10.7	15.3	8.1											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	906	De Crescenzo (2020)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5		reverse	0,37		-0,79	1,53															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	12	907	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12		reverse	-0,18		-0,96	0,61															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	25	908	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	SMD	29	28		reverse	0,37		-0,16	0,89															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	909	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	11.96777906	0.7	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	23	16		reverse	-0,56		-1,21	0,09															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	17.8	5.3		1	0	1	1	New Zealand	Oceania	DSM-V	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	39	910	De Crescenzo (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	3.68239356	1.4	g/day	Home	100	0	0			100		Disruptive behaviors	Irritability	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	SMD	7	6		reverse	-0,03		-1,12	1,06															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	911	De Crescenzo (2020)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Adverse events	Adverse events	Report		0	0	100		Amminger	2007	RCT	RR	7	5		reverse	0.75	1.92570333	0.0172147061216171	32.6755505453357															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	12	912	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Adverse events	Adverse events	Report		0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	14	13		reverse	1.16071428571429	0.54922523	0.395570564928064	3.40585921327647															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	27	913	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		Adverse events	Adverse events	Report		0	0	100		Bent	2014	RCT	RR	29	28		reverse	1.60919540229885	0.44324894	0.675016831023494	3.83621522274255															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	914	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	5.98388953	0.2	g/day	Home	100	0	0			100		Adverse events	Adverse events	Report		0	0	100	10.1097/MPG.0000000000000260	Voigt	2014	RCT	RR	24	24		reverse	7	1.48516473	0.380998729019461	128.609352913346															high	100	0	100	0	0	0	low	low	unclear	unclear	high	unclear	Placebo ()	0	16.7	6.1		1	0	1	1	USA	North America	DSM-IV CARS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	48	915	De Crescenzo (2020)	Voigt_2014	2-6 months		6-12 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	3.68239356	1.4	g/day	Home	100	0	0			100		Adverse events	Adverse events	Report		0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	RR	7	6		reverse	0.875	1.93187548	0.0198423299027825	38.5854384919099															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	916	De Crescenzo (2020)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5		reverse	0.81		-0.4	2.02	13	5.2	8.8	4.1											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	12	917	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	Aberrant Behavior Checklist	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12		reverse	-0.85		-1.68	-0.03	2.1	3	5.7	5											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	25	918	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	Aberrant Behavior Checklist	0	0	100		Bent	2014	RCT	SMD	29	28		reverse	0.2		-0.32	0.72	6	6	4.9	4.7											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	919	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	11.96777906	0.7	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	23	16		reverse	-0.16		-0.8	0.48	3.1	4.1	3.7	2.9											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	17.8	5.3		1	0	1	1	New Zealand	Oceania	DSM-V	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	39	920	De Crescenzo (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	omega-3	omega-3	1.84119678	1	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	SMD	40	37		reverse	0.30		-0.15	0.75	86.83	15.84	81.75	17.33											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.2	9.7		1	0	1	1	Spain	Europe	DSM-IV-TR (Pervasive developmental disorder)	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	77	921	De Crescenzo (2020)	Parellada_2017	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	3.68239356	1.4	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	Restricted repetitive behaviors	Report	Aberrant Behavior Checklist	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	SMD	7	6		reverse	-0.32		-1,42	0,78	3.4	4.9	5.2	5.7											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	922	De Crescenzo (2020)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	Omega 3	Omega 3	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Aberrant Behavior Checklist	0	0	100		Amminger	2007	RCT	SMD	7	5	outcomes		-0,19		-1,34	0,96	18.9	13.3	21	2											high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	10.4		1	0	1	1	Austria	Europe	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	12	923	De Crescenzo (2020)	Amminger_2007	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	13	12	outcomes		0,05		-0,73	0,83	77.8	11	77.3	8											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.1	5.8		1	0	1	1	USA	North America	DSM-IV-TR ADOS SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	25	924	De Crescenzo (2020)	Bent_2011	2-6 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100		Bent	2014	RCT	SMD	29	28	outcomes		0,43		-0,10	0,95	87.1	12.7	82.2	9.7											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.2		1	0	1	1	USA	North America	Parent-report SCQ	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	57	925	De Crescenzo (2020)	Bent_2014	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	11.96777906	0.7	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Aberrant Behavior Checklist	0	0	100	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	23	16	outcomes		-0,84		-1,51	-0,18	5.7	5.9	12	9											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	17.8	5.3		1	0	1	1	New Zealand	Oceania	DSM-V	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	39	926	De Crescenzo (2020)	Mazahery_2018/2019	7-12 months		< 6 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	omega-3	omega-3	1.84119678	1	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	SMD	40	37	outcomes		0,3		-0,15	0,75	80.92	8.65	78.13	9.53											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	16.2	9.7		1	0	1	1	Spain	Europe	DSM-IV-TR (Pervasive developmental disorder)	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	77	927	De Crescenzo (2020)	Parellada_2017	< 2 months		6-12 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
De Crescenzo (2020)	De Crescenzo	2020	https://doi.org/10.1186/s12955-020-01284-5	3.5	Low	Complementary	PUFA	PUFA	PUFAs	PUFAs	3.68239356	1.4	g/day	Home	100	0	0			100		Social-communication	Social communication	Report	Social Responsiveness Scale	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	SMD	7	6	outcomes		-0,16		-1,25	0,93	89.3	28.4	93.2	13.2											low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV ADI-R ADOS	1	0	1	0.5	1.0	1	0.5	0.5	1.0	0	1	1	1	1	1	1	13	928	De Crescenzo (2020)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.3	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.5	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0		Amminger	2007	RCT	RR	7	6		reverse	0.291666666666667	1.54880907	0.0140132261527536	6.07065378929378															high	100	0	0	0	100	100	unclear	unclear	low	low	high	low	Placebo ()	0	0	10.5		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	929	Siafis (child) (2022)	Amminger_2007	< 2 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	14	13		reverse	1.54761904761905	0.62046892	0.458690727693424	5.22165496694784															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	27	930	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0		Bent	2014	RCT	RR	29	28		reverse	1.93103448275862	0.47937768	0.754645544078778	4.94125248980943															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	931	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	0.4	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.5114/pedm.2020.101806	Doaei	2021	RCT	RR	28	26		reverse	0.931034482758621	1.98203941	0.0191359825253083	45.2981814202221															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	32.1428571428572	8.1		1	0	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	932	Siafis (child) (2022)	Doaei_2021	< 2 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.52359033	1.5	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT	RR	19	19		reverse	2	0.80295507	0.414527552486461	9.64953952036915															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	933	Siafis (child) (2022)	Mankad_2015	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	RR	29	29		reverse	0.461538461538462	0.41788064	0.203473218826311	1.04690805359071															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	58	934	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517			Home	100	0	0			100		Acceptability	acceptability			0	0	0		NCT00467818		RCT	RR	9	8		reverse	1.33333333333333	0.77280154	0.293176308430861	6.06385211442496															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	11.1111111111111	11.7		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	17	935	Siafis (child) (2022)	NCT00467818_NA	2-6 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.99194476			Home	100	0	0			100		Acceptability	acceptability			0	0	0		NCT03550209		RCT	RR	37	35		reverse	1.41891891891892	0.60088952	0.436998046511916	4.60718512253381															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	25	4.75		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	72	936	Siafis (child) (2022)	NCT03550209_NA	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.98388953	0.2	g/day	Home	100	0	0			100		Acceptability	acceptability			0	0	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT	RR	24	24		reverse	0.555555555555556	0.47726070	0.218013028924011	1.4157042669969															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.6666666666667	5.8		1	0	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	937	Siafis (child) (2022)	Voigt_2014	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms	ADHD		ABC-H	0	0	0		Amminger	2007	RCT	G	7	5			0.99		-0.26	2.23	4.00	2.4000	-3.00	9.9000											high	100	0	0	0	100	100	unclear	unclear	low	low	high	low	Placebo ()	0	0	10.5		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	12	938	Siafis (child) (2022)	Amminger_2007	< 2 months		6-12 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms	ADHD		ABC-H	0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12			0.38		-0.41	1.18	2.70	4.8000	0.30	7.2000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	939	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms	ADHD		ABC-H	0	0	0		Bent	2014	RCT	G	29	28			0.26		-0.27	0.78	5.30	7.2000	3.40	7.5000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	940	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		ADHD symptoms	ADHD		ABC-H	0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16			0.39		-0.26	1.03	3.40	6.5466	0.80	6.5466											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	941	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	3.68239356	1.44	g/day	Home	100	0	0			100		ADHD symptoms	ADHD		ABC-H	0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6			0.10		-0.99	1.19	6.30	10.3233	5.00	13.4280											high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	14.2857142857143	13.9	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	942	Siafis (child) (2022)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	14	13		reverse	1.16071428571429	0.54922523	0.395570564928064	3.40585921327647															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	27	943	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0		Bent	2014	RCT	RR	29	28		reverse	1.60919540229885	0.44324894	0.675016831023494	3.83621522274255															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	944	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.52359033	1.5	g/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT	RR	19	19		reverse	1	0.05063697	0.905519348385759	1.1043386337163															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	945	Siafis (child) (2022)	Mankad_2015	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517			Home	100	0	0			100		Adverse events	any adverse events			0	0	0		NCT00467818		RCT	RR	9	8		reverse	0.3	1.56702124	0.0139081818345923	6.47101116956587															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	11.1111111111111	11.7		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	17	946	Siafis (child) (2022)	NCT00467818_NA	2-6 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.99194476			Home	100	0	0			100		Adverse events	any adverse events			0	0	0		NCT03550209		RCT	RR	37	35		reverse	1.09851787271142	0.06661371	0.964063037804726	1.25172469988509															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	25	4.75		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	72	947	Siafis (child) (2022)	NCT03550209_NA	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	3.68239356	1.44	g/day	Home	100	0	0			100		Adverse events	any adverse events			0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	RR	7	6		reverse	0.875	1.93187548	0.0198423299027825	38.5854384919099															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	14.2857142857143	13.9	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	948	Siafis (child) (2022)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS	0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12			-0.11		-0.90	0.67	0.90	6.5000	1.70	7.2000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	949	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS	0	0	0		Bent	2014	RCT	G	29	28			-0.43		-0.95	0.10	2.60	8.3000	6.10	7.8000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	950	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	0.4	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		GARS-2	0	0	0	10.5114/pedm.2020.101806	Doaei	2021	RCT	G	28	26			0.41		-0.13	0.95	4.63	10.5654	-0.35	13.0541											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	32.1428571428572	8.1		1	0	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	951	Siafis (child) (2022)	Doaei_2021	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.52359033	1.5	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		PDDBI	0	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT	G	18	19			-0.24		-0.88	0.41	4.50	7.9400	6.40	7.7800											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	37	952	Siafis (child) (2022)	Mankad_2015	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS	0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16			0.57		-0.08	1.22	17.00	19.3240	5.80	19.3240											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	953	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	1	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS	0	0	0	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35			0.16		-0.31	0.64	2.98	8.6701	1.51	9.0183											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	20	9.39		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	68	954	Siafis (child) (2022)	Parellada_2017	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	3.68239356	1.44	g/day	Home	100	0	0			100		Overall ASD symptoms	OV ASD		SRS	0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6			-0.11		-1.20	0.99	43.70	29.8985	46.80	23.7344											high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	14.2857142857143	13.9	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	955	Siafis (child) (2022)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors	irritability		ABC-I	0	0	0		Amminger	2007	RCT	G	7	5			0.02		-1.13	1.16	4.70	3.5000	4.60	7.5000											high	100	0	0	0	100	100	unclear	unclear	low	low	high	low	Placebo ()	0	0	10.5		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	12	956	Siafis (child) (2022)	Amminger_2007	< 2 months		6-12 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	irritability		ABC-I	0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12			-0.06		-0.84	0.73	0.80	4.7000	1.10	5.1000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	957	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors	irritability		ABC-I	0	0	0		Bent	2014	RCT	G	29	28			-0.02		-0.54	0.50	2.00	6.9000	2.10	4.4000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	958	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		Disruptive behaviors	irritability		ABC-I	0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16			1.07		0.38	1.75	5.00	5.3301	-0.80	5.3301											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	959	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517			Home	100	0	0			100		Disruptive behaviors	irritability		ABC-I	0	0	0		NCT00467818		RCT	G	6	6			0.68		-0.50	1.86	-5.66	5.0000	-8.50	2.1000											high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	11.1111111111111	11.7		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	12	960	Siafis (child) (2022)	NCT00467818_NA	2-6 months		6-12 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	3.68239356	1.44	g/day	Home	100	0	0			100		Disruptive behaviors	irritability		ABC-I	0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6			0.04		-1.05	1.13	3.90	10.3793	3.50	8.2656											high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	14.2857142857143	13.9	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	961	Siafis (child) (2022)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC-S	0	0	0		Amminger	2007	RCT	G	7	5			0.81		-0.41	2.02	1.40	2.2000	-1	3.4000											high	100	0	0	0	100	100	unclear	unclear	low	low	high	low	Placebo ()	0	0	10.5		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	12	962	Siafis (child) (2022)	Amminger_2007	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC-S	0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12			0.19		-0.59	0.98	0.70	1.2000	0.30	2.6000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	963	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC-S	0	0	0		Bent	2014	RCT	G	29	28			0.46		-0.07	0.99	2.00	3.7000	0.50	2.6000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	964	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	0.4	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		GARS-2-S	0	0	0	10.5114/pedm.2020.101806	Doaei	2021	RCT	G	28	26			0.26		-0.28	0.79	1.32	5.0650	-0,19	6.5308											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	32.1428571428572	8.1		1	0	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	965	Siafis (child) (2022)	Doaei_2021	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.52359033	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		PDDBI-RRBI	0	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT	G	18	19			-0.39		-1.04	0.26	2.90	5.4500	5.05	5.3500											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	37	966	Siafis (child) (2022)	Mankad_2015	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC-S	0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16			-0.19		-0.83	0.45	0.70	3.0807	1.30	3.0807											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	967	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	1	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		SRS-AM	0	0	0	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35			0.12		-0.35	0.60	3.87	16.4067	1.81	16.7268											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	20	9.39		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	68	968	Siafis (child) (2022)	Parellada_2017	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	3.68239356	1.44	g/day	Home	100	0	0			100		Restricted/repetitive behaviors	RRB		ABC-S	0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6			0.20		-0.90	1.29	4.20	6.8286	2.80	6.3222											high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	14.2857142857143	13.9	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	969	Siafis (child) (2022)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication	social-communication		ABC-L/SW	0	0	0		Amminger	2007	RCT	G	7	5			0.13		-1.02	1.28	5.60	8.1000	4.60	5.6000											high	100	0	0	0	100	100	unclear	unclear	low	low	high	low	Placebo ()	0	0	10.5		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	12	970	Siafis (child) (2022)	Amminger_2007	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication	social-communication		ABC-L/SW	0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	G	13	12			0.15		-0.64	0.93	2.70	4.8000	1.90	5.7000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	971	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication	social-communication		ABC-L/SW	0	0	0		Bent	2014	RCT	G	29	28			0.62		0.09	1.15	2.10	4.20	-0,1	2.6000											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	972	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	0.4	g/day	Home	100	0	0			100		Social-communication	social-communication		GARS-2-SI	0	0	0	10.5114/pedm.2020.101806	Doaei	2021	RCT	G	28	26			0.16		-0.37	0.70	0.92	4.1216	0.23	4.2270											low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	32.1428571428572	8.1		1	0	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	973	Siafis (child) (2022)	Doaei_2021	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.52359033	1.5	g/day	Home	100	0	0			100		Social-communication	social-communication		VABS-S	0	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT	G	18	19			-0.20		-0.84	0.45	-0,3	5.6300	0.80	5.3900											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	37	974	Siafis (child) (2022)	Mankad_2015	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		Social-communication	social-communication		ABC-L/SW	0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	G	23	16			0.65		-0.01	1.30	3.40	5.1418	0	5.1418											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	975	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	1	g/day	Home	100	0	0			100		Social-communication	social-communication		SRS-SC	0	0	0	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	G	33	35			0.15		-0.32	0.63	2.75	8.5117	1.43	8.6134											high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	20	9.39		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	68	976	Siafis (child) (2022)	Parellada_2017	< 2 months		6-12 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.98388953	0.2	g/day	Home	100	0	0			100		Social-communication	social-communication		BASC-S	0	0	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT	G	13	12			-0.38		-1.17	0.42	-0,2	6.9549	3.00	9.4144											high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.6666666666667	5.8		1	0	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	25	977	Siafis (child) (2022)	Voigt_2014	2-6 months		< 6 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	3.68239356	1.44	g/day	Home	100	0	0			100		Social-communication	social-communication		ABC-L/SW	0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	G	7	6			0.39		-0.71	1.50	15.80	9.2698	12.30	6.8505											high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	14.2857142857143	13.9	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	978	Siafis (child) (2022)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.7	13.9	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.5	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0		Amminger	2007	RCT	RR	7	6		reverse	0.875	1.93187548	0.0198423299027825	38.5854384919099															high	100	0	0	0	100	100	unclear	unclear	low	low	high	low	Placebo ()	0	0	10.5		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	979	Siafis (child) (2022)	Amminger_2007	< 2 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517	1.3	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	RR	14	13		reverse	1.85714285714286	1.16260413	0.190210675055167	18.1324186501963															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	7.14285714285714	5.85		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	27	980	Siafis (child) (2022)	Bent_2011	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.38089758	1.3	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0		Bent	2014	RCT	RR	29	28		reverse	0.966666666666667	1.98297350	0.0198320056945845	47.1180000064043															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	981	Siafis (child) (2022)	Bent_2014	< 2 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	1.84119678	0.4	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.5114/pedm.2020.101806	Doaei	2021	RCT	RR	28	26		reverse	0.931034482758621	1.98203941	0.0191359825253083	45.2981814202221															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	32.1428571428572	8.1		1	0	1	1	Iran			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	982	Siafis (child) (2022)	Doaei_2021	< 2 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.52359033	1.5	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT	RR	19	19		reverse	1	1.37649440	0.0673481762464326	14.8482120189998															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	21.0526315789474	3.7		1	0	1	1	Canada	North America	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	983	Siafis (child) (2022)	Mankad_2015	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	11.96777906	0.7	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	RR	29	29		reverse	1	1.98326330	0.0205042182058012	48.7704524972854															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	58	984	Siafis (child) (2022)	Mazahery_2018/2019	7-12 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.76179517			Home	100	0	0			100		Tolerability	tolerability			0	0	0		NCT00467818		RCT	RR	9	8		reverse	0.888888888888889	1.32811479	0.0658194305865556	12.0044103959708															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	unclear	Placebo ()	0	11.1111111111111	11.7		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	17	985	Siafis (child) (2022)	NCT00467818_NA	2-6 months		6-12 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	2.99194476			Home	100	0	0			100		Tolerability	tolerability			0	0	0		NCT03550209		RCT	RR	37	35		reverse	0.947368421052632	1.98643058	0.0193048367093988	46.4912984615298															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	25	4.75		1	0	1	1	USA			1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	72	986	Siafis (child) (2022)	NCT03550209_NA	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Siafis (child) (2022)	Siafis (child)	2022	https://doi.org/10.1186/s13229-022-00488-4	5.0	Low	Complementary	PUFA	n-3	oral	oral	5.98388953	0.2	g/day	Home	100	0	0			100		Tolerability	tolerability			0	0	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT	RR	24	24		reverse	1	1.97989899	0.0206398685275337	48.4499210189249															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.6666666666667	5.8		1	0	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	48	987	Siafis (child) (2022)	Voigt_2014	2-6 months		< 6 yo	3.7	11.7	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	active group MT; singing, dancing, playing musical instruments while listening to music;	active group MT; singing, dancing, playing musical instruments while listening to music;	3	1.75	hour/week		0	0	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1186/s41983-019-0091-x	Bharathi	2019	NRCT	G	26	26	outcomes		0.14000000000000001		-0.4	0.69															high	0	0	0	100	100	0	high	high	unclear	high	low	low	Non-therapeutic ()	0	50	9.5		1	0	1	1	India	Asia	DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	52	988	Geretsegger (2022)	Bharathi_2019	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	142	129	outcomes		-0.02		-0.26	0.22															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	271	989	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	2.76179517	1.66666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	"10.3760/
cma.j.issn.0254-1424.2013.07.019"	Chen	2013	RCT	G	18	9	outcomes		2.31		1.27	3.35															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	0	4.5		1	0	1	1	China	Asia	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	27	990	Geretsegger (2022)	Chen_2013	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	relational MT; improvisation not using a structured protocol;	relational MT; improvisation not using a structured protocol;	3.68239356	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1080/08098131.2011.566933	Gattino	2011	RCT	G	12	12	outcomes		-0.23		-1.03	0.57999999999999996															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	0	9.75		1	0	1	1	Brazil	South America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	24	991	Geretsegger (2022)	Gattino_2011	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT OrI -Schulwerk; 12 sessions (2 sessions of 1 h/week) in 45 days, delivered
by two music therapists, including music listening, singing songs and chants, clapping, movement
and dancing, special musical drama, playing of instruments, etc."	"MT OrI -Schulwerk; 12 sessions (2 sessions of 1 h/week) in 45 days, delivered
by two music therapists, including music listening, singing songs and chants, clapping, movement
and dancing, special musical drama, playing of instruments, etc."	3.22209436	2	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.4103/2277-9175.161584	Ghasemtabar	2015	NRCT	G	13	14	outcomes		0.83		0.03	1.62															high	0	0	0	100	100	0	high	high	unclear	unclear	low	low	No intervention ()	0	48.15	9.1		1	0	1	1	Iran	Asia		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	27	992	Geretsegger (2022)	Ghasemtabar_2015	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	improvisational MT	improvisational MT	4	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1007/s10803-008-0566-6	Kim	2008	Cross-over RCT	G	10	10	outcomes		0.15		-0.73	1.03															high	100	0	100	0	100	0	low	unclear	unclear	unclear	high	low	Non-therapeutic ()	0	0	4.25		1	0	1	1	Korea	Asia		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	20	993	Geretsegger (2022)	Kim_2008	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	1.15074799	1.66666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1093/jmt/thu012	LaGasse	2014	RCT	G	9	8	outcomes		0.44		-0.52	1.41															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	23.53	7.58		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	17	994	Geretsegger (2022)	LaGasse_2014	< 2 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	MT; Alvin model of‘Free Improvisation’ plus TAU	MT; Alvin model of‘Free Improvisation’ plus TAU	2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1111/jcpp.12656	Porter	2017	RCT	G	16	18	outcomes		-0.11		-0.79	0.56000000000000005															high	100	0	100	100	100	0	low	low	unclear	high	low	low	TAU ()	0	27.66	12		1	0	1	1	Northern Ireland	Europe	ICD-10	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	34	995	Geretsegger (2022)	Porter_2017	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	7.36478711	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	G	19	17	outcomes		-0.5		-1.1599999999999999	0.17															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Non-therapeutic ()	0	13.51	5.5		1	0	1	1	France	Europe	CARS	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	36	996	Geretsegger (2022)	Rabeyron_2020	7-12 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	social stories	social stories	0.09836066	5.83333333333333	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1016/j.aip.2013.06.001	Schwartzberg	2013	RCT	G	12	11	outcomes		0.13		-0.69	0.95															high	100	0	0	0	100	0	unclear	unclear	unclear	high	high	low	Active ()	100	3.3	15.79		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	23	997	Geretsegger (2022)	Schwartzberg_2013	< 2 months		13-19 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	2.30149597	0.75	hour/week		0	0	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	10.1038/s41398-018-0287-3	Sharda	2018	RCT	G	26	25	outcomes		0.14000000000000001		-0.41	0.69															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	15.69	9	98	1	1	1	1	Canada	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	51	998	Geretsegger (2022)	Sharda_2018	2-6 months	Average (80-119)	6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"home-based,family-centredMT (using songs, improvisation, structuredmusic
interactions) plus standard care"	"home-based,family-centredMT (using songs, improvisation, structuredmusic
interactions) plus standard care"	3.68239356	0.5	hour/week	Home	100	0	0			100		Social-communication	Social interaction-Immediately post-intervention	Report		0	0	100	16 sessions	Thompson	2014	RCT	G	11	10	outcomes		0.96		0.05	1.87															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	TAU ()	0	17.39	4.5		1	0	1	1	Australia	Australia	ASD	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	21	999	Geretsegger (2022)	Thompson_2014	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT OrI -Schulwerk; 12 sessions (2 sessions of 1 h/week) in 45 days, delivered
by two music therapists, including music listening, singing songs and chants, clapping, movement
and dancing, special musical drama, playing of instruments, etc."	"MT OrI -Schulwerk; 12 sessions (2 sessions of 1 h/week) in 45 days, delivered
by two music therapists, including music listening, singing songs and chants, clapping, movement
and dancing, special musical drama, playing of instruments, etc."	3.22209436	2	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-1-5 months post-intervention	Report		0	0	100	10.4103/2277-9175.161584	Ghasemtabar	2015	NRCT	G	13	14	outcomes		0.9		0.11	1.7															high	0	0	0	100	100	0	high	high	unclear	unclear	low	low	No intervention ()	0	48.15	9.1		1	0	1	1	Iran	Asia		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	27	1000	Geretsegger (2022)	Ghasemtabar_2015	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	MT; Alvin model of‘Free Improvisation’ plus TAU	MT; Alvin model of‘Free Improvisation’ plus TAU	2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-1-5 months post-intervention	Report		0	0	100	10.1111/jcpp.12656	Porter	2017	RCT	G	14	18	outcomes		0.24		-0.46	0.94															high	100	0	100	100	100	0	low	low	unclear	high	low	low	TAU ()	0	27.66	12		1	0	1	1	Northern Ireland	Europe	ICD-10	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	32	1001	Geretsegger (2022)	Porter_2017	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Social interaction-6-11 months post-intervention	Report		0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	132	126	outcomes		-0.06		-0.3	0.18															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	258	1002	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	2.76179517	1.66666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	"10.3760/
cma.j.issn.0254-1424.2013.07.019"	Chen	2013	RCT	G	18	9	outcomes		1.1599999999999999		0.3	2.0299999999999998															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	0	4.5		1	0	1	1	China	Asia	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	27	1003	Geretsegger (2022)	Chen_2013	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	relational MT; improvisation not using a structured protocol;	relational MT; improvisation not using a structured protocol;	3.68239356	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	10.1080/08098131.2011.566933	Gattino	2011	RCT	G	12	12	outcomes		-0.35		-1.1599999999999999	0.45															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	0	9.75		1	0	1	1	Brazil	South America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	24	1004	Geretsegger (2022)	Gattino_2011	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	improvisational MT	improvisational MT	4	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	10.1007/s10803-008-0566-6	Kim	2008	Cross-over RCT	G	10	10	outcomes		0.55000000000000004		-0.35	1.45															high	100	0	100	0	100	0	low	unclear	unclear	unclear	high	low	Non-therapeutic ()	0	0	4.25		1	0	1	1	Korea	Asia		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	20	1005	Geretsegger (2022)	Kim_2008	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	1.15074799	1.66666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	10.1093/jmt/thu012	LaGasse	2014	RCT	G	9	8	outcomes		0.26		-0.7	1.21															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	23.53	7.58		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	17	1006	Geretsegger (2022)	LaGasse_2014	< 2 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	7.36478711	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	G	19	17	outcomes		-0.25		-0.91	0.41															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Non-therapeutic ()	0	13.51	5.5		1	0	1	1	France	Europe	CARS	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	36	1007	Geretsegger (2022)	Rabeyron_2020	7-12 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	2.30149597	0.75	hour/week		0	0	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	10.1038/s41398-018-0287-3	Sharda	2018	RCT	G	24	23	outcomes		0.28999999999999998		-0.28000000000000003	0.87															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	15.69	9	98	1	1	1	1	Canada	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	47	1008	Geretsegger (2022)	Sharda_2018	2-6 months	Average (80-119)	6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"home-based,family-centredMT (using songs, improvisation, structuredmusic
interactions) plus standard care"	"home-based,family-centredMT (using songs, improvisation, structuredmusic
interactions) plus standard care"	3.68239356	0.5	hour/week	Home	100	0	0			100		Social-communication	Non-verbal communication-Immediately post-intervention	Report		0	0	100	16 sessions	Thompson	2014	RCT	G	11	10	outcomes		0.63		-0.25	1.52															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	TAU ()	0	17.39	4.5		1	0	1	1	Australia	Australia	ASD	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	21	1009	Geretsegger (2022)	Thompson_2014	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	2.76179517	1.66666666666667	hour/week	Clinic	0	100	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	"10.3760/
cma.j.issn.0254-1424.2013.07.019"	Chen	2013	RCT	G	18	9	outcomes		2.2799999999999998		1.24	3.32															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	0	4.5		1	0	1	1	China	Asia	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	27	1010	Geretsegger (2022)	Chen_2013	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	relational MT; improvisation not using a structured protocol;	relational MT; improvisation not using a structured protocol;	3.68239356	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	10.1080/08098131.2011.566933	Gattino	2011	RCT	G	12	12	outcomes		0.09		-0.71	0.89															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	0	9.75		1	0	1	1	Brazil	South America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	24	1011	Geretsegger (2022)	Gattino_2011	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	music training; 'Developmental Speech and Language Training through Music'; videotaped songs with target words;	music training; 'Developmental Speech and Language Training through Music'; videotaped songs with target words;	0.16393443	3	hour/week	Clinic	0	100	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	10.1093/jmt/47.1.2	Lim	2010	RCT	G	18	32			0.56999999999999995		-0.02	1.1599999999999999															low	100	100	0	100	100	100	unclear	unclear	unclear	low	low	low	Active ()	100	12	4.8		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	50	1012	Geretsegger (2022)	Lim_2010	< 2 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"music training (""music incorporated Applied Behavior Analysis Verbal Behavior""; sung instructions, songs with target words)"	"music training (""music incorporated Applied Behavior Analysis Verbal Behavior""; sung instructions, songs with target words)"	0.46029919	1.5	hour/week		0	0	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	10.1093/mtp/28.2.95	Lim	2011	Cross-over RCT	G	22	22			7.0000000000000007E-2		-0.52	0.66															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Active ()	100	22.72	4.3		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	44	1013	Geretsegger (2022)	Lim_2011	< 2 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	7.36478711	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	G	19	17	outcomes		-0.72		-1.4	-0.04															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Non-therapeutic ()	0	13.51	5.5		1	0	1	1	France	Europe	CARS	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	36	1014	Geretsegger (2022)	Rabeyron_2020	7-12 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	social stories	social stories	0.09836066	5.83333333333333	hour/week	Clinic	0	100	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	10.1016/j.aip.2013.06.001	Schwartzberg	2013	RCT	G	12	11	outcomes		-0.14000000000000001		-0.96	0.68															high	100	0	0	0	100	0	unclear	unclear	unclear	high	high	low	Active ()	100	3.3	15.79		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	23	1015	Geretsegger (2022)	Schwartzberg_2013	< 2 months		13-19 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	2.30149597	0.75	hour/week		0	0	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	10.1038/s41398-018-0287-3	Sharda	2018	RCT	G	26	25	outcomes		0.32		-0.23	0.87															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	15.69	9	98	1	1	1	1	Canada	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	51	1016	Geretsegger (2022)	Sharda_2018	2-6 months	Average (80-119)	6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"home-based,family-centredMT (using songs, improvisation, structuredmusic
interactions) plus standard care"	"home-based,family-centredMT (using songs, improvisation, structuredmusic
interactions) plus standard care"	3.68239356	0.5	hour/week	Home	100	0	0			100		Social-communication	Verbal communication-Immediately post-intervention	Mixed		0	0	0	16 sessions	Thompson	2014	RCT	G	11	10	outcomes		0.41		-0.46	1.28															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	TAU ()	0	17.39	4.5		1	0	1	1	Australia	Australia	ASD	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	21	1017	Geretsegger (2022)	Thompson_2014	2-6 months		< 6 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	active group MT; singing, dancing, playing musical instruments while listening to music;	active group MT; singing, dancing, playing musical instruments while listening to music;	3	1.75	hour/week		0	0	0			100		Social-communication	Verbal communication-1-5 months post-intervention	Mixed		0	0	0	10.1186/s41983-019-0091-x	Bharathi	2019	NRCT	G	26	26	outcomes		0.22		-0.33	0.76															high	0	0	0	100	100	0	high	high	unclear	high	low	low	Non-therapeutic ()	0	50	9.5		1	0	1	1	India	Asia	DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	52	1018	Geretsegger (2022)	Bharathi_2019	2-6 months		6-12 yo	4.25	15.79	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Quality of life	Quality of life-Immediately post-intervention	Report		0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	136	129	outcomes		0.19		-0.05	0.44															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	265	1019	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	5.055	9	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	2.30149597	0.75	hour/week		0	0	0			100		Quality of life	Quality of life-Immediately post-intervention	Report		0	0	100	10.1038/s41398-018-0287-3	Sharda	2018	RCT	G	26	25			0.51		-0.05	1.07															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	15.69	9	98	1	1	1	1	Canada	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	51	1020	Geretsegger (2022)	Sharda_2018	2-6 months	Average (80-119)	6-12 yo	5.055	9	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"improvisational MT; led by a music therapist and ""mostly one-on-one, sometimes groups of three"""	"improvisational MT; led by a music therapist and ""mostly one-on-one, sometimes groups of three"""	1.84119678	1.33333333333333	hour/week		0	0	0			100		Quality of life	Quality of life-Immediately post-intervention	Report		0	0	100	10.5455/apd.12505	Yurteri	2019	NRCT	G	12	12			0.76		-7.0000000000000007E-2	1.6															high	0	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	0	7.05		1	0	1	1	Turkey	Asia	ASD	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	24	1021	Geretsegger (2022)	Yurteri_2019	< 2 months		6-12 yo	5.055	9	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Quality of life	Quality of life-6-11 months post-intervention	Report		0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	125	124	outcomes		0.04		-0.21	0.28999999999999998															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	249	1022	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	5.055	9	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	active group MT; singing, dancing, playing musical instruments while listening to music;	active group MT; singing, dancing, playing musical instruments while listening to music;	3	1.75	hour/week		0	0	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	10.1186/s41983-019-0091-x	Bharathi	2019	NRCT	G	26	26	outcomes	reverse	-1.1299999999999999		-1.72	-0.54															high	0	0	0	100	100	0	high	high	unclear	high	low	low	Non-therapeutic ()	0	50	9.5		1	0	1	1	India	Asia	DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	52	1023	Geretsegger (2022)	Bharathi_2019	2-6 months		6-12 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	165	148	outcomes	reverse	0.17		-0.05	0.39															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	313	1024	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"comprehensive treatment (medicine and education, including auditory integration training, sensory integration training, special education, language therapy, play therapy,
etc.) plusMT;"	"comprehensive treatment (medicine and education, including auditory integration training, sensory integration training, special education, language therapy, play therapy,
etc.) plusMT;"	2.76179517	2	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	"10.3969/
j.issn.1671-8348.2010.18.042"	Chen	2010	RCT	G	15	15		reverse	-0.95		-1.72	-0.19															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Active ()	100	10	4		1	0	1	1	China	Asia	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	30	1025	Geretsegger (2022)	Chen_2010	2-6 months		< 6 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	"social stories MT (including learning to sing social story songs, performing
social story content, etc.), in addition to standard care;/MT without lyrics (music group, including learning the tune of the song learned
by the social story group,the lyrics replaced by meaningless pronunciation such as ""ah..""), in addition
to standard care;"	2.76179517	1.66666666666667	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	"10.3760/
cma.j.issn.0254-1424.2013.07.019"	Chen	2013	RCT	G	18	9		reverse	-1.87		-2.83	-0.9															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	0	4.5		1	0	1	1	China	Asia	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	27	1026	Geretsegger (2022)	Chen_2013	2-6 months		< 6 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"integrated therapy; mainly including auditory integration training, speech therapy,
sensory integration training, play therapy, special education training, etc"	"integrated therapy; mainly including auditory integration training, speech therapy,
sensory integration training, play therapy, special education training, etc"	1.84119678	0.75	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	"6 sessions per week for 3 weeks (18 sessions), 30-35 minutes each, then 10 days rest, followed by another
period of 3 weeks with 6 sessions each (18 more sessions), followed by another period of rest until
day 60"	Huang	2015	RCT	G	30	30		reverse	-1.35		-1.91	-0.78															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Active ()	100	21.67	5.5		1	0	1	1	China	Asia		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	60	1027	Geretsegger (2022)	Huang_2015	< 2 months		< 6 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	1.15074799	1.66666666666667	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	10.1093/jmt/thu012	LaGasse	2014	RCT	G	9	8	outcomes	reverse	-0.26		-1.22	0.69															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	23.53	7.58		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	17	1028	Geretsegger (2022)	LaGasse_2014	< 2 months		6-12 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"music training (""music incorporated Applied Behavior Analysis Verbal Behavior""; sung instructions, songs with target words)"	"music training (""music incorporated Applied Behavior Analysis Verbal Behavior""; sung instructions, songs with target words)"	4.14269275	2	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	10.1016/j.aip.2013.09.004	Mateos-Moreno	2013	NRCT	G	8	8	outcomes	reverse	-1.93		-3.18	-0.68															high	0	0	0	100	100	0	high	high	unclear	unclear	low	low	TAU ()	0	6.25	25		1	0	1	1	USA	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	16	1029	Geretsegger (2022)	Mateos-Moreno_2013	2-6 months		>= 20 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	7.36478711	0.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	G	19	17	outcomes	reverse	0.22		-0.44	0.87															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Non-therapeutic ()	0	13.51	5.5		1	0	1	1	France	Europe	CARS	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	36	1030	Geretsegger (2022)	Rabeyron_2020	7-12 months		< 6 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"improvisational MT; led by a music therapist and ""mostly one-on-one, sometimes groups of three"""	"improvisational MT; led by a music therapist and ""mostly one-on-one, sometimes groups of three"""	1.84119678	1.33333333333333	hour/week		0	0	0			100		Overall ASD symptoms	total autism symptom severity-immediately post-intervention	Mixed		0	0	0	10.5455/apd.12505	Yurteri	2019	NRCT	G	12	12	outcomes	reverse	-0.83		-1.67	0.01															high	0	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	TAU ()	0	0	7.05		1	0	1	1	Turkey	Asia	ASD	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	24	1031	Geretsegger (2022)	Yurteri_2019	< 2 months		6-12 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	active group MT; singing, dancing, playing musical instruments while listening to music;	active group MT; singing, dancing, playing musical instruments while listening to music;	3	1.75	hour/week		0	0	0			100		Overall ASD symptoms	total autism symptom severity-1-5 months post-intervention	Mixed		0	0	0	10.1186/s41983-019-0091-x	Bharathi	2019	NRCT	G	26	26	outcomes	reverse	-1.31		-1.91	-0.7															high	0	0	0	100	100	0	high	high	unclear	high	low	low	Non-therapeutic ()	0	50	9.5		1	0	1	1	India	Asia	DSM-5	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	52	1032	Geretsegger (2022)	Bharathi_2019	2-6 months		6-12 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	"MT group; twice a week for 50 minutes, over 5 weeks; small groups (3-4
children/group) led by board-certified music therapist (the Transformational Design Model (Thaut
2000) was used to create music experiences that were functionally similar to the non-musical experiences, with the addition of music experiences and cues to facilitate the desired social skills. The primary role of the music was to provide anticipatory cues to aid in follow-through with all tasks and
to use engagement in music-making to practice the social skills. Rhythmic cues and music structure
were used to help the child plan their response, anticipate the timing for the response, and follow
through with the response)."	1.15074799	1.66666666666667	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-1-5 months post-intervention	Mixed		0	0	0	10.1093/jmt/thu012	LaGasse	2014	RCT	G	9	8	outcomes	reverse	-0.4		-1.36	0.56999999999999995															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	23.53	7.58		1	0	1	1	USA	North America		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	17	1033	Geretsegger (2022)	LaGasse_2014	< 2 months		6-12 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	total autism symptom severity-6-11 months post-intervention	Mixed		0	0	0	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	154	135	outcomes	reverse	0.18		-0.05	0.41															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	289	1034	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	4	25	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Adaptive behaviors	Adaptive behaviour-Immediately post-intervention	Report		0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	165	148	outcomes		-7.0000000000000007E-2		-0.28999999999999998	0.16															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	313	1035	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"comprehensive treatment (medicine and education, including auditory integration training, sensory integration training, special education, language therapy, play therapy,
etc.) plusMT;"	"comprehensive treatment (medicine and education, including auditory integration training, sensory integration training, special education, language therapy, play therapy,
etc.) plusMT;"	2.76179517	2	hour/week	Clinic	0	100	0			100		Adaptive behaviors	Adaptive behaviour-Immediately post-intervention	Report		0	0	100	"10.3969/
j.issn.1671-8348.2010.18.042"	Chen	2010	RCT	G	15	15			0.17		-0.55000000000000004	0.88															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Active ()	100	10	4		1	0	1	1	China	Asia	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	30	1036	Geretsegger (2022)	Chen_2010	2-6 months		< 6 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	MT; Alvin model of‘Free Improvisation’ plus TAU	MT; Alvin model of‘Free Improvisation’ plus TAU	2.76179517	1	hour/week	Clinic	0	100	0			100		Adaptive behaviors	Adaptive behaviour-Immediately post-intervention	Report		0	0	100	10.1111/jcpp.12656	Porter	2017	RCT	G	15	18	outcomes		0.08		-0.61	0.76															high	100	0	100	100	100	0	low	low	unclear	high	low	low	TAU ()	0	27.66	12		1	0	1	1	Northern Ireland	Europe	ICD-10	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	33	1037	Geretsegger (2022)	Porter_2017	2-6 months		6-12 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	"MT; 25 weekly, structured, 30-minute sessions (5 minutes opening ritual of
music listening, 20 minutes instrumental and vocal improvisation, 5 minutes closing ritual of music
listening) performed by a music therapist and a co-therapist (nurse or educator)"	7.36478711	0.5	hour/week	Clinic	0	100	0			100		Adaptive behaviors	Adaptive behaviour-Immediately post-intervention	Report		0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	G	19	17			0.04		-0.61	0.7															low	100	100	100	100	100	100	low	unclear	unclear	low	low	low	Non-therapeutic ()	0	13.51	5.5		1	0	1	1	France	Europe	CARS	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	36	1038	Geretsegger (2022)	Rabeyron_2020	7-12 months		< 6 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	"MT; use of musical instruments, songs and rhythmic cues while targeting
communication, turn-taking, sensorimotor integration, social appropriateness and musical interaction;"	2.30149597	0.75	hour/week		0	0	0			100		Adaptive behaviors	Adaptive behaviour-Immediately post-intervention	Report		0	0	100	10.1038/s41398-018-0287-3	Sharda	2018	RCT	G	26	24			0.06		-0.49	0.62															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Active ()	100	15.69	9	98	1	1	1	1	Canada	North America	DSM-IV	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	50	1039	Geretsegger (2022)	Sharda_2018	2-6 months	Average (80-119)	6-12 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	MT; Alvin model of‘Free Improvisation’ plus TAU	MT; Alvin model of‘Free Improvisation’ plus TAU	2.76179517	1	hour/week	Clinic	0	100	0			100		Adaptive behaviors	Adaptive behaviour-1-5 months post-intervention	Report		0	0	100	10.1111/jcpp.12656	Porter	2017	RCT	G	16	19	outcomes		0.56000000000000005		-0.12	1.24															high	100	0	100	100	100	0	low	low	unclear	high	low	low	TAU ()	0	27.66	12		1	0	1	1	Northern Ireland	Europe	ICD-10	1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	35	1040	Geretsegger (2022)	Porter_2017	2-6 months		6-12 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Geretsegger (2022)	Geretsegger	2022	https://doi.org/10.1002/14651858.CD004381.pub4.	5.0	High	Complementary	MUSIC	MUSIC	individual improvisational music therapy	individual improvisational music therapy	5	0.5	hour/week	Clinic	0	100	0			100		Adaptive behaviors	Adaptive behaviour-6-11 months post-intervention	Report		0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	G	155	135	outcomes		-0.12		-0.36	0.11															low	100	100	100	100	100	100	low	low	unclear	low	low	low	TAU ()	0	16.8478260869565	5.055		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	1	1.0	1.0	1	1.0	1.0	1.0	1	1	1	1	1	1	1	290	1041	Geretsegger (2022)	Bieleninik_2017	2-6 months		< 6 yo	4	12	98	98	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT, Standard care	MT, Standard care	5	0.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	symptoms severity	Observation	ADOS,SRS	0	100	0	10.1001/jama.2017.9478	Bieleninik	2017	RCT	SMD	154	136	outcomes	reverse	0.18		-0.05	0.41															low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	16.8478260869565	5.46		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	290	1042	Ke (2022)	Bieleninik_2017	2-6 months		< 6 yo	4.5	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT	MT	2	2	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	symptoms severity	Observation	CARS,SRS	0	100	0	10.4103/2277-9175.161584	Ghasemtabar	2015	NRCT	SMD	13	14		reverse	-0.04		-0.79	0.72															high	0	0	0	100	100	0	unclear	low	unclear	unclear	low	low	No intervention ()	0	48.15	9.5		1	0	1	1	Iran	Asia		1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	27	1043	Ke (2022)	Ghasemtabar_2015	2-6 months		6-12 yo	4.5	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT (music therapy)	MT (music therapy)	8	0.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	symptoms severity	Observation	CGI,CARS,ABC	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17		reverse	0.22		-0.44	0.87															high	100	0	0	100	0	0	unclear	unclear	unclear	unclear	low	unclear	Non-therapeutic ()	0	13.51	5.5		1	0	1	1	France	Europe	CARS	1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	36	1044	Ke (2022)	Rabeyron_2020	7-12 months		< 6 yo	4.5	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT, Standard care	MT, Standard care	5	0.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	SRS score	Report	SRS (Social Responsiveness Scale)	0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	SMD	132	126	outcomes		0.21		-0.04	0.45															low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	16.8478260869565	5.46		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	258	1045	Ke (2022)	Bieleninik_2017	2-6 months		< 6 yo	4.5	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	Music intervention	Music intervention	2.30149597	0.75	hour/week		0	0	0			100		Overall ASD symptoms	SRS score	Report	SRS (Social Responsiveness Scale)	0	0	100	Non-music intervention	Meghan	2018	RCT	SMD	26	25			0.34		-0.22	0.89															low	100	100	100	100	100	0	low	unclear	low	unclear	low	low	Non-therapeutic ()	0		9		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	51	1046	Ke (2022)	Meghan_2018	2-6 months		6-12 yo	4.5	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT,Early intervention	MT,Early intervention	3.68239356	0.583333333333333	hour/week	Home	100	0	0			100		Overall ASD symptoms	SRS score	Report	SRS (Social Responsiveness Scale)	0	0	100	Early intervention	Thompson	2014	RCT	SMD	11	10			0.46		-0.41	1.33															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	17.39	4.5		1	0	1	1	Australia	Australia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	21	1047	Ke (2022)	Thompson_2014	2-6 months		< 6 yo	4.5	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	Music intervention	Music intervention	2.30149597	0.75	hour/week		0	0	0			100		Social-communication	social adaptation	Report	VABS,SRS-II	0	0	100	Non-music intervention	Meghan	2018	RCT	SMD	24	26			-0.06		-0.61	0.50															low	100	100	100	100	100	0	low	unclear	low	unclear	low	low	Non-therapeutic ()	0		9		1	0	1	1				1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	50	1048	Ke (2022)	Meghan_2018	2-6 months		6-12 yo	4	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT,Early intervention	MT,Early intervention	3.68239356	0.583333333333333	hour/week	Home	100	0	0			100		Social-communication	social adaptation	Report	VSEEC,SRS-PS	0	0	100	Early intervention	Thompson	2014	RCT	SMD	12	11			0.20		-0.62	1.02															low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	Active ()	100	17.39	4.5		1	0	1	1	Australia	Australia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	23	1049	Ke (2022)	Thompson_2014	2-6 months		< 6 yo	4	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT,Activities	MT,Activities	3.68239356	0.5	hour/week	Clinic	0	100	0			100		Social-communication	speech	Report	CARS-BR	0	0	100	10.1080/08098131.2011.566933	Gattino	2011	RCT	SMD	12	12			-0.09		-0.89	0.71															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Non-therapeutic ()	0	0	9.5		1	0	1	1	Brazil	South America		1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	24	1050	Ke (2022)	Gattino_2011	2-6 months		6-12 yo	4	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	MT, ABA (Applied Behavior Analysis) (VB)	MT, ABA (Applied Behavior Analysis) (VB)	0.46029919	1.5	hour/week		0	0	0			100		Social-communication	speech	Report	VPES	0	0	100	10.1093/mtp/28.2.95	Lim	2011	RCT	SMD	18	18			0.09		-0.56	0.74															high	100	0	100	0	0	0	low	unclear	unclear	unclear	unclear	unclear	Active ()	100	22.72	4		1	0	1	1	USA	North America		1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	36	1051	Ke (2022)	Lim_2011	< 2 months		< 6 yo	4	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Ke (2022)	Ke	2022	https://doi.org/10.3389/fpsyt.2022.905113	2.0	Critically low	Complementary	MUSIC	MUSIC	Music training	Music training	0.09836066	3	hour/week	Clinic	0	100	0			100		Social-communication	speech	Report	VPES	0	0	100	10.1093/jmt/47.1.2	Lim	2010	RCT	SMD	11	11			0.10		-0.74	0.93															high	100	0	100	0	0	0	low	unclear	unclear	unclear	unclear	unclear	Active ()	100	12	4		1	0	1	1	USA	North America		1	0	0	0.0	1.0	0	0.0	0.5	1.0	0	0	1	1	1	0	1	22	1052	Ke (2022)	Lim_2010	< 2 months		< 6 yo	4	9.5	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Maw (2018)	Maw	2018	https://doi.org/10.1016/j.heliyon.2018.e00763	3.5	Critically low	Complementary	MUSIC	MUSIC	In home FCMT	In home FCMT	3.68239356	0.5	hour/week	Home	100	0	0			100		Social-communication	Social communication	Report		0	0	100	16 sessions	Thompson	2014	RCT	G	12	11			0.62		-0.26	1.5															high	100	0	0	100	100	0	unclear	low	high	high	low	low	Active ()	100	17.39	4		1	0	1	1	Norway	Europe	ASD	1	1	1	0.5	0.0	1	0.0	0.5	1.0	0	1	1	0	0	1	1	23	1053	Maw (2018)	Thompson_2014	2-6 months		< 6 yo	4	4	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Maw (2018)	Maw	2018	https://doi.org/10.1016/j.heliyon.2018.e00763	3.5	Critically low	Complementary	MUSIC	MUSIC	Music incorporated ABA VB	Music incorporated ABA VB	0.46029919	1.5	hour/week		0	0	0			100		Social-communication	Social communication		Verbal production evaluation scale	0	0	0	10.1093/mtp/28.2.95	Lim	2011	RCT	G	11	11			0.6		-0.28	1.48															low	100	100	100	100	100	100	low	high	high	low	low	low	Active ()	100	22.72	4		1	0	1	1	USA	North America		1	1	1	0.5	0.0	1	0.0	0.5	1.0	0	1	1	0	0	1	1	22	1054	Maw (2018)	Lim_2011	< 2 months		< 6 yo	4	4	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Maw (2018)	Maw	2018	https://doi.org/10.1016/j.heliyon.2018.e00763	3.5	Critically low	Complementary	MUSIC	MUSIC	"Improvisational music
therapy"	"Improvisational music
therapy"	4	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Social communication	Report	Pervasive developmental disorder behavior inventory ;  Early social communication scale	0	0	100	10.1007/s10803-008-0566-6	Kim	2008	RCT	G	5	5			0.4		-0.22	1.02															high	100	0	0	100	100	0	unclear	high	high	high	low	low	Non-therapeutic ()	0	0	4		1	0	1	1	Korea	Asia		1	1	1	0.5	0.0	1	0.0	0.5	1.0	0	1	1	0	0	1	1	10	1055	Maw (2018)	Kim_2008	2-6 months		< 6 yo	4	4	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Nei Yang Gong	Nei Yang Gong	0.92059839	2	hour/week	Clinic	0	100	0			100		Social-communication		Report	ATEC	0	0	100	10.1371/journal.pone.0068184	Chan	2013	RCT	SMC	20	19			-0.13		-0.76	0.5					-0.25	6.050000	-2.90	6.489253							high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0		11.85		1	0	1	1	Hong Kong	Asia	DSM-IV-TR	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	39	1056	Jia (2023)	Chan_2013	< 2 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Karate	Karate	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication		Report	GARS-2	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMC	13	13	outcomes		1.1200000000000001		0.28999999999999998	1.96					-6.93	4.623062	-0.16	6.035503							high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	26	1057	Jia (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Comprehensive physical training	Comprehensive physical training	1.84119678	3	hour/week	Clinic	0	100	0			100		Social-communication		Report	GARS-2	0	0	100	10.1007/s10803-022-05731-8	Haghighi	2022	RCT	SMC	8	8			7.0000000000000007E-2		-0.91	1.05					-2.00	14.726120	-1.00	12.278600							high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0		8		1	0	1	1	Iran	West Asia		1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	16	1058	Jia (2023)	Haghighi_2022	< 2 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Karate	Karate	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication		Report	GARS-2	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMC	15	15	outcomes		0.66		-7.0000000000000007E-2	1.4					-6.18	6.865792	-0.55	9.453957							high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1059	Jia (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Mixed martial arts interventions	Mixed martial arts interventions	2.99194476	0.9	hour/week	Clinic	0	100	0			100		Social-communication		Report	SSIS	0	0	100	10.1007/s10803-019-04072-3	Phung	2019	RCT	SMC	14	20			-0.56000000000000005		-1.26	0.14000000000000001					8.00	14.106180	-1.60	18.413940							high	100	0	100	100	100	0	low	high	high	high	low	low	WLC ()	0		9.347059	82.5	1	1	1	1	USA	North America		1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	34	1060	Jia (2023)	Phung_2019	2-6 months	Average (80-119)	6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Mini-baseketball training	Mini-baseketball training	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication		Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMC	18	15	outcomes		0.54		-0.16	1.24					-11.06	28.169180	2.21	17.159690							high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.923636		1	0	1	1	China	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	33	1061	Jia (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Mini-baseketball training	Mini-baseketball training	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication		Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMC	15	14	outcomes		0.86		0.09	1.63					-4.00	11.052510	4.72	8.355040							high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.923636		1	0	1	1	China	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	29	1062	Jia (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Mini-baseketball training	Mini-baseketball training	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication		Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMC	15	15	outcomes		1.01		0.24	1.78					-5.87	10.529960	4.00	8.366152							high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.923636		1	0	1	1	China	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1063	Jia (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	SPARK	SPARK	2.76179517	1.98	hour/week	Clinic	0	100	0			100		Social-communication		Report	GARS-2	0	0	100	10.1016/j.pedneo.2017.12.005	Najafabadi	2018	RCT	SMC	12	14			0.99		0.2	1.78					-5.67	6.808105	2.14	8.390369							high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0		7.613077		1	0	1	1	Iran	West Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	26	1064	Jia (2023)	Najafabadi_2018	2-6 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Swim	Swim	5.52359033	0.5	hour/week	Clinic	0	100	0			100		Social-communication		Report	SRS-2	0	0	100	10.1007/s10803-019-04128-4	Zanobini	2019	RCT	SMC	13	12			0.18		-0.61	0.97					-4.00	9.236985	-2.16	10.559920							low	100	100	100	100	100	100	low	low	high	low	low	low	TAU ()	0		5.5552		1	0	1	1	Italy	Europe		1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	25	1065	Jia (2023)	Zanobini_2019	2-6 months		< 6 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Dance movement	Dance movement	1.61104718	1	hour/week	Clinic	0	100	0			100		Social-communication		Report	FBT	0	0	100	10.1177/1362361314522353	Koch	2015	NRCT	SMC	16	15			-0.49		-1.21	0.23					0.07	0.660908	-0.21	0.413280							high	0	0	0	0	100	0	high	high	high	high	high	low	No intervention ()	0	25.8064516129032	22	100	1	1	1	1	Germany	Europe	ICD-10	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	31	1066	Jia (2023)	Koch_2015	< 2 months	Average (80-119)	>= 20 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Mini-baseketball training	Mini-baseketball training	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication		Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMC	15	15	outcomes		0.93		0.17	1.69					-3.30	8.877364	4.80	8.075042							high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.923636		1	0	1	1	China	Asia	DSM-V	1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1067	Jia (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Dance movement	Dance movement	1.15074799	1.32	hour/week	Clinic	0	100	0			100		Social-communication		Report	SCQ	0	0	100		Aithal	2021	RCT	SMC	10	16			0.35		-0.44	1.1499999999999999					-1.80	3.581243	-0.20	4.815942							high	100	0	100	100	100	0	low	high	high	high	low	low	No intervention ()	0		10.446923		1	0	1	1	UK	Europe		1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	26	1068	Jia (2023)	Aithal_2021	< 2 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Jia (2023)	Jia	2023	https://doi.org/10.3389/fped.2023.1193648	5.0	Critically low	Complementary	PHYS	PHYS	Sensory intergration training	Sensory intergration training	2.76179517			Clinic	0	100	0			100		Social-communication		Report	ABC	0	0	100	10.24869/psyd.2019.340	Xu	2019	RCT	SMC	50	53			0.77		0.37	1.17					-15.80	10.395150	-7.18	11.830860							high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0		6.175146		1	0	1	1	China	Asia		1	1	1	1.0	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	103	1069	Jia (2023)	Xu_2019	2-6 months		6-12 yo	4.923636	22	82.5	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Mini-baseketball training	Mini-baseketball training	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (inverse scale)	Report	SRS-2: social responsiveness scale	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMC	15	15	outcomes	reverse	-0.49		-1.22	0.24					82.80	27.830000	95.47	22.300000							high	0	0	0	100	0	0	high	high	high	high	low	unclear	No intervention ()	0	13.7931034482759	4.75		1	0	1	1	China	Asia	DSM-V	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	30	1070	Ojeda (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Ball game, rhythmic movements, resistance training	Ball game, rhythmic movements, resistance training	1.84119678	3	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (inverse scale)	Report	GARS-2: Gilliam Autism Rating Scale	0	0	100	10.1007/s10803-022-05731-8	Haghighi	2022	RCT	SMC	8	8	outcomes	reverse	7.0000000000000007E-2		-0.91	1.05					16.37	14.620000	15.37	12.650000							low	100	100	100	100	100	100	low	low	high	low	low	low	No intervention ()	0		8.55		1	0	1	1	Iran	West Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	16	1071	Ojeda (2023)	Haghighi_2022	< 2 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Karate techniques training	Karate techniques training	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (inverse scale)	Report	GARS-2: Gilliam Autism Rating Scale	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMC	13	13	outcomes	reverse	-1.39		-2.2599999999999998	-0.52					9.46	3.130000	16.38	6.080000							high	100	0	100	100	0	0	low	low	high	high	low	unclear	TAU ()	0	10	9.1		1	0	1	1	Iran	Asia	DSM-IV	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	26	1072	Ojeda (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	SPARK program (intervention on social and motor skills)	SPARK program (intervention on social and motor skills)	2.76179517	2	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (inverse scale)	Report	GARS-2: Gilliam Autism Rating Scale	0	0	100	10.1016/j.pedneo.2017.12.005	Najafabadi	2018	RCT	SMC	12	14	outcomes	reverse	-0.77		-1.58	0.03					14.58	7.790000	21.28	8.870000							low	100	100	100	100	100	100	low	high	high	low	low	low	TAU ()	0		7.538462		1	0	1	1	Iran	West Asia	DSM-IV	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	26	1073	Ojeda (2023)	Najafabadi_2018	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	SPARK program (intervention on social and motor skills)	SPARK program (intervention on social and motor skills)	2.76179517	2	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (inverse scale)	Report	ATEC: Autism treatment evaluation checklist for 'sociability'	0	0	100	10.1016/j.pedneo.2017.12.005	Najafabadi	2018	RCT	SMC	12	14	outcomes	reverse	-0.89		-1.7	-7.0000000000000007E-2					5.54	4.220000	10.85	6.870000							low	100	100	100	100	100	100	low	high	high	low	low	low	TAU ()	0		7.538462		1	0	1	1	Iran	West Asia	DSM-IV	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	26	1074	Ojeda (2023)	Najafabadi_2018	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Water-related activities	Water-related activities	5.52359033	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (inverse scale)	Report	SRS: social responsiveness scale	0	0	100	10.1007/s10803-019-04128-4	Zanobini	2019	RCT	SMC	13	12	outcomes	reverse	-0.24		-1.03	0.55000000000000004					91.30	24.312000	97.75	27.490000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	TAU ()	0		5.556		1	0	1	1	Italy	Europe		1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	25	1075	Ojeda (2023)	Zanobini_2019	2-6 months		< 6 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Aquatic programme	Aquatic programme	3.68239356			Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	CEPI-PE: Computerized Evaluation Protocol of Interactions in Physical Education	0	100	0	10.1016/j.rasd.2012.02.003	Chu	2012	RCT	SMC	7	7	outcomes		0.75		-0.35	1.85					0.27	0.260000	0.11	0.110000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	NA ()			8.85		1	0	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	14	1076	Ojeda (2023)	Chu_2012	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Aquatic programme	Aquatic programme	3.68239356			Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	CEPI-PE: Computerized Evaluation Protocol of Interactions in Physical Education	0	100	0	10.1016/j.rasd.2012.02.003	Chu	2012	RCT	SMC	7	7	outcomes		0		-1.05	1.05					0.13	0.060000	0.13	0.170000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	NA ()			8.85		1	0	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	14	1077	Ojeda (2023)	Chu_2012	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Aquatic programme	Aquatic programme	3.68239356			Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	CEPI-PE: Computerized Evaluation Protocol of Interactions in Physical Education	0	100	0	10.1016/j.rasd.2012.02.003	Chu	2012	RCT	SMC	7	7	outcomes		0.96		-0.17	2.09					0.03	0.040000	0.00	0.010000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	NA ()			8.85		1	0	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	14	1078	Ojeda (2023)	Chu_2012	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Aquatic programme	Aquatic programme	3.68239356			Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	CEPI-PE: Computerized Evaluation Protocol of Interactions in Physical Education	0	100	0	10.1016/j.rasd.2012.02.003	Chu	2012	RCT	SMC	7	7	outcomes		0.56000000000000005		-0.52	1.64					0.51	0.940000	0.11	0.110000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	NA ()			8.75		1	0	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	14	1079	Ojeda (2023)	Chu_2012	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Aquatic programme	Aquatic programme	3.68239356			Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	CEPI-PE: Computerized Evaluation Protocol of Interactions in Physical Education	0	100	0	10.1016/j.rasd.2012.02.003	Chu	2012	RCT	SMC	7	7	outcomes		0.17		-0.88	1.22					0.18	0.360000	0.13	0.170000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	NA ()			8.75		1	0	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	14	1080	Ojeda (2023)	Chu_2012	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Aquatic programme	Aquatic programme	3.68239356			Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	CEPI-PE: Computerized Evaluation Protocol of Interactions in Physical Education	0	100	0	10.1016/j.rasd.2012.02.003	Chu	2012	RCT	SMC	7	7	outcomes		0.59		-0.49	1.67					0.01	0.020000	0.00	0.010000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	NA ()			8.75		1	0	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	14	1081	Ojeda (2023)	Chu_2012	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Creative drama	Creative drama	3.68239356	1	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	BASC	0	100	0	10.1016/j.aip.2012.09.002	Guli	2013	RCT	SMC	18	14	outcomes		0.22		-0.48	0.92					61.89	13.550000	58.79	13.610000							high	100	0	100	100	0	0	low	low	high	high	low	unclear	NA ()			10.725	100	1	1	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	32	1082	Ojeda (2023)	Guli_2013	2-6 months	Average (80-119)	6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Creative drama	Creative drama	3.68239356	1	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Observation	BASC	0	100	0	10.1016/j.aip.2012.09.002	Guli	2013	RCT	SMC	8	9	outcomes		0.9		-0.11	1.91					14.75	9.040000	6.89	7.570000							high	100	0	100	100	0	0	low	low	high	high	low	unclear	NA ()			10.725	100	1	1	0	1				1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	17	1083	Ojeda (2023)	Guli_2013	2-6 months	Average (80-119)	6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Structured physical activities	Structured physical activities	2.76179517	2	hour/week	Clinic	0	100	0			100		Social-communication	Socialization (direct scaling)	Report	SSIS	0	0	100	10.1155/2018/1825046	Zhao	2018	RCT	SMC	21	20			1.2		0.53	1.87					51.57	5.470000	45.15	5.030000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	WLC ()	0	42	6.1		1	0	1	1			DSM	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	41	1084	Ojeda (2023)	Zhao_2018	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Karate techniques training	Karate techniques training	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	Communication (inverse scale)	Report	GARS-2: Gilliam Autism Rating Scale	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMC	15	15	outcomes	reverse	-0.6		-1.34	0.13					15.18	6.460000	20.36	9.910000							high	100	0	100	100	0	0	low	low	high	high	low	unclear	TAU ()	0	10	9.1		1	0	1	1	Iran	Asia	DSM-IV	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	30	1085	Ojeda (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Mini-baseketball training	Mini-baseketball training	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication	Communication (inverse scale)	Report	SRS-2: social responsiveness scale	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMC	15	15	outcomes	reverse	-0.56000000000000005		-1.29	0.17					29.20	10.000000	34.60	8.650000							high	0	0	0	100	0	0	high	high	high	high	low	unclear	No intervention ()	0	13.7931034482759	4.75		1	0	1	1	China	Asia	DSM-V	1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	30	1086	Ojeda (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Ball game, rhythmic movements, resistance training	Ball game, rhythmic movements, resistance training	1.84119678	3	hour/week	Clinic	0	100	0			100		Social-communication	Communication (inverse scale)	Report	GARS-2: Gilliam Autism Rating Scale	0	0	100	10.1007/s10803-022-05731-8	Haghighi	2022	RCT	SMC	8	8	outcomes	reverse	-0.23		-1.22	0.75					13.00	11.980000	15.75	10.290000							low	100	100	100	100	100	100	low	low	high	low	low	low	No intervention ()	0		8.55		1	0	1	1	Iran	West Asia		1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	16	1087	Ojeda (2023)	Haghighi_2022	< 2 months		6-12 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Ojeda (2023)	Ojeda	2023	https://doi.org/10.1007/s40489-023-00410-5	4.0	Critically low	Complementary	PHYS	PHYS	Water-related activities	Water-related activities	5.52359033	0.5	hour/week	Clinic	0	100	0			100		Social-communication	Communication (inverse scale)	Report	SRS: social responsiveness scale	0	0	100	10.1007/s10803-019-04128-4	Zanobini	2019	RCT	SMC	13	12	outcomes	reverse	-0.26		-1.04	0.53					30.15	9.750000	32.92	11.170000							high	100	0	100	100	0	0	low	high	high	high	low	unclear	TAU ()	0		5.556		1	0	1	1	Italy	Europe		1	1	1	0.0	1.0	1	0.0	0.5	1.0	1	0	0	0	0	1	1	25	1088	Ojeda (2023)	Zanobini_2019	2-6 months		< 6 yo	4.75	10.725	100	100	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Motor	Motor	2.30149597	3	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Observation	ADOS: autism diagnosis observation	0	100	0		Arabi	2019	RCT	SMD	15	15			-0.63600000000000001		-1.37	9.7000000000000003E-2															high	100	0	0	0	0	0	high	high	high	high	high	high	NA ()			8.42		1	0	0	0				1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1089	Wang (2023)	Arabi_2019	2-6 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata Technique	Kata Technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	SSGARS-2: stereotypy subscale of Gilliam autism rating scale-second edition	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		0.66100000000000003		-7.3999999999999996E-2	1.3959999999999999															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1090	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata Technique	Kata Technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	SSGARS-2: stereotypy subscale of Gilliam autism rating scale-second edition	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		0.66100000000000003		-7.3999999999999996E-2	1.3959999999999999															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1091	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata technique	Kata technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	SSGARS-2: stereotypy subscale of Gilliam autism rating scale-second edition	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		0.66100000000000003		-7.3999999999999996E-2	1.3959999999999999															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.3		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1092	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	dong=CAI	dong=CAI	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	RBS-R: repetitive behavior scale-revised	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMD	15	15	outcomes		2.698		1.7090000000000001	3.6779999999999999															high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.795		1	0	1	1	China	Asia	DSM-V	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1093	Wang (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Therapeutic horseback riding	Therapeutic horseback riding	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	VABS : vineland adaptive behavior scales	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58			2.1000000000000001E-2		-0.34300000000000003	0.38500000000000001															high	100	0	0	0	0	0	high	high	high	high	high	high	Non therapeutic ()	0		11		1	0	1	0				1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	116	1094	Wang (2023)	Gabriels_2015	2-6 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Combined physical training	Combined physical training	1.84119678	3	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	GARS-2: autism rating scale-second edition	0	0	100	10.1007/s10803-022-05731-8	Haghighi	2022	RCT	SMD	8	8			0.875		-0.151	1.9															high	100	0	100	100	100	0	low	high	high	high	low	low	No intervention ()	0		8.565		1	0	1	1	Iran	West Asia		1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	16	1095	Wang (2023)	Haghighi_2022	< 2 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Aquatic training	Aquatic training	1.84119678	1.66666666666667	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	GARS-2: autism rating scale-second edition	0	0	100	10.3390/biology11050657	Marzouki	2022	RCT	SMD	7	7			0.255		-0.80800000000000005	1.3180000000000001															high	100	0	0	0	0	0	high	high	high	high	high	high	NA ()			6.3		1	0	0	0				1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	14	1096	Wang (2023)	Marzouki_2022	< 2 months		6-12 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	dong=CAI	dong=CAI	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Stereotyped and repetitive behaviors	Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMD	15	15	outcomes		0.505		-0.191	1.2010000000000001															high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.795		1	0	1	1	China	Asia	DSM-V	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1097	Wang (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.795	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	dong=CAI	dong=CAI	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	RBS-R: repetitive behavior scale-revised	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMD	15	15	outcomes		0.54800000000000004		-0.15	1.2450000000000001															high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.795		1	0	1	1	China	Asia	DSM-V	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1098	Wang (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata Technique	Kata Technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	CSGARS-2	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		0.67300000000000004		-6.3E-2	1.409															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1099	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata Technique	Kata Technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	CSGARS-2	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		0.67300000000000004		-6.3E-2	1.409															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1100	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata technique	Kata technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	CSGARS-2	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		0.67300000000000004		-6.3E-2	1.409															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.3		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1101	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	dong=CAI	dong=CAI	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMD	15	15	outcomes		1.026		0.26500000000000001	1.7869999999999999															high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.795		1	0	1	1	China	Asia	DSM-V	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1102	Wang (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	dong=CAI	dong=CAI	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMD	15	14	outcomes		0.90800000000000003		0.14299999999999999	1.673															high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.795		1	0	1	1	China	Asia	DSM-V	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	29	1103	Wang (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Mind–body exercise	Mind–body exercise	0.92059839	2	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	ATEC	0	0	100	10.1371/journal.pone.0068184	Chan	2013	RCT	SMD	20	19			0.13500000000000001		-0.49399999999999999	0.76400000000000001															high	100	0	100	100	100	0	low	low	high	high	low	low	Placebo ()	0		11.835385		1	0	1	1	Hong Kong	Asia	DSM-IV-TR	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	39	1104	Wang (2023)	Chan_2013	< 2 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Gross motor	Gross motor	1.38089758	4	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SRS	0	0	100		Liu	2021	RCT	SMD	13	10			1.02		0.14499999999999999	1.8959999999999999															high	100	0	0	0	0	0	high	high	high	high	high	high	NA ()			8.173478		1	0	0	0				1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	23	1105	Wang (2023)	Liu_2021	< 2 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata Technique	Kata Technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SIGARS-2: social interaction subscale of Gilliam autism rating scale-second edition	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		1.288		0.44400000000000001	2.133															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1106	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata Technique	Kata Technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SIGARS-2: social interaction subscale of Gilliam autism rating scale-second edition	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		1.288		0.44400000000000001	2.133															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1107	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Kata technique	Kata technique	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SIGARS-2: social interaction subscale of Gilliam autism rating scale-second edition	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes		1.288		0.44400000000000001	2.133															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	9.3		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1108	Wang (2023)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	SPARK	SPARK	2.76179517	1.998	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	GARS-2: autism rating scale-second edition	0	0	100	10.1016/j.pedneo.2017.12.005	Najafabadi	2018	RCT	SMD	13	13			0.93100000000000005		0.11899999999999999	1.742															high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0		7.575		1	0	1	1	Iran	West Asia	DSM-IV	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	26	1109	Wang (2023)	Najafabadi_2018	2-6 months		6-12 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	dong=CAI	dong=CAI	2.76179517	3.3	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SRS-2	0	0	100	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	SMD	15	15	outcomes		1.3089999999999999		0.52	2.097															high	0	0	0	100	100	0	high	high	high	high	low	low	No intervention ()	0	13.7931034482759	4.795		1	0	1	1	China	Asia	DSM-V	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	30	1110	Wang (2023)	Cai/Wang/Yang_2020	2-6 months		< 6 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Wang (2023)	Wang	2023	https://doi.org/10.1002/aur.3004	4.5	Critically low	Complementary	PHYS	PHYS	Outdoor activities	Outdoor activities	2.99194476	0.5	hour/week	Clinic	0	100	0			100		Social-communication	social communication deficits	Report	SRS	0	0	100	10.1111/dmcn.13337	Zachor	2017	RCT	SMD	30	21			0.55700000000000005		-1.0999999999999999E-2	1.125															high	100	0	0	100	100	0	high	high	low	high	low	low	TAU ()	0	22	5.352941	47.5	1	1	1	1			DSM	1	1	0	0.5	1.0	1	0.0	0.5	1.0	0	1	0	0	1	1	1	51	1111	Wang (2023)	Zachor_2017	2-6 months	Low (< 70)	< 6 yo	4.795	11.835385	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Therapeutic horseback	Therapeutic horseback	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on social interaction ability	Report	BOT-2 (Bruininks–Oseretsky Test, 2nd Ed); PPVT (Peabody Picture Vocabulary Test, 4th Ed); SALT (Systematic Analysis of Language Transcripts); SRS (Social Responsiveness Scale); VABS-II (Vineland Adaptive Behavior Scales-II)	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.57999999999999996		-0.95	-0.21	-6.6	10.35	-0.3	11.28											high	100	0	0	0	0	0	high	high	high	high	high	high	Non therapeutic ()	0		11		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	116	1112	Huang (2020)	Gabriels_2015	2-6 months		6-12 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Kata techniques	Kata techniques	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on social interaction ability	Report	Social Communication subscale of GARS-2 (Gilliam Autism Rating Scale-Second Edition)	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes	reverse	-1.04		-1.81	-0.27	-6.39	4.97	-0.16	6.61											high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	10.5		1	0	1	1	Iran	Asia	DSM-IV	1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	30	1113	Huang (2020)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Outdoor activities	Outdoor activities	2.99194476	0.5	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on social interaction ability	Report	SRS (Social Responsiveness Scale; VABS-II)	0	0	100	10.1111/dmcn.13337	Zachor	2017	RCT	SMD	30	21		reverse	-0.34		-0.9	0.22	-2.6	11.28	1.6	13.5											high	100	0	0	100	100	0	high	high	low	high	low	low	TAU ()	0	22	5	47.5	1	1	1	1			DSM	1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	51	1114	Huang (2020)	Zachor_2017	2-6 months	Low (< 70)	< 6 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Kata techniques	Kata techniques	3.22209436	6	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on communication ability	Report	Communication subscale of GARS-2 (Gilliam Autism Rating Scale-Second Edition)	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes	reverse	-0.61		-1.34	0.13	-6.18	7.51	-0.55000000000000004	10.35											high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	10.5		1	0	1	1	Iran	Asia	DSM-IV	1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	30	1115	Huang (2020)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Therapeutic horseback	Therapeutic horseback	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on communication ability	Report	BOT-2 (Bruininks–Oseretsky Test, 2nd Ed); PPVT (Peabody Picture Vocabulary Test, 4th Ed); SALT (Systematic Analysis of Language Transcripts); SRS (Social Responsiveness Scale); VABS-II (Vineland Adaptive Behavior Scales-II)	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.02		-0.39	0.34	5.5	38.799999999999997	6.3	36.69											high	100	0	0	0	0	0	high	high	high	high	high	high	Non therapeutic ()	0		11		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	116	1116	Huang (2020)	Gabriels_2015	2-6 months		6-12 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Water sports training	Water sports training	0.92059839	7.5	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on communication ability	Report	ABC (autism behavior checklist)	0	0	100		Wu	2017	RCT	SMD	7	7		reverse	-0.24		-1.3	0.81	-1.389	9.26	0.78600000000000003	7.44											high	100	0	0	0	0	0	high	high	high	high	high	high	No intervention ()	0		7		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	14	1117	Huang (2020)	Wu_2017	< 2 months		6-12 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Sports game	Sports game	5.52359033	9	hour/week	Clinic	0	100	0			100		Social-communication	impacts of physical activities on communication ability	Report	CARS Scale (Child Autism Rating Scale); ATEC (Autism Treatment Evaluation Checklist)	0	0	100		Yang	2016	RCT	SMD	40	40		reverse	-0.6		-1.05	-0.15	-4.0199999999999996	5.8	-0.97	4.13											high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		6.5		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	80	1118	Huang (2020)	Yang_2016	2-6 months		6-12 yo	5	11	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Kata techniques	Kata techniques	3.22209436	6	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Impacts of Physical Activities on Stereotyped Behaviors	Report	Communication subscale of GARS-2 (Gilliam Autism Rating Scale-Second Edition)	0	0	100	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	SMD	15	15	outcomes	reverse	-0.57999999999999996		-1.31	0.15	-5.33	6.97	-0.54	8.93											high	100	0	100	100	100	0	low	high	high	high	low	low	TAU ()	0	10	10.5		1	0	1	1	Iran	Asia	DSM-IV	1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	30	1119	Huang (2020)	Bahrami/Movahedi_2012/2013/2015	2-6 months		6-12 yo	10.5	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Therapeutic horseback	Therapeutic horseback	2.30149597	0.75	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Impacts of Physical Activities on Stereotyped Behaviors	Report	BOT-2 (Bruininks–Oseretsky Test, 2nd Ed); PPVT (Peabody Picture Vocabulary Test, 4th Ed); SALT (Systematic Analysis of Language Transcripts); SRS (Social Responsiveness Scale); VABS-II (Vineland Adaptive Behavior Scales-II)	0	0	100	10.1016/j.jaac.2015.04.007	Gabriels	2015	RCT	SMD	58	58	outcomes	reverse	-0.02		-0.38	0.35	-1.6	5.55	-1.5	4.95											high	100	0	0	0	0	0	high	high	high	high	high	high	Non therapeutic ()	0		11		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	116	1120	Huang (2020)	Gabriels_2015	2-6 months		6-12 yo	10.5	11	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Water sports training	Water sports training	0.92059839	7.5	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Impacts of Physical Activities on Levels of Autism	Report	ABC (autism behavior checklist)	0	0	100		Wu	2017	RCT	SMD	7	7		reverse	-0.54		-1.62	0.53	-7.1	30.06	9.5	26.94											high	100	0	0	0	0	0	high	high	high	high	high	high	No intervention ()	0		7		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	14	1121	Huang (2020)	Wu_2017	< 2 months		6-12 yo	6.5	7	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Sports game	Sports game	5.52359033	9	hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Impacts of Physical Activities on Levels of Autism	Report	CARS Scale (Child Autism Rating Scale); ATEC (Autism Treatment Evaluation Checklist)	0	0	100		Yang	2016	RCT	SMD	40	40		reverse	-0.57999999999999996		-1.02	-0.13	-5.17	8.2200000000000006	-1.1399999999999999	5.36											high	100	0	0	0	0	0	high	high	high	high	high	high	TAU ()	0		6.5		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	80	1122	Huang (2020)	Yang_2016	2-6 months		6-12 yo	6.5	7	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Huang (2020)	Huang	2020	https://doi.org/10.3390/ijerph17061950	1.0	Critically low	Complementary	PHYS	PHYS	Sports game	Sports game	5.52359033		hour/week	Clinic	0	100	0			100		Overall ASD symptoms	Impacts of Physical Activities on Levels of Autism	Report	CARS Scale (Child Autism Rating Scale); CBS (Clancy Behavior Scale)	0	0	100		Zhang	2017	RCT	SMD	30	30		reverse	-0.69		-1.21	-0.16	-7.71	8.2200000000000006	-1.36	9.99											high	100	0	0	0	0	0	high	high	high	high	high	high	No intervention ()	0		7		1	0	1	0				1	0	1	0.5	0.0	0	0.0	0.5	0.5	0	1	0	1	1	0	1	60	1123	Huang (2020)	Zhang_2017	2-6 months		6-12 yo	6.5	7	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Chen (2022b)	Chen	2022b	https://doi.org/10.1016/j.ctcp.2022.101565	3.0	Critically low	Complementary	PHYS	DANCE			2.30149597	1	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report		0	0	100	10.3390/bs6040024	Hildebrandt	2016	RCT	SMD	31	12			0.69		0	1.377															high	100	0	100	0	100	100	low	low	low	low	high	low	No intervention ()	0		21.772326		1	0	1	1			ICD-10	1	0	0	0.0	1.0	1	0.0	0.5	1.0	0	1	1	0	0	0	1	43	1124	Chen (2022b)	Hildebrandt_2016	2-6 months		>= 20 yo	10	32.96	100	107.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Chen (2022b)	Chen	2022b	https://doi.org/10.1016/j.ctcp.2022.101565	3.0	Critically low	Complementary	PHYS	DANCE			1.61104718	1	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report		0	0	100	10.1177/1362361314522353	Koch	2015	NRCT	SMD	16	15			0.77		0.03	1.5															high	0	0	0	100	100	0	high	unclear	unclear	unclear	low	low	No intervention ()	0	25.8064516129032	22	100	1	1	1	1	Germany	Europe	ICD-10	1	0	0	0.0	1.0	1	0.0	0.5	1.0	0	1	1	0	0	0	1	31	1125	Chen (2022b)	Koch_2015	< 2 months	Average (80-119)	>= 20 yo	10	32.96	100	107.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Chen (2022b)	Chen	2022b	https://doi.org/10.1016/j.ctcp.2022.101565	3.0	Critically low	Complementary	PHYS	DANCE			3	1.5	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report		0	0	100	10.1159/000441111	Koehne	2016	NRCT	SMD	16	9			1.22		0.32	2.12															high	0	0	0	0	100	100	high	unclear	unclear	low	high	low	Placebo ()	0	37.2549019607843	32.96	107.5	1	1	1	1			DSM-IV/ICD-10	1	0	0	0.0	1.0	1	0.0	0.5	1.0	0	1	1	0	0	0	1	25	1126	Chen (2022b)	Koehne_2016	2-6 months	Average (80-119)	>= 20 yo	10	32.96	100	107.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Chen (2022b)	Chen	2022b	https://doi.org/10.1016/j.ctcp.2022.101565	3.0	Critically low	Complementary	PHYS	DANCE			8	2	hour/week	Clinic	0	100	0			100		Social-communication	Social-Communication	Report		0	0	100	https://psychomotor.gr/the-effect-of-a-greek-traditional-dance-programme-on-the-social-skills-of-children-with-autism-spectrum-disorder/	Marouli	2021	RCT	SMD	4	4			1.45		-0.26	3.16															high	100	0	100	100	100	0	low	unclear	unclear	high	low	low	No intervention ()	0	25	10		1	0	1	1				1	0	0	0.0	1.0	1	0.0	0.5	1.0	0	1	1	0	0	0	1	8	1127	Chen (2022b)	Marouli_2021	7-12 months		6-12 yo	10	32.96	100	107.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	MBTP	MBTP	12	3.33333333333333	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	G	15	14	outcomes		0.69		-7.0000000000000007E-2	1.44															high	0	0	0	100	100	0	high	high	low	high	low	low	No intervention ()	0	13.7931034482759	4.925455		1	0	1	1	China	Asia	DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	29	1128	Li (2023)	Cai/Wang/Yang_2020	7-12 months		< 6 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	MBTP	MBTP	12	3.33333333333333	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	G	15	15	outcomes		0.49		-0.24	1.22															high	0	0	0	100	100	0	high	high	low	high	low	low	No intervention ()	0	13.7931034482759	4.925455		1	0	1	1	China	Asia	DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	30	1129	Li (2023)	Cai/Wang/Yang_2020	7-12 months		< 6 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	MBTP	MBTP	12	3.33333333333333	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	G	18	15	outcomes		0.55000000000000004		-0.15	1.25															high	0	0	0	100	100	0	high	high	low	high	low	low	No intervention ()	0	13.7931034482759	4.925455		1	0	1	1	China	Asia	DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	33	1130	Li (2023)	Cai/Wang/Yang_2020	7-12 months		< 6 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	MBTP	MBTP	12	3.33333333333333	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	G	15	15	outcomes		1		0.23	1.76															high	0	0	0	100	100	0	high	high	low	high	low	low	No intervention ()	0	13.7931034482759	4.925455		1	0	1	1	China	Asia	DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	30	1131	Li (2023)	Cai/Wang/Yang_2020	7-12 months		< 6 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Outdoor	Outdoor	13	0.5	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.1111/dmcn.13337	Zachor	2017	NRCT	G	30	21			0.43		-0.14000000000000001	0.99															high	0	0	0	100	100	0	high	high	low	high	low	low	TAU ()	0	22	5.352941	47.5	1	1	1	1			DSM	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	51	1132	Li (2023)	Zachor_2017	> 12 months	Low (< 70)	< 6 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Football	Football	12	1.25	hour/week		0	0	0			100		Social-communication	social			0	0	0		Howells	2020	NRCT	G	19	21	outcomes		0.45		-0.18	1.08															high	0	0	0	100	100	0	high	high	low	high	low	low	WLC ()	0	7.5	8.316		1	0	1	1			DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	40	1133	Li (2023)	Howells_2020	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Motor	Motor	12	2	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.1016/j.pedneo.2017.12.005	Najafabadi	2018	RCT	G	12	14			0.77		-0.03	1.58															high	100	0	100	100	100	0	low	low	low	high	low	low	TAU ()	0		7.613077		1	0	1	1	Iran	West Asia	DSM-IV	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	26	1134	Li (2023)	Najafabadi_2018	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Yoga	Yoga	8	1.5	hour/week		0	0	0			100		Social-communication	social			0	0	0		Sotoodeh	2017	RCT	G	15	14	outcomes		0.23		-0.5	0.96															low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	27.5862068965517	10.655172		1	0	1	1			ADI	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	29	1135	Li (2023)	Sotoodeh_2017	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Aquatic	Aquatic	40	1.5	hour/week		0	0	0			100		Social-communication	social			0	0	0		Caputo	2018	NRCT	G	13	13	outcomes		0.41		-0.37	1.19															high	0	0	0	100	100	100	high	high	low	low	low	low	TAU ()	0	34.6153846153846	8		1	0	1	1			DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	26	1136	Li (2023)	Caputo_2018	> 12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Aquatic	Aquatic	10	3	hour/week		0	0	0			100		Social-communication	social			0	0	0		Pan	2010	NRCT	G	8	8			0.6		-0.41	1.61															high	0	0	0	100	100	100	high	low	low	low	low	low	TAU ()	0	0	7.235		1	0	1	1			DSM	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	16	1137	Li (2023)	Pan_2010	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Motor	Motor	12	2	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.1155/2018/1825046	Zhao	2018	RCT	G	25	25	outcomes		1.2		0.6	1.81															high	100	0	100	100	100	0	low	low	low	high	low	low	WLC ()	0	42	6.12		1	0	1	1			DSM	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	50	1138	Li (2023)	Zhao_2018	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Karate	Karate	14	4	hour/week	Clinic	0	100	0			100		Social-communication	social			0	0	0	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	G	15	15	outcomes		1.4		0.59	2.2000000000000002															low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	30	1139	Li (2023)	Bahrami/Movahedi_2012/2013/2015	> 12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Aquatic	Aquatic	40	1.5	hour/week		0	0	0			100		Social-communication	communcation			0	0	0		Caputo	2018	NRCT	G	13	13	outcomes		0.61		-0.18	1.4															high	0	0	0	100	100	100	high	high	low	low	low	low	TAU ()	0	34.6153846153846	8		1	0	1	1			DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	26	1140	Li (2023)	Caputo_2018	> 12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Motor	Motor	12	2	hour/week	Clinic	0	100	0			100		Social-communication	communcation			0	0	0	10.1155/2018/1825046	Zhao	2018	RCT	G	25	25	outcomes		0.9		0.32	1.49															high	100	0	100	100	100	0	low	low	low	high	low	low	WLC ()	0	42	6.12		1	0	1	1			DSM	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	50	1141	Li (2023)	Zhao_2018	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Karate	Karate	14	4	hour/week	Clinic	0	100	0			100		Social-communication	communcation			0	0	0	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	G	15	15	outcomes		0.6		-0.13	1.34															low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	30	1142	Li (2023)	Bahrami/Movahedi_2012/2013/2015	> 12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Football	Football	12	1.25	hour/week		0	0	0			100		Social-communication	communcation			0	0	0		Howells	2020	NRCT	G	19	21	outcomes		0.45		-0.18	1.08															high	0	0	0	100	100	0	high	high	low	high	low	low	WLC ()	0	7.5	8.316		1	0	1	1			DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	40	1143	Li (2023)	Howells_2020	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Yoga	Yoga	8	1.5	hour/week		0	0	0			100		Social-communication	communcation			0	0	0		Sotoodeh	2017	RCT	G	15	14	outcomes		0.18		-0.55000000000000004	0.91															low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	27.5862068965517	10.655172		1	0	1	1			ADI	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	29	1144	Li (2023)	Sotoodeh_2017	7-12 months		6-12 yo	4.925455	10.655172	47.5	47.5	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Motor	Motor	8	1.75	hour/week		0	0	0			100		Restricted/repetitive behaviors				0	0	0		Nazemzadegan	2016	NRCT	G	8	8			0.42		-0.57999999999999996	1.41															high	0	0	0	100	100	0	high	high	low	high	low	low	TAU ()	0	0	9		1	0	1	1			DSM	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	16	1145	Li (2023)	Nazemzadegan_2016	7-12 months		6-12 yo	4.925455	9.13	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Karate	Karate	14	4	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors				0	0	0	10.1016/j.rasd.2013.04.012	Bahrami/Movahedi	2012/2013/2015	RCT	G	15	15			0.9		0.15	1.66															low	100	100	100	100	100	100	low	low	low	low	low	low	No intervention ()	0	10	9.13		1	0	1	1	Iran	Asia	DSM-IV	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	30	1146	Li (2023)	Bahrami/Movahedi_2012/2013/2015	> 12 months		6-12 yo	4.925455	9.13	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	MBTP	MBTP	12	3.33333333333333	hour/week	Clinic	0	100	0			100		Restricted/repetitive behaviors				0	0	0	10.2478/hukin-2020-0007	Cai/Wang/Yang	2020	NRCT	G	18	15			0.52		-0.18	1.22															high	0	0	0	100	100	0	high	high	low	high	low	low	No intervention ()	0	13.7931034482759	4.925455		1	0	1	1	China	Asia	DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	33	1147	Li (2023)	Cai/Wang/Yang_2020	7-12 months		< 6 yo	4.925455	9.13	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Li (2023)	Li	2023		3.5	Critically low	Complementary	PHYS	PHYS	Motor	Motor	12	3	hour/week		0	0	0			100		Restricted/repetitive behaviors				0	0	0		Moradi	2020	RCT	G	25	25			0.82		0.24	1.4															high	100	0	100	100	100	0	low	low	low	high	low	low	No intervention ()	0	0	7.42		1	0	1	1			DSM-V	1	1	0	0.0	0.5	1	0.0	1.0	1.0	0	1	0	1	0	1	1	50	1148	Li (2023)	Moradi_2020	7-12 months		6-12 yo	4.925455	9.13	Inf	-Inf	30	3	Social-communication | Restricted/repetitive behaviors | Overall ASD symptoms	6	Jia (2023) | Ojeda (2023) | Wang (2023) | Huang (2020) | Chen (2022b) | Li (2023)	https://doi.org/10.3389/fped.2023.1193648 | https://doi.org/10.1007/s40489-023-00410-5 | https://doi.org/10.1002/aur.3004 | https://doi.org/10.3390/ijerph17061950 | https://doi.org/10.1016/j.ctcp.2022.101565 | NA	4.75	32.96	47.5	107.5
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	Deep  rTMS	Deep  rTMS	0.46029919	5	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	repetitive and restricted behavior	Report	Repetitive Behavior Scale-Revised (RBS-R), stereotypy subscale of the Aberrant Behavior Checklist (ABC), Attention Switching subscale of the Autism Spectrum Quotient, or compulsion subscale of the Yale-Brown Obsessive-Compulsive Scale.	0	0	100	10.1016/j.brs.2013.10.004	Enticott	2014	RCT	G	15	13		reverse	-0.8		-1.59	-0.01															high	100	0	100	0	0	100	low	low	low	low	unclear	high	Sham ()	0	17.9	32.323929		1	0	1	0				1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	28	1149	Barahona-Correa (2018)	Enticott_2014	< 2 months		>= 20 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	4.14269275	1	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	repetitive and restricted behavior	Report	Repetitive Behavior Scale-Revised (RBS-R), stereotypy subscale of the Aberrant Behavior Checklist (ABC), Attention Switching subscale of the Autism Spectrum Quotient, or compulsion subscale of the Yale-Brown Obsessive-Compulsive Scale.	0	0	100	10.3389/fnsys.2014.00134	Sokhadze	2014	NRCT	G	27	27	groups	reverse	-0.84		-1.48	-0.2															high	0	0	0	100	0	0	high	high	high	high	low	high	WLC ()	0		14.45	100	1	1	1	0	America	North America		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	99999	Barahona-Correa (2018)	Sokhadze_2014	2-6 months	Average (80-119)	13-19 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	2.76179517	1	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	repetitive and restricted behavior	Report	Repetitive Behavior Scale-Revised (RBS-R), stereotypy subscale of the Aberrant Behavior Checklist (ABC), Attention Switching subscale of the Autism Spectrum Quotient, or compulsion subscale of the Yale-Brown Obsessive-Compulsive Scale.	0	0	100		Casanova	2012	RCT	G	25	20		reverse	-0.74		-1.35	-0.13															high	100	0	100	100	0	0	low	low	high	high	low	high	WLC ()	0		12.988889	100	1	1	1	0				1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	45	1151	Barahona-Correa (2018)	Casanova_2012	2-6 months	Average (80-119)	6-12 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	4.14269275	1	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	repetitive and restricted behavior	Report	Repetitive Behavior Scale-Revised (RBS-R), stereotypy subscale of the Aberrant Behavior Checklist (ABC), Attention Switching subscale of the Autism Spectrum Quotient, or compulsion subscale of the Yale-Brown Obsessive-Compulsive Scale.	0	0	100	10.3389/fnsys.2014.00134	Sokhadze	2014	NRCT	G	20	22	groups	reverse	-0.42		-0.96	0.12															high	0	0	0	100	0	0	high	high	high	high	low	high	WLC ()	0		14.45	100	1	1	1	0	America	North America		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	42	99999	Barahona-Correa (2018)	Sokhadze_2014	2-6 months	Average (80-119)	13-19 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	iTBS (Intermittent Theta-burst stimulation)	iTBS (Intermittent Theta-burst stimulation)	0.69044879	1	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	repetitive and restricted behavior	Report	Repetitive Behavior Scale-Revised (RBS-R), stereotypy subscale of the Aberrant Behavior Checklist (ABC), Attention Switching subscale of the Autism Spectrum Quotient, or compulsion subscale of the Yale-Brown Obsessive-Compulsive Scale.	0	0	100	10.1016/j.bj.2021.07.008	Ni	2017	RCT	G	19	19		reverse	-0.25		-0.63	0.13															high	100	0	100	100	0	0	low	low	high	high	low	high	Sham ()	0	26.3	20.8	100	1	1	1	0			DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	1153	Barahona-Correa (2018)	Ni_2017	< 2 months	Average (80-119)	>= 20 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	Deep  rTMS	Deep  rTMS	0.46029919	5	session/week	Clinic	0	100	0			100		Social-communication	social behavior	Report	Social Responsiveness Scale (SRS), Lethargy and Social Withdrawal subscale of the ABC, or Social Relatedness subscale of the Ritvo Autism-Aspergers Diagnostic Scale (RAADS).	0	0	100	10.1016/j.brs.2013.10.004	Enticott	2014	RCT	G	15	13		reverse	-1.1499999999999999		-1.97	-0.33															high	100	0	100	0	0	100	low	low	low	low	unclear	high	Sham ()	0	17.9	32.323929		1	0	1	0				1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	28	1154	Barahona-Correa (2018)	Enticott_2014	< 2 months		>= 20 yo	14.45	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	4.14269275	1	session/week	Clinic	0	100	0			100		Social-communication	social behavior	Report	Social Responsiveness Scale (SRS), Lethargy and Social Withdrawal subscale of the ABC, or Social Relatedness subscale of the Ritvo Autism-Aspergers Diagnostic Scale (RAADS).	0	0	100	10.3389/fnsys.2014.00134	Sokhadze	2014	NRCT	G	20	22	groups	reverse	-0.64		-1.27	-0.01															high	0	0	0	100	0	0	high	high	high	high	low	high	WLC ()	0		14.45	100	1	1	1	0	America	North America		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	42	99999	Barahona-Correa (2018)	Sokhadze_2014	2-6 months	Average (80-119)	13-19 yo	14.45	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	4.14269275	1	session/week	Clinic	0	100	0			100		Social-communication	social behavior	Report	Social Responsiveness Scale (SRS), Lethargy and Social Withdrawal subscale of the ABC, or Social Relatedness subscale of the Ritvo Autism-Aspergers Diagnostic Scale (RAADS).	0	0	100	10.3389/fnsys.2014.00134	Sokhadze	2014	NRCT	G	27	27	groups	reverse	-0.36		-0.9	0.18															high	0	0	0	100	0	0	high	high	high	high	low	high	WLC ()	0		14.45	100	1	1	1	0	America	North America		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	99999	Barahona-Correa (2018)	Sokhadze_2014	2-6 months	Average (80-119)	13-19 yo	14.45	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	iTBS (Intermittent Theta-burst stimulation)	iTBS (Intermittent Theta-burst stimulation)	0.69044879	1	session/week	Clinic	0	100	0			100		Social-communication	social behavior	Report	Social Responsiveness Scale (SRS), Lethargy and Social Withdrawal subscale of the ABC, or Social Relatedness subscale of the Ritvo Autism-Aspergers Diagnostic Scale (RAADS).	0	0	100	10.1016/j.bj.2021.07.008	Ni	2017	RCT	G	19	19		reverse	-0.3		-0.44	-0.15															high	100	0	100	100	0	0	low	low	high	high	low	high	Sham ()	0	26.3	20.8	100	1	1	1	0			DSM-IV-TR	1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	38	1157	Barahona-Correa (2018)	Ni_2017	< 2 months	Average (80-119)	>= 20 yo	14.45	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	Deep  rTMS	Deep  rTMS	0.46029919	5	session/week	Clinic	0	100	0			100		Disruptive behaviors	irritability.	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.1016/j.brs.2013.10.004	Enticott	2014	RCT	G	15	13		reverse	0.17		-0.59	0.93															high	100	0	100	0	0	100	low	low	low	low	unclear	high	Sham ()	0	17.9	32.323929		1	0	1	0				1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	28	1158	Barahona-Correa (2018)	Enticott_2014	< 2 months		>= 20 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	2.76179517	1	session/week	Clinic	0	100	0			100		Disruptive behaviors	irritability.	Report	Autism Behavioral Checklist (ABC)	0	0	100		Casanova	2012	RCT	G	25	20		reverse	-0.7		-1.32	-0.1															high	100	0	100	100	0	0	low	low	high	high	low	high	WLC ()	0		12.988889	100	1	1	1	0				1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	45	1159	Barahona-Correa (2018)	Casanova_2012	2-6 months	Average (80-119)	6-12 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Barahona-Correa (2018)	Barahona-Correa	2018	https://doi.org/10.3389/fnint.2018.00027	3.0	Critically low	Complementary	rTMS	rTMS	rTMS	rTMS	4.14269275	1	session/week	Clinic	0	100	0			100		Disruptive behaviors	irritability.	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.3389/fnsys.2014.00134	Sokhadze	2014	NRCT	G	27	27		reverse	-0.26		-0.81	0.28000000000000003															high	0	0	0	100	0	0	high	high	high	high	low	high	WLC ()	0		14.45	100	1	1	1	0	America	North America		1	0	1	0.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	1160	Barahona-Correa (2018)	Sokhadze_2014	2-6 months	Average (80-119)	13-19 yo	12.988889	32.323929	100	100	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-0.01		-0.63	0.61															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1161	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-0.04		-0.66	0.57999999999999996															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1162	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language	Report	ATEC	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	22	21		reverse	-0.1		-0.7	0.5															low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	9		1	0	1	1	Jordan	Afica	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	43	1163	Garcia-Gonzalez (2021)	Hadoush_2020	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Social-communication	Social	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-0.79		-1.44	-0.15															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1164	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Social-communication	Social	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-0.77		-1.41	-0.12															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1165	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Social-communication	Social	Report	ATEC	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	22	21		reverse	-0.68		-1.05	-0.32															low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	9		1	0	1	1	Jordan	Afica	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	43	1166	Garcia-Gonzalez (2021)	Hadoush_2020	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Sensory Profile	Sensory and cognitive awareness	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-0.79		-1.43	-0.14000000000000001															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1167	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Sensory Profile	Sensory and cognitive awareness	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-0.17		-0.79	0.45															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1168	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Sensory Profile	Sensory and cognitive awareness	Report	ATEC	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	22	21		reverse	-0.09		-0.69	0.5															low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	9		1	0	1	1	Jordan	Afica	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	43	1169	Garcia-Gonzalez (2021)	Hadoush_2020	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ATEC total score	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-1.49		-2.2000000000000002	-0.78															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1170	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ATEC total score	Report	ATEC	0	0	100		Amatachaya	2014/2015	RCT Cross over	G	20	20	outcomes	reverse	-1.06		-1.72	-0.39															high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.5		1	0	1	1	Thailand	Asia	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	40	1171	Garcia-Gonzalez (2021)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Garcia-Gonzalez (2021)	Garcia-Gonzalez	2021	https://doi.org/10.1016/j.euroneuro.2021.02.017	2.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ATEC total score	Report	ATEC	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	22	21		reverse	-0.43		-1.04	0.17															low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	9		1	0	1	1	Jordan	Afica	ASD	1	0	0	0.0	1.0	0	0.0	0.5	1.0	1	0	0	1	1	1	0	43	1172	Garcia-Gonzalez (2021)	Hadoush_2020	< 2 months		6-12 yo	6.5	9	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			2.76179517	1	session/week	Clinic	0	100	0			100		ADHD symptoms	Hyperactivity	Report	Autism Behavioral Checklist (ABC)	0	0	100		Baruth	2010	RCT	G	16	9		reverse	-0.54		-1.37	0.28999999999999998	10.8	7.1	14.8	7.3											low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	WLC ()	0		13.756	86	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	25	1173	Liu (2023)	Baruth_2010	2-6 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			0.69044879	2	session/week	Clinic	0	100	0			100		ADHD symptoms	Hyperactivity	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.1007/s10803-008-0662-7	Sokhadze	2009	NRCT	G	8	5		reverse	-0.49		-1.63	0.65	6.3	6.8	10.1	8											high	0	0	0	100	0	0	high	high	unclear	unclear	low	unclear	WLC ()	0	0	17.2	102.3	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	13	1174	Liu (2023)	Sokhadze_2009	< 2 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			4.14269275	1	session/week	Clinic	0	100	0			100		ADHD symptoms	Hyperactivity	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.3389/fnsys.2018.00020	Sokhadze	2018	RCT	G	86	26		reverse	-0.72		-1.17	-0.27	10.75	9.2200000000000006	18.09	12.74											low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	WLC ()	0	16.96	13.146429	100	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	112	1175	Liu (2023)	Sokhadze_2018	2-6 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			2.76179517	1	session/week	Clinic	0	100	0			100		Disruptive behaviors	Irritability	Report	Autism Behavioral Checklist (ABC)	0	0	100		Baruth	2010	RCT	G	16	9		reverse	-1.21		-2.11	-0.32	4.3	4.2	10.3	5.7											low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	WLC ()	0		13.756	86	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	25	1176	Liu (2023)	Baruth_2010	2-6 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			0.69044879	2	session/week	Clinic	0	100	0			100		Disruptive behaviors	Irritability	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.1007/s10803-008-0662-7	Sokhadze	2009	NRCT	G	8	5		reverse	-0.36		-1.49	0.77	8.6999999999999993	7	11.2	5.4											high	0	0	0	100	0	0	high	high	unclear	unclear	low	unclear	WLC ()	0	0	17.2	102.3	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	13	1177	Liu (2023)	Sokhadze_2009	< 2 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			4.14269275	1	session/week	Clinic	0	100	0			100		Disruptive behaviors	Irritability	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.3389/fnsys.2018.00020	Sokhadze	2018	RCT	G	86	26		reverse	-0.98		-1.43	-0.52	6.38	4.59	12.39	9.6300000000000008											low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	WLC ()	0	16.96	13.146429	100	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	112	1178	Liu (2023)	Sokhadze_2018	2-6 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS	Qiu=SUN? NO	Qiu=SUN? NO	0.69044879	5	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ABC total score	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.1155/2021/6627507	Qiu	2021	RCT	G	20	20	outcomes	reverse	0		-0.62	0.62	53.5	24.9	53.5	27.3											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	25	4		1	0	1	1	China	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	40	1179	Liu (2023)	Qiu_2021	< 2 months		< 6 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS	SUN=QIU ? NO	SUN=QIU ? NO	0.92059839	3	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ABC total score	Report	Autism Behavioral Checklist (ABC)	0	0	100	10.3389/fnins.2022.721987	Sun	2022	RCT	G	19	18		reverse	-0.67		-1.34	-0.01	59.32	17.3	71.39	17.91											low	100	100	0	100	100	100	unclear	low	low	low	low	low	Sham ()	0	18.92	7.805405		1	0	1	1	China	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	37	1180	Liu (2023)	Sun_2022	< 2 months		6-12 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.01		-0.89	0.87	10.5	5.39	10.55	5.2											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1181	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.04		-0.91	0.84	10.75	5.15	10.95	5.03											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1182	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	25	25		reverse	-0.1		-0.65	0.46	19.18	7.41	19.809999999999999	4.82											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	7.8		1	0	1	1	Jordan	Afica	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	50	1183	Liu (2023)	Hadoush_2020	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Social-communication	Social	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.77		-1.69	0.14000000000000001	14.45	4.8499999999999996	17.7	2.98											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1184	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Social-communication	Social	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.75		-1.66	0.16	14.55	4.9800000000000004	17.8	3.11											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1185	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Social-communication	Social	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	25	25		reverse	-0.52		-1.08	0.05	16.09	7.91	19.57	4.9800000000000004											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	7.8		1	0	1	1	Jordan	Afica	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	50	1186	Liu (2023)	Hadoush_2020	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Sensory Profile	Sensory and cognitive awareness	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.77		-1.68	0.15	18.350000000000001	5.35	22.3	4.47											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1187	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Sensory Profile	Sensory and cognitive awareness	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.16		-1.04	0.71	21.1	4.8899999999999997	21.9	4.4400000000000004											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1188	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Sensory Profile	Sensory and cognitive awareness	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	25	25		reverse	-0.1		-0.65	0.46	18.82	7.74	19.43	4.32											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	7.8		1	0	1	1	Jordan	Afica	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	50	1189	Liu (2023)	Hadoush_2020	< 2 months		6-12 yo	6.4	7.8	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ATEC total score	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-1.46		-2.4700000000000002	-0.44	58	5.85	69.650000000000006	9.1300000000000008											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1190	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ATEC total score	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-1.03		-1.98	-0.09	61.7	6.7	70.150000000000006	8.83											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1191	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.15074799	2	session/week	Clinic	0	100	0			100		Overall ASD symptoms	ATEC total score	Report	Autism Treatment Evaluation Checklist (ATEC)	0	0	100	10.1002/aur.2290	Hadoush	2020	RCT	G	25	25		reverse	-0.44		-1	0.12	71.95	28.26	82.48	18.14											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	18	7.8		1	0	1	1	Jordan	Afica	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	50	1192	Liu (2023)	Hadoush_2020	< 2 months		6-12 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS			1.84119678	1	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Childhood autism rating scale	Observation	Childhood autism rating scale (CARS)	0	100	0		Amatachaya	2014/2015	RCT	G	10	10	outcomes	reverse	-0.65		-1.55	0.26	32.200000000000003	3.98	35	4.3											high	100	0	100	0	0	100	low	unclear	low	low	unclear	unclear	Sham ()	0	0	6.4		1	0	1	1	Thailand	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	20	1193	Liu (2023)	Amatachaya_2014/2015	< 2 months		6-12 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	tDCS	tDCS	Qiu=SUN? NO	Qiu=SUN? NO	0.69044879	5	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Childhood autism rating scale	Observation	Childhood autism rating scale (CARS)	0	100	0	10.1155/2021/6627507	Qiu	2021	RCT	G	20	20	outcomes	reverse	0.1		-0.52	0.72	33.799999999999997	3	33.5	3											low	100	100	100	100	100	100	low	unclear	low	low	low	low	Sham ()	0	25	4		1	0	1	1	China	Asia	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	40	1194	Liu (2023)	Qiu_2021	< 2 months		< 6 yo	4	7.805405	Inf	-Inf	4	4	Language (Overall skills) | Social-communication | Sensory Profile | Overall ASD symptoms	2	Garcia-Gonzalez (2021) | Liu (2023)	https://doi.org/10.1016/j.euroneuro.2021.02.017 | https://doi.org/10.3389/fpsyt.2023.1147327	4	9	Inf	-Inf
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			2.76179517	1	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Repetitive Behavior Scale-Revised	Report	Repetitive Behavior Scale-Revised (RBS-R)	0	0	100		Baruth	2010	RCT	G	16	9		reverse	-0.86		-1.72	-0.01	18.5	12.8	30.8	15.4											low	100	100	100	100	100	0	low	unclear	unclear	unclear	low	low	WLC ()	0		13.756	86	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	25	1195	Liu (2023)	Baruth_2010	2-6 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			0.69044879	2	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Repetitive Behavior Scale-Revised	Report	Repetitive Behavior Scale-Revised (RBS-R)	0	0	100	10.1007/s10803-008-0662-7	Sokhadze	2009	NRCT	G	8	5		reverse	-1.08		-2.2999999999999998	0.15	15.3	7	23.2	6.5											high	0	0	0	100	0	0	high	high	unclear	unclear	low	unclear	WLC ()	0	0	17.2	102.3	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	13	1196	Liu (2023)	Sokhadze_2009	< 2 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Liu (2023)	Liu	2023	https://doi.org/10.3389/fpsyt.2023.1147327	3.0	Critically low	Complementary	rTMS	rTMS			4.14269275	1	session/week	Clinic	0	100	0			100		Restricted/repetitive behaviors	Repetitive Behavior Scale-Revised	Report	Repetitive Behavior Scale-Revised (RBS-R)	0	0	100	10.3389/fnsys.2018.00020	Sokhadze	2018	RCT	G	86	26		reverse	-0.88		-1.34	-0.43	14.6	12.8	26.5	15.2											low	100	100	0	100	100	100	unclear	unclear	low	low	low	low	WLC ()	0	16.96	13.146429	100	1	1	1	1	America	North America	ASD	1	0	1	0.0	1.0	1	0.0	0.5	1.0	0	0	0	0	1	1	1	112	1197	Liu (2023)	Sokhadze_2018	2-6 months	Average (80-119)	13-19 yo	13.146429	17.2	86	102.3	7	4	Restricted/repetitive behaviors | Social-communication | Disruptive behaviors | ADHD symptoms	2	Barahona-Correa (2018) | Liu (2023)	https://doi.org/10.3389/fnint.2018.00027 | https://doi.org/10.3389/fpsyt.2023.1147327	12.988889	32.323929	86	102.3
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Improvement in total score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.4	0.38	0.22	0.45											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1198	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Improvement in total score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.1	0.27	0.05	0.26											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1199	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensorimotor score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.28	0.55	0.08	0.46											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1200	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensorimotor score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.06	0.36	0.11	0.32											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1201	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Social-communication	Improvement in social score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.3	0.76	0.24	1											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1202	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Social-communication	Improvement in social score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.11	0.33	0.02	0.38											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1203	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensory response score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.35	0.65	0.3	0.33											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1204	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensory response score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.04	0.39	0	0.39											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1205	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Mood related symptoms	Improvement in affectual score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.62	0.59	0.35	0.76											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1206	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Mood related symptoms	Improvement in affectual score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.13	0.54	0.05	0.39											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1207	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Language (Overall skills)	Improvement in Language skills score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25							0.44	0.28	0.32	0.4											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1208	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Language (Overall skills)	Improvement in Language skills score (RFRLRS) - CONV + SHAM/CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25							0.13	0.32	0.03	0.35											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1209	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Language (Receptive skills)	comprehension (RDSL) - CONV + SHAM/CONV	Test	Reynell Developmental Language Scales	100	0	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.21	0.19	0.06	0.28											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1210	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Language (Receptive skills)	comprehension (RDSL) - CONV + SHAM/CONV	Test	Reynell Developmental Language Scales	100	0	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.12	0.4	0.03	0.51											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1211	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Language (Expressive skills)	Language ability-expression age (RDSL) - CONV + SHAM/CONV	Test	Reynell Developmental Language Scales	100	0	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						0.25	0.3	0.2	0.26											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1212	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Language (Expressive skills)	Language ability-expression age (RDSL) - CONV + SHAM/CONV	Test	Reynell Developmental Language Scales	100	0	0	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						0.09	0.7	0.05	1.09											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1213	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Adaptive behaviors	Improvement in total score (WeeFIM) - CONV + SHAM/CONV	Report	Functional Independence Measure for Children	0	0	100	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						7.92	4.96	3.04	4.02											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1214	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Adaptive behaviors	Improvement in total score (WeeFIM) - CONV + SHAM/CONV	Report	Functional Independence Measure for Children	0	0	100	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						1.03	3.85	-0.08	6.7											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1215	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in cognition (WeeFIM) - CONV + SHAM/CONV	Report	Functional Independence Measure for Children	0	0	100	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010a	RCT	SMD	25	25	outcomes						1.28	1.37	0.42	1.61											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	12	6.12		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	50	1216	Cheuk (2011)	Wong_2010a	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	electroacupuncture	electroacupuncture	0.92059839	3	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in cognition (WeeFIM) - CONV + SHAM/CONV	Report	Functional Independence Measure for Children	0	0	100	https://pubmed.ncbi.nlm.nih.gov/20806998/	Wong	2010b	RCT	SMD	30	25	outcomes						1.07	1.29	0.56	1.92											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	20.34	9.36		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	55	1217	Cheuk (2011)	Wong_2010b	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Improvement in total score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0		Wong	2002	RCT	SMD	15	14							0.1527	0.1923	-0.02	0.2624											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	29	1218	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Improvement in total score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.143	0.311	0.16	0.252											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1219	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensorimotor score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0		Wong	2002	RCT	SMD	15	15	outcomes						0.2487	0.5079	0.1	0.2941											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	30	1220	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensorimotor score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.182	0.499	0.18	0.68											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1221	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Social-communication	Improvement in social score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0		Wong	2002	RCT	SMD	15	15							0.02867	0.3437	0.17	0.3971											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	30	1222	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Social-communication	Improvement in social score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.061	0.496	0.09	0.341											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1223	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Mood related symptoms	Improvement in affectual score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0		Wong	2002	RCT	SMD	15	15	outcomes						0.3727	0.151	0.12	0.72											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	30	1224	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Mood related symptoms	Improvement in affectual score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.222	0.489	0.26	0.515											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1225	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensory response score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0		Wong	2002	RCT	SMD	15	15	outcomes						0.157	0.281	-0.03	0.358											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	30	1226	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Sensory Profile	Improvement in sensory response score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.15	0.325	0.25	0.505											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1227	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.36	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Language (Overall skills)	Improvement in language score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0		Wong	2002	RCT	SMD	15	15							0.08667	0.3021	-0.07	0.3754											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	30	1228	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Language (Overall skills)	Improvement in language score  (RFRLRS) - CONV + CONV	Observation	Ritvo-Freeman Real Life Rating Scale	0	100	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.1	0.341	0	0.361											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1229	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Improvement in total score  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100		Wong	2007	RCT	SMD	12	9							9.83	13.57	2.67	7.665											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1230	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Overall ASD symptoms	Improvement in total score  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						6.167	17.504	1.44	19.8											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1231	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Language (Overall skills)	Improvement in communication and speech  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100		Wong	2007	RCT	SMD	12	9	outcomes						3.17	3.099	0.33	2.121											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1232	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Language (Overall skills)	Improvement in communication and speech  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.444	2.617	0.67	4.537											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1233	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Social-communication	Improvement in sociability  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100		Wong	2007	RCT	SMD	12	9	outcomes						3.5	6.708	1	3.464											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1234	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Social-communication	Improvement in sociability  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						1.944	7.28	0.89	7.045											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1235	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in sensory and cognitive awareness  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100		Wong	2007	RCT	SMD	12	9	outcomes						2.25	4.07	-0.22	3.768											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1236	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in sensory and cognitive awareness  (ATEC) - CONV + CONV	Report	Autism Treatment Evaluation Checklist	0	0	100	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						1.611	6.572	-0.89	4.922											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1237	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language skills  (SPT) - CONV + CONV	Test	Symbolic Play Test	100	0	0		Wong	2007	RCT	SMD	12	9	outcomes						2.25	3.251	0.89	1.054											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1238	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Language (Overall skills)	Language skills  (SPT) - CONV + CONV	Test	Symbolic Play Test	100	0	0	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.611	3.127	1	5.053											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1239	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Adaptive behaviors	Improvement in total score  (WeeFIM) - CONV + CONV	Report	Functional Independence Measure for Children	0	0	100		Wong	2002	RCT	SMD	15	13							8	5.606	1	1.354											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	28	1240	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Adaptive behaviors	Improvement in total score  (WeeFIM) - CONV + CONV	Report	Functional Independence Measure for Children	0	0	100		Wong	2007	RCT	SMD	12	9							4.01	3.008	-0.08	1.434											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1241	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Adaptive behaviors	Improvement in total score  (WeeFIM) - CONV + CONV	Report	Functional Independence Measure for Children	0	0	100	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18							1.278	8.532	3.5	7.312											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1242	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Tongue acupuncture	Tongue acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in cognition  (WeeFIM) - CONV + CONV	Report	Functional Independence Measure for Children	0	0	100		Wong	2002	RCT	SMD	15	13							8.533	6.534	1.46	2.025											high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	3.33	7.17		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	28	1243	Cheuk (2011)	Wong_2002	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Needle acupuncture	Needle acupuncture	1.84119678	5	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in cognition  (WeeFIM) - CONV + CONV	Report	Functional Independence Measure for Children	0	0	100		Wong	2007	RCT	SMD	12	9	outcomes						10.34	6.488	1.96	2.316											low	100	100	100	100	100	100	low	low	low	low	low	low	TAU ()	0	0	9.59		1	0	1	1	China	Asia	DSM + ADI-R + CARS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	21	1244	Cheuk (2011)	Wong_2007	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Cheuk (2011)	Cheuk	2011	https://doi.org/10.1002/14651858.CD007849.pub2.	5.0	High	Complementary	ACUP	ACUP	Electroacupuncture	Electroacupuncture	1.84119678	3	session/week	Clinic	0	100	0			100		Global cognition (IQ)	Improvement in cognition  (WeeFIM) - CONV + CONV	Report	Functional Independence Measure for Children	0	0	100	http://hdl.handle.net/10722/54430	Wong	2008	RCT cross over	SMD	18	18	outcomes						0.472	3.16	-0.14	4.321											high	100	0	100	100	100	0	low	unclear	high	high	low	low	TAU ()	0	5.6	7.51		1	0	1	1	China	Asia	DSM + ADI-R + ADOS	1	1	1	1.0	1.0	1	1.0	0.5	1.0	0	1	1	1	1	1	1	36	1245	Cheuk (2011)	Wong_2008	< 2 months		6-12 yo	6.12	9.59	Inf	-Inf	5	9	Overall ASD symptoms | Sensory Profile | Social-communication | Mood related symptoms | Language (Overall skills) | Language (Receptive skills) | Language (Expressive skills) | Adaptive behaviors | Global cognition (IQ)	1	Cheuk (2011)	https://doi.org/10.1002/14651858.CD007849.pub2.	6.12	9.59	Inf	-Inf
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			0.92059839	5	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Report	sleep onset latency (SOL) diary scores	0	0	100		Garstang	2006	Crossover RCT	SMD	11	11	outcomes		3.45	0.79000000																	high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	36.4	8.64		1	0	1	1	UK	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	22	1246	Salanitro (2022)	Garstang_2006	< 2 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			3	5	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Report	sleep onset latency (SOL) diary scores	0	0	100	10.1007/s10803-010-1036-5	Wright	2011	Crossover RCT	MD	17	17	outcomes	reverse	-51.71		-89.93	-13.49	78.430000000000007	40.729999999999997	130.13999999999999	69.319999999999993											low	100	100	100	100	100	100	low	low	high	low	low	low	Placebo ()	0	20	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	34	1247	Salanitro (2022)	Wright_2011	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			2.99194476	5	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Report	sleep onset latency (SOL) diary scores	0	0	100	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	MD	51	44		reverse	-30.69		-49.86	-11.52	55.6	49.18	86.29	48.57											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.4	8.69		1	0	1	1	United States and Europe	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	95	1248	Salanitro (2022)	Gringras_2017	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			2.76179517	1.5	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Observation	SOL actigraphy scores	0	100	0	10.1016/j.sleep.2010.01.010	Cortesi	2012	RCT	MD	34	32	outcomes	reverse	-34.39		-47.9	-20.88	45.21	23.21	79.599999999999994	31.85											high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	19.6	6.56		1	0	1	1	Italy	Europe	DSM-IV-TR	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	66	1249	Salanitro (2022)	Cortesi_2012	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			0.92059839	3	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Observation	SOL actigraphy scores	0	100	0	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670334/	Wirojanan	2009	Crossover RCT	MD	8	8	outcomes	reverse	-28.05		-63.44	7.34	25.3	16.53	53.35	60.33											high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	8.3	6		1	0	1	1	USA	North America		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	16	1250	Salanitro (2022)	Wirojanan_2009	< 2 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			0.92059839	5	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Report	total sleep time (TST) diary scores	0	0	100		Garstang	2006	Crossover RCT	SMD	11	11			2.47	0.61000000																	high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	36.4	8.64		1	0	1	1	UK	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	22	1251	Salanitro (2022)	Garstang_2006	< 2 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			3	5	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Report	total sleep time (TST) diary scores	0	0	100	10.1007/s10803-010-1036-5	Wright	2011	Crossover RCT	MD	17	17			48.45		6.29	90.61	556.11	53.39	507.66	70.67											low	100	100	100	100	100	100	low	low	high	low	low	low	Placebo ()	0	20	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	34	1252	Salanitro (2022)	Wright_2011	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			2.99194476	5	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Report	total sleep time (TST) diary scores	0	0	100	10.1016/j.jaac.2017.09.414	Gringras	2017	RCT	MD	51	44			45.65		16.149999999999999	75.150000000000006	514.70000000000005	75.430000000000007	469.05	74.959999999999994											low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.4	8.69		1	0	1	1	United States and Europe	North America and Europe	DSM-IV-TR, DSM-5, ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	95	1253	Salanitro (2022)	Gringras_2017	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			2.76179517	1.5	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Observation	total sleep time (TST) actigraphy scores	0	100	0	10.1016/j.sleep.2010.01.010	Cortesi	2012	RCT	MD	34	32			64.87		46.1	83.64	481.1	33.15	416.23	43.6											high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	19.6	6.56		1	0	1	1	Italy	Europe	DSM-IV-TR	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	66	1254	Salanitro (2022)	Cortesi_2012	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			0.92059839	3	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Observation	total sleep time (TST) actigraphy scores	0	100	0	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670334/	Wirojanan	2009	Crossover RCT	MD	8	8			21		-35.9	77.900000000000006	435	75	414	67											high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	8.3	6		1	0	1	1	USA	North America		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	16	1255	Salanitro (2022)	Wirojanan_2009	< 2 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			2.76179517	1.5	mg/day	Home	100	0	0			100		Sleep quality	nocturnal awakenings (frequency)	Observation	nocturnal awakenings (NA) scores	0	100	0	10.1016/j.sleep.2010.01.010	Cortesi	2012	RCT	SMD	34	32	outcomes	reverse	-2.88		-3.57	-2.19	5.03	1.1000000000000001	7.86	0.81											high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	19.6	6.56		1	0	1	1	Italy	Europe	DSM-IV-TR	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	66	1256	Salanitro (2022)	Cortesi_2012	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			0.92059839	5	mg/day	Home	100	0	0			100		Sleep quality	nocturnal awakenings (frequency)	Observation	nocturnal awakenings (NA) scores	0	100	0		Garstang	2006	Crossover RCT	SMD	11	11	outcomes		1.32	0.41000000																	high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	36.4	8.64		1	0	1	1	UK	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	22	1257	Salanitro (2022)	Garstang_2006	< 2 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			0.92059839	3	mg/day	Home	100	0	0			100		Sleep quality	nocturnal awakenings (frequency)	Observation	nocturnal awakenings (NA) scores	0	100	0	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2670334/	Wirojanan	2009	Crossover RCT	SMD	8	8	outcomes	reverse	-0.06		-0.86	0.74	1.99	1.2	2.0699999999999998	1.5											high	100	0	100	100	0	100	low	low	low	low	low	high	Placebo ()	0	8.3	6		1	0	1	1	USA	North America		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	16	1258	Salanitro (2022)	Wirojanan_2009	< 2 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Salanitro (2022)	Salanitro	2022	https://doi.org/10.1016/j.neubiorev.2022.104723	4.5	Low	Complementary	MELAT	MELAT			3	5	mg/day	Home	100	0	0			100		Sleep quality	nocturnal awakenings (frequency)	Observation	nocturnal awakenings (NA) scores	0	100	0	10.1007/s10803-010-1036-5	Wright	2011	Crossover RCT	SMD	17	17	outcomes	reverse	-0.21		-0.89	0.46	0.43	0.64	0.57999999999999996	0.74											low	100	100	100	100	100	100	low	low	high	low	low	low	Placebo ()	0	20	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	1	1	34	1259	Salanitro (2022)	Wright_2011	2-6 months		6-12 yo	6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			0.92059839	5	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Report	Sleep diary	0	0	100		Garstang	2006	RCT	SMD	7	7			2.47	0.61000000																	high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	36.4	8.6		1	0	1	1	UK	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	14	1260	Parker (2019)	Garstang_2006	< 2 months		6-12 yo	6.557576	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			3	2	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Report	Sleep diary	0	0	100	10.1007/s10803-010-1036-5	Wright	2011	RCT	MD	17	17			52.3		26.04	78.56															high	100	0	0	0	0	100	unclear	low	low	low	high	high	Placebo ()	0	22.2222222222222	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	34	1261	Parker (2019)	Wright_2011	2-6 months		6-12 yo	6.557576	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			2.76179517	3	mg/day	Home	100	0	0			100		Sleep quantity	Total sleep time	Report	actigraphy	0	0	100	10.1016/j.sleep.2010.01.010	Cortesi	2012	RCT	MD	34	32			64.900000000000006		46.28	83.52															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	17.5	6.557576		1	0	1	1	Italy	Europe	DSM-IV-TR	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	66	1262	Parker (2019)	Cortesi_2012	2-6 months		6-12 yo	6.557576	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			0.92059839	5	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Observation	Sleep diary	0	100	0		Garstang	2006	RCT	SMD	7	7	outcomes		3.45	0.79000000																	high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	36.4	8.6		1	0	1	1	UK	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	14	1263	Parker (2019)	Garstang_2006	< 2 months		6-12 yo	8.6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			3	2	mg/day	Home	100	0	0			100		Sleep quality	sleep onset latency	Observation	patient report	0	100	0	10.1007/s10803-010-1036-5	Wright	2011	RCT	MD	17	16	outcomes	reverse	-46.7		-72.77	-20.63															high	100	0	0	0	0	100	unclear	low	low	low	high	high	Placebo ()	0	22.2222222222222	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	33	1264	Parker (2019)	Wright_2011	2-6 months		6-12 yo	8.6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			0.92059839	5	mg/day	Home	100	0	0			100		Sleep quality	Parent-reported number of night wakings	Observation	patient report	0	100	0		Garstang	2006	RCT	SMD	7	7	outcomes		1.32	0.41000000																	high	100	0	100	100	0	0	low	low	high	high	low	high	Placebo ()	0	36.4	8.6		1	0	1	1	UK	Europe		1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	14	1265	Parker (2019)	Garstang_2006	< 2 months		6-12 yo	8.6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Parker (2019)	Parker	2019	https://doi.org/10.1111/dmcn.14157	4.5	Critically low	Complementary	MELAT	MELAT			3	2	mg/day	Home	100	0	0			100		Sleep quality	Parent-reported number of night wakings	Observation	patient report	0	100	0	10.1007/s10803-010-1036-5	Wright	2011	RCT	MD	17	17	outcomes	reverse	-0.1		-0.3	0.1															high	100	0	0	0	0	100	unclear	low	low	low	high	high	Placebo ()	0	22.2222222222222	9		1	0	1	1	UK	Europe	ICD-10	1	1	1	0.5	1.0	1	0.0	0.5	1.0	0	1	1	1	1	0	1	34	1266	Parker (2019)	Wright_2011	2-6 months		6-12 yo	8.6	9	Inf	-Inf	6	7	Acceptability | ADHD symptoms | Adverse events | Disruptive behaviors | Tolerability | Sleep quality | Sleep quantity	3	Siafis (child) (2022) | Salanitro (2022) | Parker (2019)	https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.neubiorev.2022.104723 | https://doi.org/10.1111/dmcn.14157	6	10.8	91.53846	91.53846
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	OXYT	OXYT			2.76179517	24	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1038/tp.2016.152	Kosaka	2016	RCT	SMD	20	20			0.6		-0.04	1.23															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	23.3	100	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	40	1267	Zhou (2021)	Kosaka_2016	2-6 months	Average (80-119)	>= 20 yo	11.265	35.1	84.61538	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	OXYT	OXYT			0.13114754	18	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1007/s10803-013-1899-3	Dadds	2014	RCT	SMD	19	19			-0.08		-0.71	0.56000000000000005															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	0	11.265	89.555	1	1	1	1	Australia	Oceania	DSM	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	38	1268	Zhou (2021)	Dadds_2014	< 2 months	Average (80-119)	6-12 yo	11.265	35.1	84.61538	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	OXYT	OXYT			1.84119678	42	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1111/jcpp.12305	Guastella	2015	RCT	SMD	25	25			0.12		-0.44	0.67															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	13.85	84.61538	1	1	1	1	Australia	Oceania	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	50	1269	Zhou (2021)	Guastella_2015	< 2 months	Average (80-119)	13-19 yo	11.265	35.1	84.61538	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1093/brain/awv249	Takamitsu/Watanabe	2015	RCT	SMD	9	9			-0.26		-1.19	0.67															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	0	35.1	105	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	18	1270	Zhou (2021)	Takamitsu/Watanabe_2015	< 2 months	Average (80-119)	>= 20 yo	11.265	35.1	84.61538	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0		Anagnostou	2012	RCT	SMD	10	9			0.48		-0.43	1.39															low	100	100	100	100	100	0	low	low	unclear	unclear	low	low	Placebo ()	0	10	33.8	100	1	1	1	1	USA	North America	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	19	1271	Zhou (2021)	Anagnostou_2012	< 2 months	Average (80-119)	>= 20 yo	11.265	35.1	84.61538	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	OXYT	OXYT			1.38089758	48	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1038/s41380-018-0097-2	Yamasue	2020	RCT	SMD	52	51			0.3		-0.09	0.69															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	27.6	107	1	1	1	1	Japan	Asia	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	103	1272	Zhou (2021)	Yamasue_2020	< 2 months	Average (80-119)	>= 20 yo	11.265	35.1	84.61538	107	28	11	Social-communication | Restricted/repetitive behaviors | Anxiety | Overall ASD symptoms | Adverse events | Disruptive behaviors | Acceptability | ADHD symptoms | Quality of life | Tolerability | Mood related symptoms	13	Hu (2023) | Bakermans-Kranenburg (2013) | Kiani (2023) | Cai (2018) | Keech (2018) | Ooi (2016) | Wang (2019) | Martins (2021) | Siafis (adult) (2022) | Siafis (child) (2022) | Linden (2023) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1007/s00228-023-03545-w | https://doi.org/10.1038/tp.2013.34 | https://doi.org/10.2174/1871527321666220517112612 | https://doi.org/10.1111/pcn.12627 | https://doi.org/10.1016/j.psyneuen.2017.09.022 | https://doi.org/10.1055/s-0042-109400 | https://doi.org/10.1016/j.rasd.2019.03.007 | https://doi.org/10.1111/bph.15451 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1177/13623613221117931 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	5	37.5	32	111.91
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0		Bent	2014	RCT	SMD	28	29			0.49		-0.04	1.02															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	10.3448275862069	7.35		1	0	1	1	USA	North America	(SCQ)	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	57	1273	Zhou (2021)	Bent_2014	< 2 months		6-12 yo	5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0		Amminger	2007	RCT	SMD	6	6			0.88		-0.33	2.08															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	12	1274	Zhou (2021)	Amminger_2007	< 2 months		6-12 yo	5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT	SMD	12	13			0.19		-0.6	0.98															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.5		1	0	1	1	USA	North America	ADOS SCQ DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	25	1275	Zhou (2021)	Bent_2011	2-6 months		< 6 yo	5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	PUFA	n-3			11.96777906	0.7	g/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	24	24			-0.16		-0.8	0.47															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	17.2413793103448	5		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	48	1276	Zhou (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	PUFA	n-3			1.84119678	1	g/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	SMD	18	17	outcomes		-0.01		-0.48	0.46															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	20	9.39		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	35	1277	Zhou (2021)	Parellada_2017	< 2 months		6-12 yo	5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	PUFA	n-3			1.84119678	1	g/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1016/j.euroneuro.2017.08.426	Parellada	2017	RCT	SMD	17	16	outcomes		0.37		-0.24	0.98															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	20	9.39		1	0	1	1	Spain	Europe	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	33	1278	Zhou (2021)	Parellada_2017	< 2 months		6-12 yo	5	11	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	SECRET	SECRET			0.03278689			Clinic	0	100	0			100		Restricted/repetitive behaviors				0	0	0	10.1097/00004583-200211000-00012	Unis	2002	RCT	SMD	30	29			0.15		-0.39	0.68															high	100	0	100	100	0	100	low	low	unclear	low	low	high	Placebo ()	0		6.5	55	1	1	1	1	USA		DSM-IV	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	59	1279	Zhou (2021)	Unis_2002	< 2 months	Low (< 70)	6-12 yo	5.1	7.5	39	62	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	SECRET	SECRET							0	0	0			100		Restricted/repetitive behaviors				0	0	0		Owey	2001	RCT	SMD	27	27			0.24		-0.28999999999999998	0.78															high	100	0	0	0	0	0	high	high	high	high	high	high	NA ()					0	0	0	0				1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	54	1280	Zhou (2021)	Owey_2001				5.1	7.5	39	62	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	SECRET	SECRET			0.03278689				0	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1017/s0012162200001481	Dunn-Geier	2000	RCT	SMD	42	43			-0.02		-0.42	0.39															high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0		5.1	39	1	1	1	0			DSM-IV	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	85	1281	Zhou (2021)	Dunn-Geier_2000	< 2 months	Low (< 70)	< 6 yo	5.1	7.5	39	62	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	SECRET	SECRET			0.03278689				0	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1056/NEJM199912093412404	Sandler	1999	RCT	SMD	27	27			-0.16		-0.7	0.37															high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0		7.5	62	1	1	1	0			DSM-IV	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	54	1282	Zhou (2021)	Sandler_1999	< 2 months	Low (< 70)	6-12 yo	5.1	7.5	39	62	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	NAC	NAC			2.76179517	1800	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1016/j.biopsych.2012.01.014	Hardan	2012	RCT	SMD	15	14			0.38		-0.36	1.1100000000000001															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	13.3333333333333	7		1	0	1	1	USA	North America	DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	29	1283	Zhou (2021)	Hardan_2012	2-6 months		6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	NAC	NAC			5.52359033	500	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1177/0004867416652735	Dean	2017/2019	RCT	SMD	54	54			-0.17		-0.56999999999999995	0.23															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.7647058823529	6.53	73	1	1	1	1	Australia		DSM-IV-TR	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	108	1284	Zhou (2021)	Dean_2017/2019	2-6 months	Limit (70-79)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	NAC	NAC			2.76179517	1680	mg/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1186/s13229-016-0088-6	Wink	2016	RCT	SMD	15	16			0.41		-0.3	1.1200000000000001															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	25	7.63	86.27	1	1	1	1	USA	North America	DSM-IV	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	31	1285	Zhou (2021)	Wink_2016	2-6 months	Average (80-119)	6-12 yo	6.53	7.63	73	86.27	5	8	Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Social-communication | Overall ASD symptoms | Acceptability | Tolerability | Adverse events	5	Liu (2022) | Lee (2020) | Siafis (child) (2022) | Iffland (2023) | Zhou (2021)	https://doi.org/10.1016/j.pnpbp.2021.110476 | https://doi.org/10.1177/0004867420952540 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007	6.37	8.35	73	86.27
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	VIT-D	VIT-D			4.60299194	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1136/archdischild-2017-312783	Kerley	2017	RCT	SMD	19	19			-0.36		-1	0.28000000000000003															high	100	0	0	0	100	100	unclear	low	low	low	high	low	Placebo ()	0	13.6363636363636	7.9		1	0	1	1	Ireland	Europe	DSM	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	38	1286	Zhou (2021)	Kerley_2017	2-6 months		6-12 yo	5.2	7.9	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	VIT-D	VIT-D			11.96777906	2000	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	17	18			-0.15		-0.81	0.52															high	100	0	100	0	100	100	low	low	low	low	high	low	Placebo ()	0	9.67741935483871	5.2		1	0	1	1	New Zealand	Oceania	DSM-5	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	35	1287	Zhou (2021)	Mazahery_2018/2019	7-12 months		< 6 yo	5.2	7.9	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Zhou (2021)	Zhou	2021	https://doi.org/10.1016/j.jaac.2020.03.007	3.0	Critically low	Complementary	VIT-D	VIT-D			2.99194476	2500	IU/day	Home	100	0	0			100		Restricted/repetitive behaviors				0	0	0	10.1080/20473869.2018.1502068	Moradi	2018	RCT	SMD	25	25			0.08		-0.48	0.63															high	100	0	0	0	0	0	unclear	unclear	unclear	unclear	unclear	high	Placebo ()	0	0	7.62	100	1	1	1	1	Iran	Asia	DSM-5	1	1	1	0.0	1.0	1	0.0	0.0	0.0	0	1	0	0	1	1	1	50	1288	Zhou (2021)	Moradi_2018	2-6 months	Average (80-119)	6-12 yo	5.2	7.9	100	100	7	7	Overall ASD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | ADHD symptoms | Acceptability | Tolerability	5	Zhang (2023) | Li (2022) | Song (2020) | Siafis (child) (2022) | Zhou (2021)	https://doi.org/10.9758/cpn.2023.21.2.240 | https://doi.org/10.1080/1028415X.2020.1815332 | https://doi.org/10.9758/cpn.2020.18.2.203 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007	5.2	10	100	100
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile Overall Score	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.4644		-0.2215	1.1503															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1289	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile: Sensory Seeking Subscale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.9086		0.1981	1.6192															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1290	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile: Inattention and Distractibility Subscale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		1.2290		0.4917	1.9663															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1291	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile: Sensory Sensitivity Subscale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.4026		-0.2811	1.0863															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1292	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile: Sedentary Subscale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		1.1675		0.4359	1.8992															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1293	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile: Fine Motor Subscale	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.2299		-0.4492	0.9091															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1294	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Overall ASD symptoms		Report	Social Response Scale Overall Score	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15			0.7460		0.0462	1.4457															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1295	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication		Report	Social Response Scale: Social Cognition	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.4543		-0.2312	1.1399															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1296	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication		Report	Social Response Scale: Social Awareness	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.4097		-0.2743	1.0936															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1297	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			2.76179517	1	hour/week	Clinic	0	100	0			100		Social-communication		Report	Social Response Scale: Social Motivation	0	0	100	10.1007/s10803-009-0734-3	Bass	2009	RCT	SMD	19	15	outcomes		0.5908		-0.1006	1.2822															high	100	0	0	0	0	0	unclear	low	high	high	high	high	WLC ()	0	14.7	7.291667	70	1	1	1	1	USA	North America	DSM-IV-TR	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	34	1298	Sandbank (2023)	Bass_2009	2-6 months	Limit (70-79)	6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Overall ASD symptoms		Report	Social Communication Questionnaire (total score?)	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		1.2851		0.0634	2.5068															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1299	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Overall ASD symptoms		Report	Social Responsiveness Scale  (SRS) Total	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		1.6410		0.3579	2.9241															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1300	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	SRS Social Awareness	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.5935		-0.5469	1.7339															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1301	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	SRS Social Cognition	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		1.5327		0.2696	2.7959															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1302	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	SRS Social Communication	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		1.4485		0.2001	2.6969															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1303	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	SRS Social Motivation	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.6118		-0.5300	1.7536															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1304	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Restricted/repetitive behaviors		Report	SRS Autistic Mannerisms	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5			1.2440		0.0286	2.4594															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1305	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.541667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Child Behavior Checklist (CBCL) Total	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.4772		-0.6551	1.6095															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1306	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	CBCL Internalizing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.2767		-0.8457	1.3991															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1307	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	CBCL Competence	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.1182		-1.0001	1.2365															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1308	Sandbank (2023)	Page_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	Sensory Profile (SP) Auditory Processing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.0411		-1.0763	1.1586															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1309	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Visual Processing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		1.0923		-0.1013	2.2859															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1310	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Vestibular Processing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.8928		-0.2761	2.0616															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1311	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Touch Processing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.7183		-0.4327	1.8692															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1312	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Multisensory Processing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.5485		-0.5885	1.6856															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1313	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Oral Sensitivity	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.4827		-0.6499	1.6154															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1314	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Sensory Related to tone	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.0824		-1.0354	1.2002															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1315	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Modulation Related to Body Position	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.6170		-0.5252	1.7592															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1316	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP modulation of movement affecting activity level	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		1.3924		0.1535	2.6313															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1317	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Modulation of sensory input affecing emotional regulation	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		-0.5638		-1.7020	0.5743															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1318	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Modulation of visual input affecting emotional response and activity level	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		-0.2848		-1.4075	0.8379															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1319	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Behavioral and emotional	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		-0.4075		-1.5358	0.7208															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1320	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Behavioral Outcomes of Sensory Processing	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.1854		-0.9342	1.3050															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1321	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Ittems indicating thresholds for response	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.2713		-0.8509	1.3935															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1322	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP sensory seeking	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.8039		-0.3554	1.9632															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1323	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Emotional reactivity	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.2294		-0.8914	1.3503															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1324	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Low endurance	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.0749		-1.0428	1.1926															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1325	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP oral sensory sensitivity	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.6411		-0.5031	1.7853															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1326	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Inattention	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.5762		-0.5629	1.7153															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1327	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Poor registration	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		-0.0401		-1.1575	1.0774															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1328	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP sensory sensitivity	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.5090		-0.6253	1.6434															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1329	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Sensory Profile		Report	SP Sedentary	0	0	100	"https://www.proquest.com/openview/bc7a5738f6c97076c0dee3bdc330e7dc/1?pq-origsite=gscholar&cbl=18750&diss=y
"	Page	2012	NRCT	SMD	8	5	outcomes		0.0877		-1.0302	1.2055															high	0	0	0	0	100	0	high	high	high	high	high	low	NA ()		46.2	7.541667		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1330	Sandbank (2023)	Page_2012			6-12 yo	7.291667	7.541667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Presence of a Therapeutic Service Dog	0	0	0			100		Social-communication		Observation	Joint Attention Total by Time	0	100	0	https://www.scirp.org/reference/referencespapers?referenceid=2546457	Welsh	2009	RCT	SMD	13	11			-0.4047		-1.2157	0.4064															high	100	0	100	0	100	0	low	low	high	high	unclear	low	Non-therapeutic ()	0	12.5	6.383333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1331	Sandbank (2023)	Welsh_2009			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Canine Assistance	0	0	0			100		Social-communication		Report	Reciprocal Social Interaction from the SRS	0	0	100	https://eric.ed.gov/?id=ED549941	Wild	2012	NRCT	SMD	10	10			0.5689		-0.3252	1.4629															high	0	0	0	100	100	0	high	high	high	high	low	low	NA ()		20	6.75		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	20	1332	Sandbank (2023)	Wild_2012			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Canine Assistance	0	0	0			100		Adaptive behaviors		Report	Adaptive Behavior from the ABAS-II	0	0	100	https://eric.ed.gov/?id=ED549941	Wild	2012	NRCT	SMD	10	10			0.8207		-0.0919	1.7334															high	0	0	0	100	100	0	high	high	high	high	low	low	NA ()		20	6.75		1	0	0	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	20	1333	Sandbank (2023)	Wild_2012			6-12 yo	4.1	7.891667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			1.84119678	0.5	hour/week	Clinic	0	100	0			100		Language (Overall skills)		Test	Reception from Receptive and Expressive Vocabulary Test	100	0	0	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	18	11	outcomes		0.2435		-0.5092	0.9962															high	0	0	0	100	100	0	unclear	unclear	high	unclear	low	low	TAU ()	0	44.83	7.934483	67	1	1	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	29	1334	Sandbank (2023)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	4.441667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			1.84119678	0.5	hour/week	Clinic	0	100	0			100		Language (Overall skills)		Test	Expression from Receptive and Expressive Vocabulary Test	100	0	0	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	18	11	outcomes		0.3367		-0.4184	1.0917															high	0	0	0	100	100	0	unclear	unclear	high	unclear	low	low	TAU ()	0	44.83	7.934483	67	1	1	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	29	1335	Sandbank (2023)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	4.441667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			1.84119678	0.5	hour/week	Clinic	0	100	0			100		Language (Overall skills)		Test	Reception from the Preschool Receptive Expressive Language Scale	100	0	0	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	12	8	outcomes		0.4342		-0.4704	1.3389															high	0	0	0	0	100	0	unclear	unclear	high	unclear	high	low	TAU ()	0	44.83	7.934483	67	1	1	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	20	1336	Sandbank (2023)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	4.441667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			1.84119678	0.5	hour/week	Clinic	0	100	0			100		Language (Overall skills)		Test	Expression from the Preschool Receptive Expressive Language Scale	100	0	0	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	12	8	outcomes		0.4271		-0.4772	1.3315															high	0	0	0	0	100	0	unclear	unclear	high	unclear	high	low	TAU ()	0	44.83	7.934483	67	1	1	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	20	1337	Sandbank (2023)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	4.441667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			1.84119678	0.5	hour/week	Clinic	0	100	0			100		Global cognition (IQ)		Test	Cognitive Domain of the BSID-II	100	0	0	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	13	9	outcomes		-0.2099		-1.0621	0.6423															high	0	0	0	0	100	0	unclear	unclear	high	unclear	high	low	TAU ()	0	44.83	7.934483	67	1	1	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	22	1338	Sandbank (2023)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI			1.84119678	0.5	hour/week	Clinic	0	100	0			100		Global cognition (IQ)		Test	K-ABC	100	0	0	10.5535/arm.2019.43.3.279	Kwon	2019	NRCT	SMD	5	2	outcomes		0.1265		-1.5146	1.7677															high	0	0	0	0	100	0	unclear	unclear	high	unclear	high	low	TAU ()	0	44.83	7.934483	67	1	1	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	7	1339	Sandbank (2023)	Kwon_2019	< 2 months	Low (< 70)	6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Global cognition (IQ)		Test	WISC IQ	100	0	0	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-1.2061		-2.6341	0.2218															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1340	Sandbank (2023)	Uccheddu_2019			6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Global cognition (IQ)		Test	WISC Fluid Reasoning Index	100	0	0	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.0180		-1.3328	1.2968															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1341	Sandbank (2023)	Uccheddu_2019			6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Global cognition (IQ)		Test	WISC Processing Speed Index	100	0	0	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-2.1202		-3.7598	-0.4807															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1342	Sandbank (2023)	Uccheddu_2019			6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Global cognition (IQ)		Test	WISC Verbal Comprehension Index	100	0	0	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.7623		-2.1234	0.5988															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1343	Sandbank (2023)	Uccheddu_2019			6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Global cognition (IQ)		Test	WISC Working Memory Index	100	0	0	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.5788		-1.9205	0.7629															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1344	Sandbank (2023)	Uccheddu_2019			6-12 yo	7.891667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Adaptive behaviors		Report	Vineland Comprehensive Results (ABC)	0	0	100	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.0696		-1.3847	1.2456															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1345	Sandbank (2023)	Uccheddu_2019			6-12 yo	4.1	7.891667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Social-communication		Report	Vineland Communication	0	0	100	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.0493		-1.3643	1.2657															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1346	Sandbank (2023)	Uccheddu_2019			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Adaptive behaviors		Report	Vineland Daily Living Skills	0	0	100	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.0517		-1.3667	1.2633															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1347	Sandbank (2023)	Uccheddu_2019			6-12 yo	4.1	7.891667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Reading Education Assistance Dogs (READ) Programme	0	0	0			100		Social-communication		Report	Vineland Socialization	0	0	100	https://doi.org/10.3390/ani9080491	Uccheddu	2019	RCT	SMD	5	4	outcomes		-0.1317		-1.4479	1.1845															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	22.22	7.891667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	9	1348	Sandbank (2023)	Uccheddu_2019			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	ADOS-G Language and Communication Domain Score	0	100	0	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	22	17	outcomes		-0.1049		-0.7382	0.5285															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	39	1349	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	ADOS-G Frequency of Vocalizations Item Score	0	100	0	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	22	17	outcomes		0.5803		-0.0656	1.2262															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	39	1350	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	ADOS-G Gestures Score	0	100	0	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	22	17	outcomes		0.3150		-0.3217	0.9518															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	39	1351	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	ADOS-G Social Interaction Domain Score	0	100	0	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	22	17	outcomes		0.3097		-0.3270	0.9463															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	39	1352	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Language (Overall skills)		Test	Reynell Comprehension Scale	100	0	0	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	24	19	outcomes		0.3112		-0.2943	0.9166															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	43	1353	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.441667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Language (Overall skills)		Test	Reynell Expression Scale	100	0	0	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	24	19	outcomes		0.0000		-0.6019	0.6019															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	43	1354	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.441667	7.934483	67	67	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Vineland Communication Scale	0	0	100	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	24	19	outcomes		-0.0227		-0.6246	0.5792															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	43	1355	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Vineland Socialization Scale	0	0	100	https://doi.org/10.1080/08927936.2021.1885140	Hernandez-Espeso	2021	RCT	SMD	24	19	outcomes		-0.2197		-0.8234	0.3839															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Non-therapeutic ()	0	23.3	4.441667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	43	1356	Sandbank (2023)	Hernandez-Espeso_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Canine-assisted Occupational Therapy	0	0	0			100		Adaptive behaviors		Observation	Canadian Occupational Performance Measure - Performance	0	100	0	https://doi.org/10.1111/1440-1630.12659	Hill	2020	RCT	SMD	11	11	outcomes		0.1672		-0.6700	1.0043															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	27.27	5.55		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	22	1357	Sandbank (2023)	Hill_2020			< 6 yo	4.1	7.891667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Canine-assisted Occupational Therapy	0	0	0			100		Adaptive behaviors		Observation	Canadian Occupational Performance Measure - Satisfaction	0	100	0	https://doi.org/10.1111/1440-1630.12659	Hill	2020	RCT	SMD	11	11	outcomes		0.2911		-0.5491	1.1312															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	27.27	5.55		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	22	1358	Sandbank (2023)	Hill_2020			< 6 yo	4.1	7.891667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Dog Training Intervention	0	0	0			100		Social-communication		Observation	Spence Children's Anxiety Scale (SCAS) total	0	100	0	https://doi.org/10.1177/13623613211000501	Ben-Itzchak	2021	NRCT	SMD	37	36	outcomes		-0.5821		-1.0506	-0.1137															high	0	0	0	100	100	0	high	high	high	high	low	low	TAU ()	0	16.44	4.1		1	0	1	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	73	1359	Sandbank (2023)	Ben-Itzchak_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Dog Training Intervention	0	0	0			100		Social-communication		Report	VABS communication	0	0	100	https://doi.org/10.1177/13623613211000501	Ben-Itzchak	2021	NRCT	SMD	37	36	outcomes		0.1848		-0.2750	0.6446															high	0	0	0	100	100	0	high	high	high	high	low	low	TAU ()	0	16.44	4.1		1	0	1	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	73	1360	Sandbank (2023)	Ben-Itzchak_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Dog Training Intervention	0	0	0			100		Adaptive behaviors		Report	VABS Daily Living Skills	0	0	100	https://doi.org/10.1177/13623613211000501	Ben-Itzchak	2021	NRCT	SMD	37	36			-0.0751		-0.5341	0.3839															high	0	0	0	100	100	0	high	high	high	high	low	low	TAU ()	0	16.44	4.1		1	0	1	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	73	1361	Sandbank (2023)	Ben-Itzchak_2021			< 6 yo	4.1	7.891667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Dog Training Intervention	0	0	0			100		Social-communication		Report	VABS socialization	0	0	100	https://doi.org/10.1177/13623613211000501	Ben-Itzchak	2021	NRCT	SMD	37	36	outcomes		0.7756		0.2998	1.2513															high	0	0	0	100	100	0	high	high	high	high	low	low	TAU ()	0	16.44	4.1		1	0	1	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	73	1362	Sandbank (2023)	Ben-Itzchak_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Dog Training Intervention	0	0	0			100		Social-communication		Report	Social Responsiveness Scale (SRS-2) Social Communication and Interaction	0	0	100	https://doi.org/10.1177/13623613211000501	Ben-Itzchak	2021	NRCT	SMD	37	36	outcomes		0.6224		0.1526	1.0922															high	0	0	0	100	100	0	high	high	high	high	low	low	TAU ()	0	16.44	4.1		1	0	1	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	73	1363	Sandbank (2023)	Ben-Itzchak_2021			< 6 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Dog Training Intervention	0	0	0			100		Restricted/repetitive behaviors		Report	SRS-2 Restricted Interests and Repetitive Behaviors	0	0	100	https://doi.org/10.1177/13623613211000501	Ben-Itzchak	2021	NRCT	SMD	37	36			0.5984		0.1294	1.0674															high	0	0	0	100	100	0	high	high	high	high	low	low	TAU ()	0	16.44	4.1		1	0	1	0				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	73	1364	Sandbank (2023)	Ben-Itzchak_2021			< 6 yo	4.1	7.541667	Inf	-Inf	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Overall Social Skills from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.9334		0.4048	1.4619															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1365	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Communication from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.7222		0.2042	1.2403															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1366	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Cooperation from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.3531		-0.1528	0.8589															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1367	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Assertion from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.4472		-0.0610	0.9554															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1368	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Responsibility from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.7213		0.2033	1.2394															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1369	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Empathy from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.3028		-0.2020	0.8076															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1370	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Engagement from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.4772		-0.0319	0.9862															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1371	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Self-Control from the SSIS at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.7548		0.2353	1.2744															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1372	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Report	Overall Social Interaction from the ABLLS-R at Post	0	0	100	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		2.2357		1.5959	2.8755															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1373	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Says please at Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.2672		-0.2370	0.7714															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1374	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Responds well when others start a conversationat Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.4732		-0.0358	0.9821															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1375	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Speaks in appropriate tone of voice at Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.3668		-0.1394	0.8730															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1376	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Take turns in conversations at Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.0184		-0.4836	0.5203															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1377	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Says thank you at Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.6681		0.1523	1.1839															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1378	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Makes eye contact when talking at Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.3862		-0.1205	0.8928															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1379	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	AAI	AAI						Clinic	0	100	0			100		Social-communication		Observation	Uses gesutres or body appropriately with others at Post	0	100	0	https://doi.org/10.3390/ijerph18052656	Zhao	2021	RCT	SMD	31	30	outcomes		0.4409		-0.0671	0.9489															high	100	0	0	0	100	0	unclear	unclear	high	high	high	low	TAU ()	0	27.9	7.1		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	61	1380	Sandbank (2023)	Zhao_2021			6-12 yo	4.1	7.891667	70	70	23	10	Social-communication | Disruptive behaviors | Restricted/repetitive behaviors | ADHD symptoms | Overall ASD symptoms | Language (Expressive skills) | Sensory Profile | Adaptive behaviors | Language (Overall skills) | Global cognition (IQ)	5	Chen (2022a) | Dimolareva (2020) | Madigand (2023) | Xiao (2023) | Sandbank (2023)	https://doi.org/10.3390/ijerph192114449 | https://doi.org/10.1007/s1080 3-020-04715 -w | https://doi.org/10.1016/j.pnpbp.2023.110765 | https://doi.org/10.3390/ijerph20032630 | https://doi.org/10.1136/bmj-2023-076733	4.1	11	67	101.5
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			5	0.5	hour/week	Improvisational Music Therapy	0	0	0			100		Social-communication		Observation	ADOS Social Affect at 5 mo	0	100	0	10.1001/jama.2017.9478	Bieleninik	2017	RCT	SMD	165	149	outcomes		-0.1751		-0.3970	0.0469															low	100	100	100	100	100	100	low	low	high	low	low	low	TAU ()	0	18.1	5.425		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	314	1381	Sandbank (2023)	Bieleninik_2017	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			5	0.5	hour/week	Improvisational Music Therapy	0	0	0			100		Social-communication		Observation	ADOS Social Affect at 12 mo	0	100	0	10.1001/jama.2017.9478	Bieleninik	2017	RCT	SMD	154	136	outcomes		-0.1824		-0.4135	0.0487															low	100	100	100	100	100	100	low	low	high	low	low	low	TAU ()	0	18.1	5.425		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	290	1382	Sandbank (2023)	Bieleninik_2017	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			5	0.5	hour/week	Improvisational Music Therapy	0	0	0			100		Social-communication		Report	Social Responsiveness Scale Total at 5 mo	0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	SMD	142	129	outcomes		0.1424		-0.0963	0.3811															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.1	5.425		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	271	1383	Sandbank (2023)	Bieleninik_2017	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			5	0.5	hour/week	Improvisational Music Therapy	0	0	0			100		Social-communication		Report	Social Responsiveness Scale Total at 12 mo	0	0	100	10.1001/jama.2017.9478	Bieleninik	2017	RCT	SMD	132	126	outcomes		0.0715		-0.1727	0.3157															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.1	5.425		1	0	1	1	Australia, Austria, Brazil, Israel, Italy, Korea, Norway, UK, USA	Mix		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	258	1384	Sandbank (2023)	Bieleninik_2017	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Social-communication		Observation	Eye Gaze from Session Videos	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		1.1370		0.1108	2.1631															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1385	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Social-communication		Observation	Joint Attention with Child from Session Videos	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		1.1600		0.1309	2.1891															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1386	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Social-communication		Observation	Joint Attention with Adult from Session Videos	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		-0.8481		-1.8422	0.1460															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1387	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Social-communication		Observation	Initiation of communication with adult	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		-0.5152		-1.4832	0.4528															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1388	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Social-communication		Observation	Initiation of communication with child	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		0.6304		-0.3452	1.6061															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1389	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Social-communication		Observation	Response to communication	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		-0.2089		-1.1639	0.7460															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1390	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Disruptive behaviors		Observation	Withdraw/behaviors	0	100	0	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8			0.5256		-0.4430	1.4942															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1391	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	5.133333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Overall ASD symptoms		Report	Social Responsiveness Scale	0	0	100	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	8	8	outcomes		0.4612		-0.5317	1.4542															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	16	1392	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.583333	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Overall ASD symptoms		Report	Autism Treatment Evaluation Checklist immediate post-scores	0	0	100	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	9	8	outcomes		0.2781		-0.6788	1.2351															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	17	1393	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.583333	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			1.15074799	1.66666666666667	hour/week	Music Therapy	0	0	0			100		Overall ASD symptoms		Report	Autism Treatment Evaluation Checklist 3 week post scores	0	0	100	10.1093/jmt/thu012	LaGasse	2014	RCT	SMD	7	6	outcomes		0.4192		-0.6830	1.5215															high	100	0	100	0	100	0	low	low	high	high	high	low	Active ()	100	23.5	7.583333		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	13	1394	Sandbank (2023)	LaGasse_2014	< 2 months		6-12 yo	3.783333	7.583333	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			0.16393443	3	hour/week	Developmental Speech and Language Training through Music	0	0	0			100		Language (Overall skills)		Observation	Verbal Production Evaluation Scale Scores	0	100	0	10.1093/jmt/47.1.2	Lim	2010	RCT	SMD	18	14			1.2542		0.4912	2.0173															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	Active ()	100	12	4.666667		1	0	1	1	USA	North America		1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	32	1395	Sandbank (2023)	Lim_2010	< 2 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Report	Vineland Social Emotional Early Childhood Scales (VSEEC) Total Raw Score	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		1.6315		0.6432	2.6199															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1396	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Observation	VSEEC Interpersonal relationships subscale raw	0	100	0	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		1.4118		0.4549	2.3687															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1397	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Observation	VSEEC Play&Leisure time subscale raw score POST	0	100	0	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		1.6218		0.6349	2.6087															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1398	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Language (Overall skills)		Report	MBCDI total score POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.4607		-0.4070	1.3283															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1399	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Language (Overall skills)		Report	MBCDI 1B phrases understood subscale POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.2081		-0.6506	1.0668															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1400	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Language (Overall skills)		Report	MBCDI 1D words understood subscale POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.4542		-0.4131	1.3215															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1401	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Language (Overall skills)		Report	MBCDI 1D words produced subscale POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.2838		-0.5768	1.1445															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1402	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Report	MBCDI 2A-E Actions & Gestures subscale POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.6603		-0.2191	1.5396															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1403	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Overall ASD symptoms		Report	SRS total raw score POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10			0.2776		-0.5828	1.1381															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1404	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.583333	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Report	SRS Social Awareness subscale Raw POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.4025		-0.4625	1.2675															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1405	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Report	SRS Social Cognition subscale Raw POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.1491		-0.7085	1.0066															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1406	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Report	SRS Social Communication subscale Raw POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.2451		-0.6144	1.1047															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1407	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Social-communication		Report	SRS Social Motivation subscale Raw POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10	outcomes		0.3844		-0.4798	1.2487															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1408	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			3.68239356	0.5	hour/week	Family-Centered Music Therapy	0	0	0			100		Restricted/repetitive behaviors		Report	SRS Autistic Mannerisms subscale Raw POST	0	0	100	16 sessions	Thompson	2014	RCT	SMD	11	10			0.1808		-0.6773	1.0389															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	17.4	3.783333		1	0	1	1	Australia	Australia	ASD	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	21	1409	Sandbank (2023)	Thompson_2014	2-6 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensorimotor Enrichment	0	0	0			100		Global cognition (IQ)		Test	Leiter-R Raw Scores	100	0	0	https://doi.org/10.1037/bne0000068	Woo	2015	RCT	SMD	26	19	outcomes		0.3381		-0.2576	0.9338															high	100	0	100	0	100	100	low	low	high	low	high	low	TAU ()	0	14	4.666667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	45	1410	Sandbank (2023)	Woo_2015			< 6 yo	4.666667	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensorimotor Enrichment	0	0	0			100		Sensory Profile		Report	Short Sensory Profile Score	0	0	100	https://doi.org/10.1037/bne0000068	Woo	2015	RCT	SMD	28	20			-0.2882		-0.8649	0.2885															high	100	0	100	0	100	0	low	low	high	high	high	low	TAU ()	0	14	4.666667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	48	1411	Sandbank (2023)	Woo_2015			< 6 yo	4.358333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensorimotor Enrichment	0	0	0			100		Language (Overall skills)		Test	Reynell Receptive Language Score	100	0	0	https://doi.org/10.1037/bne0000068	Woo	2015	RCT	SMD	26	19	outcomes		0.3179		-0.2773	0.9130															high	100	0	100	0	100	100	low	low	high	low	high	low	TAU ()	0	14	4.666667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	45	1412	Sandbank (2023)	Woo_2015			< 6 yo	4.666667	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensorimotor Enrichment	0	0	0			100		Language (Overall skills)		Test	Reynell Expressive Language Score	100	0	0	https://doi.org/10.1037/bne0000068	Woo	2015	RCT	SMD	26	19	outcomes		0.0714		-0.5203	0.6631															high	100	0	100	0	100	100	low	low	high	low	high	low	TAU ()	0	14	4.666667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	45	1413	Sandbank (2023)	Woo_2015			< 6 yo	4.666667	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensorimotor Enrichment	0	0	0			100		Global cognition (IQ)		Test	Leiter-R IQ Scores	100	0	0	https://doi.org/10.1037/bne0000068	Woo	2015	RCT	SMD	26	19	outcomes		0.5377		-0.0642	1.1396															high	100	0	100	0	100	100	low	low	high	low	high	low	TAU ()	0	14	4.666667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	45	1414	Sandbank (2023)	Woo_2015			< 6 yo	4.666667	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensory Enrichment	0	0	0			100		Global cognition (IQ)		Test	Leiter-R Test scores	100	0	0	https://doi.org/10.1037/a0033010	Woo	2013	RCT	SMD	13	10			0.6846		-0.1632	1.5325															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	TAU ()	0	0	6.6		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	23	1415	Sandbank (2023)	Woo_2013			6-12 yo	4.666667	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensory Enrichment	0	0	0			100		Overall ASD symptoms		Observation	CARS Score	0	100	0	https://doi.org/10.1037/a0033010	Woo	2013	RCT	SMD	12	14	outcomes		1.1774		0.3426	2.0122															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	TAU ()	0	0	6.6		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	26	1416	Sandbank (2023)	Woo_2013			6-12 yo	5.983333	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensory Enrichment	0	0	0			100		Language (Overall skills)		Test	Expressive One-Word Picture Vocabulary Test	100	0	0	https://doi.org/10.1037/a0033010	Woo	2013	RCT	SMD	13	15			0.2560		-0.4897	1.0018															low	100	100	0	100	100	100	unclear	unclear	high	low	low	low	TAU ()	0	0	6.6		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	28	1417	Sandbank (2023)	Woo_2013			6-12 yo	4.666667	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensory Enrichment	0	0	0			100		Overall ASD symptoms		Observation	Improvement of Autism Symptoms (Parent-report)	0	100	0	https://doi.org/10.1037/a0033010	Woo	2013	RCT	SMD	13	13	outcomes		0.8942		-0.0241	1.8125															high	100	0	0	0	100	0	unclear	unclear	high	high	unclear	low	TAU ()	0	0	6.6		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	26	1418	Sandbank (2023)	Woo_2013			6-12 yo	5.983333	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Language (Overall skills)		Observation	Total Word Count of Responses to Standard Social Bids	0	100	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	10	12			0.6353		-0.2246	1.4953															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	22	1419	Sandbank (2023)	Srinivasan_2015			6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Social-communication		Observation	Percent duration of social verbalization to trainer across sessions	0	100	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	12	12	outcomes		0.0327		-0.7675	0.8329															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1420	Sandbank (2023)	Srinivasan_2015			6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Social-communication		Observation	Percent duration of social verbalization to model across sessions	0	100	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	12	12	outcomes		-0.1702		-0.9718	0.6314															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1421	Sandbank (2023)	Srinivasan_2015			6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Restricted/repetitive behaviors		Observation	Frequency of Sensory Behaviors	0	100	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	12	12	outcomes		1.1597		0.2949	2.0244															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1422	Sandbank (2023)	Srinivasan_2015			6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Disruptive behaviors		Observation	Frequency of Negative Behaviors	0	100	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	12	12			-0.3407		-1.1466	0.4652															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1423	Sandbank (2023)	Srinivasan_2015			6-12 yo	5.133333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Restricted/repetitive behaviors		Observation	Frequency of Stereotyped Behaviors	0	100	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	12	12	outcomes		-0.2969		-1.1014	0.5077															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1424	Sandbank (2023)	Srinivasan_2015			6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC						Rhythm Intervention	0	0	0			100		Social-communication		Test	Training-specific test of imitation praxis	100	0	0	https://doi.org/10.1155/2015/736516	Srinivasan	2015	RCT	SMD	12	12	outcomes		-0.5120		-1.3252	0.3011															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	12.5	7.616667		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	24	1425	Sandbank (2023)	Srinivasan_2015			6-12 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Adaptive behaviors		Report	PEDI Self Care Caregiver Assistance Scaled score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.7320		-0.0135	1.4775															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1426	Sandbank (2023)	Schaaf_2014			< 6 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Adaptive behaviors		Report	PEDI Self Care Functional Skills Scaled score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.1912		-0.5326	0.9149															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1427	Sandbank (2023)	Schaaf_2014			< 6 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Report	PEDI Social Function Caregiver Assistance Scaled score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.6860		-0.0567	1.4286															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1428	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Report	PEDI Social Function Functional Skills Scaled score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.1163		-0.6064	0.8390															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1429	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Adaptive behaviors		Report	Vineland II Adaptive Behavior Composite	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.3905		-0.3384	1.1193															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1430	Sandbank (2023)	Schaaf_2014			< 6 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Report	Vineland II Communication Standard score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.5599		-0.1760	1.2957															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1431	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Adaptive behaviors		Report	Vineland II Daily Living Skills Standard score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.2368		-0.4878	0.9615															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1432	Sandbank (2023)	Schaaf_2014			< 6 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Report	Vineland II Socialization Skills Standard score	0	0	100	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.8373		0.0848	1.5899															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1433	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Overall ASD symptoms		Test	PDDBI Autism Composite	100	0	0	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	12			0.2290		-0.5124	0.9703															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	29	1434	Sandbank (2023)	Schaaf_2014			< 6 yo	5.983333	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Test	PDDBI Specific Fears	100	0	0	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.5299		-0.2046	1.2643															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1435	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Test	PDDBI Semantic/Pragmatic Problems	100	0	0	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.3789		-0.3496	1.1073															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1436	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Sensory Profile		Test	PDDBI Sensory/Perceptual approach Behaviors	100	0	0	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	12			0.3214		-0.4222	1.0650															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	29	1437	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Occupational Therapy with Sensory Integration	0	0	0			100		Social-communication		Test	PDDBI Social Pragmatic Problems	100	0	0	https://doi.org/10.1007/s10803-013-1983-8	Schaaf	2014	RCT	SMD	17	13	outcomes		0.4508		-0.2802	1.1819															high	100	0	100	100	100	0	low	low	high	high	low	low	TAU ()	0	18.75	5.983333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	30	1438	Sandbank (2023)	Schaaf_2014			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Contextual Intervention Adapted for Autism Spectrum Disorder	0	0	0			100		Adaptive behaviors		Observation	Canadian Occupational Performance Measure Performance at Post	0	100	0	https://pubmed.ncbi.nlm.nih.gov/31645864/	Azari	2019	RCT	SMD	16	17	outcomes		1.0565		0.3278	1.7852															high	100	0	0	100	100	0	high	high	high	high	low	low	NA ()		21.22	6.82		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	33	1439	Sandbank (2023)	Azari_2019			6-12 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Contextual Intervention Adapted for Autism Spectrum Disorder	0	0	0			100		Adaptive behaviors		Observation	Canadian Occupational Performance Measure Performance at Follow-up	0	100	0	https://pubmed.ncbi.nlm.nih.gov/31645864/	Azari	2019	RCT	SMD	16	17	outcomes		1.5545		0.7756	2.3334															high	100	0	0	100	100	0	high	high	high	high	low	low	NA ()		21.22	6.82		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	33	1440	Sandbank (2023)	Azari_2019			6-12 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Contextual Intervention Adapted for Autism Spectrum Disorder	0	0	0			100		Adaptive behaviors		Observation	COPM Satisfaction at Post	0	100	0	https://pubmed.ncbi.nlm.nih.gov/31645864/	Azari	2019	RCT	SMD	16	17	outcomes		1.2135		0.4707	1.9564															high	100	0	0	100	100	0	high	high	high	high	low	low	NA ()		21.22	6.82		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	33	1441	Sandbank (2023)	Azari_2019			6-12 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Contextual Intervention Adapted for Autism Spectrum Disorder	0	0	0			100		Adaptive behaviors		Observation	COPM Satisfaction at Follow-up	0	100	0	https://pubmed.ncbi.nlm.nih.gov/31645864/	Azari	2019	RCT	SMD	16	17	outcomes		1.5798		0.7979	2.3617															high	100	0	0	100	100	0	high	high	high	high	low	low	NA ()		21.22	6.82		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	33	1442	Sandbank (2023)	Azari_2019			6-12 yo	5.983333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Contextual Intervention Adapted for Autism Spectrum Disorder	0	0	0			100		Sensory Profile		Observation	Goal Attainment Scaling at Post	0	100	0	https://pubmed.ncbi.nlm.nih.gov/31645864/	Azari	2019	RCT	SMD	16	17	outcomes		3.2695		2.2263	4.3127															high	100	0	0	100	100	0	high	high	high	high	low	low	NA ()		21.22	6.82		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	33	1443	Sandbank (2023)	Azari_2019			6-12 yo	4.358333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Contextual Intervention Adapted for Autism Spectrum Disorder	0	0	0			100		Sensory Profile		Observation	Goal Attainment Scaling at Follow-up	0	100	0	https://pubmed.ncbi.nlm.nih.gov/31645864/	Azari	2019	RCT	SMD	16	17	outcomes		2.8663		1.8946	3.8381															high	100	0	0	100	100	0	high	high	high	high	low	low	NA ()		21.22	6.82		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	33	1444	Sandbank (2023)	Azari_2019			6-12 yo	4.358333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Home-based Sensory Intervention	100	0	0			100		Sensory Profile		Observation	Parent-rated 10 item Likert Scales (PRILS-10)	0	100	0	https://doi.org/10.1007/s12098-018-2747-4	Padmanabha	2019	RCT	SMD	21	19			1.4934		0.7918	2.1950															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	15	4.358333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	40	1445	Sandbank (2023)	Padmanabha_2019			< 6 yo	4.358333	6.82	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Home-based Sensory Intervention	100	0	0			100		Social-communication		Report	PedsQL Emotional Functioning	0	0	100	https://doi.org/10.1007/s12098-018-2747-4	Padmanabha	2019	RCT	SMD	21	19	outcomes		0.0579		-0.5628	0.6786															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	15	4.358333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	40	1446	Sandbank (2023)	Padmanabha_2019			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Home-based Sensory Intervention	100	0	0			100		Social-communication		Report	PedsQL Social Functioning	0	0	100	https://doi.org/10.1007/s12098-018-2747-4	Padmanabha	2019	RCT	SMD	21	19	outcomes		0.8364		0.1894	1.4835															high	100	0	100	100	100	0	low	low	high	high	low	low	WLC ()	0	15	4.358333		1	0	1	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	40	1447	Sandbank (2023)	Padmanabha_2019			< 6 yo	4.358333	5.983333	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Overall ASD symptoms		Observation	CARS Total Score	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17			-0.2208		-0.8771	0.4356															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1448	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.583333	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	CARS Relationship to people	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.5000		-1.1644	0.1644															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1449	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	CARS Imitation	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.3511		-1.0105	0.3082															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1450	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	CARS Emotional Response	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.5920		-0.0764	1.2605															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1451	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Restricted/repetitive behaviors		Observation	CARS Body Use	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.1179		-0.7727	0.5370															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1452	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Restricted/repetitive behaviors		Observation	CARS Object Use	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.6669		-1.3391	0.0053															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1453	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	CARS Adaptation to change	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.2460		-0.9028	0.4108															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1454	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	CARS Visual Response	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.2500		-0.9069	0.4069															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1455	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	CARS Listening Response	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.0000		-0.6543	0.6543															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1456	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Restricted/repetitive behaviors		Observation	CARS Taste-Smell-Touch Response and Use	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.2500		-0.9069	0.4069															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1457	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	Fear and Nervousness	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.2500		-0.4069	0.9069															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1458	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	Verbal Communication	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.6667		-1.3389	0.0055															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1459	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	Nonverbal Communication	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.2357		-0.8923	0.4209															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1460	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Restricted/repetitive behaviors		Observation	Activity Level	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.0000		-0.6543	0.6543															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1461	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	Level and Consistency of Intellectual Response	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.3748		-1.0349	0.2852															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1462	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Observation	General Impressions	0	100	0	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.5714		-1.2389	0.0961															low	100	100	100	100	100	100	low	low	high	low	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1463	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Disruptive behaviors		Report	ABC Total Score	0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.0431		-0.6113	0.6975															high	100	0	100	100	100	0	low	low	high	high	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1464	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	5.133333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Disruptive behaviors		Report	ABC Irritability	0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.1459		-0.5093	0.8011															high	100	0	100	100	100	0	low	low	high	high	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1465	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	5.133333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Social-communication		Report	ABC Lethargy	0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.0159		-0.6702	0.6384															high	100	0	100	100	100	0	low	low	high	high	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1466	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Restricted/repetitive behaviors		Report	ABC Stereotypy	0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.3096		-0.3486	0.9678															high	100	0	100	100	100	0	low	low	high	high	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1467	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	3.783333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Disruptive behaviors		Report	ABC Inappropriate Speech	0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		0.0649		-0.5896	0.7194															high	100	0	100	100	100	0	low	low	high	high	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1468	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	5.133333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	MUSIC	MUSIC			7.36478711	0.5	hour/week	Music therapy	0	0	0			100		Disruptive behaviors		Report	ABC Hyperactivity	0	0	100	10.1016/j.psychres.2020.113377	Rabeyron	2020	RCT	SMD	19	17	outcomes		-0.2289		-0.8854	0.4275															high	100	0	100	100	100	0	low	low	high	high	low	low	Non-therapeutic ()	0	13.9	5.133333		1	0	1	1	France	Europe	CARS	1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	36	1469	Sandbank (2023)	Rabeyron_2020	7-12 months		< 6 yo	5.133333	7.616667	Inf	-Inf	20	7	Social-communication | Quality of life | Overall ASD symptoms | Adaptive behaviors | Disruptive behaviors | Language (Overall skills) | Restricted/repetitive behaviors	4	Geretsegger (2022) | Ke (2022) | Maw (2018) | Sandbank (2023)	https://doi.org/10.1002/14651858.CD004381.pub4. | https://doi.org/10.3389/fpsyt.2022.905113 | https://doi.org/10.1016/j.heliyon.2018.e00763 | https://doi.org/10.1136/bmj-2023-076733	3.783333	25	98	98
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensory Integration Therapy and Exercise	0	0	0			100		Overall ASD symptoms		Observation	CARS Score	0	100	0		Xu	2019	RCT	SMD	50	53	outcomes		0.4350		0.0440	0.8259															high	100	0	0	100	100	0	unclear	unclear	high	unclear	low	low	NA ()		14.6	6.175		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	103	1470	Sandbank (2023)	Xu_2019			6-12 yo	5.983333	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Sandbank (2023)	Sandbank	2023	https://doi.org/10.1136/bmj-2023-076733	5.0	Low	Complementary	SENS	SENS						Sensory Integration Therapy and Exercise	0	0	0			100		Overall ASD symptoms		Report	Autism Behavior Checklist Score	0	0	100		Xu	2019	RCT	SMD	50	53	outcomes		0.6125		0.2171	1.0078															high	100	0	0	100	100	0	unclear	unclear	high	high	low	low	NA ()		14.6	6.175		1	0	0	1				1	1	0	1.0	1.0	1	0.0	1.0	1.0	1	1	1	1	1	1	1	103	1471	Sandbank (2023)	Xu_2019			6-12 yo	5.983333	6.6	Inf	-Inf	19	6	Overall ASD symptoms | Global cognition (IQ) | Sensory Profile | Language (Overall skills) | Adaptive behaviors | Social-communication	2	Li (2018) | Sandbank (2023)	https://doi.org/10.1042/BSR20181412 | https://doi.org/10.1136/bmj-2023-076733	4	6.82	Inf	-Inf
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.5	g/day	Home	100	0	0			100		ADHD symptoms		Report	ABC: Hyperactivity	0	0	100		Amminger	2007	RCT DB	SMD	7	5			-0.294		-1.606	1.017															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11.166667		1	0	1	1	Austria	Europe	ASD (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	12	1472	Fraguas (2019)	Amminger_2007	< 2 months		6-12 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors		Report	ABC: Irritability	0	0	100		Amminger	2007	RCT DB	SMD	7	5			-0.402		-1.719	0.916															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11.166667		1	0	1	1	Austria	Europe	ASD (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	12	1473	Fraguas (2019)	Amminger_2007	< 2 months		6-12 yo	5.8	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.5	g/day	Home	100	0	0			100		Social-communication		Report	ABC: Social Withdrawal	0	0	100		Amminger	2007	RCT DB	SMD	7	5			0.202		-1.106	1.510															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11.166667		1	0	1	1	Austria	Europe	ASD (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	12	1474	Fraguas (2019)	Amminger_2007	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	ABC: Stereotypy	0	0	100		Amminger	2007	RCT DB	SMD	7	5			0.877		-0.487	2.241															high	100	0	0	100	100	0	unclear	unclear	unclear	unclear	low	low	Placebo ()	0	0	11.166667		1	0	1	1	Austria	Europe	ASD (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	12	1475	Fraguas (2019)	Amminger_2007	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms		Report	ABC: hiperactivity	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			0.377		-0.458	1.212															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1476	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Disruptive behaviors		Report	ABC: Irritability	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			-0.061		-0.890	0.767															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1477	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	5.8	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Social-communication		Report	ABC: lethargy	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			0.151		-0.678	0.980															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1478	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	ABC: Stereotypy	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			-0.190		-1.020	0.640															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1479	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		ADHD symptoms		Report	BASC: hyperactivity	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			0.148		-0.682	0.977															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1480	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Language (Overall skills)		Test	EVT	100	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			-0.552		-1.396	0.291															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1481	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.694595	5.8	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Language (Overall skills)		Test	PPVT	100	0	0	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			0.067		-0.762	0.895															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1482	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.694595	5.8	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			2.76179517	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms		Report	SRS	0	0	100	10.1007/s10803-010-1078-8	Bent	2011	RCT DB	SMD	13	12			0.382		-0.453	1.218															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	11.11	5.8		1	0	1	1	USA	North America	ASD (ADOS, SCQ, DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	25	1483	Fraguas (2019)	Bent_2011	2-6 months		< 6 yo	3.447391	7.201754	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication		Report	ABC: Lethargy Parent	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.538		-0.009	1.086															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1484	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Social-communication		Report	ABC: Lethargy Teacher	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.026		-0.518	0.569															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1485	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	ABC: Stereotipy Parent	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			-0.348		-0.900	0.204															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1486	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	ABC: Sterotipy Teacher	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			-0.019		-0.557	0.519															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1487	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms		Report	ABC-Hyperactivity Parent	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.283		-0.295	0.861															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1488	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		ADHD symptoms		Report	ABC-Hyperactivity Teacher	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.225		-0.313	0.763															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1489	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors		Report	ABC-Irritability Parent	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			-0.187		-0.739	0.364															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1490	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	5.8	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors		Report	ABC-Irritability Teacher	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.122		-0.411	0.654															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1491	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	5.8	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	SRS autistic mannerism	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.513		-0.059	1.084															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1492	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			1.38089758	1.3	g/day	Home	100	0	0			100		Overall ASD symptoms		Report	SRS Total	0	0	100		Bent	2014	IB RCT DB	SMD	29	28			0.469		-0.108	1.045															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	12.3	7.201754		1	0	1	1	USA	North America	ASD (professional) + SCQ	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	57	1493	Fraguas (2019)	Bent_2014	< 2 months		6-12 yo	3.447391	7.201754	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	L-CARNIT	L-CARNIT						Home	100	0	0			100		Social-communication		Report	CARS	0	0	100		Fahmy	2013	RCT DB	SMD	16	14			-0.440		-1.199	0.318															high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0	16.95	5.731333		1	0	1	0			Autism	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	30	1494	Fraguas (2019)	Fahmy_2013			< 6 yo	5.731333	6.462963	Inf	-Inf	2	1	Social-communication	1	Fraguas (2019)	https://doi.org/10.1542/peds.2018-3218	5.731333	6.462963	Inf	-Inf
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	L-CARNIT	L-CARNIT						Home	100	0	0			100		Social-communication		Report	ATEC sociability	0	0	100		Geier	2011	RCT DB	SMD	16	11			0.357		-0.456	1.170															high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0	15.35	6.462963		1	0	1	0			ASD (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	27	1495	Fraguas (2019)	Geier_2011			6-12 yo	5.731333	6.462963	Inf	-Inf	2	1	Social-communication	1	Fraguas (2019)	https://doi.org/10.1542/peds.2018-3218	5.731333	6.462963	Inf	-Inf
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	L-CARNIT	L-CARNIT						Home	100	0	0			100		Social-communication		Report	CARS	0	0	100		Geier	2011	RCT DB	SMD	16	11			0.766		-0.069	1.601															high	100	0	0	0	0	0	high	high	high	high	high	high	Placebo ()	0	15.35	6.462963		1	0	1	0			ASD (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	27	1496	Fraguas (2019)	Geier_2011			6-12 yo	5.731333	6.462963	Inf	-Inf	2	1	Social-communication	1	Fraguas (2019)	https://doi.org/10.1542/peds.2018-3218	5.731333	6.462963	Inf	-Inf
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3						Home	100	0	0			100		ADHD symptoms		Report	CBCL: ADHD	0	0	100		Johnson	2010	RC not blinded	SMD	10	13			0.312		-0.568	1.192															high	100	0	0	0	0	0	high	high	high	high	high	high	No intervention ()	0		3.447391		1	0	1	0			ASD, DSM-IV	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	23	1497	Fraguas (2019)	Johnson_2010			< 6 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3						Home	100	0	0			100		Overall ASD symptoms		Report	CBCL: Total	0	0	100		Johnson	2010	RC not blinded	SMD	10	13			-0.175		-1.051	0.701															high	100	0	0	0	0	0	high	high	high	high	high	high	No intervention ()	0		3.447391		1	0	1	0			ASD, DSM-IV	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	23	1498	Fraguas (2019)	Johnson_2010			< 6 yo	3.447391	7.201754	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Social-communication		Report	BASC: teacher functional communication	0	0	100	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	11	8			-0.050		-1.031	0.930															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	19	1499	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Social-communication		Observation	Investigator CGI: social interaction (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			-0.171		-2.432	2.090															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1500	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Social-communication		Observation	Investigator CGI: social interaction (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			0.224		-1.198	1.645															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1501	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Observation	Investigator CGI: stereotyped behavior (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			0.171		-2.090	2.432															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1502	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Observation	Investigator CGI: stereotyped behavior (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			0.811		-1.048	2.671															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1503	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Social-communication		Observation	Parent CGI: social interaction (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			-0.259		-1.046	0.528															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1504	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Social-communication		Observation	Parent CGI: social interaction (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			0.186		-0.638	1.009															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1505	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Observation	Parent CGI: stereotyped behavior (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			-0.664		-1.974	0.646															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1506	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.98388953	0.2	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Observation	Parent CGI: stereotyped behavior (much or very much improved)	0	100	0	10.1097/MPG.0000000000000260	Voigt	2014	RCT DB	SMD	22	16			-0.268		-1.162	0.626															high	100	0	100	0	0	100	low	low	low	low	high	high	Placebo ()	0	16.7	6.094737		1	0	1	1	USA	North America	Autism (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	38	1507	Fraguas (2019)	Voigt_2014	2-6 months		6-12 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			3.68239356	1.44	g/day	Home	100	0	0			100		ADHD symptoms		Report	ABC: Hyperactivity	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT DB	SMD	7	6			0.344		-0.890	1.577															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.15	14.638462	100	1	1	1	1	Japan	Asia	Autistic disoder or Asperger syndrome (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	13	1508	Fraguas (2019)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.447391	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			3.68239356	1.44	g/day	Home	100	0	0			100		Disruptive behaviors		Report	ABC: Irritability	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT DB	SMD	7	6			0.032		-1.193	1.256															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.15	14.638462	100	1	1	1	1	Japan	Asia	Autistic disoder or Asperger syndrome (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	13	1509	Fraguas (2019)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.8	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			3.68239356	1.44	g/day	Home	100	0	0			100		Social-communication		Report	ABC: Social withdrawal	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT DB	SMD	7	6			1.431		0.059	2.802															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.15	14.638462	100	1	1	1	1	Japan	Asia	Autistic disoder or Asperger syndrome (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	13	1510	Fraguas (2019)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			3.68239356	1.44	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	ABC: Stereotypy	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT DB	SMD	7	6			-0.341		-1.574	0.892															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.15	14.638462	100	1	1	1	1	Japan	Asia	Autistic disoder or Asperger syndrome (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	13	1511	Fraguas (2019)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			3.68239356	1.44	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Report	SRS: Mannerisms	0	0	100	10.1097/JCP.0b013e3182485791	Yui	2012	RCT DB	SMD	7	6			-0.362		-1.597	0.872															high	100	0	0	0	100	100	unclear	low	low	low	unclear	low	Placebo ()	0	7.15	14.638462	100	1	1	1	1	Japan	Asia	Autistic disoder or Asperger syndrome (DSM-IV)	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	13	1512	Fraguas (2019)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Social-communication		Report	BASC: social	0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			-0.568		-1.249	0.113															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1513	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Overall ASD symptoms		Test	PDDBI: autism composite	100	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			0.246		-0.424	0.917															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1514	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.447391	7.201754	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Language (Overall skills)		Test	PDDBI: expressive language	100	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			0.278		-0.393	0.949															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1515	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	5.8	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Restricted/repetitive behaviors		Test	PDDBI: ritualism	100	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			0.429		-0.247	1.104															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1516	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Social-communication		Test	PDDBI: social approach	100	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			0.185		-0.484	0.855															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1517	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Social-communication		Test	PDDBI: social pragmatic	100	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			-0.367		-1.041	0.306															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1518	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Language (Overall skills)		Test	PLS: total language score	100	0	0	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			-0.197		-0.867	0.472															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1519	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	5.8	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Language (Overall skills)		Report	VABS: communication	0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			-0.097		-0.765	0.572															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1520	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	5.8	Inf	-Inf	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Fraguas (2019)	Fraguas	2019	https://doi.org/10.1542/peds.2018-3218	2.0	Critically low	Complementary	PUFA	n-3			5.52359033	1.5	g/day	Home	100	0	0			100		Social-communication		Report	VABS: social	0	0	100	10.1186/s13229-015-0010-7	Mankad	2015	RCT DB	SMD	18	19			-0.199		-0.868	0.471															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	26.9	3.694595		1	0	1	1	Canada	North America	ASD (DSM IV) + ADOS + ADI-R	1	0	0	0.0	1.0	1	0.0	0.5	0.0	1	1	1	1	1	1	1	37	1521	Fraguas (2019)	Mankad_2015	2-6 months		< 6 yo	3.694595	14.638462	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	PUFA				1.38089758	1.5	g/day	Home	100	0	0			100		Disruptive behaviors				0	0	0		Amminger	2007	RCT	SMD	7	5			-0.402		-1.719	0.916															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	0	11.2		1	0	1	1	Austria	Europe	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	12	1522	Salazar de Pablo (2023)	Amminger_2007	< 2 months		6-12 yo	5.1	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	PUFA				1.38089758	1.3	g/day	Home	100	0	0			100		Disruptive behaviors				0	0	0		Bent	2014	RCT	SMD	29	28			-0.187		-0.739	0.364															high	100	0	100	0	0	100	low	low	low	low	unclear	unclear	Placebo ()	0	14	7.2		1	0	1	1	USA	North America	(SCQ)	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	57	1523	Salazar de Pablo (2023)	Bent_2014	< 2 months		6-12 yo	5.1	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	SECRET				0.03278689			Clinic	0	100	0			100		Disruptive behaviors				0	0	0		Carey	2002	RCT	SMD	8	8			-0.166		-1.240	0.908															low	100	100	100	100	100	100	low	low	unclear	low	low	low	Placebo ()	0	0	5	45.83333	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	16	1524	Salazar de Pablo (2023)	Carey_2002	< 2 months	Low (< 70)	< 6 yo	5	6.7	45.83333	56.4	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	PUFA				11.96777906	0.7	g/day	Home	100	0	0			100		Disruptive behaviors				0	0	0	10.1016/j.jsbmb.2018.10.017	Mazahery	2018/2019	RCT	SMD	23	16			0.573		-0.099	1.246															low	100	100	100	0	100	100	low	low	low	low	unclear	low	Placebo ()	0	20.5	5.1		1	0	1	1	New Zeland	Oceania	DSM-5	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	39	1525	Salazar de Pablo (2023)	Mazahery_2018/2019	7-12 months		< 6 yo	5.1	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	SECRET				0.03278689			Clinic	0	100	0			100		Disruptive behaviors				0	0	0	10.1097/00004583-200111000-00009	Owley	2001	RCT	SMD	24	25			0.007		-0.568	0.582															low	100	100	100	100	100	100	low	low	low	low	low	low	Placebo ()	0	14.3	6.7	56.4	1	1	1	1	USA		ADI-R+ADOS	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	49	1526	Salazar de Pablo (2023)	Owley_2001	< 2 months	Low (< 70)	6-12 yo	5	6.7	45.83333	56.4	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	SECRET				0.03278689			Clinic	0	100	0			100		Disruptive behaviors				0	0	0	10.1097/00004583-200211000-00012	Unis	2002	RCT	SMD	25	29			-0.788		-1.441	-0.136															high	100	0	100	100	0	100	low	low	unclear	low	low	high	Placebo ()	0		6.4	55	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	54	1527	Salazar de Pablo (2023)	Unis_2002	< 2 months	Low (< 70)	6-12 yo	5	6.7	45.83333	56.4	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	SECRET				0.03278689			Clinic	0	100	0			100		Disruptive behaviors				0	0	0	10.1097/00004583-200211000-00012	Unis	2002	RCT	SMD	23	29			-0.021		-0.766	0.725															high	100	0	100	100	0	100	low	low	unclear	low	low	high	Placebo ()	0		6.4	55	1	1	1	1	USA		DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	52	1528	Salazar de Pablo (2023)	Unis_2002	< 2 months	Low (< 70)	6-12 yo	5	6.7	45.83333	56.4	7	2	Disruptive behaviors | Restricted/repetitive behaviors	3	Iffland (2023) | Zhou (2021) | Salazar de Pablo (2023)	https://doi.org/10.1002/14651858.CD011769.pub2 | https://doi.org/10.1016/j.jaac.2020.03.007 | 10.1016/j.jaac.2022.03.033	5	7.5	39	92.5
Salazar de Pablo (2023)	Salazar de Pablo	2023	10.1016/j.jaac.2022.03.033	5.0	Low	Complementary	PUFA				3.68239356	1.44	g/day	Home	100	0	0			100		Disruptive behaviors				0	0	0	10.1097/JCP.0b013e3182485791	Yui	2012	RCT	SMD	7	6			0.559		-0.689	1.807															low	100	100	100	100	0	100	low	low	low	low	low	unclear	Placebo ()	0	7.7	14.6	100	1	1	1	1	Japan	Asia	DSM-IV	1	1	1	1.0	1.0	1	0.0	1.0	1.0	0	1	1	1	1	1	1	13	1529	Salazar de Pablo (2023)	Yui_2012	2-6 months	Average (80-119)	13-19 yo	5.1	14.6	100	100	12	11	ADHD symptoms | Social-communication | Restricted/repetitive behaviors | Disruptive behaviors | Overall ASD symptoms | Acceptability | Tolerability | Mood related symptoms | Adaptive behaviors | Adverse events | Language (Overall skills)	10	Cheng (2017) | De Andrade (2021) | Horvath (2017) | James (2011) | Mazahery (2017) | De Crescenzo (2020) | Siafis (child) (2022) | Zhou (2021) | Fraguas (2019) | Salazar de Pablo (2023)	https://doi.org/10.2147/NDT.S147305 | https://doi.org/10.1080/1028415X.2021.1913950 | https://doi.org/10.3945/jn.116.242354. | https://doi.org/10.1002/14651858.CD007992.pub2. | https://doi.org/10.3390/nu9020155 | https://doi.org/10.1186/s12955-020-01284-5 | https://doi.org/10.1186/s13229-022-00488-4 | https://doi.org/10.1016/j.jaac.2020.03.007 | https://doi.org/10.1542/peds.2018-3218 | 10.1016/j.jaac.2022.03.033	3.447391	17	100	100
